<SEC-DOCUMENT>0000320017-24-000031.txt : 20240509
<SEC-HEADER>0000320017-24-000031.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509161347
ACCESSION NUMBER:		0000320017-24-000031
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LISATA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		24930786

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALADRIUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20170808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lsta-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fe904bd3-4642-40bc-b4e0-ae39e52f235d,g:b327601d-86c0-41f4-b109-5b549ba09d67,d:0496fb3ebf9941088988bc5ca0bd6282-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:lsta="http://www.caladrius.com/20240331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lsta-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-388">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-389">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-394">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-395">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-398">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-399">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-476">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="lsta:SaleOfStockAvailableForSalePercentage" id="f-506">.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lsta-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-04</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-04</xbrli:startDate><xbrli:endDate>2024-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-05</xbrli:startDate><xbrli:endDate>2023-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-15</xbrli:startDate><xbrli:endDate>2024-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2024</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">LISATA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">908</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">842-0100</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:34.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.628%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">LSTA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:331.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of May 9, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">8,307,433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="padding-right:2.25pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including collecting amounts owed to us under various licensing and other strategic arrangements, meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the operation and/or growth of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a market is established for our products and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business,&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to diversify our pipeline of development product candidates, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population, competition with other clinical trials for similar subjects, patient and/or investigator site availability and accessibility due to external macroenvironmental factors and the need of patients to meet the inclusion criteria of the trial or otherwise;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which any future public health crisis and their long-term effects may impact, directly or indirectly, our business, including our clinical trials and financial condition; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 29, 2024 (our &#8220;2023 Form 10-K&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and elsewhere in our 2023 Form 10-K and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-bottom:3.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:3.3pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I- FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_10">Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_16">Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_16">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_16">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_16"> (unaudited) and December 31, 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_16">023</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19">Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19">March 31,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19"> 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22">Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22">March 31,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22"> 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25">Consolidated Statements of Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25">March 31,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25"> 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25"> (unaudited) </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_28">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_31">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_91">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_103">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Controls and Procedures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_106">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II- OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Proceedings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_112">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_115">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_118">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_121">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_124">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_127">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_130">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signatures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0496fb3ebf9941088988bc5ca0bd6282_133">33</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_13"></div><div><span><br/></span></div><div><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.951%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">21,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">22,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-32">21,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-33">27,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">3,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">47,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">53,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-38">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-39">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired license - intangible, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-40">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-41">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-42">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-43">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-44">48,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">54,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">2,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">4,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">4,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">5,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">6,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-52">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-53">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">5,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">6,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies (Note 13)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-56"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-57"/></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-58"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-59">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-60"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-61">500,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-62">8,308,171</ix:nonFraction></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-63">8,150,635</ix:nonFraction> shares at March 31, 2024 and December 31, 2023, respectively; and </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">outstanding, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-64">8,307,433</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-65">8,149,897</ix:nonFraction> shares at March 31, 2024 and December 31, 2023, </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-66">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-67">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-68">577,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-69">576,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="f-71">738</ix:nonFraction></ix:nonFraction> shares at March 31, 2024 and December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-72">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-73">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-74">533,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-75">528,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-76">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-77">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Lisata Therapeutics, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-78">42,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-79">48,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="f-80">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="f-81">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-82">42,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-83">47,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, non-controlling interests and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-84">48,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-85">54,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.771%"><tr><td style="width:1.0%"/><td style="width:67.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.085%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-86">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-87">3,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-89">3,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-90">6,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-91">6,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-92">6,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-93">6,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-94">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-95">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-96">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-97">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-98">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-99">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net loss before benefit from income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-100">6,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-101">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-102">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-104">5,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - net income (loss) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">5,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-110"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-111">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-112"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113">0.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-115">8,294</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-116"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-117">7,987</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:67.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.246%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">5,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-120">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-121">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment arising during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-122">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-123">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-124">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-125">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Lisata Therapeutics, Inc. common</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">stockholders</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-126">5,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-127">6,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.316%"><tr><td style="width:1.0%"/><td style="width:27.153%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.933%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.409%"/><td style="width:0.1%"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-128">7,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-129">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-130">574,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-131">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-132">507,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-133">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-134">66,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-135">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">66,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-140">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-141">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-142">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-143">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-144">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-145">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-146">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-147">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-148">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-149">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-150">7,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-151">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-152">575,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-153">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">513,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-155">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-156">60,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-157">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">60,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-159">8,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-160">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-161">576,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-162">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-163">528,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-164">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-165">48,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-166">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-167">47,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-171">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-172">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-173">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-174">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-175">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-176">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-177">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-178">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-179">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-180">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-181">8,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-182">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-183">577,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-184">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-185">533,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-186">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-187">42,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-188">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-189">42,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-192">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-193">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-194">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-195">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-197">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-198">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization/accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-200">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-201">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-202">872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-203">1,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-204">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-205">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-206">1,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-207">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-208">7,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-209">8,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-210">18,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-211">30,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-212">25,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-213">34,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Impilo Therapeutics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" id="f-214">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-216">6,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-217">4,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-218">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-219">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-220">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-221">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-222">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-223">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-224">788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-225">3,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-226">22,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-227">32,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-228">21,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-229">28,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="lsta:BusinessTextBlock" id="f-230" continuedAt="f-230-1" escape="true">The Business</ix:nonNumeric></span></div><ix:continuation id="f-230-1" continuedAt="f-230-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (&#8220;TME&#8221;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-231" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-232" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-233" continuedAt="f-233-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-233-1">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</ix:continuation>.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-234" escape="true"><ix:continuation id="f-230-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div></ix:continuation></ix:nonNumeric><div id="i0496fb3ebf9941088988bc5ca0bd6282_40"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-235" continuedAt="f-235-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-235-1" continuedAt="f-235-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-236" continuedAt="f-236-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-236-1">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-237" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-238" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-239" continuedAt="f-239-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-239-1">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-240" continuedAt="f-240-1" escape="true">The estimated useful lives of property and equipment are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-240-1" continuedAt="f-240-2"><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-46" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-241">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-242">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-243">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="f-244" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:continuation id="f-235-2" continuedAt="f-235-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-245" continuedAt="f-245-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-245-1">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-246" continuedAt="f-246-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-246-1">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-247" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="f-248" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-249" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Company's acquisition of Cend Therapeutics, Inc (the &#8220;Cend Merger&#8221;), with a value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-250">0.4</ix:nonFraction>&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of <ix:nonNumeric contextRef="c-3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-251">5</ix:nonNumeric> years. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-252">17</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2024 and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-253">18</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-254" escape="true">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.</ix:nonNumeric>  The projected amortization expense is $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-255"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-256"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-257"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-258">71</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;thousand per year for the next 3.5 years. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:continuation id="f-235-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-259" continuedAt="f-259-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-259-1">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-260"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-261">no</ix:nonFraction></ix:nonFraction> revenue recognized for the three months ended March&#160;31, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-262" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2024 and March&#160;31, 2023, the Company has <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-263"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-264">not</ix:nonFraction></ix:nonFraction> recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <ix:nonFraction unitRef="usd" contextRef="c-49" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-265">not</ix:nonFraction> recognized any royalty revenue from any collaborative arrangement.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-266" continuedAt="f-266-1" escape="true">Available-for-Sale-Securities</ix:nonNumeric></span></div><ix:continuation id="f-266-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-267" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-268">33,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-270">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-271">33,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-272">37,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-273">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-274">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-275">37,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-280">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-283">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-284">5,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-287">5,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-288">4,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-291">4,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-292">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-295">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-296">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-299">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-300">39,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-302">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-303">39,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-304">44,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-305">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-306">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-307">44,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-308" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-309">17,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-310">16,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-311">21,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-312">27,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-313">39,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-314">44,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-315" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-316">39,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-317">39,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-320">39,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-321">39,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_49"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-322" continuedAt="f-322-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-322-1"><ix:continuation id="f-240-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"/><td style="width:358.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-323">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-324">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-325">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-326">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-327">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-328">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-329">515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-330">486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-331">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-332">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-333">29</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-334">30</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_52"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-335" continuedAt="f-335-1" escape="true">Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="f-335-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-336" continuedAt="f-336-1" escape="true">At March&#160;31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-336-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-337">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-338">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-339">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-340">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-341">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-342">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_55"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-343" continuedAt="f-343-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-343-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-344" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-345">17,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-348">17,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-349">16,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-352">16,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-354">21,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-356">21,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-358">27,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-360">27,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-361">17,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-362">21,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-364">39,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-365">16,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-366">27,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-368">44,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts payable and accrued expenses approximate fair value as of March&#160;31, 2024 and December&#160;31, 2023, due to the short maturity nature of these items.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-369" continuedAt="f-369-1" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-370" escape="true"><ix:continuation id="f-369-1"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-371">1,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-372">2,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:ClinicalAndRDRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-373">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:ClinicalAndRDRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-374">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AccruedGrantFunding" scale="3" id="f-375">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:AccruedGrantFunding" scale="3" id="f-376">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:LegalSettlementCurrent" scale="3" id="f-377">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:LegalSettlementCurrent" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-379">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-380">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-381">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-382">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-383">4,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-384">4,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_61"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-385" continuedAt="f-385-1" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-386" escape="true"><ix:continuation id="f-385-1" continuedAt="f-385-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:continuation id="f-385-2"><ix:nonNumeric contextRef="c-1" name="lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="f-387" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-388"><span style="-sec-ix-hidden:f-389">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-390">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-391">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-392">267</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-393">308</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-396">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-397">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-398"><span style="-sec-ix-hidden:f-399">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-400">92</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-401">137</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-402">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-403">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the weighted average remaining lease term for our operating lease was <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-404">1.5</ix:nonNumeric> years, and the weighted average discount rate for our operating lease was <ix:nonFraction unitRef="number" contextRef="c-3" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-405">9.625</ix:nonFraction>%. As of December&#160;31, 2023, the weighted average remaining lease term for our operating leases was <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-406">1.75</ix:nonNumeric> years, and the weighted average discount rate for our operating leases was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-407">9.625</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-408" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2024 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-409">143</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-410">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-411">286</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-412">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-413">264</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_64"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-414" continuedAt="f-414-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-414-1" continuedAt="f-414-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="f-415">50.0</ix:nonFraction>&#160;million. As of the date of this filing and so long as the Company&#8217;s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#8220;Baby Shelf Limitation&#8221;), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of the Company's Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-416">26.7</ix:nonFraction>&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="lsta:OutstandingStockThreshold" format="ixt:num-dot-decimal" scale="6" id="f-417">75.0</ix:nonFraction>&#160;million at the time of such S-3 filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="lsta:SaleOfStockAvailableForSale" format="ixt:num-dot-decimal" scale="0" id="f-418">8,915,094</ix:nonFraction>, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If the Company&#8217;s public float exceeds $75.0&#160;million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. There were <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt-sec:numwordsen" id="f-419">no</ix:nonFraction> issuances of common stock under the ATM Agreement for the three months ended March&#160;31, 2024. Since inception, the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-80" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-420">64,394</ix:nonFraction> shares of common stock under the ATM Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-421">270,774</ix:nonFraction>.  </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-414-2" continuedAt="f-414-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-422" continuedAt="f-422-1" escape="true">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2024:</ix:nonNumeric></span></div><ix:continuation id="f-422-1"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-423">1,322,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-424">10.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-425">6.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-426">164.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="lsta:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-427">1,421,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="f-428">42.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-82" name="lsta:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="f-429">2.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-431">132,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-432">3.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsGranted" format="ixt:fixed-zero" scale="0" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsGranted" format="ixt:fixed-zero" scale="0" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsCanceled" format="ixt:fixed-zero" scale="0" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-443">1,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-444">1,165.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsExpired" format="ixt:fixed-zero" scale="0" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExpired" format="ixt:fixed-zero" scale="0" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-447">1,453,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-448">9.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-449">6.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-450">232.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-451">1,421,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="f-452">42.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="f-453">2.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-455">1,443,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-456">9.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-457">6.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-458">231.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:Sharesvestedandexpectedtovest" format="ixt:num-dot-decimal" scale="0" id="f-459">1,421,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="f-460">42.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" format="ixt-sec:duryear" id="f-461">2.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsvestedandexpectedtovest" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-463">1,285,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-464">9.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:OptionsVestedweightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-465">5.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="f-466">215.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:WarrantsVested" format="ixt:num-dot-decimal" scale="0" id="f-467">1,421,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="f-468">42.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermwarrantsvested" format="ixt-sec:duryear" id="f-469">2.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsvested" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-471" continuedAt="f-471-1" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-472">203,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-473">159,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-474">628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-475">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-476">one</span> and <ix:nonNumeric contextRef="c-86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-477">four years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-471-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"/><td style="width:33.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-478">125,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-479">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-480">203,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-481">3.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-482">99,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-483">5.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-486">229,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-487">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-414-3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-488" continuedAt="f-488-1" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-489">205,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-490">188,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-491">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-492">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock units issued for services in the three months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-493">3.08</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-494">3.00</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="c-89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-495">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-488-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"/><td style="width:33.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-496">112,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-497">3.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-498">97,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-499">3.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-500">100,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-501">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-504">110,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-505">3.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_70"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-507" continuedAt="f-507-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-507-1" continuedAt="f-507-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-508" continuedAt="f-508-1" escape="true">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2024 and 2023 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-508-1"><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:62.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.319%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-509">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-510">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-511">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-512">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-513">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-514">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-515" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-516">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-517">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-518">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-99" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-519">2.28</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-89" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-520">0.92</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-83" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-521">2.17</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:continuation id="f-507-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-522" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2024 and 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-523">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-524">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-525">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-526">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_73"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-527" continuedAt="f-527-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-527-1" continuedAt="f-527-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="lsta:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-528">43.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="lsta:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-529">33.7</ix:nonFraction>&#160;million respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036.  The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-530">88.2</ix:nonFraction>&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-531">34.0</ix:nonFraction>&#160;million of remaining Federal NOLs as of December&#160;31, 2022. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Cend Therapeutics, Inc. (&#8220;Cend&#8221;) had approximately $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-532">3.6</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-533">3.1</ix:nonFraction>&#160;million of Federal and $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-534">4.3</ix:nonFraction>&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="lsta:FairValueMarketOfTaxNOLs" format="ixt:num-dot-decimal" scale="6" id="f-535">36.1</ix:nonFraction>&#160;million and applying an applicable federal rate of <ix:nonFraction unitRef="number" contextRef="c-106" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-536">2.54</ix:nonFraction>% Cend will have an annual limitation of approximately $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation" format="ixt:num-dot-decimal" scale="3" id="f-537">917</ix:nonFraction>&#160;thousand each year. The Federal NOL of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="lsta:OperatingLossCarryforwardsPostAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-538">459</ix:nonFraction>&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. As of December&#160;31, 2023 and 2022, Cend&#8217;s wholly owned Australian subsidiary had approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-539">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-540">1.8</ix:nonFraction>&#160;million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had federal research and development credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-541">0.5</ix:nonFraction>&#160;million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-542">0.1</ix:nonFraction>&#160;million, which carryforward indefinitely.  Utilization of these credits may be subject to an annual limitation based on changes in ownership.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company had State NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-543">19.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-544">35.5</ix:nonFraction>&#160;million, respectively, California of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-545">9.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-546">9.2</ix:nonFraction>&#160;million, respectively, and New York City of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-547">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-548">1.9</ix:nonFraction>&#160;million, respectively, to offset future taxable income expiring from 2032 through 2043. The usage of the Company&#8217;s NOLs is limited given the change in ownership.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company&#8217;s uncertain tax positions were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-549">344</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-550">344</ix:nonFraction>&#160;thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:continuation id="f-527-2" continuedAt="f-527-3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2020, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the Company received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;) to sell $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="lsta:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" format="ixt:num-dot-decimal" scale="6" id="f-551">8.9</ix:nonFraction>&#160;million of its New Jersey net operating losses (&#8220;NJ NOLs&#8221;), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="lsta:ProceedsFromSaleOfNOLS" format="ixt:num-dot-decimal" scale="6" id="f-552">0.7</ix:nonFraction>&#160;million. The sale of NJ NOLs resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-553">0.8</ix:nonFraction>&#160;million deferred income tax benefit and a loss on sale of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="lsta:LossOnSaleOfNOL" format="ixt:num-dot-decimal" scale="6" id="f-554">0.1</ix:nonFraction>&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-527-3">On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#8217;s results of operations for the year ended December&#160;31, 2023. The Company will continue to monitor the possible future impact of changes in tax legislation.</ix:continuation>  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 12 &#8211; <ix:nonNumeric contextRef="c-1" name="lsta:ResearchAndDevelopmentTaxIncentiveTextBlock" id="f-555" continuedAt="f-555-1" escape="true">Australia Research and Development Tax Incentive</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-555-1">The Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between <ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-556">43.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-121" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-557">48.5</ix:nonFraction>% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March&#160;31, 2024 and 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="lsta:IncomeTaxIncentiveReceivable" format="ixt:num-dot-decimal" scale="6" id="f-558">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="lsta:IncomeTaxIncentiveReceivable" format="ixt:num-dot-decimal" scale="6" id="f-559">1.0</ix:nonFraction>&#160;million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_79"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 13 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-560" continuedAt="f-560-1" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-560-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022 and denied all of Lingmed&#8217;s material allegations. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022, denying all of the Company&#8217;s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company is required to pay Lingmed $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-561">0.5</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="c-122" name="lsta:LitigationSettlementPaymentTerm" format="ixt-sec:durday" id="f-562">30</ix:nonNumeric> days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to <ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="lsta:LitigationSettlementFutureMilestonePaymentsPercent" scale="-2" id="f-563">5.0</ix:nonFraction>% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="lsta:LitigationSettlementMilestonePayment" scale="3" id="f-564">250</ix:nonFraction> thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties&#8217; joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_82"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 14 &#8211; <ix:nonNumeric contextRef="c-1" name="lsta:TechnologyTransferAgreementTextBlock" id="f-565" continuedAt="f-565-1" escape="true">Technology Transfer Agreement</ix:nonNumeric></span></div><ix:continuation id="f-565-1" continuedAt="f-565-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#8220;Impilo&#8221;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-566">766,000</ix:nonFraction> shares of its pre-seed preferred stock to the Company. On October 3, 2023 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:continuation id="f-565-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with the Sanford Burnham Prebys license agreement (Note 15) Impilo cancelled the original stock certificate for <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="lsta:InvestmentOwnedCanceledShares" format="ixt:num-dot-decimal" scale="0" id="f-567">766,000</ix:nonFraction> shares and reissued <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-568">574,500</ix:nonFraction> shares of its pre-seed preferred stock to the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-569">100,000</ix:nonFraction>. As of March 31, 2024 and December 31, 2023 the Company owned <ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-570"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-571">38.6</ix:nonFraction></ix:nonFraction>% of Impilo. This investment was expensed under the equity method of accounting for the three months ended March 31, 2024 in other expense,net in the accompanying statement of operations. The SAFE has a valuation cap of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="lsta:SAFEValuationCap" format="ixt:num-dot-decimal" scale="6" id="f-572">30.0</ix:nonFraction>&#160;million and an <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="lsta:SAFEDiscountRate" scale="-2" id="f-573">80</ix:nonFraction>% discount rate.</span></div></ix:continuation><div id="i0496fb3ebf9941088988bc5ca0bd6282_85"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 15 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-574" continuedAt="f-574-1" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="f-574-1" continuedAt="f-574-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="lsta:SharesIssuedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-575">382,030</ix:nonFraction> shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="f-576">10,000</ix:nonFraction> increasing to $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" format="ixt:num-dot-decimal" scale="3" id="f-577">20,000</ix:nonFraction> on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="f-578">10.6</ix:nonFraction>&#160;million. The Company has also agreed to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="f-579">4</ix:nonFraction>% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP <ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-580">25</ix:nonFraction>% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-581">191,500</ix:nonFraction> shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP did <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="lsta:SharesHeldByThirdParty" format="ixt-sec:numwordsen" id="f-582">no</ix:nonFraction>t own shares of the Company&#8217;s common stock as of March&#160;31, 2024. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_88"></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 16 &#8211; <ix:continuation id="f-574-2" continuedAt="f-574-3">Research Collaboration and License Agreement</ix:continuation></span></div><ix:continuation id="f-574-3" continuedAt="f-574-4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-583">10.0</ix:nonFraction>&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#8220;Cend Merger&#8221;). In addition, Cend received and recognized as revenue a $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-584">5.0</ix:nonFraction>&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-585">96.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-586">125.0</ix:nonFraction>&#160;million, respectively, tiered royalties on net sales ranging from <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="f-587">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="f-588">15</ix:nonFraction>%, and tiered sublicensing revenues ranging from <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="f-589">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="f-590">35</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to <ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="lsta:LitigationSettlementFutureMilestonePaymentsPercent" scale="-2" id="f-591">5.0</ix:nonFraction>% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="lsta:LitigationSettlementMilestonePayment" scale="3" id="f-592">250</ix:nonFraction> thousand with respect to the first future milestone received by the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><ix:continuation id="f-574-4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least <ix:nonNumeric contextRef="c-136" name="lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate" format="ixt-sec:durwordsen" id="f-593">sixty days</ix:nonNumeric> written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.</span></div></ix:continuation><div><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_1113"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 17 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-594" continuedAt="f-594-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-594-1">On April 15, 2024, the Company&#8217;s Board of Directors appointed James Nisco as the Company&#8217;s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately. Effective as of April 15, 2024, Mr. Nisco shall serve as the Company&#8217;s principal financial officer and principal accounting officer.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8220;Risk Factors&#8221; in our 2023 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2023 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Our lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (&#8220;TME&#8221;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. We are exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Our goal is to develop and commercialize products that address important unmet medical needs. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted Solid Tumor Penetration via CendR Active Transport</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many solid tumor cancers, including pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;), and cholangiocarcinoma, are surrounded by dense fibrotic tissue, or stroma. This stroma often limits the efficacy of current chemotherapies for these cancers. Emerging immunotherapies including but not limited to checkpoint inhibitors and adoptive cell therapies (e.g., chimeric antigen receptor T cells (CAR-Ts)) also face challenges in penetrating solid tumors. Many tumors also exhibit an immunosuppressive TME, which suppresses patients&#8217; immune systems and can thus limit the effectiveness of immunotherapies and/or contribute to metastases. These factors negatively impact the ability of many therapeutic agents to effectively treat these cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the tumor stroma&#8217;s role as a primary impediment to effective treatment, our approach is to activate the C-end rule (&#8220;CendR&#8221;), or CendR system, a naturally occurring active transport system. Our lead investigational drug, certepetide (a specific </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">internalizing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R-G-D or iRGD peptide), activates this transport system in a tumor-specific manner (Sugahara, Science, 2010). Certepetide enables more selective and efficient uptake of systemically administered anti-cancer drugs resulting in more intratumoral drug accumulation. The overall expected result is enhanced anticancer activity without an increase in adverse side effects. While it is possible to couple/tether or conjugate some anticancer drugs to certepetide, we believe that the co-administration of certepetide with anti-cancer therapies is advantageous. Co-administration does not create a new chemical entity with its attendant development and regulatory hurdles, thereby providing an anticipated faster-to-clinic and faster-to-market product opportunity for a range of co-administration therapies. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certepetide has demonstrated favorable safety, tolerability, and activity to date in clinical trials enhancing the delivery of standard-of-care chemotherapies for mPDAC. Certepetide&#8217;s cancer-targeted delivery may enable such emerging treatment modalities to treat a range of solid tumors potentially more effectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certepetide as a treatment for solid tumor cancers in combination with other anti-cancer agents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certepetide is an investigational drug that actuates the CendR active transport mechanism. Certepetide has been shown to modify the TME, making it less immunosuppressive and thereby making the tumor more susceptible to attack by the immune system while also inhibiting the metastasis cascade. It targets tumor vasculature, endothelial cells, tumor cells and some intratumoral immunosuppressive cells by its selective affinity for alpha-v beta-3 and beta-5 integrins that are upregulated on these cells. Certepetide is a nine amino acid cyclic internalizing RGD (&#8220;iRGD&#8221;) peptide that, once bound to these integrins, is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cleaved by proteases expressed in tumors to release a linear peptide fragment, called a CendR peptide fragment. The CendR peptide fragment then binds to an adjacent receptor, called neuropilin-1, also upregulated in solid tumors, to activate a novel uptake pathway that allows circulating anticancer drugs to more selectively and effectively penetrate solid tumors. The ability of certepetide and iRGD peptides to modify the TME to enhance delivery and efficacy of co-administered drugs has been demonstrated in many preclinical models in a range of solid tumors. Lisata, its collaborators, and research groups around the world have published over 350 related scientific papers in this regard.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinically, certepetide was  the subject of a completed Phase 1b/2a trial inclusive of 31 first-line mPDAC patients, of which 29 were evaluable. Results from the trial showed that the safety profile of the certepetide combination regimen was similar to standard of care (&#8220;SoC&#8221;) alone with certepetide being well-tolerated with no-dose limiting toxicities. An Objective Response Rate (&#8220;ORR&#8221;) of 59% was observed, compared to the 23% ORR observed in the &#8220;MPACT&#8221; clinical trial that served as the basis for approval of nab-paclitaxel for use in combination with gemcitabine for the treatment of first line, mPDAC (Von Hoff, et al. 2013). A Disease Control Rate (&#8220;DCR&#8221;) (partial and complete responses plus stable disease) of over 79% was also observed in comparison to a DCR of 48% observed in the MPACT trial. Reduction in the level of circulating tumor biomarker CA19-9 was observed in 96% of patients versus 61% in the MPACT trial. Importantly, median progression-free survival and median overall survival of nearly ten months and over thirteen months were observed versus less than six months and less than nine months, respectively, in the MPACT trial. These results have been published in The Lancet Gastroenterology and Hepatology (Dean, et al. 2022).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certepetide is currently the subject of multiple ongoing and planned clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. The following diagram summarizes these studies. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><img src="lsta-20240331_g1.jpg" alt="Slide1.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><img src="lsta-20240331_g2.jpg" alt="Slide2.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad intellectual property portfolio of assets includes notable programs available for out-licensing in order to augment or continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_94"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2024 Compared to Three Months Ended March&#160;31, 2023 </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2024 and March&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"/><td style="width:50.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.636%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,401)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,187)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $5.4 million for the three months ended March&#160;31, 2024, compared to $6.2 million for the three months ended March&#160;31, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024, operating expenses totaled $6.6 million, compared to $6.8 million for the three months ended March&#160;31, 2023, representing a decrease of $0.2 million or 3.6%.  Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were approximately $3.2 million for the three months ended March&#160;31, 2024, compared to $3.2 million for the three months ended March&#160;31, 2023, representing an increase of $62.0 thousand or 2.0%. This was primarily due to an increase in expenses associated with our enrollment activities in the current year for our certepetide Phase 2a proof-of-concept Bolster trial partially offset by a reduction in expenses associated with the  Phase 2b ASCEND trial which completed enrollment in the prior year.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $3.4 million for the three months ended March&#160;31, 2024, compared to $3.7 million for the three months ended March&#160;31, 2023, representing a decrease of $0.3 million or 8.3%. This was primarily due to a decrease in staffing costs associated with the elimination of the Chief Business Officer position on May 1, 2023, a reduction in option assumption equity expense in connection with the Cend Merger, a decrease in directors and officers insurance premiums, and a reduction in spend on consulting and legal fees partially offset by one-off settlement related costs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised primarily of investment income from cash, cash equivalents and marketable securities for the three months ended March&#160;31, 2024 and 2023, with the current year period also including a loss on sale related to the sale of our New Jersey net operating losses (&#8220;NJ NOLs&#8221;) and an investment in Impilo Therapeutics, Inc which was fully expensed under the equity method of accounting. </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;) to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7 million. The $0.8 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million of our NJ NOL tax benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024, we had cash, cash equivalents and marketable securities of approximately $43.3 million, working capital of approximately $42.2 million, and stockholders&#8217; equity of approximately $43.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) or provided by, operating, investing and financing activities were as follows (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.737%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,196)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2024 was $7.0 million, which is comprised of (i) our net loss of $5.4 million, adjusted for non-cash expenses totaling $0.4&#160;million (which includes adjustments for equity-based compensation, depreciation and amortization, loss from equity method investment, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $2.1 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2023 was $8.2 million, which is comprised of (i) our net loss of $6.2 million, adjusted for non-cash expenses totaling $0.6 million (which includes adjustments for equity-based compensation, depreciation and amortization, a loss on disposal of fixed assets, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities using approximately $2.6 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the three months ended March&#160;31, 2024 totaled $6.4 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities) partially offset by an investment of $0.1 million in Impilo Therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the three months ended March&#160;31, 2023 totaled $4.3 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the three months ended March&#160;31, 2024 totaled $0.1 million and consisted of tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the three months ended March&#160;31, 2023 totaled $0.1 million and consisted of tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances, marketable securities and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of pharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand and marketable securities will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements. Our future capital requirements are difficult to forecast and will depend on many factors including the timing and nature of any other strategic transactions that we undertake; and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, we entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC as sales agent, in connection with an &#8220;at the market offering&#8221; under which we from time to time may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million. As of the date of this filing and so long as our public float remains below $75.0 million, we are subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#8220;Baby Shelf Limitation&#8221;), which limits the amount we can offer to up to one-third of our public float during any trailing 12-month period. Subsequent to the filing of our Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $26.7&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such S-3 filing, the aggregate amount of securities that we are permitted to offer and sell is now $8,915,094, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If our public float exceeds $75.0 million on a future measurement date, the Company will no longer be subject to the Baby Shelf Limitation. There were no issuances of common stock under the ATM Agreement for the three months ended March&#160;31, 2024. Since inception we have issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. </span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_100"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2024, compared to those reported in our 2023 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_103"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.<br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;Disclosure Controls and Procedures </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who serves as our principal executive officer and who served as our principal financial officer for the three months ended March 31,2024, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we evaluated, with the participation of our management, including our Chief Executive Officer, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and forms and is accumulated and communicated to management, including the Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Subsequent to March 31, 2024, the Company&#8217;s Board of Directors appointed James Nisco as the Company&#8217;s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately, and Mr. Nisco simultaneously began serving as our principal financial officer and principal accounting officer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION </span></div><div style="text-align:center"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_112"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as disclosed in &#8220;Note 13 &#8211; Contingencies&#8221; set forth in the Notes to Unaudited Consolidated Financial Statements, which are included herein, there are no material changes to the disclosures previously reported in our 2023 Form 10-K.<br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_115"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors previously reported in our 2023 Form 10-K.  See the risk factors set forth in our 2023 Annual Report on Form 10-K under the caption &#8220;Item 1A - Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_118"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_121"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_124"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_127"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-595"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-596"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-597"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-598">no director or officer of the Company adopted, modified or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_130"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.314%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LISATA THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> /s/ David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   President &amp; Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ James Nisco</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: James Nisco</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   SVP, Finance and Treasury and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></div></div></div><div id="i0496fb3ebf9941088988bc5ca0bd6282_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0496fb3ebf9941088988bc5ca0bd6282_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:461.50pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex311_20240331.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex312_20240331.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex321_20240331.htm">32.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex322_20240331.htm">32.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"/><td style="width:16.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:502.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>lsta-ex311_20240331.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i93a89562b6a94c6a88e430f367134e4d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, PhD, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2024 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; President &#38; Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>lsta-ex312_20240331.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia57bf8bd78ea4942a7d76b5622f93406_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Nisco, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2024 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Nisco&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Nisco</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President, Finance and Treasury and Chief Accounting Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>lsta-ex321_20240331.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i93c787296f024f3ca1672340d69f0b65_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2024 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David J. Mazzo, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;May&#160;9, 2024 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President &#38; Chief Executive Officer (Principal Executive Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>lsta-ex322_20240331.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic68cfa19f69e4c4191099f4eba90159e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2024 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;May&#160;9, 2024 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James Nisco     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Nisco</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance and Treasury and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lsta-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fe904bd3-4642-40bc-b4e0-ae39e52f235d,g:b327601d-86c0-41f4-b109-5b549ba09d67-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lsta="http://www.caladrius.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParentheticals" roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusiness" roleURI="http://www.caladrius.com/role/TheBusiness">
        <link:definition>0000008 - Disclosure - The Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>0000010 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.caladrius.com/role/PropertyandEquipment">
        <link:definition>0000011 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShare" roleURI="http://www.caladrius.com/role/IncomeLossPerShare">
        <link:definition>0000012 - Disclosure - Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>0000014 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>0000015 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>0000017 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentive" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive">
        <link:definition>0000019 - Disclosure - Australia Research and Development Tax Incentive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>0000020 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TechnologyTransferAgreement" roleURI="http://www.caladrius.com/role/TechnologyTransferAgreement">
        <link:definition>0000021 - Disclosure - Technology Transfer Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.caladrius.com/role/LicenseAgreements">
        <link:definition>0000022 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreement" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement">
        <link:definition>0000023 - Disclosure - Research Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.caladrius.com/role/SubsequentEvents">
        <link:definition>0000024 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>9954473 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables">
        <link:definition>9954474 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareTables" roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables">
        <link:definition>9954475 - Disclosure - Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>9954476 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>9954477 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>9954478 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>9954479 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>9954480 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>9954481 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
        <link:definition>9954483 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails">
        <link:definition>9954484 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>9954485 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails">
        <link:definition>9954486 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareDetails" roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails">
        <link:definition>9954487 - Disclosure - Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails">
        <link:definition>9954488 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>9954489 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails">
        <link:definition>9954490 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>9954491 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>9954493 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsNarrativeDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails">
        <link:definition>9954494 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails">
        <link:definition>9954495 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>9954496 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails">
        <link:definition>9954497 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>9954498 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
        <link:definition>9954499 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>9954500 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails">
        <link:definition>9954501 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentiveDetails" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails">
        <link:definition>9954502 - Disclosure - Australia Research and Development Tax Incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.caladrius.com/role/ContingenciesDetails">
        <link:definition>9954503 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TechnologyTransferAgreementDetails" roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails">
        <link:definition>9954504 - Disclosure - Technology Transfer Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails">
        <link:definition>9954505 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementDetails" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails">
        <link:definition>9954506 - Disclosure - Research Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lsta_LegalSettlementCurrent" abstract="false" name="LegalSettlementCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_AccruedGrantFunding" abstract="false" name="AccruedGrantFunding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_SaleOfStockAvailableForSale" abstract="false" name="SaleOfStockAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LitigationSettlementFutureMilestonePaymentsPercent" abstract="false" name="LitigationSettlementFutureMilestonePaymentsPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LitigationSettlementMilestonePayment" abstract="false" name="LitigationSettlementMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LitigationSettlementPaymentTerm" abstract="false" name="LitigationSettlementPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" abstract="false" name="CollaborativeArrangementRightsAndObligationsSublicensingFees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsvested" abstract="false" name="AggregateIntrinsicValueWarrantsvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_OperatingLeaseRightOfUseAssetAbstract" abstract="true" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_ClinicalAndRDRelatedLiabilities" abstract="false" name="ClinicalAndRDRelatedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_TechnologyTransferAgreementAbstract" abstract="true" name="TechnologyTransferAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_OptionsVestedweightedAverageRemainingContractualTerm" abstract="false" name="OptionsVestedweightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_SaleOfStockAvailableForSalePercentage" abstract="false" name="SaleOfStockAvailableForSalePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_EPSAbstract" abstract="true" name="EPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_SanfordBurnhamPrebysMember" abstract="true" name="SanfordBurnhamPrebysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_ImpiloMember" abstract="true" name="ImpiloMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_OutstandingStockThreshold" abstract="false" name="OutstandingStockThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WarrantsOtherDisclosuresAbstract" abstract="true" name="WarrantsOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" abstract="false" name="WeightedAverageRemainingContractualTermwarrantoutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_SharesHeldByThirdParty" abstract="false" name="SharesHeldByThirdParty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_IncomeTaxIncentiveReceivable" abstract="false" name="IncomeTaxIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermwarrantsvested" abstract="false" name="WeightedAverageRemainingContractualTermwarrantsvested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_LingmedLimitedMember" abstract="true" name="LingmedLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_SAFEValuationCap" abstract="false" name="SAFEValuationCap" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" abstract="false" name="AggregateIntrinsicValueWarrantsvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_InvestmentOwnedCanceledShares" abstract="false" name="InvestmentOwnedCanceledShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_OperatingLossCarryforwardsPostAcquisition" abstract="false" name="OperatingLossCarryforwardsPostAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_CENDMember" abstract="true" name="CENDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_TechnologyTransferAgreementTextBlock" abstract="false" name="TechnologyTransferAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lsta_OperatingLossCarryforwardsBeforeWriteDown" abstract="false" name="OperatingLossCarryforwardsBeforeWriteDown" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_SharesIssuedUnderLicenseAgreement" abstract="false" name="SharesIssuedUnderLicenseAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_BusinessTextBlock" abstract="false" name="BusinessTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" abstract="false" name="NetCarryforwardOperatingLossCarryforwardAnnualLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_QiluMember" abstract="true" name="QiluMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" abstract="false" name="RevenuePerformanceObligationPercentageOfSublicensingRevenues" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_SAFEDiscountRate" abstract="false" name="SAFEDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" abstract="false" name="ResearchCollaborationAndLicenseAgreementOptionToTerminate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_FairValueMarketOfTaxNOLs" abstract="false" name="FairValueMarketOfTaxNOLs" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_RevenuePerformanceObligationPercentageOfNetSale" abstract="false" name="RevenuePerformanceObligationPercentageOfNetSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_ExclusiveLicenseAndCollaborationAgreementMember" abstract="true" name="ExclusiveLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_ProceedsFromSaleOfNOLS" abstract="false" name="ProceedsFromSaleOfNOLS" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_LossOnSaleOfNOL" abstract="false" name="LossOnSaleOfNOL" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" abstract="false" name="ResearchAndDevelopmentTaxIncentiveTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>lsta-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fe904bd3-4642-40bc-b4e0-ae39e52f235d,g:b327601d-86c0-41f4-b109-5b549ba09d67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a5ef968-b0ba-461c-a1d4-b7c89c831c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7c9502c-bbef-452d-8398-5a3246116e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a5ef968-b0ba-461c-a1d4-b7c89c831c14" xlink:to="loc_us-gaap_StockholdersEquity_d7c9502c-bbef-452d-8398-5a3246116e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_de5a3154-73ba-431b-80cf-23ade1e6696f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a5ef968-b0ba-461c-a1d4-b7c89c831c14" xlink:to="loc_us-gaap_MinorityInterest_de5a3154-73ba-431b-80cf-23ade1e6696f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_66350a9b-e904-4c9b-b14d-823de568faff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1ba3f6f7-6c62-4973-8328-0c009de5119d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_66350a9b-e904-4c9b-b14d-823de568faff" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1ba3f6f7-6c62-4973-8328-0c009de5119d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69daba7b-d3e3-4b1e-9c3d-33fa789d68fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_66350a9b-e904-4c9b-b14d-823de568faff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69daba7b-d3e3-4b1e-9c3d-33fa789d68fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9f8ebf38-5069-4b83-afc1-b82a204a8e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_66350a9b-e904-4c9b-b14d-823de568faff" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9f8ebf38-5069-4b83-afc1-b82a204a8e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_74d2c981-f758-495e-ba98-94f47dea6f69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_66350a9b-e904-4c9b-b14d-823de568faff" xlink:to="loc_us-gaap_CommonStockValue_74d2c981-f758-495e-ba98-94f47dea6f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_f880e59f-1b6f-4dbe-91b3-9447c628fcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_66350a9b-e904-4c9b-b14d-823de568faff" xlink:to="loc_us-gaap_TreasuryStockCommonValue_f880e59f-1b6f-4dbe-91b3-9447c628fcd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e72c1263-f967-4b7e-b9f3-4e211466f07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7643d4bd-d1f6-4e06-b601-89193f250453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e72c1263-f967-4b7e-b9f3-4e211466f07b" xlink:to="loc_us-gaap_AccountsPayableCurrent_7643d4bd-d1f6-4e06-b601-89193f250453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e325e707-b112-4bd6-ac1d-7e988ced2c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e72c1263-f967-4b7e-b9f3-4e211466f07b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e325e707-b112-4bd6-ac1d-7e988ced2c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6c0e1e25-89dd-4ff2-b7b8-eb9290e44678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_56b63e27-24d6-452a-adac-ea246afbb803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c0e1e25-89dd-4ff2-b7b8-eb9290e44678" xlink:to="loc_us-gaap_LiabilitiesCurrent_56b63e27-24d6-452a-adac-ea246afbb803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_196f6df7-e898-4167-9439-afc8612a4e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c0e1e25-89dd-4ff2-b7b8-eb9290e44678" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_196f6df7-e898-4167-9439-afc8612a4e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d06221fd-30c6-4a15-82d3-0958b51a960f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_164b222a-9391-43c3-bf31-8ab92baa1f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d06221fd-30c6-4a15-82d3-0958b51a960f" xlink:to="loc_us-gaap_AssetsCurrent_164b222a-9391-43c3-bf31-8ab92baa1f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f1739180-13a9-44b5-8b95-c9a14a151537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d06221fd-30c6-4a15-82d3-0958b51a960f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f1739180-13a9-44b5-8b95-c9a14a151537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_38807a66-bed4-40a2-af71-8b6da69f9566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d06221fd-30c6-4a15-82d3-0958b51a960f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_38807a66-bed4-40a2-af71-8b6da69f9566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e5b75c2-5f6d-4005-8f0d-7f334d1837bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d06221fd-30c6-4a15-82d3-0958b51a960f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e5b75c2-5f6d-4005-8f0d-7f334d1837bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_159ac58c-9c88-4c1b-875f-74414a8a3752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3596c4b-6d7c-4c6f-8889-3022a3322478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_159ac58c-9c88-4c1b-875f-74414a8a3752" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3596c4b-6d7c-4c6f-8889-3022a3322478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_3037b880-e2aa-42ae-87c0-e8547d206655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_159ac58c-9c88-4c1b-875f-74414a8a3752" xlink:to="loc_us-gaap_MarketableSecurities_3037b880-e2aa-42ae-87c0-e8547d206655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_86216a12-8acc-4eef-8430-78e1b798a544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_159ac58c-9c88-4c1b-875f-74414a8a3752" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_86216a12-8acc-4eef-8430-78e1b798a544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bc34d1bd-e5ed-4ca4-89fd-fbbeadca5b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d2b7ec5-37c5-4e2e-ae2c-959338a64d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bc34d1bd-e5ed-4ca4-89fd-fbbeadca5b58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d2b7ec5-37c5-4e2e-ae2c-959338a64d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8d3e8660-ebc0-4ccb-9fb8-66c0d80097b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bc34d1bd-e5ed-4ca4-89fd-fbbeadca5b58" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8d3e8660-ebc0-4ccb-9fb8-66c0d80097b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ceeaac24-3e1c-4f21-99af-88b6462cada8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bc34d1bd-e5ed-4ca4-89fd-fbbeadca5b58" xlink:to="loc_us-gaap_Liabilities_ceeaac24-3e1c-4f21-99af-88b6462cada8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b5431a95-d79a-4f88-ba69-bf387818a6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e0c8813-3ec4-4757-8b9c-9de9e00496e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b5431a95-d79a-4f88-ba69-bf387818a6a4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e0c8813-3ec4-4757-8b9c-9de9e00496e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_29e177e8-e934-47b0-a254-cf725db970d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b5431a95-d79a-4f88-ba69-bf387818a6a4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_29e177e8-e934-47b0-a254-cf725db970d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b4a56023-144a-4d49-8667-2083f2f0cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_18c0060b-b1fb-4c34-a56d-042d03f9477a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b4a56023-144a-4d49-8667-2083f2f0cc30" xlink:to="loc_us-gaap_OperatingExpenses_18c0060b-b1fb-4c34-a56d-042d03f9477a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ee43b8ea-f7f4-4938-af9f-ea1b1fab5443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a4b00208-e1e7-44f7-9738-73729e9f8497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee43b8ea-f7f4-4938-af9f-ea1b1fab5443" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a4b00208-e1e7-44f7-9738-73729e9f8497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_889b48e1-01d2-4503-a429-ef0dadb5faa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee43b8ea-f7f4-4938-af9f-ea1b1fab5443" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_889b48e1-01d2-4503-a429-ef0dadb5faa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f016c2fa-36a1-42eb-914f-66a8e5bdb89c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_78b362a9-cf40-4843-aaef-b7eb54ca5279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f016c2fa-36a1-42eb-914f-66a8e5bdb89c" xlink:to="loc_us-gaap_InvestmentIncomeNet_78b362a9-cf40-4843-aaef-b7eb54ca5279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5a36486d-b2d0-432c-8275-61c963af16e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f016c2fa-36a1-42eb-914f-66a8e5bdb89c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5a36486d-b2d0-432c-8275-61c963af16e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0150b3c3-cb7a-4538-9876-78e7cc290d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f80fc073-ed3c-4477-9e4d-0a3369cf03fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0150b3c3-cb7a-4538-9876-78e7cc290d7e" xlink:to="loc_us-gaap_ProfitLoss_f80fc073-ed3c-4477-9e4d-0a3369cf03fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_8419640b-45d2-407f-8475-20b1b89dafbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0150b3c3-cb7a-4538-9876-78e7cc290d7e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_8419640b-45d2-407f-8475-20b1b89dafbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68d6724d-4b46-4dfa-a88c-37461c5e30e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_64b880b6-12eb-4cb3-b615-18f6173379c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68d6724d-4b46-4dfa-a88c-37461c5e30e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_64b880b6-12eb-4cb3-b615-18f6173379c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e0762468-4ec8-4a5d-8144-dea5a0310da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68d6724d-4b46-4dfa-a88c-37461c5e30e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e0762468-4ec8-4a5d-8144-dea5a0310da3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bd2c63e-199c-4a8a-b0ef-ef41adddea13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_364d7061-9861-4d53-afdb-1acb8a7311cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bd2c63e-199c-4a8a-b0ef-ef41adddea13" xlink:to="loc_us-gaap_ProfitLoss_364d7061-9861-4d53-afdb-1acb8a7311cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4789fec7-2381-48e4-bb73-af8ee9821ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bd2c63e-199c-4a8a-b0ef-ef41adddea13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4789fec7-2381-48e4-bb73-af8ee9821ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c559ecb8-e945-4d27-9f97-59bdefa7512c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_57d86883-40ff-4ecf-af0b-d78af0667ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c559ecb8-e945-4d27-9f97-59bdefa7512c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_57d86883-40ff-4ecf-af0b-d78af0667ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_977d29b7-40ed-4cdb-bab8-b38abb910113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c559ecb8-e945-4d27-9f97-59bdefa7512c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_977d29b7-40ed-4cdb-bab8-b38abb910113" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_367a05b6-57a4-41c8-9716-a8ce48b2dbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_367a05b6-57a4-41c8-9716-a8ce48b2dbdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1b5277df-0b68-4e59-8ef6-83d7ed71c5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_DepreciationAndAmortization_1b5277df-0b68-4e59-8ef6-83d7ed71c5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c0434612-7ea8-4340-a7de-67d68a958878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_ProfitLoss_c0434612-7ea8-4340-a7de-67d68a958878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_15b62159-f8a4-42a4-b1a7-ae4c08c033ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_15b62159-f8a4-42a4-b1a7-ae4c08c033ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a6466399-e48c-41c5-940b-034554c11abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a6466399-e48c-41c5-940b-034554c11abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a54ff9dd-68b8-4b31-866c-fb530dd4b4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a54ff9dd-68b8-4b31-866c-fb530dd4b4f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_c5718f21-d102-4b74-8915-c54ac687528d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_c5718f21-d102-4b74-8915-c54ac687528d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_74745bef-0c77-486e-ac35-45a148b37687" xlink:href="lsta-20240331.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_74745bef-0c77-486e-ac35-45a148b37687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_76f9f072-ae05-4e13-85c0-299b736fc050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73ba5ff0-fc40-418a-a247-2432cae01ad8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_76f9f072-ae05-4e13-85c0-299b736fc050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68f6c70f-792c-454a-8d96-d015aa18c8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d682dc94-ba10-4aed-8ebb-ab5f37ae9836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68f6c70f-792c-454a-8d96-d015aa18c8a8" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d682dc94-ba10-4aed-8ebb-ab5f37ae9836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_2bca5306-8c44-4ed3-9cf8-6ea0f7000dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68f6c70f-792c-454a-8d96-d015aa18c8a8" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_2bca5306-8c44-4ed3-9cf8-6ea0f7000dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2fe9ed07-16d5-4783-8f97-f9cb783cd5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68f6c70f-792c-454a-8d96-d015aa18c8a8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2fe9ed07-16d5-4783-8f97-f9cb783cd5ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fcd5249a-4299-4498-8609-3469ca81bcad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_561ff47b-d4a2-4888-a5a8-6de989753868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fcd5249a-4299-4498-8609-3469ca81bcad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_561ff47b-d4a2-4888-a5a8-6de989753868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_607f3390-ba88-4efc-9951-6743eef8db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fcd5249a-4299-4498-8609-3469ca81bcad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_607f3390-ba88-4efc-9951-6743eef8db0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54902769-9ead-44f1-bb77-96fcede733fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fcd5249a-4299-4498-8609-3469ca81bcad" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54902769-9ead-44f1-bb77-96fcede733fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_26291a20-b2a2-43a0-82cb-2d0214995f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fcd5249a-4299-4498-8609-3469ca81bcad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_26291a20-b2a2-43a0-82cb-2d0214995f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4bc2a71-6c7e-443b-8ffb-d32a21c6d2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bdbffca5-8b2d-45fb-867b-14aa2d3c2b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4bc2a71-6c7e-443b-8ffb-d32a21c6d2e4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bdbffca5-8b2d-45fb-867b-14aa2d3c2b75" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0508e1e-4da7-4d0c-80c3-f0f083b086ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4157d336-6773-4149-a4ca-fa59ce708194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0508e1e-4da7-4d0c-80c3-f0f083b086ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4157d336-6773-4149-a4ca-fa59ce708194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_07da3f92-cdc8-4850-bed1-52d7d0b9b0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0508e1e-4da7-4d0c-80c3-f0f083b086ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_07da3f92-cdc8-4850-bed1-52d7d0b9b0ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9859b75a-b5f6-42c2-a236-57f3e22cc0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0508e1e-4da7-4d0c-80c3-f0f083b086ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9859b75a-b5f6-42c2-a236-57f3e22cc0a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_db6aee03-cd60-45f3-9c6a-82f3340e1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_4cf961f4-aec6-48e2-a38d-d5163f0e75b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_db6aee03-cd60-45f3-9c6a-82f3340e1b33" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_4cf961f4-aec6-48e2-a38d-d5163f0e75b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_d5708d77-cba6-478f-b809-b853a8f09d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_db6aee03-cd60-45f3-9c6a-82f3340e1b33" xlink:to="loc_us-gaap_MarketableSecurities_d5708d77-cba6-478f-b809-b853a8f09d32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8ff8dba8-0442-4b70-b643-1151f5cb914d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_3342309c-fa83-4583-82a2-3d32c6ab72bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8ff8dba8-0442-4b70-b643-1151f5cb914d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_3342309c-fa83-4583-82a2-3d32c6ab72bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_3b44a3cf-07cb-4869-82f3-a0a7be1c9220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8ff8dba8-0442-4b70-b643-1151f5cb914d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_3b44a3cf-07cb-4869-82f3-a0a7be1c9220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4524991-9bb7-49ef-95eb-b4cc8e22e2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_e9ae25b7-1072-411e-a6cf-a0f80432e5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4524991-9bb7-49ef-95eb-b4cc8e22e2e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_e9ae25b7-1072-411e-a6cf-a0f80432e5c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_a4d5a486-03b3-4b6b-ba63-de70ecaaba7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4524991-9bb7-49ef-95eb-b4cc8e22e2e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_a4d5a486-03b3-4b6b-ba63-de70ecaaba7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ab9f72f4-6ea8-49c3-a4e9-71dfde1ff86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7737deee-2224-4a2a-8eda-f5b9e2bdca22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ab9f72f4-6ea8-49c3-a4e9-71dfde1ff86c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7737deee-2224-4a2a-8eda-f5b9e2bdca22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_dcf2d6dc-b635-4d56-a499-6cee51ec6779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ab9f72f4-6ea8-49c3-a4e9-71dfde1ff86c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_dcf2d6dc-b635-4d56-a499-6cee51ec6779" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0908a1a1-4600-4c61-aad1-8c7748ed4a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77b4d736-cd12-43db-98a2-84d20f342a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0908a1a1-4600-4c61-aad1-8c7748ed4a65" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77b4d736-cd12-43db-98a2-84d20f342a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_73a070c9-dffa-4440-82ce-6cfbb1fb64a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0908a1a1-4600-4c61-aad1-8c7748ed4a65" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_73a070c9-dffa-4440-82ce-6cfbb1fb64a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8962d7bd-d4cc-4b4f-99dc-9b3144493772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3328a005-b1bf-4c91-ba47-6eeafd515242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8962d7bd-d4cc-4b4f-99dc-9b3144493772" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3328a005-b1bf-4c91-ba47-6eeafd515242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding_13df5072-3a6e-49a8-88be-54c4181103d3" xlink:href="lsta-20240331.xsd#lsta_AccruedGrantFunding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8962d7bd-d4cc-4b4f-99dc-9b3144493772" xlink:to="loc_lsta_AccruedGrantFunding_13df5072-3a6e-49a8-88be-54c4181103d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ae1626f7-e084-4e4f-9cf5-90479dfffb27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8962d7bd-d4cc-4b4f-99dc-9b3144493772" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ae1626f7-e084-4e4f-9cf5-90479dfffb27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LegalSettlementCurrent_a67fbcab-7d2c-4ba2-be70-fb8a52231be1" xlink:href="lsta-20240331.xsd#lsta_LegalSettlementCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8962d7bd-d4cc-4b4f-99dc-9b3144493772" xlink:to="loc_lsta_LegalSettlementCurrent_a67fbcab-7d2c-4ba2-be70-fb8a52231be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities_5cf83cd3-837d-49a5-a7c1-b8864a135928" xlink:href="lsta-20240331.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8962d7bd-d4cc-4b4f-99dc-9b3144493772" xlink:to="loc_lsta_ClinicalAndRDRelatedLiabilities_5cf83cd3-837d-49a5-a7c1-b8864a135928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b5f6c06c-e943-4106-94f6-d1c47117836b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8962d7bd-d4cc-4b4f-99dc-9b3144493772" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b5f6c06c-e943-4106-94f6-d1c47117836b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_70b7060e-a98b-4dd1-b4e1-e476da5e3256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e7f227f3-8006-4b8b-90f8-4af07a9792f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_70b7060e-a98b-4dd1-b4e1-e476da5e3256" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e7f227f3-8006-4b8b-90f8-4af07a9792f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb100715-28cd-4b15-a91d-0b52379b97e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_70b7060e-a98b-4dd1-b4e1-e476da5e3256" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb100715-28cd-4b15-a91d-0b52379b97e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0bdcce41-7788-417f-98df-a7cec4f22c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e63607f7-2dc1-4b9c-97b2-f81c9ef37b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0bdcce41-7788-417f-98df-a7cec4f22c71" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e63607f7-2dc1-4b9c-97b2-f81c9ef37b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c57f4898-5f5b-4b5b-8c1c-c945d67bd418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0bdcce41-7788-417f-98df-a7cec4f22c71" xlink:to="loc_us-gaap_OperatingLeaseLiability_c57f4898-5f5b-4b5b-8c1c-c945d67bd418" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b3829711-d1a9-4fef-ab60-acb467158545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c30cb3ba-c6a3-4cfc-a261-4a2f21147135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b3829711-d1a9-4fef-ab60-acb467158545" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c30cb3ba-c6a3-4cfc-a261-4a2f21147135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4465b270-c1c2-4a24-a548-db833dc4cb90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b3829711-d1a9-4fef-ab60-acb467158545" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4465b270-c1c2-4a24-a548-db833dc4cb90" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lsta-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fe904bd3-4642-40bc-b4e0-ae39e52f235d,g:b327601d-86c0-41f4-b109-5b549ba09d67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4322977e-729e-4a7d-af0d-a1ce8c01c65a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_114a10ea-c718-4509-a360-b437fcb1ac7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4322977e-729e-4a7d-af0d-a1ce8c01c65a" xlink:to="loc_us-gaap_StatementTable_114a10ea-c718-4509-a360-b437fcb1ac7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7b78f958-1c64-4835-ac86-77305ca068a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_114a10ea-c718-4509-a360-b437fcb1ac7a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7b78f958-1c64-4835-ac86-77305ca068a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b78f958-1c64-4835-ac86-77305ca068a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7b78f958-1c64-4835-ac86-77305ca068a6" xlink:to="loc_us-gaap_EquityComponentDomain_7b78f958-1c64-4835-ac86-77305ca068a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7b78f958-1c64-4835-ac86-77305ca068a6" xlink:to="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:to="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f04ec27e-4547-4b56-926f-b73f192384cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_CommonStockMember_f04ec27e-4547-4b56-926f-b73f192384cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d68b77d5-ffc8-4b80-b859-e86a5b5f362d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d68b77d5-ffc8-4b80-b859-e86a5b5f362d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c2cd1f7-3469-4f94-8319-53823285c405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c2cd1f7-3469-4f94-8319-53823285c405" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c67c6110-1f1d-465e-baf4-9b41e4d6bcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_RetainedEarningsMember_c67c6110-1f1d-465e-baf4-9b41e4d6bcbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b3ce49dd-885b-492a-822e-ce5d1ff9ab3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b3ce49dd-885b-492a-822e-ce5d1ff9ab3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1d35111a-bd73-4334-a3c2-f81e573c436e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1d35111a-bd73-4334-a3c2-f81e573c436e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4322977e-729e-4a7d-af0d-a1ce8c01c65a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b17ab911-1a99-4286-97a4-e8a36aa28d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b17ab911-1a99-4286-97a4-e8a36aa28d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f400b04e-9a06-43ac-b9f1-2b37622dda9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f400b04e-9a06-43ac-b9f1-2b37622dda9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bff9c84d-1a88-46db-affd-fdb2d50d0c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_ProfitLoss_bff9c84d-1a88-46db-affd-fdb2d50d0c2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_627df7af-7464-46fe-92f3-12b907c658ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_627df7af-7464-46fe-92f3-12b907c658ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ac6e7abe-f09d-49e2-83f9-8bed2ce91e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ac6e7abe-f09d-49e2-83f9-8bed2ce91e1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7b3b3f33-605d-4add-8fd8-3dde72f05c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7b3b3f33-605d-4add-8fd8-3dde72f05c4a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f300145-5937-4037-93d0-d228409678c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f300145-5937-4037-93d0-d228409678c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_910d5f03-a066-4007-bb20-67272befd96e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0f5b3483-aef5-4c58-b6c3-19814f93eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_766ceb15-5d5e-48ad-bae8-88339820a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4da382f6-ada5-4fce-a339-fe6363deabcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_766ceb15-5d5e-48ad-bae8-88339820a4be" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4da382f6-ada5-4fce-a339-fe6363deabcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ba044c-85cf-439c-9b99-2c1cedf0cfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4da382f6-ada5-4fce-a339-fe6363deabcc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ba044c-85cf-439c-9b99-2c1cedf0cfe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15ba044c-85cf-439c-9b99-2c1cedf0cfe7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ba044c-85cf-439c-9b99-2c1cedf0cfe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15ba044c-85cf-439c-9b99-2c1cedf0cfe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ba044c-85cf-439c-9b99-2c1cedf0cfe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_08d2cfb8-cce1-4d42-a69d-21e9449ba5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_08d2cfb8-cce1-4d42-a69d-21e9449ba5a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7f063ee3-f4bf-428f-88f5-e911039f221f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:to="loc_us-gaap_ComputerEquipmentMember_7f063ee3-f4bf-428f-88f5-e911039f221f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_c250ac9a-0c4e-4059-a5a7-ad24e609074c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_c250ac9a-0c4e-4059-a5a7-ad24e609074c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bc51b97e-f4c4-491e-97ee-b49f2153df19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_766ceb15-5d5e-48ad-bae8-88339820a4be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bc51b97e-f4c4-491e-97ee-b49f2153df19" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4f6fe450-11eb-40a6-bd92-4a52484289cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6007d14-7b02-4285-bcbc-2a7cdf26013c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4f6fe450-11eb-40a6-bd92-4a52484289cc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6007d14-7b02-4285-bcbc-2a7cdf26013c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5e34d66-1a48-444d-8a8f-e767d55cdc4a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6007d14-7b02-4285-bcbc-2a7cdf26013c" xlink:to="loc_srt_ProductOrServiceAxis_e5e34d66-1a48-444d-8a8f-e767d55cdc4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5e34d66-1a48-444d-8a8f-e767d55cdc4a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e5e34d66-1a48-444d-8a8f-e767d55cdc4a" xlink:to="loc_srt_ProductsAndServicesDomain_e5e34d66-1a48-444d-8a8f-e767d55cdc4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5977dba-ba5d-44d2-bdec-5e204cb87546" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e5e34d66-1a48-444d-8a8f-e767d55cdc4a" xlink:to="loc_srt_ProductsAndServicesDomain_e5977dba-ba5d-44d2-bdec-5e204cb87546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_fd151d20-0eb4-49ea-9261-3857f54f4bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5977dba-ba5d-44d2-bdec-5e204cb87546" xlink:to="loc_us-gaap_RoyaltyMember_fd151d20-0eb4-49ea-9261-3857f54f4bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4108edeb-edfd-4552-a5eb-79190ddcc59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4f6fe450-11eb-40a6-bd92-4a52484289cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4108edeb-edfd-4552-a5eb-79190ddcc59e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_978dcccc-197a-48dc-9b20-d9a69a503697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_978dcccc-197a-48dc-9b20-d9a69a503697" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_978dcccc-197a-48dc-9b20-d9a69a503697" xlink:to="loc_us-gaap_FinancialInstrumentAxis_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7b9d1caa-ba67-48fd-927c-d701b6727862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7b9d1caa-ba67-48fd-927c-d701b6727862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b5b0310b-432c-4506-9e41-89ac87b783e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_CommercialPaperMember_b5b0310b-432c-4506-9e41-89ac87b783e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_39976656-d1b4-493a-9a2d-3cebd986745d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_MoneyMarketFundsMember_39976656-d1b4-493a-9a2d-3cebd986745d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_a5d1e874-4f3c-416f-944c-80d3642b3fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_a5d1e874-4f3c-416f-944c-80d3642b3fda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_13b03205-ba08-4637-b9e6-a2e3ca147805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_13b03205-ba08-4637-b9e6-a2e3ca147805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_db9e8cc7-a8f8-4898-8cad-9d78ac4a8d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_db9e8cc7-a8f8-4898-8cad-9d78ac4a8d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03152c87-fe48-49ca-8244-3d5c66aa7dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03152c87-fe48-49ca-8244-3d5c66aa7dd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_53a984a9-d86c-4691-9696-32c9d96a254e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_53a984a9-d86c-4691-9696-32c9d96a254e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84d9ebea-1d8e-448c-9ae6-f6dc0c8821c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84d9ebea-1d8e-448c-9ae6-f6dc0c8821c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ec7f63a-73b6-4e32-b770-1947d9af32e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84d9ebea-1d8e-448c-9ae6-f6dc0c8821c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ec7f63a-73b6-4e32-b770-1947d9af32e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ec7f63a-73b6-4e32-b770-1947d9af32e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ec7f63a-73b6-4e32-b770-1947d9af32e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ec7f63a-73b6-4e32-b770-1947d9af32e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ec7f63a-73b6-4e32-b770-1947d9af32e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_40cf4389-ed7d-407e-9919-c51574adc36e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:to="loc_us-gaap_ComputerEquipmentMember_40cf4389-ed7d-407e-9919-c51574adc36e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_36980823-01f0-4592-a6fe-c9de27315093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_36980823-01f0-4592-a6fe-c9de27315093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0d4bf1c4-6788-4c31-a30a-df7bb643c423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0d4bf1c4-6788-4c31-a30a-df7bb643c423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e2fc895a-f2c7-42ba-80d7-4ac1be632c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e2fc895a-f2c7-42ba-80d7-4ac1be632c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31b88967-a14e-4824-ad64-a1e29c91c350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31b88967-a14e-4824-ad64-a1e29c91c350" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f0e4362c-65ac-418d-956b-c8f4ee0d5189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_Depreciation_f0e4362c-65ac-418d-956b-c8f4ee0d5189" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#IncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cebbe17-ce61-44a4-927a-5f2fee31d472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_40782d6a-181d-4d0d-9a9c-fe24775783e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cebbe17-ce61-44a4-927a-5f2fee31d472" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_40782d6a-181d-4d0d-9a9c-fe24775783e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d701d373-9223-4eef-a52b-6408524f7ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_40782d6a-181d-4d0d-9a9c-fe24775783e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d701d373-9223-4eef-a52b-6408524f7ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d701d373-9223-4eef-a52b-6408524f7ddd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d701d373-9223-4eef-a52b-6408524f7ddd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d701d373-9223-4eef-a52b-6408524f7ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d701d373-9223-4eef-a52b-6408524f7ddd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a6ae09cb-c71c-419c-8c17-a721878322bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a6ae09cb-c71c-419c-8c17-a721878322bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_53529ebd-ba84-4219-8f49-724207ebc620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:to="loc_us-gaap_WarrantMember_53529ebd-ba84-4219-8f49-724207ebc620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_daa4981e-232c-4895-a1b9-ade2329c7457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_daa4981e-232c-4895-a1b9-ade2329c7457" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c376d92-5c2d-4066-ba0e-906d07c506ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cebbe17-ce61-44a4-927a-5f2fee31d472" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c376d92-5c2d-4066-ba0e-906d07c506ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83705997-83cc-490c-9aff-85ec0e591f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83705997-83cc-490c-9aff-85ec0e591f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83705997-83cc-490c-9aff-85ec0e591f25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83705997-83cc-490c-9aff-85ec0e591f25" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83705997-83cc-490c-9aff-85ec0e591f25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83705997-83cc-490c-9aff-85ec0e591f25" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b194ed5a-0319-45a0-ba37-e8997841f2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b194ed5a-0319-45a0-ba37-e8997841f2e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e78c76e6-ef33-4471-812f-49517bcf6f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e78c76e6-ef33-4471-812f-49517bcf6f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a0bf72aa-fd4f-47a8-837c-ae10cfb5d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a0bf72aa-fd4f-47a8-837c-ae10cfb5d3ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe293095-09dd-40b1-810a-4ee83e26a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe293095-09dd-40b1-810a-4ee83e26a0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b377f859-04ff-4d31-b778-d9e73bcde543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe293095-09dd-40b1-810a-4ee83e26a0d6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b377f859-04ff-4d31-b778-d9e73bcde543" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a68c9570-1329-4eec-8758-c2424a578212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a68c9570-1329-4eec-8758-c2424a578212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_caa64eb6-0ce2-42d0-8c6e-23f1fe0f9e00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_caa64eb6-0ce2-42d0-8c6e-23f1fe0f9e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9ae3943a-aa88-46c5-8bd5-e7db5ed4c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9ae3943a-aa88-46c5-8bd5-e7db5ed4c56c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0fe14745-61dc-44a7-8fd8-7456cbdbded7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0fe14745-61dc-44a7-8fd8-7456cbdbded7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fe14745-61dc-44a7-8fd8-7456cbdbded7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0fe14745-61dc-44a7-8fd8-7456cbdbded7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fe14745-61dc-44a7-8fd8-7456cbdbded7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0cbbb73-f9d3-4d14-adb7-6e685c8eb42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0fe14745-61dc-44a7-8fd8-7456cbdbded7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0cbbb73-f9d3-4d14-adb7-6e685c8eb42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember_1f2bbd62-3cf5-47a2-b436-35c69c5dec11" xlink:href="lsta-20240331.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0cbbb73-f9d3-4d14-adb7-6e685c8eb42b" xlink:to="loc_lsta_AtTheMarketOfferingAgreementMember_1f2bbd62-3cf5-47a2-b436-35c69c5dec11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_580685bc-88bc-46b7-a221-aa05393590e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_580685bc-88bc-46b7-a221-aa05393590e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_580685bc-88bc-46b7-a221-aa05393590e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_580685bc-88bc-46b7-a221-aa05393590e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_580685bc-88bc-46b7-a221-aa05393590e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7cbed2a1-952f-4820-8073-57e7c018e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_580685bc-88bc-46b7-a221-aa05393590e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7cbed2a1-952f-4820-8073-57e7c018e3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_084c4034-ff58-4f8b-b9bb-3ef21853890d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7cbed2a1-952f-4820-8073-57e7c018e3dc" xlink:to="loc_us-gaap_SubsequentEventMember_084c4034-ff58-4f8b-b9bb-3ef21853890d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2fd56bd9-374b-4922-910c-38616a7b472b" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2fd56bd9-374b-4922-910c-38616a7b472b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d3e552ca-bf28-4687-9406-cc2704b088d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d3e552ca-bf28-4687-9406-cc2704b088d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold_444efefa-8381-45c6-872f-08c03e0cd107" xlink:href="lsta-20240331.xsd#lsta_OutstandingStockThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_OutstandingStockThreshold_444efefa-8381-45c6-872f-08c03e0cd107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale_cf533229-dfcc-4846-93e1-237d8f9c4084" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_SaleOfStockAvailableForSale_cf533229-dfcc-4846-93e1-237d8f9c4084" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage_677d65c4-f163-4c76-8e1e-7ee7d676f493" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_SaleOfStockAvailableForSalePercentage_677d65c4-f163-4c76-8e1e-7ee7d676f493" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7163226-df08-4faf-b757-10cc2cb7d60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7163226-df08-4faf-b757-10cc2cb7d60c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b09b176e-95fb-4a13-a94e-4437528707e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b09b176e-95fb-4a13-a94e-4437528707e5" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityStockOptionsandWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_295d2810-03f3-44ad-bcb4-4a92060090fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_295d2810-03f3-44ad-bcb4-4a92060090fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b856f9a-231a-4a6d-92f7-65500b8c388c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:to="loc_us-gaap_AwardTypeAxis_7b856f9a-231a-4a6d-92f7-65500b8c388c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b856f9a-231a-4a6d-92f7-65500b8c388c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7b856f9a-231a-4a6d-92f7-65500b8c388c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b856f9a-231a-4a6d-92f7-65500b8c388c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f874bdf-01b4-48fa-b376-380b6f81f7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7b856f9a-231a-4a6d-92f7-65500b8c388c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f874bdf-01b4-48fa-b376-380b6f81f7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a9ec9832-4dbe-4f1f-9221-d6f3a2dbc1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f874bdf-01b4-48fa-b376-380b6f81f7ca" xlink:to="loc_us-gaap_RestrictedStockMember_a9ec9832-4dbe-4f1f-9221-d6f3a2dbc1a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6e5fd2d-b22b-4f81-971c-fe426f9186c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:to="loc_srt_RangeAxis_b6e5fd2d-b22b-4f81-971c-fe426f9186c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6e5fd2d-b22b-4f81-971c-fe426f9186c9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b6e5fd2d-b22b-4f81-971c-fe426f9186c9" xlink:to="loc_srt_RangeMember_b6e5fd2d-b22b-4f81-971c-fe426f9186c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b6e5fd2d-b22b-4f81-971c-fe426f9186c9" xlink:to="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3da892e-49ca-4919-94d4-fec3f7ed93fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:to="loc_srt_MinimumMember_f3da892e-49ca-4919-94d4-fec3f7ed93fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b5e3fc36-f14e-43ef-bdb8-b9700fe99e58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:to="loc_srt_MaximumMember_b5e3fc36-f14e-43ef-bdb8-b9700fe99e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0c89883-160f-4597-995b-858b4351db23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_295d2810-03f3-44ad-bcb4-4a92060090fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0c89883-160f-4597-995b-858b4351db23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44ae78f8-65df-4cc5-abea-77e7b46d33b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44ae78f8-65df-4cc5-abea-77e7b46d33b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_863d6dc1-f096-4ea9-82b6-1e5518d68b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44ae78f8-65df-4cc5-abea-77e7b46d33b9" xlink:to="loc_us-gaap_AwardTypeAxis_863d6dc1-f096-4ea9-82b6-1e5518d68b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863d6dc1-f096-4ea9-82b6-1e5518d68b04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_863d6dc1-f096-4ea9-82b6-1e5518d68b04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863d6dc1-f096-4ea9-82b6-1e5518d68b04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_863d6dc1-f096-4ea9-82b6-1e5518d68b04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_77ae3023-776e-4754-926c-7f5a62cc0815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_77ae3023-776e-4754-926c-7f5a62cc0815" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0171cfdf-13d9-431d-9730-9a34636c532c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:to="loc_us-gaap_RestrictedStockMember_0171cfdf-13d9-431d-9730-9a34636c532c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3435c8b5-2a8a-455b-9485-e28cfee5a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3435c8b5-2a8a-455b-9485-e28cfee5a6cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_6e2f8583-5862-4d45-92f7-e2e2c02711d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_6e2f8583-5862-4d45-92f7-e2e2c02711d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5769f858-c47e-4746-b267-dfc728a1c4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5769f858-c47e-4746-b267-dfc728a1c4e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31dbf21-b269-4921-a474-f4857f97f9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31dbf21-b269-4921-a474-f4857f97f9dd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6005f2db-711d-4f6c-b740-f00ea19aac28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6005f2db-711d-4f6c-b740-f00ea19aac28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d760337f-6069-4b9b-be6c-9105c313a181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6005f2db-711d-4f6c-b740-f00ea19aac28" xlink:to="loc_us-gaap_AwardTypeAxis_d760337f-6069-4b9b-be6c-9105c313a181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d760337f-6069-4b9b-be6c-9105c313a181_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d760337f-6069-4b9b-be6c-9105c313a181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d760337f-6069-4b9b-be6c-9105c313a181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d760337f-6069-4b9b-be6c-9105c313a181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b85b563e-6bfa-4f8b-b652-c55709692c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:to="loc_us-gaap_RestrictedStockMember_b85b563e-6bfa-4f8b-b652-c55709692c89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_41780032-a5c1-46a4-9280-3f5bec5f5e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_41780032-a5c1-46a4-9280-3f5bec5f5e3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67fa583a-880f-433c-814d-882587a61605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67fa583a-880f-433c-814d-882587a61605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d7ffe8c-e31f-4829-815a-a835de6a75d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d7ffe8c-e31f-4829-815a-a835de6a75d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_47bbb4e6-790b-4a27-8e4a-9e4a86fb26ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_47bbb4e6-790b-4a27-8e4a-9e4a86fb26ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24084e03-c230-454d-9aed-87923890b89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24084e03-c230-454d-9aed-87923890b89b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b4dabcc5-f067-499e-9892-817fcd56179f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0af212-52fb-4de8-b7bc-7c87ca3146eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0af212-52fb-4de8-b7bc-7c87ca3146eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57c1b673-4ca1-4142-9ae9-da6b4349abb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57c1b673-4ca1-4142-9ae9-da6b4349abb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_453e2573-9ab2-4d9b-95e1-7af6c9f931ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_453e2573-9ab2-4d9b-95e1-7af6c9f931ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23a65a88-bffe-40f9-98f6-e8b1934a2e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23a65a88-bffe-40f9-98f6-e8b1934a2e7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bfe9a9ec-a0b0-4fdc-8263-64280d625e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691a7be8-4b37-4d30-9bb4-a6848d86623e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ece0df7d-ff35-44b1-97a3-879caf0fff38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691a7be8-4b37-4d30-9bb4-a6848d86623e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ece0df7d-ff35-44b1-97a3-879caf0fff38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_562bc64c-8cf7-4276-b4a4-a5ef69fbf299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ece0df7d-ff35-44b1-97a3-879caf0fff38" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_562bc64c-8cf7-4276-b4a4-a5ef69fbf299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_562bc64c-8cf7-4276-b4a4-a5ef69fbf299_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_562bc64c-8cf7-4276-b4a4-a5ef69fbf299" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_562bc64c-8cf7-4276-b4a4-a5ef69fbf299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_562bc64c-8cf7-4276-b4a4-a5ef69fbf299" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5b6381ee-a20d-4c0f-878e-95c25de36c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5b6381ee-a20d-4c0f-878e-95c25de36c63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dccca4e4-0f35-4b51-b81e-f0ad6a52d8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dccca4e4-0f35-4b51-b81e-f0ad6a52d8d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ece745e1-1690-42c9-aba4-014d76c7c0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691a7be8-4b37-4d30-9bb4-a6848d86623e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ece745e1-1690-42c9-aba4-014d76c7c0aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0378ea08-c50c-4e65-9dde-c731477a215e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0378ea08-c50c-4e65-9dde-c731477a215e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_daa977c8-b56d-4203-b317-5c028140ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0378ea08-c50c-4e65-9dde-c731477a215e" xlink:to="loc_us-gaap_AwardTypeAxis_daa977c8-b56d-4203-b317-5c028140ddc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_daa977c8-b56d-4203-b317-5c028140ddc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_daa977c8-b56d-4203-b317-5c028140ddc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_daa977c8-b56d-4203-b317-5c028140ddc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_daa977c8-b56d-4203-b317-5c028140ddc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_be6d6521-0381-4804-821c-304b2cbbce76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_be6d6521-0381-4804-821c-304b2cbbce76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_16405873-08b8-454c-ae0d-e361e4578644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_16405873-08b8-454c-ae0d-e361e4578644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1157711e-c1a1-471a-b42e-884fac9358f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:to="loc_us-gaap_RestrictedStockMember_1157711e-c1a1-471a-b42e-884fac9358f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc8762f4-f8bc-48e5-b343-0fd9a7e4786a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc8762f4-f8bc-48e5-b343-0fd9a7e4786a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2fa2f04-dd1b-4957-a586-5e0168946f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2fa2f04-dd1b-4957-a586-5e0168946f0d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98346733-5270-4071-b0c6-641be0f8c7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98346733-5270-4071-b0c6-641be0f8c7bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91a5408c-476b-4816-9309-857a516b58ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98346733-5270-4071-b0c6-641be0f8c7bc" xlink:to="loc_us-gaap_AwardTypeAxis_91a5408c-476b-4816-9309-857a516b58ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91a5408c-476b-4816-9309-857a516b58ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_91a5408c-476b-4816-9309-857a516b58ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91a5408c-476b-4816-9309-857a516b58ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a75e8027-1856-4bdd-a662-0e39331fc002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_91a5408c-476b-4816-9309-857a516b58ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a75e8027-1856-4bdd-a662-0e39331fc002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a380c71-359f-4377-87cb-2a22ef4fb905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a75e8027-1856-4bdd-a662-0e39331fc002" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a380c71-359f-4377-87cb-2a22ef4fb905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_06e02ae7-ff47-4e56-8f85-9e27da3e8f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_06e02ae7-ff47-4e56-8f85-9e27da3e8f0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d85d2b4-8621-402c-b5cd-7ab3b9c957db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d85d2b4-8621-402c-b5cd-7ab3b9c957db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d1311860-d561-4209-a3a1-f11d00d097c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d1311860-d561-4209-a3a1-f11d00d097c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d1311860-d561-4209-a3a1-f11d00d097c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d1311860-d561-4209-a3a1-f11d00d097c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d1311860-d561-4209-a3a1-f11d00d097c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d1311860-d561-4209-a3a1-f11d00d097c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_69986fbd-36d4-48c7-b550-f33099ab56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:to="loc_us-gaap_DomesticCountryMember_69986fbd-36d4-48c7-b550-f33099ab56f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e36e4962-2f29-49f1-9180-703e65960969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e36e4962-2f29-49f1-9180-703e65960969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_daff5249-529a-4333-8232-2c361795297e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:to="loc_us-gaap_ForeignCountryMember_daff5249-529a-4333-8232-2c361795297e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_4510527f-4fb6-4d2c-b054-71a759d66272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_4510527f-4fb6-4d2c-b054-71a759d66272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_4510527f-4fb6-4d2c-b054-71a759d66272_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_4510527f-4fb6-4d2c-b054-71a759d66272" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_4510527f-4fb6-4d2c-b054-71a759d66272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_4510527f-4fb6-4d2c-b054-71a759d66272" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_bc26045f-67fa-48fc-ad97-f3d01a17ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_bc26045f-67fa-48fc-ad97-f3d01a17ad1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_ffff8512-a6e9-4830-8106-f6402bc6a7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_ffff8512-a6e9-4830-8106-f6402bc6a7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_a0bb3bca-8bc6-4297-9a5e-de1b47625a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_a0bb3bca-8bc6-4297-9a5e-de1b47625a15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a2862fdf-4025-4764-a36c-93267509702f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_dei_LegalEntityAxis_a2862fdf-4025-4764-a36c-93267509702f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a2862fdf-4025-4764-a36c-93267509702f_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a2862fdf-4025-4764-a36c-93267509702f" xlink:to="loc_dei_EntityDomain_a2862fdf-4025-4764-a36c-93267509702f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f8f9850-d82c-4cc6-b2c1-5cd41420207a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a2862fdf-4025-4764-a36c-93267509702f" xlink:to="loc_dei_EntityDomain_2f8f9850-d82c-4cc6-b2c1-5cd41420207a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_acbdb86b-51e7-48fa-9514-c00eafff9b3d" xlink:href="lsta-20240331.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2f8f9850-d82c-4cc6-b2c1-5cd41420207a" xlink:to="loc_lsta_CENDMember_acbdb86b-51e7-48fa-9514-c00eafff9b3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c5495ce4-202e-422d-8872-c6e0ca28909a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c5495ce4-202e-422d-8872-c6e0ca28909a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c5495ce4-202e-422d-8872-c6e0ca28909a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c5495ce4-202e-422d-8872-c6e0ca28909a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c5495ce4-202e-422d-8872-c6e0ca28909a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_72d739d1-207d-46e9-80fb-aab27398de95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c5495ce4-202e-422d-8872-c6e0ca28909a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_72d739d1-207d-46e9-80fb-aab27398de95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_5c6b6f75-e373-4c51-8ba8-4a5975fafee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_72d739d1-207d-46e9-80fb-aab27398de95" xlink:to="loc_us-gaap_ResearchMember_5c6b6f75-e373-4c51-8ba8-4a5975fafee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_9b05aa67-1674-4f92-a05e-7311d923a509" xlink:href="lsta-20240331.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_9b05aa67-1674-4f92-a05e-7311d923a509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1781885d-727f-4a6e-8d31-b0f5682145cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1781885d-727f-4a6e-8d31-b0f5682145cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_90fdd5ae-3ada-48ad-87cc-137f26cdfb24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_90fdd5ae-3ada-48ad-87cc-137f26cdfb24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs_488b4f1d-1ff8-401f-bafb-0814179ee1be" xlink:href="lsta-20240331.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_FairValueMarketOfTaxNOLs_488b4f1d-1ff8-401f-bafb-0814179ee1be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a279b3d7-29ce-45b8-b3b7-ae44109bbadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a279b3d7-29ce-45b8-b3b7-ae44109bbadf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_5c43cf8c-a437-4088-8f60-7729afaae535" xlink:href="lsta-20240331.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_5c43cf8c-a437-4088-8f60-7729afaae535" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition_64520c85-6b11-48a1-8663-9e9cd8f6ea03" xlink:href="lsta-20240331.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_OperatingLossCarryforwardsPostAcquisition_64520c85-6b11-48a1-8663-9e9cd8f6ea03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e6010604-e439-4850-a4b3-208ec129af96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e6010604-e439-4850-a4b3-208ec129af96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_728d7e6c-7294-452d-a6ba-b1089567ba2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_728d7e6c-7294-452d-a6ba-b1089567ba2c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_124bc285-add2-4c1a-943b-22bf2bef42cf" xlink:href="lsta-20240331.xsd#lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_124bc285-add2-4c1a-943b-22bf2bef42cf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS_d576f744-728f-46fd-a3de-90ef208899fe" xlink:href="lsta-20240331.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_ProceedsFromSaleOfNOLS_d576f744-728f-46fd-a3de-90ef208899fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c06d7b17-c704-4097-8c2a-6b82f338564f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c06d7b17-c704-4097-8c2a-6b82f338564f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL_f251709e-7bdc-44ef-9a35-a11a03c8494e" xlink:href="lsta-20240331.xsd#lsta_LossOnSaleOfNOL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_LossOnSaleOfNOL_f251709e-7bdc-44ef-9a35-a11a03c8494e" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AustraliaResearchandDevelopmentTaxIncentiveDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_2aa57451-d0a8-413e-a962-a7fed4d3dca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_2aa57451-d0a8-413e-a962-a7fed4d3dca3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55838743-989c-477d-81d1-08ed325a35b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_2aa57451-d0a8-413e-a962-a7fed4d3dca3" xlink:to="loc_srt_RangeAxis_55838743-989c-477d-81d1-08ed325a35b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_55838743-989c-477d-81d1-08ed325a35b0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_55838743-989c-477d-81d1-08ed325a35b0" xlink:to="loc_srt_RangeMember_55838743-989c-477d-81d1-08ed325a35b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_55838743-989c-477d-81d1-08ed325a35b0" xlink:to="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bc9ef81-1355-4448-a440-bda99afdcb81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:to="loc_srt_MinimumMember_4bc9ef81-1355-4448-a440-bda99afdcb81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56a539cf-9c6a-4f31-9485-e9d62259ef7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:to="loc_srt_MaximumMember_56a539cf-9c6a-4f31-9485-e9d62259ef7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f9f100ff-9205-4891-ad25-8462a3d1f2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f9f100ff-9205-4891-ad25-8462a3d1f2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable_efac3c03-e2aa-400e-9946-6428b3e4b447" xlink:href="lsta-20240331.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:to="loc_lsta_IncomeTaxIncentiveReceivable_efac3c03-e2aa-400e-9946-6428b3e4b447" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7753646a-232c-46f4-84cd-d03d99d3f99d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_us-gaap_LossContingenciesTable_7753646a-232c-46f4-84cd-d03d99d3f99d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3446c8d7-2418-4472-b63a-486f3af1e890" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7753646a-232c-46f4-84cd-d03d99d3f99d" xlink:to="loc_srt_LitigationCaseAxis_3446c8d7-2418-4472-b63a-486f3af1e890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3446c8d7-2418-4472-b63a-486f3af1e890_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3446c8d7-2418-4472-b63a-486f3af1e890" xlink:to="loc_srt_LitigationCaseTypeDomain_3446c8d7-2418-4472-b63a-486f3af1e890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1313149d-8062-4145-873d-9832c56cfbae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3446c8d7-2418-4472-b63a-486f3af1e890" xlink:to="loc_srt_LitigationCaseTypeDomain_1313149d-8062-4145-873d-9832c56cfbae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_58e4f165-41e8-4edd-9caf-6b9483748b56" xlink:href="lsta-20240331.xsd#lsta_LingmedLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1313149d-8062-4145-873d-9832c56cfbae" xlink:to="loc_lsta_LingmedLimitedMember_58e4f165-41e8-4edd-9caf-6b9483748b56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_423ac52f-11e0-496a-8e77-00595f557c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_423ac52f-11e0-496a-8e77-00595f557c8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementPaymentTerm_02d7c164-8cad-4963-a45a-f1ea49a8a38a" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_lsta_LitigationSettlementPaymentTerm_02d7c164-8cad-4963-a45a-f1ea49a8a38a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_33bfd884-c414-453d-992a-d97c68da59f7" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_33bfd884-c414-453d-992a-d97c68da59f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_7ff10ac4-5a10-4bae-9dfa-96250085d2e2" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_7ff10ac4-5a10-4bae-9dfa-96250085d2e2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#TechnologyTransferAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_21b24fe1-4de4-486a-a7a2-f89793785ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_21b24fe1-4de4-486a-a7a2-f89793785ab5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd5d4e09-da68-4977-a8ef-c298610f695e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_21b24fe1-4de4-486a-a7a2-f89793785ab5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd5d4e09-da68-4977-a8ef-c298610f695e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cd5d4e09-da68-4977-a8ef-c298610f695e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd5d4e09-da68-4977-a8ef-c298610f695e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cd5d4e09-da68-4977-a8ef-c298610f695e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_698cd1e0-61d6-4962-8050-841bf7b72c0c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd5d4e09-da68-4977-a8ef-c298610f695e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_698cd1e0-61d6-4962-8050-841bf7b72c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_350333b8-460a-4d13-9328-e12eea39803f" xlink:href="lsta-20240331.xsd#lsta_ImpiloMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_698cd1e0-61d6-4962-8050-841bf7b72c0c" xlink:to="loc_lsta_ImpiloMember_350333b8-460a-4d13-9328-e12eea39803f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3027d76d-3742-4644-9716-e4515823d1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3027d76d-3742-4644-9716-e4515823d1c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares_ad7c43b2-a3a7-4360-aa73-381fc677174b" xlink:href="lsta-20240331.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_lsta_InvestmentOwnedCanceledShares_ad7c43b2-a3a7-4360-aa73-381fc677174b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0a5fa041-946b-4d48-ad71-8b793a7b26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0a5fa041-946b-4d48-ad71-8b793a7b26bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_e7a8a208-34d8-466d-a3ff-cdbdba844cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_e7a8a208-34d8-466d-a3ff-cdbdba844cf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b54ee183-23ec-4aba-a3c7-b807a06a300f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b54ee183-23ec-4aba-a3c7-b807a06a300f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEValuationCap_9f83afdd-57cd-4853-8cdd-0ee89d1df222" xlink:href="lsta-20240331.xsd#lsta_SAFEValuationCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_lsta_SAFEValuationCap_9f83afdd-57cd-4853-8cdd-0ee89d1df222" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEDiscountRate_5f5d7054-6dd5-454a-b532-7e5778d183bc" xlink:href="lsta-20240331.xsd#lsta_SAFEDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_lsta_SAFEDiscountRate_5f5d7054-6dd5-454a-b532-7e5778d183bc" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cb1cb62d-78eb-4f06-a282-ab2647867d99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:to="loc_srt_CounterpartyNameAxis_cb1cb62d-78eb-4f06-a282-ab2647867d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb1cb62d-78eb-4f06-a282-ab2647867d99_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cb1cb62d-78eb-4f06-a282-ab2647867d99" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb1cb62d-78eb-4f06-a282-ab2647867d99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63b0cccc-ede8-4a4e-8d43-76168e8660e4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cb1cb62d-78eb-4f06-a282-ab2647867d99" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63b0cccc-ede8-4a4e-8d43-76168e8660e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember_38c5812a-74a1-4e04-a92a-54432ca3e482" xlink:href="lsta-20240331.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63b0cccc-ede8-4a4e-8d43-76168e8660e4" xlink:to="loc_lsta_SanfordBurnhamPrebysMember_38c5812a-74a1-4e04-a92a-54432ca3e482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a643c037-3667-49ce-b6bf-603ff3faa7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a643c037-3667-49ce-b6bf-603ff3faa7da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a643c037-3667-49ce-b6bf-603ff3faa7da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a643c037-3667-49ce-b6bf-603ff3faa7da" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a643c037-3667-49ce-b6bf-603ff3faa7da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e919f0b-b99c-4184-a81b-008b75961daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a643c037-3667-49ce-b6bf-603ff3faa7da" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e919f0b-b99c-4184-a81b-008b75961daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_da227193-16c2-410a-ad85-3a57cc83685e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e919f0b-b99c-4184-a81b-008b75961daf" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_da227193-16c2-410a-ad85-3a57cc83685e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85ba9156-9892-4674-a4b7-62bfe941365b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85ba9156-9892-4674-a4b7-62bfe941365b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_85ba9156-9892-4674-a4b7-62bfe941365b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85ba9156-9892-4674-a4b7-62bfe941365b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_85ba9156-9892-4674-a4b7-62bfe941365b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a158c33e-bbe3-4f32-a930-53919623e136" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85ba9156-9892-4674-a4b7-62bfe941365b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a158c33e-bbe3-4f32-a930-53919623e136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_ae52cf30-1164-44df-b443-a0db1d44ad52" xlink:href="lsta-20240331.xsd#lsta_ImpiloMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a158c33e-bbe3-4f32-a930-53919623e136" xlink:to="loc_lsta_ImpiloMember_ae52cf30-1164-44df-b443-a0db1d44ad52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement_b51c48dd-853c-4ba0-b5e4-c177b2fb3660" xlink:href="lsta-20240331.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_SharesIssuedUnderLicenseAgreement_b51c48dd-853c-4ba0-b5e4-c177b2fb3660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_b36e28c6-96c2-45f0-ad18-ac237120a133" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_b36e28c6-96c2-45f0-ad18-ac237120a133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_ef0fd99a-6a5a-4564-96d0-cff5952fa0cb" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_ef0fd99a-6a5a-4564-96d0-cff5952fa0cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_d8dbba42-1411-4efc-87be-a8174113f5b1" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_d8dbba42-1411-4efc-87be-a8174113f5b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_1ccb8af4-8aed-4a4c-b2ed-bdd96b7d7bfb" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_1ccb8af4-8aed-4a4c-b2ed-bdd96b7d7bfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_486f3f10-bd4d-4a98-8915-a52e8e2613c1" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_486f3f10-bd4d-4a98-8915-a52e8e2613c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_1b99dd43-11a5-499a-b89b-fcdf1ccfabc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_1b99dd43-11a5-499a-b89b-fcdf1ccfabc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty_150ca386-5778-4a49-b790-f36216cdbc11" xlink:href="lsta-20240331.xsd#lsta_SharesHeldByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_SharesHeldByThirdParty_150ca386-5778-4a49-b790-f36216cdbc11" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0de2eecc-594e-4126-9d0b-ec72113e0da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0de2eecc-594e-4126-9d0b-ec72113e0da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0de2eecc-594e-4126-9d0b-ec72113e0da8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0de2eecc-594e-4126-9d0b-ec72113e0da8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0de2eecc-594e-4126-9d0b-ec72113e0da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fe7cdd2-0623-4573-a8e6-cecd2ee26c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0de2eecc-594e-4126-9d0b-ec72113e0da8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fe7cdd2-0623-4573-a8e6-cecd2ee26c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_9c192d79-b945-4ba8-96e4-aac5524ff76a" xlink:href="lsta-20240331.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fe7cdd2-0623-4573-a8e6-cecd2ee26c49" xlink:to="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_9c192d79-b945-4ba8-96e4-aac5524ff76a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e05dbc5-abc0-418e-b94a-83e06791bae0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_CounterpartyNameAxis_7e05dbc5-abc0-418e-b94a-83e06791bae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e05dbc5-abc0-418e-b94a-83e06791bae0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7e05dbc5-abc0-418e-b94a-83e06791bae0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e05dbc5-abc0-418e-b94a-83e06791bae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae79f79-4417-417b-87b8-a768cee8c66f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7e05dbc5-abc0-418e-b94a-83e06791bae0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae79f79-4417-417b-87b8-a768cee8c66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember_08a7472b-38a6-47a6-966f-f5103cf036ae" xlink:href="lsta-20240331.xsd#lsta_QiluMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae79f79-4417-417b-87b8-a768cee8c66f" xlink:to="loc_lsta_QiluMember_08a7472b-38a6-47a6-966f-f5103cf036ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b4bdb651-d643-4375-8c58-66a11cd19e22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_ProductOrServiceAxis_b4bdb651-d643-4375-8c58-66a11cd19e22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4bdb651-d643-4375-8c58-66a11cd19e22_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b4bdb651-d643-4375-8c58-66a11cd19e22" xlink:to="loc_srt_ProductsAndServicesDomain_b4bdb651-d643-4375-8c58-66a11cd19e22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b2492dac-fbaa-40d8-82d8-887a2ce7ec28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b4bdb651-d643-4375-8c58-66a11cd19e22" xlink:to="loc_srt_ProductsAndServicesDomain_b2492dac-fbaa-40d8-82d8-887a2ce7ec28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_31cbc482-3448-4959-9b69-6fd1afc034c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b2492dac-fbaa-40d8-82d8-887a2ce7ec28" xlink:to="loc_us-gaap_LicenseMember_31cbc482-3448-4959-9b69-6fd1afc034c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_RangeAxis_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1" xlink:to="loc_srt_RangeMember_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1" xlink:to="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fef6a1be-a79a-495a-8cdb-489382b6fd33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:to="loc_srt_MinimumMember_fef6a1be-a79a-495a-8cdb-489382b6fd33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1820299-3981-40b2-9644-4116b39dbaa6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:to="loc_srt_MaximumMember_f1820299-3981-40b2-9644-4116b39dbaa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f95adc22-64e0-4f62-96ae-406357ced72c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_LitigationCaseAxis_f95adc22-64e0-4f62-96ae-406357ced72c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f95adc22-64e0-4f62-96ae-406357ced72c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f95adc22-64e0-4f62-96ae-406357ced72c" xlink:to="loc_srt_LitigationCaseTypeDomain_f95adc22-64e0-4f62-96ae-406357ced72c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0e311633-644e-4805-ae5f-0f7ae4b9394a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f95adc22-64e0-4f62-96ae-406357ced72c" xlink:to="loc_srt_LitigationCaseTypeDomain_0e311633-644e-4805-ae5f-0f7ae4b9394a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_92bdf582-f749-4128-8765-169935946604" xlink:href="lsta-20240331.xsd#lsta_LingmedLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0e311633-644e-4805-ae5f-0f7ae4b9394a" xlink:to="loc_lsta_LingmedLimitedMember_92bdf582-f749-4128-8765-169935946604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4f25e0c0-324b-45c7-bafb-fa1a36f9e2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4f25e0c0-324b-45c7-bafb-fa1a36f9e2c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_e24d478e-a889-4933-a84f-cf3dcd4b02e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_e24d478e-a889-4933-a84f-cf3dcd4b02e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_0c76c1e5-b8ec-4f21-b796-1e12d3ee1082" xlink:href="lsta-20240331.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_0c76c1e5-b8ec-4f21-b796-1e12d3ee1082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_75cade23-60c8-4f00-9dc9-25d05dc722a5" xlink:href="lsta-20240331.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_75cade23-60c8-4f00-9dc9-25d05dc722a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_65803511-eaea-4af3-b8c4-4ecd35eddcef" xlink:href="lsta-20240331.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_65803511-eaea-4af3-b8c4-4ecd35eddcef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_84539973-917c-46f2-80ef-c6e7f2243497" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_84539973-917c-46f2-80ef-c6e7f2243497" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_82cf3892-9e25-454a-97f0-01e36472b41f" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_82cf3892-9e25-454a-97f0-01e36472b41f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_6e24e7b3-86da-4559-b5f3-7b4f73700ac9" xlink:href="lsta-20240331.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_6e24e7b3-86da-4559-b5f3-7b4f73700ac9" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lsta-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fe904bd3-4642-40bc-b4e0-ae39e52f235d,g:b327601d-86c0-41f4-b109-5b549ba09d67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_3dcc8a24-cd2d-481b-85a0-23f94ed75d9c_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage held by non-affiliates</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_label_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale, Percentage</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAvailableForSalePercentage" xlink:to="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4ede667b-df22-497d-a5d1-5cc2f4be6513_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ea14f771-b29a-43ca-84ee-f3ed2aa3633f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_51cb49ee-17c3-4c70-81f1-4ebd55a9be8a_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6668793b-adcb-43f3-8ada-2b3e279f41e7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_06556bc1-eac8-4b40-ae81-cdde5091caa2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db92c192-a550-48d4-9a17-01a4fae67baa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_46fc0d1b-00ed-483f-bb58-08aee17f9a48_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_84735747-0a08-4d07-8091-1bf4bae04f45_terseLabel_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_Sharesvestedandexpectedtovest" xlink:href="lsta-20240331.xsd#lsta_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_Sharesvestedandexpectedtovest" xlink:to="lab_lsta_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_447501cc-8784-4d11-80c6-962f19473c06_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b7fac8e-b357-49d5-be42-e8c574e1da76_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fbddad87-6529-4596-b57c-9f101c2020cb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_72821b05-4a80-4859-8162-6a53be389058_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_026bd2f6-e32b-49b0-a66f-15a88d7aeb05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_074d0e6b-32fb-49e5-abd5-7e6cbb828c21_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e03d142a-d616-471c-8102-fe9896667e82_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f97abfae-7ae3-4e54-84d6-1d7ab710d06f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_94be6754-3052-452a-b753-647551cc749a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f905ea51-93b9-4265-9247-7073ad06dde4_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_74028a19-5edd-4894-bceb-35d12fe52dd2_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_015e0205-d855-4519-b836-5c48e96a0d65_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0c507ae3-4563-415b-a8eb-dafa6c4eeceb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a385f370-7b3c-4c49-96a3-f9c25e7dacbd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_a220e699-6273-41c6-a0dc-cbd5c6482091_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_642d69d0-140b-4c34-95f5-2ab3f909bfb6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_10446f47-a2b6-40af-97b8-dd126fbedc3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_93115753-cd47-4a90-a344-c00e7941ae10_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_773c5600-44ad-4aa1-8787-cbd4de1442ca_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_49d4c5b7-238a-493f-9cb1-649cd844bde1_terseLabel_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to terminate</link:label>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_label_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_documentation_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:href="lsta-20240331.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:to="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f7e571de-5863-42f9-9ccd-f4aa288c571a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_7a428d0e-a655-4f80-adaa-0df8c451b0a7_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f4284056-220e-4076-82f8-3f43c5e2bca5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_1fc1063f-f66c-420c-8de5-b5900345ab2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:to="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_01620b95-d562-4bff-b47a-05e5154ce9de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7eedeb8f-7377-4e1d-a1a1-b2ee71635d76_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_da3fed2f-c8ab-404a-adc6-37e2d564fdae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_cf736003-af87-4a20-a454-b27ac44707d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3f3f141b-467c-47fa-b3df-0c628ca0acf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d94401c4-70b9-49ca-8fef-8819030bfd88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_23e6a907-d08a-47ff-a46b-edc68f629606_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_b002e23b-f103-4935-b1ce-c4acf7e706a9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9c448be-7980-4c10-aeec-a6f7266f6097_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d59abda9-6166-4b26-9015-57f771f681d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_17eab082-f099-4cef-b9f8-66ed245ded8b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_983c60e3-2742-4c0b-9cb1-5c1034c69cab_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49b6e68d-5b84-444d-a7d3-2a3817134a17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_418f0a0a-5a3c-45fb-8963-d013f87e2f3a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities - available for sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_28818f33-7e37-43c9-8226-a1c4093082cd_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublicensing fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faad5654-94ec-47ea-aa45-1a907f94d8d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f94095f4-67e8-43d6-bb22-d1e520cc31d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average estimated fair value of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bfa879c7-5202-4e66-9882-39b0f7d2ee5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d4539d3f-145c-49dc-bbf1-3a9939373a17_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9558c0a5-cbe8-4596-b464-0f610daffc11_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_eaf9c67a-7194-4008-863b-6e5408018deb_terseLabel_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares canceled (in shares)</link:label>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_label_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Canceled, Shares</link:label>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_documentation_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Owned, Canceled, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares" xlink:href="lsta-20240331.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_InvestmentOwnedCanceledShares" xlink:to="lab_lsta_InvestmentOwnedCanceledShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f6bc8f72-e876-44a8-92d4-1a4bf1fc3f29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_734e0e50-051c-411e-b983-4260898c7e34_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SAFEDiscountRate_6cb6776a-3b8c-4531-82fc-c3ed21e30b40_terseLabel_en-US" xlink:label="lab_lsta_SAFEDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAFE, discount rate</link:label>
    <link:label id="lab_lsta_SAFEDiscountRate_label_en-US" xlink:label="lab_lsta_SAFEDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAFE, Discount Rate</link:label>
    <link:label id="lab_lsta_SAFEDiscountRate_documentation_en-US" xlink:label="lab_lsta_SAFEDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAFE, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEDiscountRate" xlink:href="lsta-20240331.xsd#lsta_SAFEDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SAFEDiscountRate" xlink:to="lab_lsta_SAFEDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c506a733-7190-4f98-bd83-4753e87d5377_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_dafbf7b8-3ddf-4022-a696-743618593256_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d72b235e-3093-428c-a3b0-9acc45e82310_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_9eb354a9-bc32-4ca9-8f18-6c1ff98e8f3d_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4fe86aa0-d1da-4f41-9bbe-f5b6eeb93129_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a3ca46ed-5a8c-40b2-949e-6e721fa04030_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_62dc0582-5cf9-43d1-9690-3f46612ba74a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7ab5c7f5-c52f-4db3-9da2-d03d315aac14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_7efe82ee-ee41-408b-849e-53e9f6df5856_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual license maintenance fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_144aafc3-3ffb-46aa-839e-cb7901058831_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_88649d13-5fe8-4091-8023-c1ec7552df8d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Compensation Cost Related to Nonvested Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_df83cc2e-2c36-48c2-97a8-a8c4b21e78d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8b429a8c-a1ec-4bd1-a43f-05078b1d4b91_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2f9f1b10-46ec-4d04-b530-4b749f26c464_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_45321140-0de9-4399-82a7-469acaa68c09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_23c35494-5001-474e-8dfa-2d76e5bcb3e4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ccde3f8c-126b-4f33-b2ae-f3d0e967b8ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_1a8511ab-a28e-48f0-a4d9-c7d249603f51_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e9772ec-20c5-47d1-a98a-d77a0663bc11_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_87b56e7a-e607-435f-9ce2-2da86e1b469c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_80ef6573-d991-4ef5-9f4d-8dcd78f3c5f9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8bd647a8-0197-4b8c-bf2e-145ffb4ce679_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_950317cf-a53b-4504-8270-83bf05931837_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available for sale securities - net unrealized loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f505fc24-6e0a-47ab-8279-7066f640aa4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_0c8c96a9-3b58-43b4-886f-dac6a39f0c0f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a4bf6f91-74a7-4053-bd05-5fdc70287dc0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_cc578918-1b73-41ee-9951-afa96bc00703_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5a3e8402-f664-4e73-9de8-c9efe4ff01b6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_074db056-bb11-4af9-a16f-3cbc2a431b50_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_e1b80664-3de9-4bd7-86c1-f36e3d3529bc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_dafedea9-97f9-492b-92c4-a8b33177833b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecf96524-dbb2-4397-9491-e9e1f26a4f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ac2c27df-dcc5-4a79-b4f8-fb17bc91bd9c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1c45c015-1c56-4879-b245-f94fd7cc4aa6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_TechnologyTransferAgreementAbstract_label_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement [Abstract]</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementAbstract_documentation_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract" xlink:href="lsta-20240331.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract" xlink:to="lab_lsta_TechnologyTransferAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_92e837a1-6b61-46b0-b71e-8888f68e7ee0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_eb162840-69f8-4972-9f7f-67cbd1f853d0_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_374c997b-7354-4202-bbf8-aa755b14118b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b1bcf2b5-3aac-4aba-b141-27202aa35628_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d77584d1-5ae8-4f32-b20c-5f0702d4f8a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_22366de1-f17b-4bbc-8620-732fda7b4fa7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_157ef27e-72a2-404d-a32f-f5f3aef89f06_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_98a613dd-b9b1-4d43-808e-2d4776a76a41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_03de217b-9346-4f00-b4e6-9a9d1b56ec12_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4538024d-8909-4cbf-a313-8572a24b9d68_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12e4ea45-876d-46e2-b349-bc96f2061add_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fddce864-e6ae-4a93-82d5-688c7a05aff9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_533d4664-e714-4739-a48a-edfad98b57fb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a69b22d2-ccf6-4b2b-9bf5-1f1d9196a2d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SharesHeldByThirdParty_02240a9d-4877-4023-8fc1-bf9bcdf2a25a_terseLabel_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares held by third party (in shares)</link:label>
    <link:label id="lab_lsta_SharesHeldByThirdParty_label_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:label id="lab_lsta_SharesHeldByThirdParty_documentation_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty" xlink:href="lsta-20240331.xsd#lsta_SharesHeldByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SharesHeldByThirdParty" xlink:to="lab_lsta_SharesHeldByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7ab56f0-c713-46ca-994e-4c23c0460574_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5156922a-4463-43d4-b820-f043407370f4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8d3721aa-5abf-4ecb-9cda-ec1c2007ccf8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_be3cc225-1f09-4834-8d4d-d532823c6ff9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_4df4b3ed-0a6b-4d19-b5f4-12bace2abf6c_terseLabel_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax incentive receivable</link:label>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_label_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Incentive Receivable</link:label>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_documentation_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Incentive Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable" xlink:href="lsta-20240331.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_IncomeTaxIncentiveReceivable" xlink:to="lab_lsta_IncomeTaxIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_200cd4c2-2e0d-40ad-9db4-1ff705a5ae7f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected amortization, remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_aff9ace8-061a-4fa4-ada7-1908efa2198e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e13731bc-c8f1-439c-b2ea-a1532defb74b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1172d405-535a-4d00-84c3-1a94eaf75787_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_80cd2df2-bb52-4412-a597-940b7e1d630c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_79d7a385-5bc6-4b57-ad17-c46aa23463d8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_39d017f8-1681-4dfb-bbaa-6507e476d475_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_15f74076-1e3f-4c8b-8df4-acd45655d078_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_e4e76551-9767-47c8-8ab4-d2f3a95faade_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bae8825a-f98f-4c23-b0bf-458e8a64dd18_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities &#8212; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b6a48524-f671-4303-8084-03a616755fb7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_f9027112-f7d6-44ca-aa31-07a8bb7a0b10_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_eea80f72-33c4-4e86-97b7-4db4b52450a3_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsGranted_0a00a195-e664-45e3-852b-c930f37b5b6f_terseLabel_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Granted (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsGranted_label_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_lsta_WarrantsGranted_documentation_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsGranted" xlink:href="lsta-20240331.xsd#lsta_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsGranted" xlink:to="lab_lsta_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_6e018557-2150-45f9-bd61-9bb1a87c28ee_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_dc81386f-555e-4353-8128-8077b2d4a1c5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2aa80ed6-b499-4cf0-b94b-70139c6d6e19_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ed560d25-634c-437c-8797-8b77bfe56f33_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1ccaf696-e902-4a6c-b086-37a399920bd4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired license - intangible, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_26fd03bf-d116-4ee7-9b1f-7c015850aaf2_periodStartLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_fc689661-deb7-471f-ae0a-8ab241458553_periodEndLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_07069cc0-a189-410c-b7de-984af249f30b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4a8c128-80b4-47c0-84a7-f7778c93db65_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09f92e15-1878-4f90-a22c-15a866b1db2a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_158eadb7-c608-4649-b140-e9d11dc6c7a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_86cf02cb-922a-448e-af7c-50117cf3e816_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2dcea48b-43cc-4249-82bb-404f6645b928_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d0583f4d-3848-41c1-8a25-a5a1053003ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Share-based Compensation Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_a7c5d627-dcc4-472a-a8f4-da12e7cf183f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5941af28-dfa3-4efe-91c0-8fb3cf46b020_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b3939e25-4efe-4904-a644-4455a9a54c26_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1bcf559f-f004-4d1d-a251-00f733d99113_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_23bee746-a691-4ba6-b99d-fbb0e92f00a8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d8796ba-c43e-454d-97cf-e82e2d024cad_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_44a113c0-9380-4c43-b3da-26609b26db73_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6a90a2cd-e034-48f0-8e0a-cd089ba7d28c_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0146c793-2179-48ac-b189-410816efd77c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_fb72dd46-8c09-43be-a897-723c59f40a3c_terseLabel_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Assets:</link:label>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_label_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset [Abstract]</link:label>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_documentation_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:href="lsta-20240331.xsd#lsta_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_815c52bc-dc5e-4445-a931-eeeb158f28c1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_334cc140-fd13-4ec8-8f77-2b3191b632d0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_577bf3ac-1062-43ef-9fa8-92003bedb128_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52276196-a029-44e7-b356-0554ed079bf1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_e378a53c-0c84-4fde-8e1b-1dfe98f808c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_527ddba6-df8e-4228-980f-fa94ae191393_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_55d5cf3e-43cc-4248-a025-6bf81c229526_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_67751a8a-adf2-459b-9739-521b70b88199_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_584961c3-447c-44c0-bf8b-c47d284780d9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_391cbb5e-f610-44bc-9adf-d836bc8bb64a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_57b4cdf9-a0a2-48ee-8f1d-b1c98415212d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_0d8856e0-fd9f-406b-86a8-dea0e7518e02_terseLabel_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exclusive License and Collaboration Agreement</link:label>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exclusive License and Collaboration Agreement [Member]</link:label>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exclusive License and Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:href="lsta-20240331.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:to="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e105dd36-c46f-4924-acf1-15a9495c3dfe_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f3064f6a-b502-4fcb-ac46-6d5d2f36efc7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1c3a5f0f-b501-44e0-9ea0-9fe8c0848627_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de00e43b-29c4-4c14-9c66-c2b307c852db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_90a4b474-061a-416e-a379-5d82dc103c1b_terseLabel_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, post acquisition</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_label_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_documentation_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:href="lsta-20240331.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:to="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_63f00df4-1f02-4ccf-8b9c-3a9fdf3937d6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_f79500c7-b5db-401f-ae4a-4bfb0e7c5f8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_15101722-7450-4fd7-942c-2823563d3b69_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_64daaf35-26f9-46d8-9f03-5e21cfad928f_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="lsta-20240331.xsd#lsta_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_07f0961d-adf3-46e1-a052-995d44f7c866_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8981b20c-f8d6-4fe7-a2a6-c6ce3975c3a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3735e7ac-e7df-4022-a112-7629751eb623_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7c64983b-2568-4534-9e73-9423ef14a67d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_85c91e7d-90c7-4e61-aa1f-07ce2964081a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_4ec05844-520d-4698-8b0e-9ec367b88f01_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0fee58a6-08a8-4eef-9450-65a17e26af13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e108a675-4b1a-490a-9369-009df068962f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1d9e39f3-da25-4184-985b-e4fd682f5d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9321db95-58d7-47b3-9d3b-181ae35577a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_556fb737-23b9-4ad4-b4cf-9d103f8e30ec_terseLabel_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember" xlink:href="lsta-20240331.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AtTheMarketOfferingAgreementMember" xlink:to="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_193164c7-dd17-46f0-88ff-a83855a6805f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53c6b288-715e-4d7e-baeb-e9e1b7748c4d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b1bc0400-f8d6-4571-872e-299fffd35c4e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_28726d47-2cb7-4995-9626-4b7095f2e48a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CommonStockWarrantsShares_c652b53b-96d7-46a3-9a18-a13fba3c93c2_periodStartLabel_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_25359a7b-9cf8-4584-aebf-af6db97d83eb_periodEndLabel_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_label_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares" xlink:href="lsta-20240331.xsd#lsta_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CommonStockWarrantsShares" xlink:to="lab_lsta_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c5586bcb-6a2f-432b-aa09-fee75ce8da87_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a5f4a4d2-7e94-4213-8030-24b471154234_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1c7ae07f-3892-468b-ad85-2f2419775c2e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e0bb7eac-b9ce-44f9-ab1d-9aec27c33673_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_54abafc1-650e-407b-a112-2d0afd4da581_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fc95d696-32e4-4d15-be98-5428d57827e6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LitigationSettlementMilestonePayment_ae81c0cd-4bd0-494f-8bc7-a961765b9a58_terseLabel_en-US" xlink:label="lab_lsta_LitigationSettlementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, first milestone payment</link:label>
    <link:label id="lab_lsta_LitigationSettlementMilestonePayment_label_en-US" xlink:label="lab_lsta_LitigationSettlementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Milestone Payment</link:label>
    <link:label id="lab_lsta_LitigationSettlementMilestonePayment_documentation_en-US" xlink:label="lab_lsta_LitigationSettlementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LitigationSettlementMilestonePayment" xlink:to="lab_lsta_LitigationSettlementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_87a31173-75d1-4751-a58f-e274895c8757_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_0edece22-3d12-458b-838a-ca5acc2ea707_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Lisata Therapeutics, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_a6602beb-93d5-4ae2-9cfc-39887952c480_terseLabel_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL annual limitation</link:label>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_label_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Carryforward Operating Loss Carryforward Annual Limitation</link:label>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_documentation_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Carryforward Operating Loss Carryforward Annual Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:href="lsta-20240331.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:to="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c831bbf9-e0b3-468e-9e9e-b665a47476dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba215fb7-88e4-46ab-aa41-e0a4486ad99d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_30a8f125-2799-4d51-ba97-f8ad72b7633c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_878368df-eb91-4599-951d-81df7db1164c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91ec1e7d-5990-4f87-85c3-171ec37d7954_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0a66bda9-7f9f-4439-9b52-155335cf1070_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c9dcdfa5-8de7-424d-8fca-78d8bae88085_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_02a5cdd4-b257-4cb5-81b0-6a4e3fc59d63_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_EPSAbstract_eb8ae0b4-8acd-4cc3-b73d-81223d2737fe_terseLabel_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_lsta_EPSAbstract_label_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EPS [Abstract]</link:label>
    <link:label id="lab_lsta_EPSAbstract_documentation_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_EPSAbstract" xlink:href="lsta-20240331.xsd#lsta_EPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_EPSAbstract" xlink:to="lab_lsta_EPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f76fd14e-71ab-4732-8332-d315a7af9b83_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_94cc0c59-6a98-4d48-9805-d1776f3bcc00_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_877be1a0-36c2-4d28-bdfd-41b61b70079d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Holiday [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Holiday [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayTable" xlink:to="lab_us-gaap_IncomeTaxHolidayTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7c20fe85-ea91-498f-8f66-225b3e50e756_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_33dc5216-728b-4d1b-9122-75eba0dae205_terseLabel_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_label_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Other Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsOtherDisclosuresAbstract" xlink:href="lsta-20240331.xsd#lsta_WarrantsOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract" xlink:to="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c698aed9-ec52-429f-9729-f0bb5a788cc3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8b87dfd8-7192-4113-9cc4-3412506a1167_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected amortization, year one</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_57fdd480-4ac3-441a-b2a8-f5f47c68dad3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_dba988f0-afbb-4b5b-b6e1-7eeb2c260f59_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ff612c7f-be19-43c2-8639-6d2adbc21003_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b5884e72-1651-453a-95df-c20956d00dc6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_076cea89-897f-4857-88f1-467600ff4c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5997ab92-a5e8-4f49-956c-68353599ee56_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e2163944-6c0d-49e1-b218-cd82df527965_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_caa5ce36-7d1b-40a9-8171-460cbecb14c3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_c77860f7-baac-4a8f-838a-404a245c27ab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c0233266-fd36-4ebf-8027-f24179fa72ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_6bd581c0-d561-4b08-8e40-a8347d894d63_terseLabel_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_label_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement [Text Block]</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_documentation_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementTextBlock" xlink:href="lsta-20240331.xsd#lsta_TechnologyTransferAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_TechnologyTransferAgreementTextBlock" xlink:to="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bacb8590-fd60-4ecb-a04e-8046b0cf94de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_28878f02-4090-4bd5-ad78-d9e881f93996_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9d286594-2e19-4448-9513-6c22f1cebd7d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_87d6e90b-5098-4b89-b78f-085e84126af0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3a86f4d3-f15a-4d0d-9de7-c4b2c2f395b1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_3be38514-b762-4756-b1b7-f6afa7315dad_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_ff7ca5ce-2097-42a5-9d21-dda2a34937e7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_52249f9a-8fd3-4a87-aca6-07024ad88125_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d92721c-da76-4930-b52c-b88f73f3d5a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_2606a07d-a846-4b86-b1c8-fb35365d7f9a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d7599908-b1e0-49c7-9c60-d6da41c8acb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3dafd7ad-96b0-469e-9083-63e8f330021b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent_a362dd27-95cb-4b9d-9e53-186222960d7a_terseLabel_en-US" xlink:label="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, future milestone payments</link:label>
    <link:label id="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent_label_en-US" xlink:label="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Future Milestone Payments, Percent</link:label>
    <link:label id="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent_documentation_en-US" xlink:label="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Future Milestone Payments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:to="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1186f561-1d9a-4a8c-a81d-f0686a16148c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8291690-f897-484d-adf7-863fcda76e34_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_741b6d00-5ec5-437b-8429-43df744bc344_terseLabel_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under license agreement (in shares)</link:label>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_label_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement" xlink:href="lsta-20240331.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SharesIssuedUnderLicenseAgreement" xlink:to="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ae1b5c81-b6e7-49b0-bbd4-741cd15b5229_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_430950d9-cfb8-4498-8ff3-1705931d8bcd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_e9ff7a36-dbf4-4d5e-baa9-f480b25c0714_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock available for sale</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_label_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAvailableForSale" xlink:to="lab_lsta_SaleOfStockAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_a4a812ad-9b66-4878-b862-5595392e3f5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_c191a2fa-2ca8-425d-bbcf-ceda31f99132_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_fa03ecd8-65b9-4c98-a099-4b1cc857ddad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c63d3d27-8d60-43a0-a7a2-55708416a4b6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b4b289b8-e6c1-48c6-a235-b3d6b766b4fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, noncurrent, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_aea0862c-f600-4dc7-bc74-b63e4d61189c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_f9038b99-7d52-436d-93fc-bb6f5d16c1df_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual license maintenance fee, year seven</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_7c63e5b3-cd51-42d6-a0d3-585d3f0fa3e8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SAFEValuationCap_c0fdf7de-83e9-4a81-9e5a-8599fafd5775_terseLabel_en-US" xlink:label="lab_lsta_SAFEValuationCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAFE, valuation cap</link:label>
    <link:label id="lab_lsta_SAFEValuationCap_label_en-US" xlink:label="lab_lsta_SAFEValuationCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAFE, Valuation Cap</link:label>
    <link:label id="lab_lsta_SAFEValuationCap_documentation_en-US" xlink:label="lab_lsta_SAFEValuationCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAFE, Valuation Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEValuationCap" xlink:href="lsta-20240331.xsd#lsta_SAFEValuationCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SAFEValuationCap" xlink:to="lab_lsta_SAFEValuationCap" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LossOnSaleOfNOL_900d8d5c-f456-4c40-bfee-f09cde2845ef_terseLabel_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of NOL</link:label>
    <link:label id="lab_lsta_LossOnSaleOfNOL_label_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Sale of NOL</link:label>
    <link:label id="lab_lsta_LossOnSaleOfNOL_documentation_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Sale of NOL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL" xlink:href="lsta-20240331.xsd#lsta_LossOnSaleOfNOL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LossOnSaleOfNOL" xlink:to="lab_lsta_LossOnSaleOfNOL" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_57066126-ac15-4899-91a4-198fbea44ad4_terseLabel_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of NOLs, gross</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_label_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_documentation_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:href="lsta-20240331.xsd#lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:to="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_787efed9-e48c-4884-8e2b-d39b914c412a_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_c44270a5-d46e-4857-baab-3ff6e222aa02_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_05628ddf-9285-4bc1-a213-b416ab97a252_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7c214269-98d6-44d3-a488-b4cbc3d86871_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_12987b90-3550-4f9e-829e-ab560f87a75b_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Exercised (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a1fe4f22-9f9e-4044-9703-c5036740b874_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2e8b3fe4-c92c-49aa-a176-9cd91edcc635_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_467388ef-8978-4759-9129-c357e59e08d6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4e7c246a-bb36-4682-9001-3d1c05c497cb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_13f4fa6d-c220-4aba-be81-c202a3150b8b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9c1ebfb9-59dc-4578-baf0-3eec97fab2ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm_e9f5ebd0-934e-4d08-842d-db4679fe70d3_terseLabel_en-US" xlink:label="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:href="lsta-20240331.xsd#lsta_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:to="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsExpired_e48d06a8-6824-4c30-9ffd-a47bae314c7a_negatedTerseLabel_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Expired (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsExpired_label_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_lsta_WarrantsExpired_documentation_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExpired" xlink:href="lsta-20240331.xsd#lsta_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsExpired" xlink:to="lab_lsta_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8517f9eb-bf0e-4c30-af98-96d7fd9dd17a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average estimated fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_76877810-0661-4eac-8115-ee42c421073b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsExercised_e2fac377-f486-438e-9407-b6fd69896895_negatedTerseLabel_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Exercised (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsExercised_label_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_lsta_WarrantsExercised_documentation_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExercised" xlink:href="lsta-20240331.xsd#lsta_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsExercised" xlink:to="lab_lsta_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6238d474-308e-4eea-a89a-1ba26b3cf048_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ccfccf78-5b74-4637-8d4b-9803a6eb2bfd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ImpiloMember_97d3db7e-3edd-4b05-9fc0-239e0cc426d1_terseLabel_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impilo</link:label>
    <link:label id="lab_lsta_ImpiloMember_label_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impilo [Member]</link:label>
    <link:label id="lab_lsta_ImpiloMember_documentation_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impilo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember" xlink:href="lsta-20240331.xsd#lsta_ImpiloMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ImpiloMember" xlink:to="lab_lsta_ImpiloMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_5a56b284-e1ca-4f1a-838a-c7a520136139_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_820c58a8-1d90-4485-963a-2ec51052cbc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in Impilo Therapeutics</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_f48c61c6-c960-4e6e-864e-09728adb2875_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire Impilo SAFE</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fcc5dca2-97ea-4933-9f62-dbe1501a0939_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4caec3aa-43ee-4ffb-b18b-12c5bafda45f_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_3aa63184-dd5e-4122-a3b2-cc42b378e31b_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties, net of sales</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ac314f53-7875-4ef0-bdd8-0b4eef2af656_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c4e4a65e-fd04-4a09-aab1-5826a09bcdb1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Lisata Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_01dcb1d2-af73-4685-8b29-67aa27a30c66_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsVested_790ba066-6e0b-471d-acb2-301e4a14c21d_terseLabel_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsVested_label_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_lsta_WarrantsVested_documentation_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsVested" xlink:href="lsta-20240331.xsd#lsta_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsVested" xlink:to="lab_lsta_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b94215ea-4d82-4296-aa3b-b40a0991ead8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6f1e40e-bf90-4aaf-bf5b-ccea5fde4768_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f8ab4ea0-9add-412c-a949-7c6aaf03d4eb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LingmedLimitedMember_08e27422-075c-4803-9712-5ce526d3faa4_terseLabel_en-US" xlink:label="lab_lsta_LingmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lingmed Limited</link:label>
    <link:label id="lab_lsta_LingmedLimitedMember_label_en-US" xlink:label="lab_lsta_LingmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lingmed Limited [Member]</link:label>
    <link:label id="lab_lsta_LingmedLimitedMember_documentation_en-US" xlink:label="lab_lsta_LingmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lingmed Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember" xlink:href="lsta-20240331.xsd#lsta_LingmedLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LingmedLimitedMember" xlink:to="lab_lsta_LingmedLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5ecfb1c7-fca3-42e7-8109-2a2ab5ed6fd6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative translation adjustment arising during the period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_baf3f7f4-2703-40d8-88ea-89604becc679_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_88019c57-863b-4a68-9bab-f50c3eb0196d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_dd4311da-8f29-486d-91c6-e1a79df02ae2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4a20ed39-88b3-47c0-b2bf-05b9ae8c75dc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before benefit from income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_BusinessTextBlock_7448eb4f-3a19-4d2b-b851-3419b1ee479a_terseLabel_en-US" xlink:label="lab_lsta_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Business</link:label>
    <link:label id="lab_lsta_BusinessTextBlock_label_en-US" xlink:label="lab_lsta_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:label id="lab_lsta_BusinessTextBlock_documentation_en-US" xlink:label="lab_lsta_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_BusinessTextBlock" xlink:href="lsta-20240331.xsd#lsta_BusinessTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_BusinessTextBlock" xlink:to="lab_lsta_BusinessTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_82ecea16-932b-49e2-8f53-e2efc1856cca_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_338e720f-298d-41d2-af02-1b8fbaaedb57_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_740cea26-af32-4e93-9cec-c38f8b6de227_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8c72b2a8-bf7e-496d-aada-2b1a82ea3fc6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_87d69768-886f-46d6-a3fc-02f5f0605d87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested_f9e2e96d-6769-4d72-ac99-e04137e7973c_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_70cef2ee-4433-4359-b0ce-baf31e70356f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_03c34282-609e-4d24-bfaf-b0df0490306d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0d14e38e-5d07-486a-9851-20431a88d283_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_c8e380f0-ecd6-49be-8a2f-3dafced1ea22_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d476fa72-05f3-4566-af6c-bb5acbb6ae0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_c6479958-a314-4e0e-89e0-2cf73bdda06d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less - net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_39ce993f-7123-4f6a-9fe9-e51b533a05fc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LitigationSettlementPaymentTerm_427aaece-5a2a-404b-913e-bfa165c9ee92_terseLabel_en-US" xlink:label="lab_lsta_LitigationSettlementPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, payment term</link:label>
    <link:label id="lab_lsta_LitigationSettlementPaymentTerm_label_en-US" xlink:label="lab_lsta_LitigationSettlementPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payment Term</link:label>
    <link:label id="lab_lsta_LitigationSettlementPaymentTerm_documentation_en-US" xlink:label="lab_lsta_LitigationSettlementPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementPaymentTerm" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LitigationSettlementPaymentTerm" xlink:to="lab_lsta_LitigationSettlementPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cdfbbe1b-6b74-4d64-b3ed-eb4ece99dd53_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ccb86b2f-5800-4914-b1e6-cd74949cfec2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9de59f9d-b51e-4ae0-b65f-5cdde63ac3ce_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6bb46f37-ec04-4213-a897-c08f5e2a440a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding. Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93593cc7-7ff7-482e-b542-e2f89a5dbaf0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1e97c531-3bc5-4fba-bacc-6a9278e95896_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_7754554e-7b95-4a7e-9497-261600f52408_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_61a4b736-4fe2-4705-b0d9-06cd10d1bc19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5754f1ca-39a2-4ab1-9e40-0b09f72ebde8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_35c2b71c-1d6c-4588-9f22-8e601b259d5c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_820ffe21-d841-49a0-87de-e735247a5bd5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4a770117-58fd-425e-87c3-d6fb0cc9b5ba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b5a7465c-b501-4b84-8040-779cad882e83_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_65e4db03-a099-4976-805b-cfb5e3cc5cec_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_18fe4e73-e001-42b2-855c-ad83e01633aa_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_390068d8-5f92-464e-bf75-afd5dec5e505_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e109c334-6073-4670-9972-98c4ed2918f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fbf3b670-fa89-4138-8b8a-740eb069a3b0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3075462e-559e-407c-bbf6-d4f861a78ccf_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7eaf680-3969-4cb0-8675-6edbb9e9d9c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CENDMember_e4b15c2e-fe2c-4e17-b403-eee35740bb9a_terseLabel_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CEND</link:label>
    <link:label id="lab_lsta_CENDMember_label_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CEND [Member]</link:label>
    <link:label id="lab_lsta_CENDMember_documentation_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CEND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember" xlink:href="lsta-20240331.xsd#lsta_CENDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CENDMember" xlink:to="lab_lsta_CENDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_164d50ff-d37e-472b-ba0a-3ccf0172ee44_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ac9a70fb-8dd3-47c8-9ddb-d34f0cf8a193_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cc8c7fea-92ec-421b-8989-d43e707d3333_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_12d14aaf-70cd-4303-a2bc-dcf198d4dd76_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_81920ba8-5b48-4092-b8ac-accc6e98ad9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option and Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_edda9f7d-d34a-483d-93d8-0f095abc563a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b0d66ed3-7c53-41f4-9fab-4fd4d93fbcf9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0acce5f1-89d0-4e5a-955d-9794f1a75590_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_f5dc3c58-828b-4ccb-b3d0-360ccdfcc57a_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Expired (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df70efde-c5f0-41c9-9f0d-d94de8ca107b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_1e377018-d7d8-4ca2-83db-4bed5fc4a692_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_de47901c-8260-43bc-b4fb-dc9b9b8c2007_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_14625225-9259-4136-b07b-1caf4215c09a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_74a762c4-337f-400e-a531-e4176c2a5a0f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_af9142ac-aafa-47fb-a127-51b63195cc3b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_80d289a8-2421-4843-bee8-79592ca3a0d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e3859f97-5457-41e3-a256-e5e5e9f2c38c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsCanceled_57388b66-134e-4cc0-b755-f736fa878a81_negatedLabel_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrants, Forfeited (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsCanceled_label_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_lsta_WarrantsCanceled_documentation_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsCanceled" xlink:href="lsta-20240331.xsd#lsta_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsCanceled" xlink:to="lab_lsta_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_959b8142-8bfe-4e6a-b80e-0a3acb14b5a0_terseLabel_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of sublicensing revenues</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_label_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_documentation_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:href="lsta-20240331.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:to="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_58bbf9fe-85b0-42e2-b5ff-8a1fc8c8f6c6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_447532cf-e71a-4a99-8c16-58497a50a4c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LegalSettlementCurrent_520a6949-f1cb-4048-b77c-3dd21491d663_terseLabel_en-US" xlink:label="lab_lsta_LegalSettlementCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal settlement</link:label>
    <link:label id="lab_lsta_LegalSettlementCurrent_label_en-US" xlink:label="lab_lsta_LegalSettlementCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Settlement, Current</link:label>
    <link:label id="lab_lsta_LegalSettlementCurrent_documentation_en-US" xlink:label="lab_lsta_LegalSettlementCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal Settlement, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LegalSettlementCurrent" xlink:href="lsta-20240331.xsd#lsta_LegalSettlementCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LegalSettlementCurrent" xlink:to="lab_lsta_LegalSettlementCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_65acf750-9534-4667-9de6-d94b322db7ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d2672767-736b-436b-a98e-ff8ca72c4165_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization/accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_176369ca-44cd-4642-89fc-6c3c477a9799_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, non-controlling interests and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_25ea6cf5-91be-4ceb-b3cd-0b8e59158530_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_b8fd5a70-3f33-4a7b-8bac-83e29da0d725_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_489be9a2-2d1d-4fd2-b52d-fba8e15970cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_e2efa82e-2a9e-481d-b3bc-c19d829f2459_terseLabel_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of net sale</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_label_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_documentation_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:href="lsta-20240331.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:to="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_93885ce5-cd94-42f1-9f88-e809bd0aab1b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_87137d53-8047-46e5-b96d-378ea4c5d2b8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1be470ff-daf1-4b17-acaa-1c7cf8b9fb8f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d74a073b-5c0f-42e7-8d0b-8446344ec3f6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67ea4c2c-8102-4d62-9034-8b1e0b40e8dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_390cbb6b-5d28-4a1a-81b4-88a01fdabc4a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a39c1815-9b8f-4121-ada6-8a472e47f417_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a7fbb818-3d39-4888-8869-df069e3c4c66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_045dfe10-1db9-4c34-a760-c50615313961_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_34c7f1a1-3a8c-45ec-bbe3-102959f48bcf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6f82c88d-6621-46ab-acee-d515ad0b8a6e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d9593f02-bcb9-44c4-b1ae-7201b6e56575_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_ef24545f-aca4-4c8c-a3e8-ced394caf4c3_terseLabel_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration amounts, milestones</link:label>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="lsta-20240331.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_7456e201-0282-44e0-8909-cb86865830ed_terseLabel_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value market of tax NOLs</link:label>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_label_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_documentation_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs" xlink:href="lsta-20240331.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_FairValueMarketOfTaxNOLs" xlink:to="lab_lsta_FairValueMarketOfTaxNOLs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_37fc629d-63f2-4747-a813-3749e39c0131_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9541ec58-a787-48c6-af51-e914b6ca5859_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d3742a6-5249-42a1-964e-5fe55ffc4a27_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cbde9a98-4817-4bac-b4e6-bd6e245b526f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_618904ff-1a87-4e31-b169-5fffff35ccfb_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b61c11ae-072c-4245-8d30-4c28af208409_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d187bf9-f331-4b13-83fc-3bc4b4eeab3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e8f5144-e90e-4ff4-84b3-2c567bf8c731_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_2a880b28-db19-4a8f-851b-849ab65a1cd0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_aba429ed-ee80-4910-a4ea-8c235509cdb0_terseLabel_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="lsta-20240331.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OutstandingStockThreshold_79275e2c-dfc0-45b4-9b20-1b22bbc41c59_terseLabel_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock threshold</link:label>
    <link:label id="lab_lsta_OutstandingStockThreshold_label_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Stock Threshold</link:label>
    <link:label id="lab_lsta_OutstandingStockThreshold_documentation_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outstanding Stock Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold" xlink:href="lsta-20240331.xsd#lsta_OutstandingStockThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OutstandingStockThreshold" xlink:to="lab_lsta_OutstandingStockThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85d78686-5b66-41cb-bbb1-5f5588d7f903_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_3f8a0306-d60e-46fe-b001-629119d93739_terseLabel_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, prior to write down</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_label_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_documentation_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:href="lsta-20240331.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:to="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_9b0037ef-e2e1-4641-b2fb-1a711b6069ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, value, outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_70ab9ee5-f762-4ffe-9b54-c2777b5ba43e_terseLabel_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="lsta-20240331.xsd#lsta_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_34ada084-3fe5-463d-ab6c-e74239c44df4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8982191-1c15-4766-91a4-8ef9233d1f7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_da505507-14e7-427b-88a7-c2a0fc2bd7e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_672e3459-233e-47fe-8e56-86e4736382ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61b30d31-c946-48e3-b3c5-f3802b186b70_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_ffcd3ff8-a667-449f-9457-7138fbf88ddb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestones, Royalties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_74fbea39-ba9b-4491-9c5d-7ddf9b115e80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26b2ad15-b4a6-425f-acda-3a7288b1eea1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_abd5617d-893d-49bf-b413-e35648f67d8e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected amortization, year three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_242a9e49-9fcd-4da9-8226-be4457681fee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AccruedGrantFunding_7547965b-9831-4198-8b39-c3ac99174a44_terseLabel_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting &amp; tax consulting liabilities</link:label>
    <link:label id="lab_lsta_AccruedGrantFunding_label_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:label id="lab_lsta_AccruedGrantFunding_documentation_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding" xlink:href="lsta-20240331.xsd#lsta_AccruedGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AccruedGrantFunding" xlink:to="lab_lsta_AccruedGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_768a252b-4a7c-40e3-b761-09edd1b5d39e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d07f26c1-3e3b-4dcd-a2f5-3eee83794f85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_866f994d-df2f-4b18-84cb-8c37a04fe7f3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9cdf3e9f-e658-476a-a00c-ca1545670cd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a3b513d7-5403-45b5-8e2e-aaa5a456f35a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected amortization, year two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_27098e67-3011-488d-a05d-1d50f4c3c3f5_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_608951da-1c82-489c-af02-3a5aa3c3328e_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:href="lsta-20240331.xsd#lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_389befce-5562-49ed-ae29-2944cc83d985_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_33870cee-ea67-4571-b74c-fe26bb21f432_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_a1ae9072-f775-431a-af3b-70c88ee21fbe_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Granted (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_4a4b74d0-6aa8-480b-a346-0b085cc4f950_terseLabel_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_label_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanford Burnham Prebys [Member]</link:label>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_documentation_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember" xlink:href="lsta-20240331.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SanfordBurnhamPrebysMember" xlink:to="lab_lsta_SanfordBurnhamPrebysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_28a3171f-ba03-4cb2-8e30-037d80889761_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_40ffffb5-933e-43a9-8ebe-3e513b3abf96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_978f641e-39e0-4f7f-b37f-f8e949dcab1d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2dd4455c-c16b-49df-b7c8-351ef5f22772_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_6b19560c-d14f-4fb8-a320-25ff7e13038d_terseLabel_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical and R&amp;D related liabilities</link:label>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_label_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_documentation_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities" xlink:href="lsta-20240331.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ClinicalAndRDRelatedLiabilities" xlink:to="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_03f0f683-ba59-4811-80b8-db816fcb4148_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_436b3d50-e1ff-46bb-8eb5-aa8862342a64_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4cda01b9-11ad-4da6-bd2a-4a39063a7544_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvested_11a295fc-ab0c-46f9-968f-431a910b084c_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvested_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvested_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvested" xlink:href="lsta-20240331.xsd#lsta_AggregateIntrinsicValueWarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsvested" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d0c7c614-d2e0-4b95-8816-d9b92a99eca4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4328949a-5900-4ff1-b072-47016012e474_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a15f83f9-2243-4171-b356-5089af4d4d60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_68574413-2469-4069-98dd-9ca2bbabced3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f35f0c1c-a23b-458e-b571-2528c403d73a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7b7c6f60-f495-4938-a715-7eba7e741e63_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46b39a74-81f4-4b80-af03-c5db57ce474b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue excluding taxes</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_611f1f32-69e5-430e-b0af-f1fba257b632_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7c0bac8a-cb38-4c07-a79f-3fac38f66044_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_7f7bd1cc-e400-4b43-a86e-7c6ffffa0ee4_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_2bfd3813-3512-4400-84ed-2325e861b9b7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_ce6c641c-a7b4-42bd-816f-b8897458097b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0cc98b6-e679-48b2-9169-3f700db3b184_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a79438f3-6058-406b-811c-ff7de80f9135_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_3c9bfaa6-5856-4567-9780-ae30771866f9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_9cedaf46-e8da-4013-983a-b8d71d344c19_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2f1b9c41-6626-45de-9455-b2a5aa19f94c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5975cb2-fba9-42d1-ad5e-b4e95ccb0367_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_826ba282-b5a3-46e4-ae4b-4af1494084d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_24bb1fbf-8c9d-4649-bbd2-95fedc5df0e2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_012eeb05-5fc3-43b1-8716-632b0b5a37c8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_724d0454-a52a-44fc-8e98-aa3ce31d0790_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0a46236c-8b0c-49e9-92fc-30db0db1a1af_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_6a1f5dab-f75c-410d-a11a-8708e40e9436_terseLabel_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of NOLs</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_label_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of NOLS</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_documentation_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of NOLS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS" xlink:href="lsta-20240331.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ProceedsFromSaleOfNOLS" xlink:to="lab_lsta_ProceedsFromSaleOfNOLS" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_e1f6e1b4-cbd3-450c-9cae-91ec0aea0e90_terseLabel_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australia Research and Development Tax Incentive</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_label_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Tax Incentive [Text Block]</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_documentation_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Tax Incentive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:href="lsta-20240331.xsd#lsta_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:to="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_242b5f1f-5f38-4834-9911-f7ef3797c2b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4c0ddf3d-4fdc-44c0-89fb-3eb5919e2b1f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7939fde0-1afe-4fd5-b0cb-78e42cd5c21f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_14c020bb-4a48-4da5-b5ba-c6d6458317a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fb2c7e2d-3679-465a-8d4f-4cd4371c41dd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_012048c0-dcb5-4d5d-a432-13a9102eaa4e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_91e548fb-4981-45a0-ae9e-15994c2880d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f66aacdd-1b64-41a6-a288-dcb4fc89b5fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8ae6f9ac-8929-4a56-8444-300063e6fdde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_470882b9-a70a-489b-a947-0b5ee6419e60_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_2b80688a-3e0e-40b0-a121-a2c83e6f91ee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_459ee185-c14c-410b-8fb3-e77393d92d6b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d02a4673-9f61-4f50-b5ef-5468759f24f0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_33af1700-99ff-4fb1-8611-d79c5e2b93db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ee611cb-40e3-4b53-b604-7c8911c255f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9473ad2f-b190-4a58-bde0-aec63a875b24_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_dc33684b-30a7-4971-8716-b0ab0d21b431_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_054868cd-52a4-49b7-8816-2893d78f6e74_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_45f28c07-a05e-48c7-9e30-4ff719f4f076_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5b8b52f3-24f8-4604-b964-d25a58950e8a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_821255cb-123f-4a3c-8e93-92f030f3bded_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_QiluMember_136ae97e-6103-45bb-85cf-3bbe0363d196_terseLabel_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qilu</link:label>
    <link:label id="lab_lsta_QiluMember_label_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qilu [Member]</link:label>
    <link:label id="lab_lsta_QiluMember_documentation_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Qilu</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember" xlink:href="lsta-20240331.xsd#lsta_QiluMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_QiluMember" xlink:to="lab_lsta_QiluMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_33df99ae-6059-46af-832d-fcf4492c9135_terseLabel_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="lsta-20240331.xsd#lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fda1e67b-4f76-407e-bb39-06e8b3208c61_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_da04a943-a7f1-489c-8c40-f2fe13f0785e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fe565bd8-5cc8-4511-8e44-e185261a0450_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33ed2b13-96c3-4a95-87c6-33ef6e7db30d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_be37d6fa-ee66-4b26-85eb-27965a132823_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_06551b35-6d28-4932-b4a0-42dabcfb5b95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_5b186ecf-676e-433f-b845-612bcfba9be0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_35d053e6-2a63-42b9-9efa-dd5cb32cccac_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_8564c982-49d1-420c-9bf3-61d921e8eb97_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lsta-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fe904bd3-4642-40bc-b4e0-ae39e52f235d,g:b327601d-86c0-41f4-b109-5b549ba09d67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="lsta-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c8172f33-41bf-4d06-8dfa-c8139bc8f6b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_DocumentType_c8172f33-41bf-4d06-8dfa-c8139bc8f6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b45ea38f-921b-4b1b-8abe-54c98a103c9f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_DocumentQuarterlyReport_b45ea38f-921b-4b1b-8abe-54c98a103c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b60897b4-9f3c-4524-9f5c-4d07542f3103" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_DocumentPeriodEndDate_b60897b4-9f3c-4524-9f5c-4d07542f3103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a3256262-4df9-48e7-927c-276d4ab18706" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_DocumentTransitionReport_a3256262-4df9-48e7-927c-276d4ab18706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a0d49f03-059f-4b31-a80b-e1c827e8c6f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityFileNumber_a0d49f03-059f-4b31-a80b-e1c827e8c6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d8d9a034-984a-4d6b-a774-2a5cc45d7dc4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityRegistrantName_d8d9a034-984a-4d6b-a774-2a5cc45d7dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a235e983-90d9-40b9-924f-dbe90b7f44fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a235e983-90d9-40b9-924f-dbe90b7f44fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_83eecce6-4446-4b70-b3e5-b426649455b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityTaxIdentificationNumber_83eecce6-4446-4b70-b3e5-b426649455b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_95d7965d-c390-4fe1-aa8d-cd6542b9c3e5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityAddressAddressLine1_95d7965d-c390-4fe1-aa8d-cd6542b9c3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_28c1e4b3-a8da-4b45-84f6-73d29125a29c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityAddressCityOrTown_28c1e4b3-a8da-4b45-84f6-73d29125a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3c6d00cf-678b-4dfc-9cb6-ce202783600c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityAddressStateOrProvince_3c6d00cf-678b-4dfc-9cb6-ce202783600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0de6e8e3-f8bc-463a-bace-f535b327fd81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityAddressPostalZipCode_0de6e8e3-f8bc-463a-bace-f535b327fd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f5fa7227-f994-470c-86db-a0a95196f7a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_CityAreaCode_f5fa7227-f994-470c-86db-a0a95196f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_79cd9ff3-4c97-42f4-983e-ac91de46e55c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_LocalPhoneNumber_79cd9ff3-4c97-42f4-983e-ac91de46e55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f350f8d1-8fe7-42ff-b6b8-3df830e9425d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_Security12bTitle_f350f8d1-8fe7-42ff-b6b8-3df830e9425d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5169236e-c19a-477a-a45c-78197a80c652" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_TradingSymbol_5169236e-c19a-477a-a45c-78197a80c652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ccfda7eb-af03-42df-8d96-a30d9dabdb65" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_SecurityExchangeName_ccfda7eb-af03-42df-8d96-a30d9dabdb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_682a49e3-16d1-4b53-bdf3-acab91bd418f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityCurrentReportingStatus_682a49e3-16d1-4b53-bdf3-acab91bd418f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_22471d74-88de-4f02-8c26-558dbcdc8f54" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityInteractiveDataCurrent_22471d74-88de-4f02-8c26-558dbcdc8f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_50b1b56c-b278-42c9-8e4e-620160cf2d89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityFilerCategory_50b1b56c-b278-42c9-8e4e-620160cf2d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0500ebfc-51fd-4314-8b91-c5a8a177ffd3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntitySmallBusiness_0500ebfc-51fd-4314-8b91-c5a8a177ffd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6f11e157-3e0c-4a9d-bce9-3af679187284" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityEmergingGrowthCompany_6f11e157-3e0c-4a9d-bce9-3af679187284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_29b91d5b-6846-4e06-a09d-67728618852f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityShellCompany_29b91d5b-6846-4e06-a09d-67728618852f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a1a836c6-6a29-4e67-8a8e-ce66cff948bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a1a836c6-6a29-4e67-8a8e-ce66cff948bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_385253c2-e7fb-4f2f-8a79-a1da9b2a2db3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_EntityCentralIndexKey_385253c2-e7fb-4f2f-8a79-a1da9b2a2db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d81f5470-6fc3-43e6-988f-6e65b8b722eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_CurrentFiscalYearEndDate_d81f5470-6fc3-43e6-988f-6e65b8b722eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d5cf1759-1208-49a8-9229-c6627a2d0176" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_DocumentFiscalYearFocus_d5cf1759-1208-49a8-9229-c6627a2d0176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cdf53090-74bc-4391-9e7a-efb967a21be4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cdf53090-74bc-4391-9e7a-efb967a21be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8750e171-a50b-4992-879f-341f9d2a338c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e6d7486-2a8f-42cd-8fce-022b6bb5e9e2" xlink:to="loc_dei_AmendmentFlag_8750e171-a50b-4992-879f-341f9d2a338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_135d522b-70e6-4b8f-8bd3-fc8cb173b1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_135d522b-70e6-4b8f-8bd3-fc8cb173b1a9" xlink:to="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b4a7c7d-d792-4718-96a7-a4215990ff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b4a7c7d-d792-4718-96a7-a4215990ff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_55767e3f-1975-4de0-a5f5-e928b9b32986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_MarketableSecurities_55767e3f-1975-4de0-a5f5-e928b9b32986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbb95a06-81f8-44c1-80cf-960bb2813f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbb95a06-81f8-44c1-80cf-960bb2813f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_61af28fe-58a7-448a-b1c3-2e9a34b92e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_AssetsCurrent_61af28fe-58a7-448a-b1c3-2e9a34b92e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5a40d6f4-c245-48bc-8f41-062dcb801fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5a40d6f4-c245-48bc-8f41-062dcb801fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf6d8924-4e61-4bc1-843b-39b9f87de5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf6d8924-4e61-4bc1-843b-39b9f87de5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9a52ca8a-edbe-4b43-a671-be37a6a0bd85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9a52ca8a-edbe-4b43-a671-be37a6a0bd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3fe5a2bd-4d0a-4f1a-bfa7-462999181de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed9f7386-058d-4fd9-a885-c26fc11c2076" xlink:to="loc_us-gaap_Assets_3fe5a2bd-4d0a-4f1a-bfa7-462999181de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ae6fe6b-6053-40ba-a498-37daf2ccbb63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_135d522b-70e6-4b8f-8bd3-fc8cb173b1a9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ae6fe6b-6053-40ba-a498-37daf2ccbb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_8e8e02d3-bd52-4f34-9324-f12b0ab3052e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ae6fe6b-6053-40ba-a498-37daf2ccbb63" xlink:to="loc_us-gaap_LiabilitiesAbstract_8e8e02d3-bd52-4f34-9324-f12b0ab3052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a3b2426f-76d8-4820-822b-a0ae24d89870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8e8e02d3-bd52-4f34-9324-f12b0ab3052e" xlink:to="loc_us-gaap_AccountsPayableCurrent_a3b2426f-76d8-4820-822b-a0ae24d89870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f0bbd608-d61c-436e-ab6b-bf9f06333505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8e8e02d3-bd52-4f34-9324-f12b0ab3052e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f0bbd608-d61c-436e-ab6b-bf9f06333505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_89a52d8c-b2ae-4f21-abf6-9e88b9a8aea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8e8e02d3-bd52-4f34-9324-f12b0ab3052e" xlink:to="loc_us-gaap_LiabilitiesCurrent_89a52d8c-b2ae-4f21-abf6-9e88b9a8aea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dfcf269a-6c3d-4df3-a176-9b493ca9e2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8e8e02d3-bd52-4f34-9324-f12b0ab3052e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_dfcf269a-6c3d-4df3-a176-9b493ca9e2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_406184e7-c4b1-47a1-9b44-e8cd208bc7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8e8e02d3-bd52-4f34-9324-f12b0ab3052e" xlink:to="loc_us-gaap_Liabilities_406184e7-c4b1-47a1-9b44-e8cd208bc7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6ade721e-0c73-4d2b-b90c-0171d7cea410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ae6fe6b-6053-40ba-a498-37daf2ccbb63" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6ade721e-0c73-4d2b-b90c-0171d7cea410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ae6fe6b-6053-40ba-a498-37daf2ccbb63" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3f068664-6cec-49a6-9c93-0921790bcb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_CommonStockValue_3f068664-6cec-49a6-9c93-0921790bcb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bc3f71b1-e4bc-4a10-ae6e-650d720626a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bc3f71b1-e4bc-4a10-ae6e-650d720626a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_0ae8334d-c0a8-4988-aca3-520cec0d2d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_TreasuryStockCommonValue_0ae8334d-c0a8-4988-aca3-520cec0d2d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b11779dc-b322-492c-bd01-bd3221dfefad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b11779dc-b322-492c-bd01-bd3221dfefad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_df6a9986-52b1-496d-9aab-b71fd4f6154f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_df6a9986-52b1-496d-9aab-b71fd4f6154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5357c22b-4921-4fed-947b-79d0c94fd2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_StockholdersEquity_5357c22b-4921-4fed-947b-79d0c94fd2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7ab05d9a-93e2-4232-9fab-818ffea02a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_MinorityInterest_7ab05d9a-93e2-4232-9fab-818ffea02a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8da167b9-2045-42a8-8f69-1daaf1418d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b3f3e65-03bc-4b1f-82d2-b6d453561a33" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8da167b9-2045-42a8-8f69-1daaf1418d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e981e0b-eb44-47e0-b39f-d8296681154c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ae6fe6b-6053-40ba-a498-37daf2ccbb63" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e981e0b-eb44-47e0-b39f-d8296681154c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDBALANCESHEETSParentheticals"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3cd46f65-3cbb-4b06-acb1-a6fb6b3a06dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a27ff313-86f3-4518-b466-c648a0ae56ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3cd46f65-3cbb-4b06-acb1-a6fb6b3a06dc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a27ff313-86f3-4518-b466-c648a0ae56ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_18540e2c-bb0b-4f6b-b9e7-05d7f28be84e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3cd46f65-3cbb-4b06-acb1-a6fb6b3a06dc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_18540e2c-bb0b-4f6b-b9e7-05d7f28be84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7131c1aa-6bb7-4fa1-bc4b-eb2031e1ed47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3cd46f65-3cbb-4b06-acb1-a6fb6b3a06dc" xlink:to="loc_us-gaap_CommonStockSharesIssued_7131c1aa-6bb7-4fa1-bc4b-eb2031e1ed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bd8161c7-b40b-4a34-84bd-f8f783f3f5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3cd46f65-3cbb-4b06-acb1-a6fb6b3a06dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bd8161c7-b40b-4a34-84bd-f8f783f3f5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b29a2a1e-317a-4207-b6ed-d93079946fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3cd46f65-3cbb-4b06-acb1-a6fb6b3a06dc" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b29a2a1e-317a-4207-b6ed-d93079946fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8427af79-089d-4028-841c-21158702b678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8427af79-089d-4028-841c-21158702b678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7790b8ae-7dac-4286-ac4f-3b6f214aef94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8427af79-089d-4028-841c-21158702b678" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7790b8ae-7dac-4286-ac4f-3b6f214aef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7586b4dc-034a-47f4-99a3-21c1806565c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8427af79-089d-4028-841c-21158702b678" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7586b4dc-034a-47f4-99a3-21c1806565c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d6c58b63-3aa4-4528-93cb-64d8d0338fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8427af79-089d-4028-841c-21158702b678" xlink:to="loc_us-gaap_OperatingExpenses_d6c58b63-3aa4-4528-93cb-64d8d0338fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_03bc4c4d-73e4-416b-b6c2-0896753f616e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_OperatingIncomeLoss_03bc4c4d-73e4-416b-b6c2-0896753f616e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_474b920b-77dc-41ed-b746-d3a96cf63ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_474b920b-77dc-41ed-b746-d3a96cf63ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_a5e21544-d4b1-41e7-9584-04f7687bdc67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_474b920b-77dc-41ed-b746-d3a96cf63ff6" xlink:to="loc_us-gaap_InvestmentIncomeNet_a5e21544-d4b1-41e7-9584-04f7687bdc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_69bfde4a-8d88-4a81-b42b-672f8357f390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_474b920b-77dc-41ed-b746-d3a96cf63ff6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_69bfde4a-8d88-4a81-b42b-672f8357f390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6075053e-2efd-4a92-a510-71bf47b75060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_474b920b-77dc-41ed-b746-d3a96cf63ff6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6075053e-2efd-4a92-a510-71bf47b75060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e89267a7-8963-4a60-8b12-847492f30578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e89267a7-8963-4a60-8b12-847492f30578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b5ad7ca2-757b-493c-8747-62bb9e27ba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b5ad7ca2-757b-493c-8747-62bb9e27ba7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f95fe09-e225-41c3-8e2d-947f7539bbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_ProfitLoss_7f95fe09-e225-41c3-8e2d-947f7539bbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_be2044d1-fee7-44cf-a248-d88ae7b0c83e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_be2044d1-fee7-44cf-a248-d88ae7b0c83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d4c3b0e7-3e19-4455-9db6-bacc986b8ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_NetIncomeLoss_d4c3b0e7-3e19-4455-9db6-bacc986b8ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_EPSAbstract_0fb8b302-6a0e-4863-8088-3e4fce7d69a6" xlink:href="lsta-20240331.xsd#lsta_EPSAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_lsta_EPSAbstract_0fb8b302-6a0e-4863-8088-3e4fce7d69a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_67d2e176-fcb1-408c-8398-94fe7ee8575a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_EPSAbstract_0fb8b302-6a0e-4863-8088-3e4fce7d69a6" xlink:to="loc_us-gaap_EarningsPerShareBasic_67d2e176-fcb1-408c-8398-94fe7ee8575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bcf0d8f8-0173-43e7-8b02-206fe7dc7bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_EPSAbstract_0fb8b302-6a0e-4863-8088-3e4fce7d69a6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bcf0d8f8-0173-43e7-8b02-206fe7dc7bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9541b795-97e7-4b15-b8ec-b9cb9b262b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d6df2a06-b6f0-464a-bf5e-efd55fb9a421" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9541b795-97e7-4b15-b8ec-b9cb9b262b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32c25c6d-f185-47c1-a9bb-f2f0aa122d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9541b795-97e7-4b15-b8ec-b9cb9b262b4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32c25c6d-f185-47c1-a9bb-f2f0aa122d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e8adf68-7c91-4f3f-8ee3-070d55aed287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9541b795-97e7-4b15-b8ec-b9cb9b262b4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e8adf68-7c91-4f3f-8ee3-070d55aed287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76362f2c-bcaf-4d8f-97c0-4611df5c71e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0866368e-4813-4489-9e24-2c128ff35e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76362f2c-bcaf-4d8f-97c0-4611df5c71e8" xlink:to="loc_us-gaap_ProfitLoss_0866368e-4813-4489-9e24-2c128ff35e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_13afcbda-31c2-4aab-b672-6070d5b457aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76362f2c-bcaf-4d8f-97c0-4611df5c71e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_13afcbda-31c2-4aab-b672-6070d5b457aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3802213a-d8c6-4e4a-a245-b23ff76d73b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_13afcbda-31c2-4aab-b672-6070d5b457aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3802213a-d8c6-4e4a-a245-b23ff76d73b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e33d26d-c941-4fcd-aa89-b86ab6ff7195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_13afcbda-31c2-4aab-b672-6070d5b457aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4e33d26d-c941-4fcd-aa89-b86ab6ff7195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_320af1d8-1193-4a02-a45b-b3d0872a4310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_13afcbda-31c2-4aab-b672-6070d5b457aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_320af1d8-1193-4a02-a45b-b3d0872a4310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3094d74c-066a-49f9-b6e9-d9c987976a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76362f2c-bcaf-4d8f-97c0-4611df5c71e8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3094d74c-066a-49f9-b6e9-d9c987976a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a163e88d-9fc3-48ca-a662-27bd3a80b412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_114a10ea-c718-4509-a360-b437fcb1ac7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a163e88d-9fc3-48ca-a662-27bd3a80b412" xlink:to="loc_us-gaap_StatementTable_114a10ea-c718-4509-a360-b437fcb1ac7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7b78f958-1c64-4835-ac86-77305ca068a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_114a10ea-c718-4509-a360-b437fcb1ac7a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7b78f958-1c64-4835-ac86-77305ca068a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7b78f958-1c64-4835-ac86-77305ca068a6" xlink:to="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:to="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f04ec27e-4547-4b56-926f-b73f192384cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_CommonStockMember_f04ec27e-4547-4b56-926f-b73f192384cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d68b77d5-ffc8-4b80-b859-e86a5b5f362d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d68b77d5-ffc8-4b80-b859-e86a5b5f362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c2cd1f7-3469-4f94-8319-53823285c405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c2cd1f7-3469-4f94-8319-53823285c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c67c6110-1f1d-465e-baf4-9b41e4d6bcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_RetainedEarningsMember_c67c6110-1f1d-465e-baf4-9b41e4d6bcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b3ce49dd-885b-492a-822e-ce5d1ff9ab3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_746b4212-9d06-4ee7-a5fc-7c7213bf6c7d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b3ce49dd-885b-492a-822e-ce5d1ff9ab3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1d35111a-bd73-4334-a3c2-f81e573c436e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73aae2db-5ef6-4f10-b7f2-a1fd50509af9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1d35111a-bd73-4334-a3c2-f81e573c436e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4322977e-729e-4a7d-af0d-a1ce8c01c65a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_114a10ea-c718-4509-a360-b437fcb1ac7a" xlink:to="loc_us-gaap_StatementLineItems_4322977e-729e-4a7d-af0d-a1ce8c01c65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4322977e-729e-4a7d-af0d-a1ce8c01c65a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b17ab911-1a99-4286-97a4-e8a36aa28d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b17ab911-1a99-4286-97a4-e8a36aa28d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f400b04e-9a06-43ac-b9f1-2b37622dda9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f400b04e-9a06-43ac-b9f1-2b37622dda9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bff9c84d-1a88-46db-affd-fdb2d50d0c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_ProfitLoss_bff9c84d-1a88-46db-affd-fdb2d50d0c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_627df7af-7464-46fe-92f3-12b907c658ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_627df7af-7464-46fe-92f3-12b907c658ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ac6e7abe-f09d-49e2-83f9-8bed2ce91e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ac6e7abe-f09d-49e2-83f9-8bed2ce91e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7b3b3f33-605d-4add-8fd8-3dde72f05c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7b3b3f33-605d-4add-8fd8-3dde72f05c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f300145-5937-4037-93d0-d228409678c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f300145-5937-4037-93d0-d228409678c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_910d5f03-a066-4007-bb20-67272befd96e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_910d5f03-a066-4007-bb20-67272befd96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0f5b3483-aef5-4c58-b6c3-19814f93eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a522a4c-d64e-4d8f-87bd-de51ebcbd44d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0f5b3483-aef5-4c58-b6c3-19814f93eca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lsta-20240331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3af12bbc-0ee7-488f-b732-8a13d6e84aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3af12bbc-0ee7-488f-b732-8a13d6e84aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c7b88c28-72f0-412f-96b4-46aeca612231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3af12bbc-0ee7-488f-b732-8a13d6e84aaf" xlink:to="loc_us-gaap_ProfitLoss_c7b88c28-72f0-412f-96b4-46aeca612231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3af12bbc-0ee7-488f-b732-8a13d6e84aaf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_71ebe918-9cc3-480b-bc32-b562ce219231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_71ebe918-9cc3-480b-bc32-b562ce219231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_16caa45d-00f3-459b-8a2b-fc87bd494218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:to="loc_us-gaap_DepreciationAndAmortization_16caa45d-00f3-459b-8a2b-fc87bd494218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_fa1d9712-3df3-4d3e-a158-de15ce58f49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_fa1d9712-3df3-4d3e-a158-de15ce58f49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_56ff99cb-79e9-46be-a20a-b0a8eddfe10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_56ff99cb-79e9-46be-a20a-b0a8eddfe10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_290d40c7-adcd-4da0-96a1-c08e1eb7c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_290d40c7-adcd-4da0-96a1-c08e1eb7c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d412abc6-53bb-413b-957a-e83dd817198e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad7829f8-b1a5-4f65-a9b4-98711201347b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d412abc6-53bb-413b-957a-e83dd817198e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9915b270-dd5b-4aa5-afe7-b6753df29e15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d412abc6-53bb-413b-957a-e83dd817198e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9915b270-dd5b-4aa5-afe7-b6753df29e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5579c01e-c01a-4f43-8db8-3b61a9db027d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d412abc6-53bb-413b-957a-e83dd817198e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5579c01e-c01a-4f43-8db8-3b61a9db027d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_0828eae4-bef0-4106-8ea1-fb9a95e95ed3" xlink:href="lsta-20240331.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d412abc6-53bb-413b-957a-e83dd817198e" xlink:to="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_0828eae4-bef0-4106-8ea1-fb9a95e95ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f25dec29-12d4-4aab-bb3a-8467fc3575e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3af12bbc-0ee7-488f-b732-8a13d6e84aaf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f25dec29-12d4-4aab-bb3a-8467fc3575e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e620296d-a0e3-4009-8ab1-76ff15906ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e620296d-a0e3-4009-8ab1-76ff15906ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_349e95a1-6228-40e4-bee3-dc9c46e5bb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e620296d-a0e3-4009-8ab1-76ff15906ee3" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_349e95a1-6228-40e4-bee3-dc9c46e5bb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6ddf9807-9db5-4b0a-9efd-e8b01e5bca6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e620296d-a0e3-4009-8ab1-76ff15906ee3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6ddf9807-9db5-4b0a-9efd-e8b01e5bca6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_016e4437-948c-48f0-a7ef-459e30676035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e620296d-a0e3-4009-8ab1-76ff15906ee3" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_016e4437-948c-48f0-a7ef-459e30676035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b1e217e6-27c4-4349-8357-d06dad1096f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e620296d-a0e3-4009-8ab1-76ff15906ee3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b1e217e6-27c4-4349-8357-d06dad1096f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12376e7c-d137-4358-ab9c-bf9e80e4b699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12376e7c-d137-4358-ab9c-bf9e80e4b699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e37329c1-ce85-4144-ad1a-6a35451251cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12376e7c-d137-4358-ab9c-bf9e80e4b699" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e37329c1-ce85-4144-ad1a-6a35451251cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e352a04-157e-4431-a3d6-7f879bc64d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12376e7c-d137-4358-ab9c-bf9e80e4b699" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e352a04-157e-4431-a3d6-7f879bc64d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8781b2b1-8b98-4d61-a1ed-75b3a005c517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8781b2b1-8b98-4d61-a1ed-75b3a005c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6a9b21e8-f23c-47e9-96cf-1a69a938fb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6a9b21e8-f23c-47e9-96cf-1a69a938fb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3a09fa8-4626-4587-bd7b-45ccd1ad536d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3a09fa8-4626-4587-bd7b-45ccd1ad536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8156e216-2c02-4623-9d88-c807d6a8db24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b8d334de-3b66-420c-8952-7a02403cfa13" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8156e216-2c02-4623-9d88-c807d6a8db24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="lsta-20240331.xsd#TheBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8f401378-b492-4c0c-86d6-4cc789ab7086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_BusinessTextBlock_ff0229c5-6e1e-403a-b47b-b19c104b1a53" xlink:href="lsta-20240331.xsd#lsta_BusinessTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8f401378-b492-4c0c-86d6-4cc789ab7086" xlink:to="loc_lsta_BusinessTextBlock_ff0229c5-6e1e-403a-b47b-b19c104b1a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lsta-20240331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad293c36-584c-4283-88d7-a6f0460bbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c63e3df9-9c38-46a7-980a-9589de7ceb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad293c36-584c-4283-88d7-a6f0460bbdca" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c63e3df9-9c38-46a7-980a-9589de7ceb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ab7efb7d-3897-431f-87b0-bada0d7a1fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_09880868-18b3-48bb-b4a1-bb07fa3fe39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ab7efb7d-3897-431f-87b0-bada0d7a1fd4" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_09880868-18b3-48bb-b4a1-bb07fa3fe39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lsta-20240331.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_19e3788b-6d7c-43f5-9366-9f38837ed2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3c6db8c6-412a-4564-8337-70bbf95e943f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_19e3788b-6d7c-43f5-9366-9f38837ed2de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3c6db8c6-412a-4564-8337-70bbf95e943f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="lsta-20240331.xsd#IncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0a48945c-fc4b-4df9-a65b-6afe79c62771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8fbe7a8a-1244-41a1-b5bc-2287b89f29ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a48945c-fc4b-4df9-a65b-6afe79c62771" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8fbe7a8a-1244-41a1-b5bc-2287b89f29ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lsta-20240331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0d3bd23c-f40e-468f-96d1-409f7ac678cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c01cfc75-02f5-4202-b727-62750233da94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0d3bd23c-f40e-468f-96d1-409f7ac678cb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c01cfc75-02f5-4202-b727-62750233da94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="lsta-20240331.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_0b580104-ca5f-49d0-a991-4bdc0617c038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_463a38a8-5fa6-47b2-bdaa-bc9b2b99a52c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_0b580104-ca5f-49d0-a991-4bdc0617c038" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_463a38a8-5fa6-47b2-bdaa-bc9b2b99a52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0c8dff8a-ec9d-4f10-8513-482fa364212d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7550aa90-435f-43cc-b251-6304f25b8d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c8dff8a-ec9d-4f10-8513-482fa364212d" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7550aa90-435f-43cc-b251-6304f25b8d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_57034d9e-bf6b-4c19-88fb-7a4f3a9b8699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dfaabc3e-a7d8-43c7-8205-c1bdc57394ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_57034d9e-bf6b-4c19-88fb-7a4f3a9b8699" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dfaabc3e-a7d8-43c7-8205-c1bdc57394ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_030fc66d-fd05-4959-8f69-7a9daa9c228c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5e9ac6b6-721a-425b-906f-a0b0e5b37ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_030fc66d-fd05-4959-8f69-7a9daa9c228c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5e9ac6b6-721a-425b-906f-a0b0e5b37ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lsta-20240331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3e7aa6fb-54b9-4a4a-aa2f-dfee19567862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4badde54-3d23-4e10-99df-caac56f83993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e7aa6fb-54b9-4a4a-aa2f-dfee19567862" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4badde54-3d23-4e10-99df-caac56f83993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="simple" xlink:href="lsta-20240331.xsd#AustraliaResearchandDevelopmentTaxIncentive"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_680746a7-9da4-44c8-a1a2-24b96c304ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_26eae0fa-d90e-4a9b-b74c-843633e09ee4" xlink:href="lsta-20240331.xsd#lsta_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_680746a7-9da4-44c8-a1a2-24b96c304ebf" xlink:to="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_26eae0fa-d90e-4a9b-b74c-843633e09ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="lsta-20240331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d057eb7-8814-474d-aab9-a223c8fafd84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_766d14f3-b4d4-4a21-8e78-be07ec1e19df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d057eb7-8814-474d-aab9-a223c8fafd84" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_766d14f3-b4d4-4a21-8e78-be07ec1e19df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreement" xlink:type="simple" xlink:href="lsta-20240331.xsd#TechnologyTransferAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract_e442903c-7373-4e22-9291-ed44c330d346" xlink:href="lsta-20240331.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementTextBlock_c1b38380-9153-490a-ad3a-787f19071beb" xlink:href="lsta-20240331.xsd#lsta_TechnologyTransferAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract_e442903c-7373-4e22-9291-ed44c330d346" xlink:to="loc_lsta_TechnologyTransferAgreementTextBlock_c1b38380-9153-490a-ad3a-787f19071beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreements" xlink:type="simple" xlink:href="lsta-20240331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_947afcd8-48d7-4fa7-8e9d-d152ea043dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e35d2410-5758-4e1d-8bfb-b6f9a38b9d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_947afcd8-48d7-4fa7-8e9d-d152ea043dca" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e35d2410-5758-4e1d-8bfb-b6f9a38b9d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="lsta-20240331.xsd#ResearchCollaborationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0112391-90e9-4c28-8d4a-eeed21ca00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_39cc9877-a977-4afb-907f-f4051740b067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0112391-90e9-4c28-8d4a-eeed21ca00a3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_39cc9877-a977-4afb-907f-f4051740b067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SubsequentEvents" xlink:type="simple" xlink:href="lsta-20240331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0629d07c-56f4-4043-ad01-f6a7cb6db49c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_02c2b5a2-006d-4889-8cfb-4d5542ed4f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0629d07c-56f4-4043-ad01-f6a7cb6db49c" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_02c2b5a2-006d-4889-8cfb-4d5542ed4f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lsta-20240331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f2a54311-fab8-4cd2-b10f-81a69299a6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f2a54311-fab8-4cd2-b10f-81a69299a6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_76d4ce57-113c-4000-8485-f7441f9efc62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_UseOfEstimates_76d4ce57-113c-4000-8485-f7441f9efc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ef1af887-9b65-4883-b3b5-5985fb9521e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ef1af887-9b65-4883-b3b5-5985fb9521e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6b349589-3920-407a-900e-cba6fc1c2a01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6b349589-3920-407a-900e-cba6fc1c2a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9fdfb5e5-3b2b-4356-ba87-ae2f2a4891e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9fdfb5e5-3b2b-4356-ba87-ae2f2a4891e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0ce4f067-bf91-4e73-842a-57e9da8f4467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_0ce4f067-bf91-4e73-842a-57e9da8f4467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_9b603d15-de37-4c37-aa06-0ed677ce1f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_9b603d15-de37-4c37-aa06-0ed677ce1f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_14794e46-cf78-4215-9963-9cc2a8798387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_14794e46-cf78-4215-9963-9cc2a8798387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_2e6e3a8e-69fa-44d3-8575-e07e1fbdce1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_2e6e3a8e-69fa-44d3-8575-e07e1fbdce1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_325ebce5-9bf8-4c03-a1db-e5adff1bab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_325ebce5-9bf8-4c03-a1db-e5adff1bab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7bd6e162-a4f8-4d21-8fdc-b8cb501959ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7bd6e162-a4f8-4d21-8fdc-b8cb501959ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_bd98b593-9bdb-415b-bf1d-86c85f70273c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_bd98b593-9bdb-415b-bf1d-86c85f70273c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_8279e5a0-0cd3-4095-b5c5-098289285b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_8279e5a0-0cd3-4095-b5c5-098289285b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2d990391-659f-4a21-8c3c-4e7a72fb2d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2d990391-659f-4a21-8c3c-4e7a72fb2d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_fe85cbc1-047e-449d-9bed-b6689dff2364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_fe85cbc1-047e-449d-9bed-b6689dff2364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9d266dff-a9b1-47e1-aa6d-fdc7272c07ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9d266dff-a9b1-47e1-aa6d-fdc7272c07ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8e1992dd-32f3-4656-994c-9ee93208084a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8e1992dd-32f3-4656-994c-9ee93208084a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9b93b322-33f6-4d25-a8a3-69e82b9f573c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38aa828b-dafb-4614-a89a-ae7133f2c4fd" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9b93b322-33f6-4d25-a8a3-69e82b9f573c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c16e257d-68b2-4f4b-8e5a-4310d47107a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b2b73dba-3ff4-4fcf-8900-e8a458519f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c16e257d-68b2-4f4b-8e5a-4310d47107a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b2b73dba-3ff4-4fcf-8900-e8a458519f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7dd13d53-d83f-427b-b5fa-3eb4d8ab5278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7a0fc802-9996-4894-8ed2-7fd5542c63ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7dd13d53-d83f-427b-b5fa-3eb4d8ab5278" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7a0fc802-9996-4894-8ed2-7fd5542c63ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_62e9f3b9-41f9-4be2-abd3-9cfe105282cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7dd13d53-d83f-427b-b5fa-3eb4d8ab5278" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_62e9f3b9-41f9-4be2-abd3-9cfe105282cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_15fb2c15-ab94-471e-b66d-8a87e82ac181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7dd13d53-d83f-427b-b5fa-3eb4d8ab5278" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_15fb2c15-ab94-471e-b66d-8a87e82ac181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d296b87d-6668-4af3-aeea-4214711815a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bbce9a36-f04a-4757-8d10-be4c80a764c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d296b87d-6668-4af3-aeea-4214711815a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bbce9a36-f04a-4757-8d10-be4c80a764c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#IncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2290700e-fd23-40b0-b81c-8501c01181ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b5ccbe89-7897-4460-8f51-4345de526ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2290700e-fd23-40b0-b81c-8501c01181ea" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b5ccbe89-7897-4460-8f51-4345de526ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_13261829-6fc1-4457-83a8-952424c447fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ad046b9e-c772-4b6c-a60f-89c0f4e0ad5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_13261829-6fc1-4457-83a8-952424c447fa" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ad046b9e-c772-4b6c-a60f-89c0f4e0ad5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_4b1b9c97-a1b3-4a7b-a9b8-278e3e664a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_26d6e036-632a-4aeb-bee0-9db88925385d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_4b1b9c97-a1b3-4a7b-a9b8-278e3e664a8b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_26d6e036-632a-4aeb-bee0-9db88925385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3df96d4c-125e-4de4-a251-62fa3d91950b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_3ce31a24-2642-45df-81a4-aad779cb39b1" xlink:href="lsta-20240331.xsd#lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3df96d4c-125e-4de4-a251-62fa3d91950b" xlink:to="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_3ce31a24-2642-45df-81a4-aad779cb39b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3049cab9-c0d3-4703-aa7d-a9437ceb1194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3df96d4c-125e-4de4-a251-62fa3d91950b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3049cab9-c0d3-4703-aa7d-a9437ceb1194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d65620d0-4a6e-4547-8d63-4bf992d0ea13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_03486a6d-afde-43fb-9297-eddacecbf7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d65620d0-4a6e-4547-8d63-4bf992d0ea13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_03486a6d-afde-43fb-9297-eddacecbf7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1eafdc54-09b6-4f81-9f88-708400b08969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d65620d0-4a6e-4547-8d63-4bf992d0ea13" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_1eafdc54-09b6-4f81-9f88-708400b08969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_7ecf7c83-c5dc-45cc-97dd-1f19f0e5413a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d65620d0-4a6e-4547-8d63-4bf992d0ea13" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_7ecf7c83-c5dc-45cc-97dd-1f19f0e5413a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b8e7239-7220-48da-a994-c4cc03a0ccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f6d4daec-44c4-4895-8b84-0e0bdbfb0a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b8e7239-7220-48da-a994-c4cc03a0ccd0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f6d4daec-44c4-4895-8b84-0e0bdbfb0a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_c8841238-83a8-4cac-8271-690970764c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b8e7239-7220-48da-a994-c4cc03a0ccd0" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_c8841238-83a8-4cac-8271-690970764c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9ca47ede-b2a9-4955-86ec-034376ffffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b8e7239-7220-48da-a994-c4cc03a0ccd0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9ca47ede-b2a9-4955-86ec-034376ffffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cb54ff68-5c2b-4998-beba-a2e9dfaa422e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4da382f6-ada5-4fce-a339-fe6363deabcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb54ff68-5c2b-4998-beba-a2e9dfaa422e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4da382f6-ada5-4fce-a339-fe6363deabcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ba044c-85cf-439c-9b99-2c1cedf0cfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4da382f6-ada5-4fce-a339-fe6363deabcc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ba044c-85cf-439c-9b99-2c1cedf0cfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15ba044c-85cf-439c-9b99-2c1cedf0cfe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_08d2cfb8-cce1-4d42-a69d-21e9449ba5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_08d2cfb8-cce1-4d42-a69d-21e9449ba5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7f063ee3-f4bf-428f-88f5-e911039f221f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:to="loc_us-gaap_ComputerEquipmentMember_7f063ee3-f4bf-428f-88f5-e911039f221f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_c250ac9a-0c4e-4059-a5a7-ad24e609074c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a537237-71e6-4910-aa16-dd08bd417784" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_c250ac9a-0c4e-4059-a5a7-ad24e609074c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_766ceb15-5d5e-48ad-bae8-88339820a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4da382f6-ada5-4fce-a339-fe6363deabcc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_766ceb15-5d5e-48ad-bae8-88339820a4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bc51b97e-f4c4-491e-97ee-b49f2153df19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_766ceb15-5d5e-48ad-bae8-88339820a4be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bc51b97e-f4c4-491e-97ee-b49f2153df19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_409231ec-44bc-4b6a-974e-48f287e928af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_409231ec-44bc-4b6a-974e-48f287e928af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9a895f97-06a5-49e4-a032-78a1a4521b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9a895f97-06a5-49e4-a032-78a1a4521b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2655aafd-7726-44d5-a1dc-dfbf7d7a699d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2655aafd-7726-44d5-a1dc-dfbf7d7a699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_259a8e3e-3f39-4b35-b431-971936c12a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_259a8e3e-3f39-4b35-b431-971936c12a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dec07149-d614-4c80-8dd8-c0d886d190c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dec07149-d614-4c80-8dd8-c0d886d190c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5eb03bbb-7dbf-4e34-a5ed-62d20b3dfd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5eb03bbb-7dbf-4e34-a5ed-62d20b3dfd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9d0bfe0f-ecb9-4758-869c-487967143a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9d0bfe0f-ecb9-4758-869c-487967143a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f376e6b-bc83-43ef-b32b-af6360057bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f376e6b-bc83-43ef-b32b-af6360057bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a6d02aad-bd34-49dc-9c43-32fb90c9f6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a6d02aad-bd34-49dc-9c43-32fb90c9f6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6007d14-7b02-4285-bcbc-2a7cdf26013c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e3681-28a3-4d34-89a8-3fb46008d4e0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6007d14-7b02-4285-bcbc-2a7cdf26013c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5e34d66-1a48-444d-8a8f-e767d55cdc4a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6007d14-7b02-4285-bcbc-2a7cdf26013c" xlink:to="loc_srt_ProductOrServiceAxis_e5e34d66-1a48-444d-8a8f-e767d55cdc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5977dba-ba5d-44d2-bdec-5e204cb87546" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e5e34d66-1a48-444d-8a8f-e767d55cdc4a" xlink:to="loc_srt_ProductsAndServicesDomain_e5977dba-ba5d-44d2-bdec-5e204cb87546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_fd151d20-0eb4-49ea-9261-3857f54f4bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5977dba-ba5d-44d2-bdec-5e204cb87546" xlink:to="loc_us-gaap_RoyaltyMember_fd151d20-0eb4-49ea-9261-3857f54f4bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4f6fe450-11eb-40a6-bd92-4a52484289cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6007d14-7b02-4285-bcbc-2a7cdf26013c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4f6fe450-11eb-40a6-bd92-4a52484289cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4108edeb-edfd-4552-a5eb-79190ddcc59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4f6fe450-11eb-40a6-bd92-4a52484289cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4108edeb-edfd-4552-a5eb-79190ddcc59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1302e528-ba8b-4727-a9ff-afc43b547db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_978dcccc-197a-48dc-9b20-d9a69a503697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1302e528-ba8b-4727-a9ff-afc43b547db3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_978dcccc-197a-48dc-9b20-d9a69a503697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_978dcccc-197a-48dc-9b20-d9a69a503697" xlink:to="loc_us-gaap_FinancialInstrumentAxis_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_62cb36cc-1dc2-4a90-9ea0-c3ba944c22c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7b9d1caa-ba67-48fd-927c-d701b6727862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7b9d1caa-ba67-48fd-927c-d701b6727862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b5b0310b-432c-4506-9e41-89ac87b783e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_CommercialPaperMember_b5b0310b-432c-4506-9e41-89ac87b783e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_39976656-d1b4-493a-9a2d-3cebd986745d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_MoneyMarketFundsMember_39976656-d1b4-493a-9a2d-3cebd986745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_a5d1e874-4f3c-416f-944c-80d3642b3fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e79d407d-31a0-4368-b4ce-81897cda2837" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_a5d1e874-4f3c-416f-944c-80d3642b3fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_978dcccc-197a-48dc-9b20-d9a69a503697" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_13b03205-ba08-4637-b9e6-a2e3ca147805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_13b03205-ba08-4637-b9e6-a2e3ca147805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_db9e8cc7-a8f8-4898-8cad-9d78ac4a8d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_db9e8cc7-a8f8-4898-8cad-9d78ac4a8d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03152c87-fe48-49ca-8244-3d5c66aa7dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03152c87-fe48-49ca-8244-3d5c66aa7dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_53a984a9-d86c-4691-9696-32c9d96a254e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_913868df-c025-458f-b5a0-0d0795db32b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_53a984a9-d86c-4691-9696-32c9d96a254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_22d6ff26-1665-4351-8acc-21f4af2531f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_666ca512-8509-4463-b93e-0efda369e496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_22d6ff26-1665-4351-8acc-21f4af2531f0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_666ca512-8509-4463-b93e-0efda369e496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_5846f555-1a2a-4149-b13f-267ab631444a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_22d6ff26-1665-4351-8acc-21f4af2531f0" xlink:to="loc_us-gaap_MarketableSecurities_5846f555-1a2a-4149-b13f-267ab631444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ef8a025-1807-46f8-9685-5ceff49187b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_22d6ff26-1665-4351-8acc-21f4af2531f0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ef8a025-1807-46f8-9685-5ceff49187b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_93882702-abf3-4763-a10a-d95bca7f892f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f53c67e5-8a48-422f-9827-5e5c5f7b2917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_93882702-abf3-4763-a10a-d95bca7f892f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f53c67e5-8a48-422f-9827-5e5c5f7b2917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_96b5a243-f309-4920-a038-647129189273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f53c67e5-8a48-422f-9827-5e5c5f7b2917" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_96b5a243-f309-4920-a038-647129189273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_daaf8261-6f78-4867-942c-0de732fba42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f53c67e5-8a48-422f-9827-5e5c5f7b2917" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_daaf8261-6f78-4867-942c-0de732fba42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b79d877f-d9d0-4ab7-acb9-83efd24d50f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f53c67e5-8a48-422f-9827-5e5c5f7b2917" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b79d877f-d9d0-4ab7-acb9-83efd24d50f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c7b5921-72da-41bf-940b-946466692aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_93882702-abf3-4763-a10a-d95bca7f892f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c7b5921-72da-41bf-940b-946466692aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_0855661b-9c97-44cd-9611-a638a8a589af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c7b5921-72da-41bf-940b-946466692aed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_0855661b-9c97-44cd-9611-a638a8a589af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_c5391f2b-57fc-44e7-9b75-49289870fd54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c7b5921-72da-41bf-940b-946466692aed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_c5391f2b-57fc-44e7-9b75-49289870fd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b5e5482-8473-42d7-af8b-356d24ac36df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c7b5921-72da-41bf-940b-946466692aed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b5e5482-8473-42d7-af8b-356d24ac36df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c59b1610-0468-46b5-8a4a-a0845ea4053e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84d9ebea-1d8e-448c-9ae6-f6dc0c8821c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c59b1610-0468-46b5-8a4a-a0845ea4053e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84d9ebea-1d8e-448c-9ae6-f6dc0c8821c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ec7f63a-73b6-4e32-b770-1947d9af32e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84d9ebea-1d8e-448c-9ae6-f6dc0c8821c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ec7f63a-73b6-4e32-b770-1947d9af32e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ec7f63a-73b6-4e32-b770-1947d9af32e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_40cf4389-ed7d-407e-9919-c51574adc36e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:to="loc_us-gaap_ComputerEquipmentMember_40cf4389-ed7d-407e-9919-c51574adc36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_36980823-01f0-4592-a6fe-c9de27315093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8afac8d-bc77-4a3d-b50a-15e2f34ee388" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_36980823-01f0-4592-a6fe-c9de27315093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84d9ebea-1d8e-448c-9ae6-f6dc0c8821c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0d4bf1c4-6788-4c31-a30a-df7bb643c423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0d4bf1c4-6788-4c31-a30a-df7bb643c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e2fc895a-f2c7-42ba-80d7-4ac1be632c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e2fc895a-f2c7-42ba-80d7-4ac1be632c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31b88967-a14e-4824-ad64-a1e29c91c350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31b88967-a14e-4824-ad64-a1e29c91c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f0e4362c-65ac-418d-956b-c8f4ee0d5189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac7130cd-ea5d-40ed-b5d7-d8e5972c5851" xlink:to="loc_us-gaap_Depreciation_f0e4362c-65ac-418d-956b-c8f4ee0d5189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#IncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a4371bdb-e590-40f2-8509-09396da6a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_40782d6a-181d-4d0d-9a9c-fe24775783e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a4371bdb-e590-40f2-8509-09396da6a1b0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_40782d6a-181d-4d0d-9a9c-fe24775783e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d701d373-9223-4eef-a52b-6408524f7ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_40782d6a-181d-4d0d-9a9c-fe24775783e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d701d373-9223-4eef-a52b-6408524f7ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d701d373-9223-4eef-a52b-6408524f7ddd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a6ae09cb-c71c-419c-8c17-a721878322bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a6ae09cb-c71c-419c-8c17-a721878322bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_53529ebd-ba84-4219-8f49-724207ebc620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:to="loc_us-gaap_WarrantMember_53529ebd-ba84-4219-8f49-724207ebc620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_daa4981e-232c-4895-a1b9-ade2329c7457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3f60939-4c4f-42e5-b1d9-811c5e8b6867" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_daa4981e-232c-4895-a1b9-ade2329c7457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cebbe17-ce61-44a4-927a-5f2fee31d472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_40782d6a-181d-4d0d-9a9c-fe24775783e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cebbe17-ce61-44a4-927a-5f2fee31d472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c376d92-5c2d-4066-ba0e-906d07c506ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cebbe17-ce61-44a4-927a-5f2fee31d472" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c376d92-5c2d-4066-ba0e-906d07c506ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3a16e4ce-a77e-4765-a91a-07d6452acd05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a16e4ce-a77e-4765-a91a-07d6452acd05" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83705997-83cc-490c-9aff-85ec0e591f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83705997-83cc-490c-9aff-85ec0e591f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83705997-83cc-490c-9aff-85ec0e591f25" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b194ed5a-0319-45a0-ba37-e8997841f2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b194ed5a-0319-45a0-ba37-e8997841f2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e78c76e6-ef33-4471-812f-49517bcf6f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e78c76e6-ef33-4471-812f-49517bcf6f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a0bf72aa-fd4f-47a8-837c-ae10cfb5d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddc4dd2b-ef8b-4e07-ab29-d586a460f261" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a0bf72aa-fd4f-47a8-837c-ae10cfb5d3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe293095-09dd-40b1-810a-4ee83e26a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df3bd4ec-c2ef-4cf7-85cb-04a133aa9b06" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe293095-09dd-40b1-810a-4ee83e26a0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b377f859-04ff-4d31-b778-d9e73bcde543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe293095-09dd-40b1-810a-4ee83e26a0d6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b377f859-04ff-4d31-b778-d9e73bcde543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2f02ff57-4968-46e8-a8f6-48bb09e36578" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a68c9570-1329-4eec-8758-c2424a578212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a68c9570-1329-4eec-8758-c2424a578212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_caa64eb6-0ce2-42d0-8c6e-23f1fe0f9e00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_caa64eb6-0ce2-42d0-8c6e-23f1fe0f9e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9ae3943a-aa88-46c5-8bd5-e7db5ed4c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf7ce491-f5c2-452b-8fa1-c58328b1ca95" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9ae3943a-aa88-46c5-8bd5-e7db5ed4c56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0c02c55-856e-4d5c-a330-bcd321a7de35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0c02c55-856e-4d5c-a330-bcd321a7de35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities_76fe6a75-4186-499e-8a51-a0f9dd2235a7" xlink:href="lsta-20240331.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:to="loc_lsta_ClinicalAndRDRelatedLiabilities_76fe6a75-4186-499e-8a51-a0f9dd2235a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding_db6c56ea-1070-419a-ba61-f45d9e6bc41f" xlink:href="lsta-20240331.xsd#lsta_AccruedGrantFunding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:to="loc_lsta_AccruedGrantFunding_db6c56ea-1070-419a-ba61-f45d9e6bc41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LegalSettlementCurrent_48a337d3-07a5-4023-9b29-648f0ecec4fa" xlink:href="lsta-20240331.xsd#lsta_LegalSettlementCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:to="loc_lsta_LegalSettlementCurrent_48a337d3-07a5-4023-9b29-648f0ecec4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b43e24fe-e01a-4f96-a4c7-6beecad2f7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b43e24fe-e01a-4f96-a4c7-6beecad2f7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19f75b34-cbe0-440a-aca4-59a5809be66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19f75b34-cbe0-440a-aca4-59a5809be66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_88658aaa-c674-439b-97a8-58fe99addcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_20be5c2b-630c-40a0-a5a8-6a567c144b26" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_88658aaa-c674-439b-97a8-58fe99addcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a5ae74dd-7ffd-42b3-90d8-643a05557594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_44e01f84-27fb-4cbb-97bd-fa4bc669638b" xlink:href="lsta-20240331.xsd#lsta_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a5ae74dd-7ffd-42b3-90d8-643a05557594" xlink:to="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_44e01f84-27fb-4cbb-97bd-fa4bc669638b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5f541b5b-6acc-4c21-ac35-4762e0b5e19c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_44e01f84-27fb-4cbb-97bd-fa4bc669638b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5f541b5b-6acc-4c21-ac35-4762e0b5e19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a0f8a991-3f90-417a-9131-dce14c761789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_5f541b5b-6acc-4c21-ac35-4762e0b5e19c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a0f8a991-3f90-417a-9131-dce14c761789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_9b2ef4df-4528-4664-bca6-96b20c3f81c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a5ae74dd-7ffd-42b3-90d8-643a05557594" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_9b2ef4df-4528-4664-bca6-96b20c3f81c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c89a9379-93b9-4ef7-a245-55a48899c6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_9b2ef4df-4528-4664-bca6-96b20c3f81c1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c89a9379-93b9-4ef7-a245-55a48899c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f5c18343-4606-4833-b8d9-5efb037297d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_c89a9379-93b9-4ef7-a245-55a48899c6f5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f5c18343-4606-4833-b8d9-5efb037297d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a41172a5-4de4-4f1f-adca-14392178b2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_9b2ef4df-4528-4664-bca6-96b20c3f81c1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a41172a5-4de4-4f1f-adca-14392178b2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d8137b37-f38d-4dca-a5b6-1183d8008804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a41172a5-4de4-4f1f-adca-14392178b2c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d8137b37-f38d-4dca-a5b6-1183d8008804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3f724c57-2640-4dff-9ca0-39ff952e6ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_9b2ef4df-4528-4664-bca6-96b20c3f81c1" xlink:to="loc_us-gaap_OperatingLeaseLiability_3f724c57-2640-4dff-9ca0-39ff952e6ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a32a9c6b-7ce1-4a25-bd57-6d5c723309f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18ffc335-fcfa-466c-b1ca-cdbba856798a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a32a9c6b-7ce1-4a25-bd57-6d5c723309f4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_18ffc335-fcfa-466c-b1ca-cdbba856798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c9e539f5-bf66-4c4d-9f37-92dd62b671a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a32a9c6b-7ce1-4a25-bd57-6d5c723309f4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c9e539f5-bf66-4c4d-9f37-92dd62b671a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bf784668-e522-4191-810d-02b8b8fcf372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_60afa566-c700-4e97-bf55-7c2a2cfdf084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf784668-e522-4191-810d-02b8b8fcf372" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_60afa566-c700-4e97-bf55-7c2a2cfdf084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5abff7c0-96c6-4385-b4d8-d2695ae4050f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_60afa566-c700-4e97-bf55-7c2a2cfdf084" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5abff7c0-96c6-4385-b4d8-d2695ae4050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fb8e9bb6-ca3c-4651-8cf8-24df3228d0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_60afa566-c700-4e97-bf55-7c2a2cfdf084" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fb8e9bb6-ca3c-4651-8cf8-24df3228d0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9ce35240-7e01-4e41-95cb-ca063e62b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_60afa566-c700-4e97-bf55-7c2a2cfdf084" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9ce35240-7e01-4e41-95cb-ca063e62b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6d142266-dad4-48b7-aa49-0cabcd259353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_60afa566-c700-4e97-bf55-7c2a2cfdf084" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6d142266-dad4-48b7-aa49-0cabcd259353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2e5a4328-d181-4dcd-877d-0a4d39dc076a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_60afa566-c700-4e97-bf55-7c2a2cfdf084" xlink:to="loc_us-gaap_OperatingLeaseLiability_2e5a4328-d181-4dcd-877d-0a4d39dc076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_00d116f4-b8b5-405e-813a-f3bbcfd7566e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_00d116f4-b8b5-405e-813a-f3bbcfd7566e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0fe14745-61dc-44a7-8fd8-7456cbdbded7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0fe14745-61dc-44a7-8fd8-7456cbdbded7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0cbbb73-f9d3-4d14-adb7-6e685c8eb42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0fe14745-61dc-44a7-8fd8-7456cbdbded7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0cbbb73-f9d3-4d14-adb7-6e685c8eb42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember_1f2bbd62-3cf5-47a2-b436-35c69c5dec11" xlink:href="lsta-20240331.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0cbbb73-f9d3-4d14-adb7-6e685c8eb42b" xlink:to="loc_lsta_AtTheMarketOfferingAgreementMember_1f2bbd62-3cf5-47a2-b436-35c69c5dec11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_580685bc-88bc-46b7-a221-aa05393590e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_580685bc-88bc-46b7-a221-aa05393590e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7cbed2a1-952f-4820-8073-57e7c018e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_580685bc-88bc-46b7-a221-aa05393590e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7cbed2a1-952f-4820-8073-57e7c018e3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_084c4034-ff58-4f8b-b9bb-3ef21853890d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7cbed2a1-952f-4820-8073-57e7c018e3dc" xlink:to="loc_us-gaap_SubsequentEventMember_084c4034-ff58-4f8b-b9bb-3ef21853890d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_be0e42f0-6869-4d91-8cba-bbb088370dcc" xlink:to="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2fd56bd9-374b-4922-910c-38616a7b472b" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2fd56bd9-374b-4922-910c-38616a7b472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d3e552ca-bf28-4687-9406-cc2704b088d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d3e552ca-bf28-4687-9406-cc2704b088d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold_444efefa-8381-45c6-872f-08c03e0cd107" xlink:href="lsta-20240331.xsd#lsta_OutstandingStockThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_OutstandingStockThreshold_444efefa-8381-45c6-872f-08c03e0cd107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale_cf533229-dfcc-4846-93e1-237d8f9c4084" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_SaleOfStockAvailableForSale_cf533229-dfcc-4846-93e1-237d8f9c4084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage_677d65c4-f163-4c76-8e1e-7ee7d676f493" xlink:href="lsta-20240331.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_lsta_SaleOfStockAvailableForSalePercentage_677d65c4-f163-4c76-8e1e-7ee7d676f493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7163226-df08-4faf-b757-10cc2cb7d60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7163226-df08-4faf-b757-10cc2cb7d60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b09b176e-95fb-4a13-a94e-4437528707e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6e9cfe0-c378-4e9a-aa47-82e8e9a88eed" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b09b176e-95fb-4a13-a94e-4437528707e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityStockOptionsandWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e8f21047-d3e0-4abf-8118-ec0de29bb602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e8f21047-d3e0-4abf-8118-ec0de29bb602" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b856f9a-231a-4a6d-92f7-65500b8c388c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:to="loc_us-gaap_AwardTypeAxis_7b856f9a-231a-4a6d-92f7-65500b8c388c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f874bdf-01b4-48fa-b376-380b6f81f7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7b856f9a-231a-4a6d-92f7-65500b8c388c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f874bdf-01b4-48fa-b376-380b6f81f7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a9ec9832-4dbe-4f1f-9221-d6f3a2dbc1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f874bdf-01b4-48fa-b376-380b6f81f7ca" xlink:to="loc_us-gaap_RestrictedStockMember_a9ec9832-4dbe-4f1f-9221-d6f3a2dbc1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6e5fd2d-b22b-4f81-971c-fe426f9186c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:to="loc_srt_RangeAxis_b6e5fd2d-b22b-4f81-971c-fe426f9186c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b6e5fd2d-b22b-4f81-971c-fe426f9186c9" xlink:to="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3da892e-49ca-4919-94d4-fec3f7ed93fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:to="loc_srt_MinimumMember_f3da892e-49ca-4919-94d4-fec3f7ed93fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b5e3fc36-f14e-43ef-bdb8-b9700fe99e58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0832b046-2207-4e83-ad90-b015ee74ee4b" xlink:to="loc_srt_MaximumMember_b5e3fc36-f14e-43ef-bdb8-b9700fe99e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_295d2810-03f3-44ad-bcb4-4a92060090fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80533a47-99be-445d-ba0a-f5aa95224816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_295d2810-03f3-44ad-bcb4-4a92060090fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0c89883-160f-4597-995b-858b4351db23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_295d2810-03f3-44ad-bcb4-4a92060090fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0c89883-160f-4597-995b-858b4351db23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aeccec76-ab16-4ffe-bf79-1a48baaeb269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aeccec76-ab16-4ffe-bf79-1a48baaeb269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2b441e91-5484-40a0-a5b6-bb1d88339877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2b441e91-5484-40a0-a5b6-bb1d88339877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e35cc770-7f75-4cc2-b928-2f61d5267bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e35cc770-7f75-4cc2-b928-2f61d5267bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f8fc14b-9fbc-4c87-931c-63af1211e759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f8fc14b-9fbc-4c87-931c-63af1211e759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55d9c376-8167-4956-a8a6-55fc01c5b6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55d9c376-8167-4956-a8a6-55fc01c5b6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cb4d5361-e770-4a8b-a22d-cc459b0ea7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cb4d5361-e770-4a8b-a22d-cc459b0ea7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3af04a1f-868a-4a89-beb9-f4c9af185ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_53a59bfa-de1a-4dd5-b0fb-c1dc93e5e668" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3af04a1f-868a-4a89-beb9-f4c9af185ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32dde1ec-2b03-4fe5-abfb-e93185e8c261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32dde1ec-2b03-4fe5-abfb-e93185e8c261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_913cd307-1228-4428-9da9-3da72d0f0c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_913cd307-1228-4428-9da9-3da72d0f0c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8604832-b3dc-449d-8afb-cca2c118ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8604832-b3dc-449d-8afb-cca2c118ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9a4787ec-4375-4a9a-9810-0e0075682d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9a4787ec-4375-4a9a-9810-0e0075682d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ddcd8ff9-543d-4c9d-badd-7c27b3b5768b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ddcd8ff9-543d-4c9d-badd-7c27b3b5768b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_25534cd3-fca8-443f-b307-4ebcc8ef1e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_25534cd3-fca8-443f-b307-4ebcc8ef1e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7bcec645-b1cb-4f9e-bf33-ef1669056a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7bcec645-b1cb-4f9e-bf33-ef1669056a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0ae7c59-22b4-459b-97c8-3787852e1c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcede29e-328c-4032-a08f-384fac95eedf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0ae7c59-22b4-459b-97c8-3787852e1c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_744d4520-456b-4373-bc5c-39a3cfa11097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_744d4520-456b-4373-bc5c-39a3cfa11097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98fca345-8ecd-4500-b685-bf37030c7983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98fca345-8ecd-4500-b685-bf37030c7983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cc138d9b-8463-46af-867b-8fbc4332c291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3766f75-14f3-4227-be0d-7ff3e209c31b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3766f75-14f3-4227-be0d-7ff3e209c31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4a4b1095-6c6f-4d5b-bd66-7ad45798fd32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4a4b1095-6c6f-4d5b-bd66-7ad45798fd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm_856fdbed-8aa5-475e-95a7-0e01b18bee30" xlink:href="lsta-20240331.xsd#lsta_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:to="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm_856fdbed-8aa5-475e-95a7-0e01b18bee30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e51c1454-2548-42d0-9b46-219fdcb981a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e51c1454-2548-42d0-9b46-219fdcb981a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0b206afa-d416-4bf8-8c81-8fb2c228f34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0b206afa-d416-4bf8-8c81-8fb2c228f34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_b7174d50-0450-4226-b52b-ae2e4a611e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab8279bb-1c07-4f74-94bc-87661ace1a20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_b7174d50-0450-4226-b52b-ae2e4a611e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aeccec76-ab16-4ffe-bf79-1a48baaeb269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares_5b69b702-f765-4f88-b7cb-dddc6eae6286" xlink:href="lsta-20240331.xsd#lsta_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:to="loc_lsta_CommonStockWarrantsShares_5b69b702-f765-4f88-b7cb-dddc6eae6286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsGranted_8f5d2f49-ef22-49f6-8662-da0e539cf352" xlink:href="lsta-20240331.xsd#lsta_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:to="loc_lsta_WarrantsGranted_8f5d2f49-ef22-49f6-8662-da0e539cf352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExercised_d2b32835-44ba-4932-a323-cbae0c23b304" xlink:href="lsta-20240331.xsd#lsta_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:to="loc_lsta_WarrantsExercised_d2b32835-44ba-4932-a323-cbae0c23b304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsCanceled_4304fcbb-550e-4e73-a0f7-03e1d65175c5" xlink:href="lsta-20240331.xsd#lsta_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:to="loc_lsta_WarrantsCanceled_4304fcbb-550e-4e73-a0f7-03e1d65175c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExpired_33c539f7-7814-4164-a56e-d68b4e70c74c" xlink:href="lsta-20240331.xsd#lsta_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:to="loc_lsta_WarrantsExpired_33c539f7-7814-4164-a56e-d68b4e70c74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares_96c93f53-5648-433b-8bc7-863df419df87" xlink:href="lsta-20240331.xsd#lsta_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f5d0e96-effc-46ad-b46f-e6c2216abae4" xlink:to="loc_lsta_CommonStockWarrantsShares_96c93f53-5648-433b-8bc7-863df419df87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_Sharesvestedandexpectedtovest_264a6fcd-dbb7-4f76-90fa-e919350b1f4b" xlink:href="lsta-20240331.xsd#lsta_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:to="loc_lsta_Sharesvestedandexpectedtovest_264a6fcd-dbb7-4f76-90fa-e919350b1f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsVested_36f3e781-2764-43b0-92ef-faa1372d6011" xlink:href="lsta-20240331.xsd#lsta_WarrantsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:to="loc_lsta_WarrantsVested_36f3e781-2764-43b0-92ef-faa1372d6011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:href="lsta-20240331.xsd#lsta_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:to="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_e7591c00-65b3-4651-a50b-97ef11c0afb7" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_e7591c00-65b3-4651-a50b-97ef11c0afb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsGranted_fc4c071f-73cb-4a32-bf90-7765a47b2824" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsGranted_fc4c071f-73cb-4a32-bf90-7765a47b2824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercised_e7ccde75-51dc-4f96-ba7a-edca6bfb58c1" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExercised_e7ccde75-51dc-4f96-ba7a-edca6bfb58c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled_c984b13e-51a1-4cfb-9282-f26e16524bf6" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled_c984b13e-51a1-4cfb-9282-f26e16524bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExpired_65d2cd05-0eb8-4573-b5d4-10be8e9c2164" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExpired_65d2cd05-0eb8-4573-b5d4-10be8e9c2164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_e57c8181-2759-4823-80f9-a3b971bf55ef" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_df19c601-2086-4d1a-a3bf-8f5bb28922d1" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_e57c8181-2759-4823-80f9-a3b971bf55ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_a7043098-65b0-4c80-841e-bc865d8f0aa7" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_a7043098-65b0-4c80-841e-bc865d8f0aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable_5d3e63a3-48d7-4667-9a0c-4c6e3a1b5337" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable_5d3e63a3-48d7-4667-9a0c-4c6e3a1b5337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:href="lsta-20240331.xsd#lsta_WarrantsOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4e0cfdc9-cba4-46d4-a961-f4f4ac3095b4" xlink:to="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_c242087a-ddd2-4000-ac44-6816b0013387" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_c242087a-ddd2-4000-ac44-6816b0013387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_6c5e7943-4951-45da-94ff-8a0fd4e4d089" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_6c5e7943-4951-45da-94ff-8a0fd4e4d089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested_757eb773-b5b4-4e4f-af2d-44bcae5f379f" xlink:href="lsta-20240331.xsd#lsta_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested_757eb773-b5b4-4e4f-af2d-44bcae5f379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding_abe98bb3-ea21-4c06-93c4-434ac851376a" xlink:href="lsta-20240331.xsd#lsta_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding_abe98bb3-ea21-4c06-93c4-434ac851376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_7094f5e1-260c-47a3-90c3-5986d65dd10f" xlink:href="lsta-20240331.xsd#lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_7094f5e1-260c-47a3-90c3-5986d65dd10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvested_dff57b35-b196-4fbc-9790-224d8a702331" xlink:href="lsta-20240331.xsd#lsta_AggregateIntrinsicValueWarrantsvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_87d0e4ad-eb90-41d5-bc53-3c978d5b775f" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsvested_dff57b35-b196-4fbc-9790-224d8a702331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c0439af9-c23e-4178-ac88-81c0cc926434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44ae78f8-65df-4cc5-abea-77e7b46d33b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c0439af9-c23e-4178-ac88-81c0cc926434" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44ae78f8-65df-4cc5-abea-77e7b46d33b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_863d6dc1-f096-4ea9-82b6-1e5518d68b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44ae78f8-65df-4cc5-abea-77e7b46d33b9" xlink:to="loc_us-gaap_AwardTypeAxis_863d6dc1-f096-4ea9-82b6-1e5518d68b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_863d6dc1-f096-4ea9-82b6-1e5518d68b04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_77ae3023-776e-4754-926c-7f5a62cc0815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_77ae3023-776e-4754-926c-7f5a62cc0815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0171cfdf-13d9-431d-9730-9a34636c532c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f572f38-0a49-45d5-8e1d-dd5b1bb02e4c" xlink:to="loc_us-gaap_RestrictedStockMember_0171cfdf-13d9-431d-9730-9a34636c532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44ae78f8-65df-4cc5-abea-77e7b46d33b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3435c8b5-2a8a-455b-9485-e28cfee5a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3435c8b5-2a8a-455b-9485-e28cfee5a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_6e2f8583-5862-4d45-92f7-e2e2c02711d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_6e2f8583-5862-4d45-92f7-e2e2c02711d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5769f858-c47e-4746-b267-dfc728a1c4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5769f858-c47e-4746-b267-dfc728a1c4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31dbf21-b269-4921-a474-f4857f97f9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9bbe3aa3-f33e-4ae5-b95a-e4d896c98943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31dbf21-b269-4921-a474-f4857f97f9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_af1cc1cc-a642-4471-8107-297c7d1e08ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6005f2db-711d-4f6c-b740-f00ea19aac28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_af1cc1cc-a642-4471-8107-297c7d1e08ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6005f2db-711d-4f6c-b740-f00ea19aac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d760337f-6069-4b9b-be6c-9105c313a181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6005f2db-711d-4f6c-b740-f00ea19aac28" xlink:to="loc_us-gaap_AwardTypeAxis_d760337f-6069-4b9b-be6c-9105c313a181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d760337f-6069-4b9b-be6c-9105c313a181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b85b563e-6bfa-4f8b-b652-c55709692c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:to="loc_us-gaap_RestrictedStockMember_b85b563e-6bfa-4f8b-b652-c55709692c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_41780032-a5c1-46a4-9280-3f5bec5f5e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9af73c5-ded8-4374-a33b-b08dd264e564" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_41780032-a5c1-46a4-9280-3f5bec5f5e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6005f2db-711d-4f6c-b740-f00ea19aac28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67fa583a-880f-433c-814d-882587a61605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67fa583a-880f-433c-814d-882587a61605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d7ffe8c-e31f-4829-815a-a835de6a75d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7d7ffe8c-e31f-4829-815a-a835de6a75d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_47bbb4e6-790b-4a27-8e4a-9e4a86fb26ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_47bbb4e6-790b-4a27-8e4a-9e4a86fb26ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24084e03-c230-454d-9aed-87923890b89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24084e03-c230-454d-9aed-87923890b89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b4dabcc5-f067-499e-9892-817fcd56179f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9273bf1d-5f03-4017-9425-c9b7d9985fcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b4dabcc5-f067-499e-9892-817fcd56179f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_545da0e5-8b50-4252-809f-27f85f0f799b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0af212-52fb-4de8-b7bc-7c87ca3146eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0af212-52fb-4de8-b7bc-7c87ca3146eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57c1b673-4ca1-4142-9ae9-da6b4349abb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57c1b673-4ca1-4142-9ae9-da6b4349abb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_453e2573-9ab2-4d9b-95e1-7af6c9f931ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_453e2573-9ab2-4d9b-95e1-7af6c9f931ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23a65a88-bffe-40f9-98f6-e8b1934a2e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23a65a88-bffe-40f9-98f6-e8b1934a2e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bfe9a9ec-a0b0-4fdc-8263-64280d625e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_192cfa65-6a19-4f1e-9c0d-4b734f38cd91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bfe9a9ec-a0b0-4fdc-8263-64280d625e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1ec6ac7-918a-4486-9b95-912426816ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ece0df7d-ff35-44b1-97a3-879caf0fff38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1ec6ac7-918a-4486-9b95-912426816ab6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ece0df7d-ff35-44b1-97a3-879caf0fff38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_562bc64c-8cf7-4276-b4a4-a5ef69fbf299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ece0df7d-ff35-44b1-97a3-879caf0fff38" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_562bc64c-8cf7-4276-b4a4-a5ef69fbf299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_562bc64c-8cf7-4276-b4a4-a5ef69fbf299" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5b6381ee-a20d-4c0f-878e-95c25de36c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5b6381ee-a20d-4c0f-878e-95c25de36c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dccca4e4-0f35-4b51-b81e-f0ad6a52d8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b824b7e-41b4-4123-a14f-79a56c977d77" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dccca4e4-0f35-4b51-b81e-f0ad6a52d8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691a7be8-4b37-4d30-9bb4-a6848d86623e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ece0df7d-ff35-44b1-97a3-879caf0fff38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691a7be8-4b37-4d30-9bb4-a6848d86623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ece745e1-1690-42c9-aba4-014d76c7c0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691a7be8-4b37-4d30-9bb4-a6848d86623e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ece745e1-1690-42c9-aba4-014d76c7c0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3153b86-0bd6-4375-8545-65f1c55e0875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0378ea08-c50c-4e65-9dde-c731477a215e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3153b86-0bd6-4375-8545-65f1c55e0875" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0378ea08-c50c-4e65-9dde-c731477a215e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_daa977c8-b56d-4203-b317-5c028140ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0378ea08-c50c-4e65-9dde-c731477a215e" xlink:to="loc_us-gaap_AwardTypeAxis_daa977c8-b56d-4203-b317-5c028140ddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_daa977c8-b56d-4203-b317-5c028140ddc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_be6d6521-0381-4804-821c-304b2cbbce76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_be6d6521-0381-4804-821c-304b2cbbce76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_16405873-08b8-454c-ae0d-e361e4578644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_16405873-08b8-454c-ae0d-e361e4578644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1157711e-c1a1-471a-b42e-884fac9358f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4af78b8a-fa3a-4e85-9fa8-cdca0e1711a0" xlink:to="loc_us-gaap_RestrictedStockMember_1157711e-c1a1-471a-b42e-884fac9358f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0378ea08-c50c-4e65-9dde-c731477a215e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc8762f4-f8bc-48e5-b343-0fd9a7e4786a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc8762f4-f8bc-48e5-b343-0fd9a7e4786a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2fa2f04-dd1b-4957-a586-5e0168946f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c824906-55e1-4125-b891-daf95c0ce382" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b2fa2f04-dd1b-4957-a586-5e0168946f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b6f9f5e-81f6-4741-a2f3-9b210045f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98346733-5270-4071-b0c6-641be0f8c7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b6f9f5e-81f6-4741-a2f3-9b210045f5a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98346733-5270-4071-b0c6-641be0f8c7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91a5408c-476b-4816-9309-857a516b58ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98346733-5270-4071-b0c6-641be0f8c7bc" xlink:to="loc_us-gaap_AwardTypeAxis_91a5408c-476b-4816-9309-857a516b58ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a75e8027-1856-4bdd-a662-0e39331fc002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_91a5408c-476b-4816-9309-857a516b58ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a75e8027-1856-4bdd-a662-0e39331fc002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a380c71-359f-4377-87cb-2a22ef4fb905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a75e8027-1856-4bdd-a662-0e39331fc002" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a380c71-359f-4377-87cb-2a22ef4fb905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98346733-5270-4071-b0c6-641be0f8c7bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_06e02ae7-ff47-4e56-8f85-9e27da3e8f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_06e02ae7-ff47-4e56-8f85-9e27da3e8f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d85d2b4-8621-402c-b5cd-7ab3b9c957db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fca0b05-e313-47aa-8427-1bf14d29d0f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d85d2b4-8621-402c-b5cd-7ab3b9c957db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0ff68a28-78eb-4eeb-8a62-bd29bc0c5744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0ff68a28-78eb-4eeb-8a62-bd29bc0c5744" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d1311860-d561-4209-a3a1-f11d00d097c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d1311860-d561-4209-a3a1-f11d00d097c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d1311860-d561-4209-a3a1-f11d00d097c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_69986fbd-36d4-48c7-b550-f33099ab56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:to="loc_us-gaap_DomesticCountryMember_69986fbd-36d4-48c7-b550-f33099ab56f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e36e4962-2f29-49f1-9180-703e65960969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e36e4962-2f29-49f1-9180-703e65960969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_daff5249-529a-4333-8232-2c361795297e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c4523043-8fe1-4905-8d49-462a431395a6" xlink:to="loc_us-gaap_ForeignCountryMember_daff5249-529a-4333-8232-2c361795297e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_4510527f-4fb6-4d2c-b054-71a759d66272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_4510527f-4fb6-4d2c-b054-71a759d66272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_4510527f-4fb6-4d2c-b054-71a759d66272" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_bc26045f-67fa-48fc-ad97-f3d01a17ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_bc26045f-67fa-48fc-ad97-f3d01a17ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_ffff8512-a6e9-4830-8106-f6402bc6a7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_ffff8512-a6e9-4830-8106-f6402bc6a7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_a0bb3bca-8bc6-4297-9a5e-de1b47625a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9b93f9d8-2205-4e35-b9a3-41e060264ce9" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_a0bb3bca-8bc6-4297-9a5e-de1b47625a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a2862fdf-4025-4764-a36c-93267509702f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_dei_LegalEntityAxis_a2862fdf-4025-4764-a36c-93267509702f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f8f9850-d82c-4cc6-b2c1-5cd41420207a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a2862fdf-4025-4764-a36c-93267509702f" xlink:to="loc_dei_EntityDomain_2f8f9850-d82c-4cc6-b2c1-5cd41420207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_acbdb86b-51e7-48fa-9514-c00eafff9b3d" xlink:href="lsta-20240331.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2f8f9850-d82c-4cc6-b2c1-5cd41420207a" xlink:to="loc_lsta_CENDMember_acbdb86b-51e7-48fa-9514-c00eafff9b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c5495ce4-202e-422d-8872-c6e0ca28909a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c5495ce4-202e-422d-8872-c6e0ca28909a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_72d739d1-207d-46e9-80fb-aab27398de95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c5495ce4-202e-422d-8872-c6e0ca28909a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_72d739d1-207d-46e9-80fb-aab27398de95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_5c6b6f75-e373-4c51-8ba8-4a5975fafee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_72d739d1-207d-46e9-80fb-aab27398de95" xlink:to="loc_us-gaap_ResearchMember_5c6b6f75-e373-4c51-8ba8-4a5975fafee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_5d6c9047-7deb-4962-b352-13fb6b089629" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_9b05aa67-1674-4f92-a05e-7311d923a509" xlink:href="lsta-20240331.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_9b05aa67-1674-4f92-a05e-7311d923a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1781885d-727f-4a6e-8d31-b0f5682145cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1781885d-727f-4a6e-8d31-b0f5682145cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_90fdd5ae-3ada-48ad-87cc-137f26cdfb24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_90fdd5ae-3ada-48ad-87cc-137f26cdfb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs_488b4f1d-1ff8-401f-bafb-0814179ee1be" xlink:href="lsta-20240331.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_FairValueMarketOfTaxNOLs_488b4f1d-1ff8-401f-bafb-0814179ee1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a279b3d7-29ce-45b8-b3b7-ae44109bbadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a279b3d7-29ce-45b8-b3b7-ae44109bbadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_5c43cf8c-a437-4088-8f60-7729afaae535" xlink:href="lsta-20240331.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_5c43cf8c-a437-4088-8f60-7729afaae535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition_64520c85-6b11-48a1-8663-9e9cd8f6ea03" xlink:href="lsta-20240331.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_OperatingLossCarryforwardsPostAcquisition_64520c85-6b11-48a1-8663-9e9cd8f6ea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e6010604-e439-4850-a4b3-208ec129af96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e6010604-e439-4850-a4b3-208ec129af96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_728d7e6c-7294-452d-a6ba-b1089567ba2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_728d7e6c-7294-452d-a6ba-b1089567ba2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_124bc285-add2-4c1a-943b-22bf2bef42cf" xlink:href="lsta-20240331.xsd#lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_124bc285-add2-4c1a-943b-22bf2bef42cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS_d576f744-728f-46fd-a3de-90ef208899fe" xlink:href="lsta-20240331.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_ProceedsFromSaleOfNOLS_d576f744-728f-46fd-a3de-90ef208899fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c06d7b17-c704-4097-8c2a-6b82f338564f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c06d7b17-c704-4097-8c2a-6b82f338564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL_f251709e-7bdc-44ef-9a35-a11a03c8494e" xlink:href="lsta-20240331.xsd#lsta_LossOnSaleOfNOL"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ea1861d-42ff-46cd-b5bd-c04b2cefa4c0" xlink:to="loc_lsta_LossOnSaleOfNOL_f251709e-7bdc-44ef-9a35-a11a03c8494e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#AustraliaResearchandDevelopmentTaxIncentiveDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_af1ca0e1-a0e8-440b-b350-ef20a82d5c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_2aa57451-d0a8-413e-a962-a7fed4d3dca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af1ca0e1-a0e8-440b-b350-ef20a82d5c66" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_2aa57451-d0a8-413e-a962-a7fed4d3dca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55838743-989c-477d-81d1-08ed325a35b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_2aa57451-d0a8-413e-a962-a7fed4d3dca3" xlink:to="loc_srt_RangeAxis_55838743-989c-477d-81d1-08ed325a35b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_55838743-989c-477d-81d1-08ed325a35b0" xlink:to="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bc9ef81-1355-4448-a440-bda99afdcb81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:to="loc_srt_MinimumMember_4bc9ef81-1355-4448-a440-bda99afdcb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56a539cf-9c6a-4f31-9485-e9d62259ef7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee4faa73-0b60-4fea-9ecf-f1840c8039cc" xlink:to="loc_srt_MaximumMember_56a539cf-9c6a-4f31-9485-e9d62259ef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_2aa57451-d0a8-413e-a962-a7fed4d3dca3" xlink:to="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f9f100ff-9205-4891-ad25-8462a3d1f2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f9f100ff-9205-4891-ad25-8462a3d1f2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable_efac3c03-e2aa-400e-9946-6428b3e4b447" xlink:href="lsta-20240331.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_cb57bced-127c-44f2-9c51-ad22a7acc748" xlink:to="loc_lsta_IncomeTaxIncentiveReceivable_efac3c03-e2aa-400e-9946-6428b3e4b447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db1070d0-5620-4df8-97bb-609de968a7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7753646a-232c-46f4-84cd-d03d99d3f99d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db1070d0-5620-4df8-97bb-609de968a7d0" xlink:to="loc_us-gaap_LossContingenciesTable_7753646a-232c-46f4-84cd-d03d99d3f99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3446c8d7-2418-4472-b63a-486f3af1e890" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7753646a-232c-46f4-84cd-d03d99d3f99d" xlink:to="loc_srt_LitigationCaseAxis_3446c8d7-2418-4472-b63a-486f3af1e890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1313149d-8062-4145-873d-9832c56cfbae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3446c8d7-2418-4472-b63a-486f3af1e890" xlink:to="loc_srt_LitigationCaseTypeDomain_1313149d-8062-4145-873d-9832c56cfbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_58e4f165-41e8-4edd-9caf-6b9483748b56" xlink:href="lsta-20240331.xsd#lsta_LingmedLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1313149d-8062-4145-873d-9832c56cfbae" xlink:to="loc_lsta_LingmedLimitedMember_58e4f165-41e8-4edd-9caf-6b9483748b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7753646a-232c-46f4-84cd-d03d99d3f99d" xlink:to="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_423ac52f-11e0-496a-8e77-00595f557c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_423ac52f-11e0-496a-8e77-00595f557c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementPaymentTerm_02d7c164-8cad-4963-a45a-f1ea49a8a38a" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementPaymentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_lsta_LitigationSettlementPaymentTerm_02d7c164-8cad-4963-a45a-f1ea49a8a38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_33bfd884-c414-453d-992a-d97c68da59f7" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_33bfd884-c414-453d-992a-d97c68da59f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_7ff10ac4-5a10-4bae-9dfa-96250085d2e2" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_17978cbd-f952-491a-925d-815bae31316a" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_7ff10ac4-5a10-4bae-9dfa-96250085d2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#TechnologyTransferAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract_960e7324-4203-49fe-ad5e-919bdec55f12" xlink:href="lsta-20240331.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_21b24fe1-4de4-486a-a7a2-f89793785ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract_960e7324-4203-49fe-ad5e-919bdec55f12" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_21b24fe1-4de4-486a-a7a2-f89793785ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd5d4e09-da68-4977-a8ef-c298610f695e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_21b24fe1-4de4-486a-a7a2-f89793785ab5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd5d4e09-da68-4977-a8ef-c298610f695e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_698cd1e0-61d6-4962-8050-841bf7b72c0c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd5d4e09-da68-4977-a8ef-c298610f695e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_698cd1e0-61d6-4962-8050-841bf7b72c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_350333b8-460a-4d13-9328-e12eea39803f" xlink:href="lsta-20240331.xsd#lsta_ImpiloMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_698cd1e0-61d6-4962-8050-841bf7b72c0c" xlink:to="loc_lsta_ImpiloMember_350333b8-460a-4d13-9328-e12eea39803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_21b24fe1-4de4-486a-a7a2-f89793785ab5" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3027d76d-3742-4644-9716-e4515823d1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3027d76d-3742-4644-9716-e4515823d1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares_ad7c43b2-a3a7-4360-aa73-381fc677174b" xlink:href="lsta-20240331.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_lsta_InvestmentOwnedCanceledShares_ad7c43b2-a3a7-4360-aa73-381fc677174b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0a5fa041-946b-4d48-ad71-8b793a7b26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0a5fa041-946b-4d48-ad71-8b793a7b26bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_e7a8a208-34d8-466d-a3ff-cdbdba844cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_e7a8a208-34d8-466d-a3ff-cdbdba844cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b54ee183-23ec-4aba-a3c7-b807a06a300f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b54ee183-23ec-4aba-a3c7-b807a06a300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEValuationCap_9f83afdd-57cd-4853-8cdd-0ee89d1df222" xlink:href="lsta-20240331.xsd#lsta_SAFEValuationCap"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_lsta_SAFEValuationCap_9f83afdd-57cd-4853-8cdd-0ee89d1df222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEDiscountRate_5f5d7054-6dd5-454a-b532-7e5778d183bc" xlink:href="lsta-20240331.xsd#lsta_SAFEDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_ff4b9192-f3c7-4edc-ae29-8d3a7a0911e5" xlink:to="loc_lsta_SAFEDiscountRate_5f5d7054-6dd5-454a-b532-7e5778d183bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_38a7405b-c058-42db-b32e-890be3db337f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_38a7405b-c058-42db-b32e-890be3db337f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cb1cb62d-78eb-4f06-a282-ab2647867d99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:to="loc_srt_CounterpartyNameAxis_cb1cb62d-78eb-4f06-a282-ab2647867d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63b0cccc-ede8-4a4e-8d43-76168e8660e4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cb1cb62d-78eb-4f06-a282-ab2647867d99" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63b0cccc-ede8-4a4e-8d43-76168e8660e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember_38c5812a-74a1-4e04-a92a-54432ca3e482" xlink:href="lsta-20240331.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63b0cccc-ede8-4a4e-8d43-76168e8660e4" xlink:to="loc_lsta_SanfordBurnhamPrebysMember_38c5812a-74a1-4e04-a92a-54432ca3e482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a643c037-3667-49ce-b6bf-603ff3faa7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a643c037-3667-49ce-b6bf-603ff3faa7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e919f0b-b99c-4184-a81b-008b75961daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a643c037-3667-49ce-b6bf-603ff3faa7da" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e919f0b-b99c-4184-a81b-008b75961daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_da227193-16c2-410a-ad85-3a57cc83685e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e919f0b-b99c-4184-a81b-008b75961daf" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_da227193-16c2-410a-ad85-3a57cc83685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85ba9156-9892-4674-a4b7-62bfe941365b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85ba9156-9892-4674-a4b7-62bfe941365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a158c33e-bbe3-4f32-a930-53919623e136" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85ba9156-9892-4674-a4b7-62bfe941365b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a158c33e-bbe3-4f32-a930-53919623e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_ae52cf30-1164-44df-b443-a0db1d44ad52" xlink:href="lsta-20240331.xsd#lsta_ImpiloMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a158c33e-bbe3-4f32-a930-53919623e136" xlink:to="loc_lsta_ImpiloMember_ae52cf30-1164-44df-b443-a0db1d44ad52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f8933b4f-328c-4975-8eb4-f48890dff3d2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement_b51c48dd-853c-4ba0-b5e4-c177b2fb3660" xlink:href="lsta-20240331.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_SharesIssuedUnderLicenseAgreement_b51c48dd-853c-4ba0-b5e4-c177b2fb3660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_b36e28c6-96c2-45f0-ad18-ac237120a133" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_b36e28c6-96c2-45f0-ad18-ac237120a133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_ef0fd99a-6a5a-4564-96d0-cff5952fa0cb" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_ef0fd99a-6a5a-4564-96d0-cff5952fa0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_d8dbba42-1411-4efc-87be-a8174113f5b1" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_d8dbba42-1411-4efc-87be-a8174113f5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_1ccb8af4-8aed-4a4c-b2ed-bdd96b7d7bfb" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_1ccb8af4-8aed-4a4c-b2ed-bdd96b7d7bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_486f3f10-bd4d-4a98-8915-a52e8e2613c1" xlink:href="lsta-20240331.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_486f3f10-bd4d-4a98-8915-a52e8e2613c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_1b99dd43-11a5-499a-b89b-fcdf1ccfabc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_1b99dd43-11a5-499a-b89b-fcdf1ccfabc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty_150ca386-5778-4a49-b790-f36216cdbc11" xlink:href="lsta-20240331.xsd#lsta_SharesHeldByThirdParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7f0f2bd2-21c3-414e-9a78-6075b4c7d2a4" xlink:to="loc_lsta_SharesHeldByThirdParty_150ca386-5778-4a49-b790-f36216cdbc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="lsta-20240331.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da5b9527-5a22-4632-8a3c-599de57749c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da5b9527-5a22-4632-8a3c-599de57749c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0de2eecc-594e-4126-9d0b-ec72113e0da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0de2eecc-594e-4126-9d0b-ec72113e0da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fe7cdd2-0623-4573-a8e6-cecd2ee26c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0de2eecc-594e-4126-9d0b-ec72113e0da8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fe7cdd2-0623-4573-a8e6-cecd2ee26c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_9c192d79-b945-4ba8-96e4-aac5524ff76a" xlink:href="lsta-20240331.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fe7cdd2-0623-4573-a8e6-cecd2ee26c49" xlink:to="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_9c192d79-b945-4ba8-96e4-aac5524ff76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e05dbc5-abc0-418e-b94a-83e06791bae0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_CounterpartyNameAxis_7e05dbc5-abc0-418e-b94a-83e06791bae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae79f79-4417-417b-87b8-a768cee8c66f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7e05dbc5-abc0-418e-b94a-83e06791bae0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae79f79-4417-417b-87b8-a768cee8c66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember_08a7472b-38a6-47a6-966f-f5103cf036ae" xlink:href="lsta-20240331.xsd#lsta_QiluMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae79f79-4417-417b-87b8-a768cee8c66f" xlink:to="loc_lsta_QiluMember_08a7472b-38a6-47a6-966f-f5103cf036ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b4bdb651-d643-4375-8c58-66a11cd19e22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_ProductOrServiceAxis_b4bdb651-d643-4375-8c58-66a11cd19e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b2492dac-fbaa-40d8-82d8-887a2ce7ec28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b4bdb651-d643-4375-8c58-66a11cd19e22" xlink:to="loc_srt_ProductsAndServicesDomain_b2492dac-fbaa-40d8-82d8-887a2ce7ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_31cbc482-3448-4959-9b69-6fd1afc034c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b2492dac-fbaa-40d8-82d8-887a2ce7ec28" xlink:to="loc_us-gaap_LicenseMember_31cbc482-3448-4959-9b69-6fd1afc034c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_RangeAxis_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_25e0b4ab-9e5f-480a-ad48-d8eebaec28a1" xlink:to="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fef6a1be-a79a-495a-8cdb-489382b6fd33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:to="loc_srt_MinimumMember_fef6a1be-a79a-495a-8cdb-489382b6fd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1820299-3981-40b2-9644-4116b39dbaa6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b29afbd6-b4ad-44db-b2ff-279fdea1a655" xlink:to="loc_srt_MaximumMember_f1820299-3981-40b2-9644-4116b39dbaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f95adc22-64e0-4f62-96ae-406357ced72c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_srt_LitigationCaseAxis_f95adc22-64e0-4f62-96ae-406357ced72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0e311633-644e-4805-ae5f-0f7ae4b9394a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f95adc22-64e0-4f62-96ae-406357ced72c" xlink:to="loc_srt_LitigationCaseTypeDomain_0e311633-644e-4805-ae5f-0f7ae4b9394a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_92bdf582-f749-4128-8765-169935946604" xlink:href="lsta-20240331.xsd#lsta_LingmedLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0e311633-644e-4805-ae5f-0f7ae4b9394a" xlink:to="loc_lsta_LingmedLimitedMember_92bdf582-f749-4128-8765-169935946604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_54af3848-0cf9-4112-9533-cd311b172d6e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4f25e0c0-324b-45c7-bafb-fa1a36f9e2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4f25e0c0-324b-45c7-bafb-fa1a36f9e2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_e24d478e-a889-4933-a84f-cf3dcd4b02e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_e24d478e-a889-4933-a84f-cf3dcd4b02e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_0c76c1e5-b8ec-4f21-b796-1e12d3ee1082" xlink:href="lsta-20240331.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_0c76c1e5-b8ec-4f21-b796-1e12d3ee1082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_75cade23-60c8-4f00-9dc9-25d05dc722a5" xlink:href="lsta-20240331.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_75cade23-60c8-4f00-9dc9-25d05dc722a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_65803511-eaea-4af3-b8c4-4ecd35eddcef" xlink:href="lsta-20240331.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_65803511-eaea-4af3-b8c4-4ecd35eddcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_84539973-917c-46f2-80ef-c6e7f2243497" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_84539973-917c-46f2-80ef-c6e7f2243497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_82cf3892-9e25-454a-97f0-01e36472b41f" xlink:href="lsta-20240331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_82cf3892-9e25-454a-97f0-01e36472b41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_6e24e7b3-86da-4559-b5f3-7b4f73700ac9" xlink:href="lsta-20240331.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f829a601-943b-4a98-ab68-d01c3de32f47" xlink:to="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_6e24e7b3-86da-4559-b5f3-7b4f73700ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>lsta-20240331_g1.jpg
<TEXT>
begin 644 lsta-20240331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:CJMSXC\;)<7US)=2+%?680,[%B%!M2<9/<FJ/\ PY_^#?\ T,OCG_P/L_\
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M_P #[/\ ^1*/[?P7=_<'URD?D#17Z_?\.?\ X-_]#+XY_P# ^S_^1*/^'/\
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M/_Y$H_X<_P#P;_Z&7QS_ .!]G_\ (E']OX+N_N#ZY2/R!HK]?O\ AS_\&_\
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MOCG_ ,#[/_Y$H_M_!=W]P?7*1^0-%?K]_P .?_@W_P!#+XY_\#[/_P"1*/\
MAS_\&_\ H9?'/_@?9_\ R)1_;^"[O[@^N4C\@:*_7[_AS_\ !O\ Z&7QS_X'
MV?\ \B4?\.?_ (-_]#+XY_\  ^S_ /D2C^W\%W?W!]<I'Y T5^OW_#G_ .#?
M_0R^.?\ P/L__D2C_AS_ /!O_H9?'/\ X'V?_P B4?V_@N[^X/KE(_(&BOU^
M_P"'/_P;_P"AE\<_^!]G_P#(E'_#G_X-_P#0R^.?_ ^S_P#D2C^W\%W?W!]<
MI'Y T5^OW_#G_P"#?_0R^.?_  /L_P#Y$H_X<_\ P;_Z&7QS_P"!]G_\B4?V
M_@N[^X/KE(_(&BOU^_X<_P#P;_Z&7QS_ .!]G_\ (E'_  Y_^#?_ $,OCG_P
M/L__ )$H_M_!=W]P?7*1^0-%?K]_PY_^#?\ T,OCG_P/L_\ Y$H_X<__  ;_
M .AE\<_^!]G_ /(E']OX+N_N#ZY2/R!HK]?O^'/_ ,&_^AE\<_\ @?9__(E'
M_#G_ .#?_0R^.?\ P/L__D2C^W\%W?W!]<I'Y T5^OW_  Y_^#?_ $,OCG_P
M/L__ )$H_P"'/_P;_P"AE\<_^!]G_P#(E']OX+N_N#ZY2/R!HK]?O^'/_P &
M_P#H9?'/_@?9_P#R)1_PY_\ @W_T,OCG_P #[/\ ^1*/[?P7=_<'URD?D#17
MZ_?\.?\ X-_]#+XY_P# ^S_^1*/^'/\ \&_^AE\<_P#@?9__ ")1_;^"[O[@
M^N4C\@:*_7[_ (<__!O_ *&7QS_X'V?_ ,B4?\.?_@W_ -#+XY_\#[/_ .1*
M/[?P7=_<'URD?D#17Z_?\.?_ (-_]#+XY_\  ^S_ /D2C_AS_P#!O_H9?'/_
M ('V?_R)1_;^"[O[@^N4C\@:*_7[_AS_ /!O_H9?'/\ X'V?_P B4?\ #G_X
M-_\ 0R^.?_ ^S_\ D2C^W\%W?W!]<I'Y T5^OW_#G_X-_P#0R^.?_ ^S_P#D
M2C_AS_\ !O\ Z&7QS_X'V?\ \B4?V_@N[^X/KE(_(&BOU^_X<_\ P;_Z&7QS
M_P"!]G_\B4?\.?\ X-_]#+XY_P# ^S_^1*/[?P7=_<'URD?D#17Z_?\ #G_X
M-_\ 0R^.?_ ^S_\ D2C_ (<__!O_ *&7QS_X'V?_ ,B4?V_@N[^X/KE(_(&B
MOU^_X<__  ;_ .AE\<_^!]G_ /(E'_#G_P"#?_0R^.?_  /L_P#Y$H_M_!=W
M]P?7*1^0-%?K]_PY_P#@W_T,OCG_ ,#[/_Y$H_X<_P#P;_Z&7QS_ .!]G_\
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MV_@N[^X/KE(_(&BOU^_X<_\ P;_Z&7QS_P"!]G_\B4?\.?\ X-_]#+XY_P#
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MK$7TNE_V)+X@72K;^UY;#;M^SM>>7YI7&.=V[@'=7Z)_\.?_ (-_]#+XY_\
M ^S_ /D2C_AS_P#!O_H9?'/_ ('V?_R)4?VIE2^Q_P"2B^L8?M^!\<?M&?MZ
MZ]X]UBSB^'5_>^'- /AN'0[O[9I=E'?L>?/5+E0\RQ/B/A9%^[]T=_(+S]JK
MXI:AKWB+6KCQ1YFI^(=&_P"$?U.?^S[4?:+';M\G:(L+QQN4!O>OTF_X<_\
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MTNBOFC_@GY\;/%OQ\^!,_B;QG?1:CK":S<68FAMT@'E)'$5&U !U=N?>O/\
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MIK6JC&;&RFNANZ?)&S?TKY)_X)N_M+>//VC]'\>W7CG4K?4)-+N;1+06]I'
M(UD64L/D S]Q>N>E=-/#3J49UUM&U_F:*FY1<^B/LRBBJ2ZUI[ZB;!;ZV:_
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MA5T:]2KG/+-W4>9+TL.,I2Q5GTN?>WQM^-%O^S_^S;J'C>6$7-QI^F0I9V[
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MMPPW)$YMU1B.P8I(!Z[&]*^Z/V8/^3:?A+_V*.D_^D<58YA5G7RZA4J;MO\
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M5=R6SN<KG@FOB.^TBX_X)M_MOZ9-;S7<W@+4$4>=,=SSZ9,0LJMM #/#(N[
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MI%N492NNUMCR_P#;6TF[_94_;LT'XGZ1 R:?JEQ#KZI'P)'#>7>PY]7&6/\
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M;X$:YX\L_P!J+QKH/PTV0>,?%3ZAH=KJ$C%5T]'NEEFN20#C9% _(&1G(R0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF1[27)R=-SX0_9&_8I^(7P0_:>\2>/\ Q%-HKZ%J$%_'"ME=O)-F:=)$RIC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG*J,5Z'XR_9!U?Q#XDA\5Z5\3+W0?&5UI?\ 9FM:M#I<3)J0,81I!$KH(F8
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MOX<C56ETF/21<"YE#$[I7,R[UZ8C(V\9.>,<OKW['^H^,/!&D:7KOQ!:;7M
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MC.2<('#Q[NP.[&!@5X5XL^,O[0?P?\0> I?%'B+3=5UKQ)>R^?X!AT^V+6L
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MB/Q)J.AZ_IOPZ^'>@Z0]Y'K5Q!:WCZC<!5/DLDFYH\L2JD+_ -]%@!XIX/\
MVLOC%\6M0^&_@6QOK'PAX@UU99[CQ$^G),9X%,@2187R@R(I,_*-Q VE17OO
MQW_9B\7?&[Q9;ZA)\3X]+T&QD66R\/R>'8[RU1P "\JR3;)V)S]]" #@#KFI
MXJ_9%USQ3)X3\0R?$VXM/B/X>#0P^)[71+>*.2 LQ2(VB,JC8&*@[L$,V0<C
M &AY3\-_CY\?OC!INH>"O#W]F?\ "2Z%K2V6L^,%AMP(+4LRB06\A"NVZ.7.
MU/NA0%!):IOAU^V-XH\$M\3H/&VL6OCW3_#\_P!CT;6+&T2V;4[UG*1VZ+&
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M ,+H^-OQ3\"#Q[IFJZ7\,_!%CH4MW)JC06UT+^]C.QX@DI=XU:16"<=,??)
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MNT74;0(P 80H\BB+(!R0"WS'! XKG+W]AKPXWPET+PC8>(-0L-7T6]?4[3Q
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M" YJ-2=3Z,^.\_Q4O+7P]IWPOCM;,WUT!J>NW/DN=.@ROS+%*</D%LX#'"X
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M7<6EW=BJW#DD\/=&5G;@E<D< D+MKZBCC6&-(T4*B *JCH .@JHWZC18M?\
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M@#LJ*XW_ (5[??\ 0[^)?^_EK_\ &*/^%>WW_0[^)?\ OY:__&* .RHKC?\
MA7M]_P!#OXE_[^6O_P 8H_X5[??]#OXE_P"_EK_\8H [*BN-_P"%>WW_ $._
MB7_OY:__ !BC_A7M]_T._B7_ +^6O_QB@#LJ*XW_ (5[??\ 0[^)?^_EK_\
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M]_+;_P",4 =?17(?\(#>_P#0Z>(_^_EM_P#&*/\ A ;W_H=/$?\ W\MO_C%
M'7T5R'_" WO_ $.GB/\ [^6W_P 8H_X0&]_Z'3Q'_P!_+;_XQ0!U]%<A_P (
M#>_]#IXC_P"_EM_\8H_X0&]_Z'3Q'_W\MO\ XQ0!U]%<A_P@-[_T.GB/_OY;
M?_&*/^$!O?\ H=/$?_?RV_\ C% '7T5R'_" WO\ T.GB/_OY;?\ QBC_ (0&
M]_Z'3Q'_ -_+;_XQ0!U]%<A_P@-[_P!#IXC_ ._EM_\ &*/^$!O?^AT\1_\
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M]E1H=.,AN9H8]NX2,RHV_:QV@=1]3_LI_%J3XV_ 'PAXJNT:#5I;4VFJ0/\
M>BO8&,-PK#L?,C8X]&%=]H/@7PUX5OKR^T3P]I6CWMY%!!<W-A91023QP)L@
M1V1066-/E0'A1P,"I_#_ (5T3PE;W4&AZ/8:+!=7,E[<1Z?:I LUQ(<R2N$
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M8Z%IFD:3-9Z1X.\82:1%8/)$=\A0ZC:*=Y';=R"2!G)^[[K_ (]V_#^=>/\
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M1_M!?%?Q1XHT/QYX$UGQ-_PL#1?!_P 0?"R:;XM^RV\#SF<EY;:3[.J0L\3
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M?P,EQ!IVE:UX0>ZTZ[CE5@&O+4WX2>:,D%'^4#'*-G->T?LK_L_O^S5\*_\
MA#Y->B\1R'4;G4&O8--73X\S/N*+ KNJ*.@"G&.@%="N><KGL%%%%,H****
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M%2%F8KF0 HN V?NCT%1^&?A+X'\%:@;_ ,/>#/#^@WQ4H;K3-+@MI=IZC<B
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M)ZT_^-T?\,V_"/\ Z)9X*_\ ">M/_C=>C44<TNX<D>QYS_PS;\(_^B6>"O\
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M_P"-T?\ #,_P@_Z)3X(_\)VS_P#C=>DT5ASR[GG\L>QYM_PS/\(/^B4^"/\
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M**P_^$Z\-_\ 0P:5_P"!L7_Q5'_"=>&_^A@TK_P-B_\ BJ -RBL/_A.O#?\
MT,&E?^!L7_Q5'_"=>&_^A@TK_P #8O\ XJ@#<HK#_P"$Z\-_]#!I7_@;%_\
M%4?\)UX;_P"A@TK_ ,#8O_BJ -RBL/\ X3KPW_T,&E?^!L7_ ,51_P )UX;_
M .A@TK_P-B_^*H W**P_^$Z\-_\ 0P:5_P"!L7_Q5'_"=>&_^A@TK_P-B_\
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ML/\ X3KPW_T,&E?^!L7_ ,51_P )UX;_ .A@TK_P-B_^*H W**P_^$Z\-_\
M0P:5_P"!L7_Q5'_"=>&_^A@TK_P-B_\ BJ -RBL/_A.O#?\ T,&E?^!L7_Q5
M'_"=>&_^A@TK_P #8O\ XJ@#<HK#_P"$Z\-_]#!I7_@;%_\ %4?\)UX;_P"A
M@TK_ ,#8O_BJ -RBL/\ X3KPW_T,&E?^!L7_ ,51_P )UX;_ .A@TK_P-B_^
M*H W**P_^$Z\-_\ 0P:5_P"!L7_Q5'_"=>&_^A@TK_P-B_\ BJ -RJ]]_JA_
MO5E_\)UX;_Z&#2O_  -B_P#BJ@O/''AQHP!K^EDY[7L?_P 536Y4=R[16-_P
MFGA[_H.Z9_X&1_\ Q5'_  FGA[_H.Z9_X&1__%5M<Z#9HK&_X33P]_T'=,_\
M#(__ (JC_A-/#W_0=TS_ ,#(_P#XJBX&S16-_P )IX>_Z#NF?^!D?_Q5'_":
M>'O^@[IG_@9'_P#%47 V:*QO^$T\/?\ 0=TS_P #(_\ XJC_ (33P]_T'=,_
M\#(__BJ+@;-%8W_":>'O^@[IG_@9'_\ %4?\)IX>_P"@[IG_ (&1_P#Q5%P-
MFBL;_A-/#W_0=TS_ ,#(_P#XJC_A-/#W_0=TS_P,C_\ BJ+@;-%8W_":>'O^
M@[IG_@9'_P#%4?\ ":>'O^@[IG_@9'_\51<#9HK&_P"$T\/?]!W3/_ R/_XJ
MC_A-/#W_ $'=,_\  R/_ .*HN!LT5C?\)IX>_P"@[IG_ (&1_P#Q5'_":>'O
M^@[IG_@9'_\ %47 V:*QO^$T\/?]!W3/_ R/_P"*H_X33P]_T'=,_P# R/\
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M /%47 V:*QO^$T\/?]!W3/\ P,C_ /BJ/^$T\/?]!W3/_ R/_P"*HN!OVO\
MQ\+^/\JT*Y6V\;>'EF4G7M, ][R/T_WJO?\ "=>&_P#H8-*_\#8O_BJSEN8S
MW-RBL/\ X3KPW_T,&E?^!L7_ ,51_P )UX;_ .A@TK_P-B_^*J#,W**P_P#A
M.O#?_0P:5_X&Q?\ Q5'_  G7AO\ Z&#2O_ V+_XJ@#<HK#_X3KPW_P!#!I7_
M (&Q?_%4?\)UX;_Z&#2O_ V+_P"*H W**P_^$Z\-_P#0P:5_X&Q?_%4?\)UX
M;_Z&#2O_  -B_P#BJ -RBL/_ (3KPW_T,&E?^!L7_P 51_PG7AO_ *&#2O\
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MGQ*M9/C/>^+M"T@7'AWQ9:Z/;Z7J?B*STW3=&MWA!>234'A1I(\C>#Y3R'>
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M,R$6/R#:=I2+8C <J><_3_AW18/#7A_3-(M7DDMM/M8K2)IB"Y2- H+$ #.
M,X K.6YC/<T****D@**** "BBB@ HHHH **** .5^*UG<:C\+_%]I:0275U/
MI%W%%!"A=Y':%PJJHY))(  K\\])^%_B5?@+\+=*T'PEXY'Q2TO7S=-8ZMIN
MH_V1:+YTS+)(ETOV1!M:,[HP#DDGG-?IC=74-E;2W%Q+'!;PH9))96"HB@9+
M$G@ #G)KAK?]H'X77EQ%!!\2?",\\K!(XH]=M69V)P  ),DD]J!GSS\*['7_
M -F/XG?&3^W?"/B7Q%8>)+S^V=(U+P]I,M^MT29&,#&(-Y3YE"CS-H.UCD#&
M?#H_V>_'OPX\!_!J74O#6LWETGC.77]1L]+L9K]]-MR;4 2+"K$$K"6P.><=
M017Z)>#/B%H7Q CU*30[J:Z73KMK*Y\ZTFM]LJ]0!*B[AS]Y<J>QKHZ N?-/
MQXM?A]\<['18O$'@CXA7MO:3LMOXATGP]>VUQI4C '=Y4D:SNIVKRD$J@@9P
M:\Z\$^&/BC#IWQIT6'4/&7B?X9-X9O+?1'\8V<J:I<WC0#:D4<J+,RC,B_<4
M$[<+FOLA?%&C-XB;0!JUB==6W^UMI8N4^U"#=M\TQ9W;-W&[&,\5RGB+XZ^"
M/"OBK4O#>I:P\.N:=IIU>YLX[&XF9+4$#S 4C(8Y(^526]J /BS4OAGXG3X!
M_LU6=]X4\3J=&\027&L6]AIUY]LL;?[269V6%?.C.W)!7#="O.*[+X\>%;3Q
MUXD^$>F^#M%^(VI65KXJANM4N=5M/$ >TA+1J9%N;Q0T0 !.8W7;C=P>:^S_
M  _KUEXHT.QU?397FL+Z%9X))(GB9D89!*. RGV8 CTK0I!<^4/@]\.M8^'/
M[8GCB/5=#UC7=&U'3HY]"\6:H+B_-D@^_:?:Y=Y&=SC:SYQ&O][F]\/_  ?K
MUG^WI\3O$%QHFHP:#>:#;0VVJ26DBVL\@2U!1)2-K,-K< Y^4^E?35]?6VEV
M<]Y>7$5I:0(9)9YW"1QJ!DLS'@ #N:P?"GQ-\'^/+B>#PUXLT/Q%/ H>6/2=
M1ANFC4G +"-C@?6F!^<$?[.&LR?LN_$.^E^'&JR^/)_%JK9^;HTK7_V,&,[H
M5*;Q&2TF67@XYZ5TWQC\'_$_Q#X&^)NC7?@C5]-FN=1MYM/TCPKX6MGM-2B6
M0'[7<72QM-)-C!(#A@2<C&X+]Y1?%SP-/XC_ .$?B\:>'I-?\TP?V4NJP&Z\
MP=4\K?NW>V,U>N?'WABS\40>&KCQ'I,'B.X7?#H\E]$MW(N"<K"6WD85CP.Q
M]*0[GQ9\/_!OB'P[9_M,ZAJV@ZII5C?>$H!:W%_92P1SE-/D#A"Z@,5/! Z'
M@U2NO _B'6OV>?V8O%>B:+?:_:^%;^"^U"STR$S7(@\U6+I&OS/CRR,*">1V
MS7W?X@T*Q\4:%J.C:G!]ITW4+>2TN8=[)YD3J5==RD$9!(R"#67X ^'VA_##
MPS;^'_#EM/9Z/;DF"VGO9[KR@?X5:9W95]%!P,G Y-,5SXV\;?#73_BI\:/B
M%XS\6?#+QGKG@*_MK'3;.6UTN2VOXYT5=UTEM(T=P8TP0=L;$[ONL*\]^(WP
MV^)EUXFL?AK\.=:^*&L?#+Q"MM97]UXMT6Z\FQ_>C< T\,;)&JA6.T1@C*Y;
MFOTNHH"Y\;_#WX5^,?V??VMK&YCT]M=\)>+])6RO;W0-'FM[+3YH$58C(IEF
MV<1K\S. ?.<C&#7:?L$_\DG\3?\ 8VZG_P"A)7T=>6J7UG/;2-(L<R-&S0RM
M$X!&"5=2&4^A4@CJ#7.?#KX8^&_A/H,NC>%M/?3M/EN9+R2.2ZFN&>9\;W+R
MNS$G [T =31110(**** "BBB@"&Z_P"/=OP_G6?6A=?\>[?A_.L^M8[&\-@H
MHHJS0**** "BBB@ HHHH **** "BBB@#RG]I#XK:O\'_  /8ZSHUO97-U/J,
M=FR7R.Z!&BE<D!64YR@[]S7S?_PW/X\_Z!/AW_P&N/\ X_7KG[<__))=)_[#
MD/\ Z3W%?#-?K'#>5X+%X!5:])2E=ZL_HS@?A_*\QR>-?%T(SGS25WY'T5_P
MW/X\_P"@3X=_\!KC_P"/T?\ #<_CS_H$^'?_  &N/_C]?.M%?4?V%EG_ #X1
M]_\ ZHY#_P! D?Q_S/HK_AN?QY_T"?#O_@-<?_'ZS_$'[8OB?Q9HUUI&N>%?
M"&LZ3=IY=Q8ZAITL\$RYSM>-YBK#('!':O!:*/["RS_GP@_U1R'_ *!(_C_F
M>Q>"?VE+CX:+=+X0^'/P_P#"JW1!G&B:&;,38Z;_ "I%W8]ZZC_AN?QY_P!
MGP[_ . UQ_\ 'Z^=:*/["RS_ )\(/]4<A_Z!(_U\SZ*_X;G\>?\ 0)\._P#@
M-<?_ !^C_AN?QY_T"?#O_@-<?_'Z^=:*/["RS_GP@_U1R'_H$C^/^9]%?\-S
M^//^@3X=_P# :X_^/T?\-S^//^@3X=_\!KC_ ./U\ZT4?V%EG_/A!_JCD/\
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M<O\ ]R5^;=%'U6C_ "_F'UJM_-^1^DG_  ^-_P"J1?\ ER__ ')1_P /C?\
MJD7_ )<O_P!R5^;=%'U6C_+^8?6JW\WY'Z2?\/C?^J1?^7+_ /<E'_#XW_JD
M7_ER_P#W)7YMT4?5:/\ +^8?6JW\WY'Z2?\ #XW_ *I%_P"7+_\ <E'_  ^-
M_P"J1?\ ER__ ')7YMT4?5:/\OYA]:K?S?D?I)_P^-_ZI%_Y<O\ ]R4?\/C?
M^J1?^7+_ /<E?FW11]5H_P OYA]:K?S?D?I)_P /C?\ JD7_ )<O_P!R4?\
M#XW_ *I%_P"7+_\ <E?FW11]5H_R_F'UJM_-^1^DG_#XW_JD7_ER_P#W)1_P
M^-_ZI%_Y<O\ ]R5^;=%'U6C_ "_F'UJM_-^1^DG_  ^-_P"J1?\ ER__ ')1
M_P /C?\ JD7_ )<O_P!R5^;=%'U6C_+^8?6JW\WY'Z2?\/C?^J1?^7+_ /<E
M'_#XW_JD7_ER_P#W)7YMT4?5:/\ +^8?6JW\WY'Z2?\ #XW_ *I%_P"7+_\
M<E'_  ^-_P"J1?\ ER__ ')7YMT4?5:/\OYA]:K?S?D?I)_P^-_ZI%_Y<O\
M]R4?\/C?^J1?^7+_ /<E?FW11]5H_P OYA]:K?S?D?I)_P /C?\ JD7_ )<O
M_P!R4?\ #XW_ *I%_P"7+_\ <E?FW11]5H_R_F'UJM_-^1^DG_#XW_JD7_ER
M_P#W)1_P^-_ZI%_Y<O\ ]R5^;=%'U6C_ "_F'UJM_-^1^DG_  ^-_P"J1?\
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M5O\ LX?$C4H/&GB"'4K7XD/86]XFJ3B:&WV-B%'#Y6//\ ./:O0_B5X3\?\
MP\\2:=IMG\0]>^(.E6/A^:]U+1X_'@TG7(96RTMZ!D%XHQ@QHP=1M((_O?84
MWPE\#7.EW6F3>#/#\NFW5U]NN+-]*@,,UQT\YT*8:3_;(S[U/XJ^&?@_QU);
MR>)/"FA^(9+=2D+:KIT-R8E/4*74X'TI#N? G[/_ (GTKX@?M/OXDTU?&_B1
M#X1CN;:VN];,.J7<\=U$CJ9//@BDC!60F,L(B%/R9XJ_\;/&6MK^T5\3M;AT
M[6?!6KVWPVE:!;BY@6[B82QXD62VFD5?;#YXZ"ONG4OA;X,UFXTRXU#PCH-]
M/I:JEA+<Z9#(UHJG<HB+*2@!&1MQ@U/JOP[\*:[J5WJ&I>&-'U&_N[7[#<W5
MU812RS6Y.3"[,I+1Y ^4G''2@+GYW:#XJ\8^,;[Q-)>?$#QA FC?"ZWUVWCL
M]?NH0UZ+6$B5]L@W'+,3G[Q.35OX6_%#XF_';4=0TW6/%<ND#2?"$,]I-<>+
M+GP^OS(N_47>""3[0RGJ),( ><G)K[_M?A;X+LOM)M_"&@P&YLAIL_E:9 OF
MV@ 46[87YH@ !L/RX XJMJ7P;\ :S8Z?9:AX&\-WUGI\9BL[>YTBWDCMD)R5
MC5D(09[+@4!<^1OVJ+CQ;=?L6^#'UWQ#9>+%&K6Z:]K7ANY^T6=Y:J\JHYD"
MKN&X1 G&-X_&NO\ CS_PK?\ M[0#X,:^7XF?\(K??\(U_P (F%*_9_LS^7YV
MP?<QNV9[YQ7UA-I%C<:6VF2V5O)IK1>0UF\2F$QXQL*8QMQQC&,5B^%/AEX/
M\!W$\_AKPGH?AV>=0DLFDZ=#:M(H.0&,:C(^M,5SXF^'4OP6@_81\.2^.)#%
M;1ZBSW+Z65&I#41.QRA^\&V;?^ >U>1>(V\7^(K.^_:3L-!UQY;3Q+%=V&JW
M%Q;-;II<!\A8W3SO-+EPBL1%M^^<\FOTGNO@G\/+_5+G4[GP%X8N-2N2YGO)
M='MVFE+@ARSE,MN!(.3R"<UN0^#= MO#)\-PZ'IL7ATQ- =(2TC%H8VSN3R0
M-FTY.1C!R:0[C_"OB2Q\9>&=*U[3)?/T[4K6.[MY/5'4,OXX-:M4M'T73_#N
MEVVFZ586VF:=;+L@L[.%888E]%10 H]@*NTR0HHHH **** "BBB@ HHHH **
M** (;K_CW;\/YUGUH77_ ![M^'\ZSZUCL;PV"BBBK- HHHH **** "BBB@ H
MHHH **** /!_VRO#>K^*/AAI=KHVEWNKW2:Q%*T%C;O,ZH()P6*J"0,D#/N*
M^-?^%/\ CS_H2?$7_@IN/_B*_4*BOK\LXCJY9AUAX4TU=O5OJ?I>0\<8C(<$
ML%2HQDDV[MOJ?E[_ ,*?\>?]"3XB_P#!3<?_ !%'_"G_ !Y_T)/B+_P4W'_Q
M%?J%17K?ZZ8C_GROO9]%_P 12QG_ $#1^]GY>_\ "G_'G_0D^(O_  4W'_Q%
M'_"G_'G_ $)/B+_P4W'_ ,17ZA44?ZZ8C_GROO8?\12QG_0-'[V?E[_PI_QY
M_P!"3XB_\%-Q_P#$4?\ "G_'G_0D^(O_  4W'_Q%?J%11_KIB/\ GROO8?\
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M\%-Q_P#$4?\ "G_'G_0D^(O_  4W'_Q%?J%11_KIB/\ GROO8?\ $4L9_P!
MT?O9^1WQ _9#^,7Q4^P?\([X#U&7[!YGG_V@T6GXW[=NW[0\>_[C9VYQQG&1
MGD/^'<_[0_\ T3W_ ,K6G?\ R17[5V/\?X?UJW7R..S>KC,1*NXI7M^"2/QK
MB#%_V]F=7,:L>64^71;:14>OH?B3_P .Y_VA_P#HGO\ Y6M._P#DBC_AW/\
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MW/L@_L^EW?\ 7R/Q9_X=X_M!?]"!_P"5G3__ )(H_P"'>/[07_0@?^5G3_\
MY(K]IJ*/K<^R#^SZ7=_U\C\6?^'>/[07_0@?^5G3_P#Y(H_X=X_M!?\ 0@?^
M5G3_ /Y(K]IJ*/K<^R#^SZ7=_P!?(_%G_AWC^T%_T('_ )6=/_\ DBC_ (=X
M_M!?]"!_Y6=/_P#DBOVFHH^MS[(/[/I=W_7R/Q9_X=X_M!?]"!_Y6=/_ /DB
MC_AWC^T%_P!"!_Y6=/\ _DBOVFHH^MS[(/[/I=W_ %\C\6?^'>/[07_0@?\
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M"BBBI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!_\ )Q/\*/[6UG_H _\ DXG^%;E% &'_ &MK/_0!_P#)Q/\ "C^UM9_Z /\
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MC_VIJ_\ T!/_ ";3_"C^U-7_ .@)_P"3:?X5L44 8_\ :FK_ /0$_P#)M/\
M"C^U-7_Z G_DVG^%;%% &/\ VIJ__0$_\FT_PH_M35_^@)_Y-I_A6Q10!C_V
MIJ__ $!/_)M/\*/[4U?_ * G_DVG^%;%% &/_:FK_P#0$_\ )M/\*/[4U?\
MZ G_ )-I_A6Q10!C_P!J:O\ ] 3_ ,FT_P */[4U?_H"?^3:?X5L44 8_P#:
MFK_] 3_R;3_"C^U-7_Z G_DVG^%;%% &/_:FK_\ 0$_\FT_PH_M35_\ H"?^
M3:?X5L44 8_]J:O_ - 3_P FT_PH_M35_P#H"?\ DVG^%;%% &/_ &IJ_P#T
M!/\ R;3_  H_M35_^@)_Y-I_A6Q10!0L]4U@;\:'GI_R]I_A5G^UM9_Z /\
MY.)_A6C8_P ?X?UJW64MS"6YA_VMK/\ T ?_ "<3_"C^UM9_Z /_ ).)_A6Y
M14D&'_:VL_\ 0!_\G$_PH_M;6?\ H _^3B?X5N44 8?]K:S_ - '_P G$_PH
M_M;6?^@#_P"3B?X5N44 8?\ :VL_] '_ ,G$_P */[6UG_H _P#DXG^%;E%
M&'_:VL_] '_R<3_"C^UM9_Z /_DXG^%;E% &'_:VL_\ 0!_\G$_PH_M;6?\
MH _^3B?X5N44 8?]K:S_ - '_P G$_PH_M;6?^@#_P"3B?X5\1>//V\?&GAB
M]^*[VNO_  Z&I>#_ !7_ &%I7@.ZL;EM:UZ#S(E!A=+W=YC>8P!6V9=R<X&<
M=9:_M,?&OQ%X=^,_BW0K#P:=.^'.M75FWAB^TR[6]O;6WA2:4?;%NBB3;&8
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M_P#)M/\ "MBBMCH,?^U-7_Z G_DVG^%']J:O_P! 3_R;3_"MBB@#'_M35_\
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MW]K:S_T ?_)Q/\*N6O\ Q\+^/\JT*SEN8SW,/^UM9_Z /_DXG^%']K:S_P!
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M%KX]\9V>EW]LMG:>%_%DEA;6 <2;@JM?VP*L5&W ;&T_=SS@_$;XO>,O@O\
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M)27P@R00.O%:_C3]G_1?%GC^#QQ8:SK?A'Q;':FQEU30+B)'N;?M'*DL<D;
M'!!VYRJ\_*,<58?MM^";_2[+71HGBB#PA=:DNDCQ/-81K91W#*#M<>;YP )V
MEO+V[@1DU?\ %/[6^C^"X[&YUCP+XXT_2M0U$Z79:C>:;#;I<3X)4"*6=9E5
ML?*SQJ#],T!J1>'?V+O 'AW6O#VI+/K.HOH][)JC0ZA=),FH7[_\O=UF/=)*
M."N&5002%^9LR7G[-.G>!?!/Q<M_!$NI-+XQT^\9?#\D\(L8[N2%U!@!13'N
M+ '<^W&.@48\>C_;,\1^(O@[XT\2ZQ8ZQX-MM)\1-IMOKGAVPL+LQ1AHPD$D
M-S=-NF(<[G5?+Q]TYXKVL?M2:)+J^LZ7HGAKQ9XU;P^UO!J]_P"'].BGCMI9
M#C84\T22,I!+")'VX/I0&IR_P_\ V;8O''[._@'PGX^TK5?"_B'PHZ26MU9W
MEO\ :;>X0Y$L3QM+&5.1PXSE>5& :ZR/]EO1DU36-</C#QE_PEVJ2PR3^)(=
M56VN]L0Q'%Y<,:0&(8^XT14]P:]+\5>,+'PCX)U7Q1>K/_9VG6,FH2H(F67R
MT0N1L8 AL#H<$'KBOG+PK\>OC9XN^%NF?$[2O"/A_5M#O[\B/PI8PW#:H;+S
M#'YBW'F^67##./* V\\=  =!\2/V(/"?QAU6'5/&OBOQ;XBU2%8XHKJ:XM(?
M+A4L3$L<-LD85BQ).W=P/F%=U\7O@/X>^)DGA75+I=4M=3\(7(O]*.ARPQ3%
ME"D0_O5*;6*)P2O0?,!FN8\2?MB^#_#MYXC5-%\2:MIOAF2WAUW5M/LXFMM-
MDE;:$DWRK(S*<[Q&C[<&O./#?[84?AWXD_&*\\5^()-4\%:1+IR>'K.PM(FE
MF:XC9ECA*JK2,X&1O;  )R!0&IZ7^Q_\//$GPV^&NL6'BG27T;4+S7[W4([6
M2>&9A#*5*$M$[KG@\9[5[G7SGXM_;F\$^ H=:B\1Z!XHT?6](GMXKG0KBUMC
M=E)DW),FV<QO'T!(?()&17>_"O\ : T3XJ>*/$/AN'2-:\.^(="2&6\TW7((
MHY1'*H9'4Q22*1@C(R",CB@#T^BO$->_:OT3PK<Z4^N^#?&>AZ-JFJC2+36=
M2TR."%YCG:3"THN%0X)#-",XXK#\2_MQ>#O"^M^,;&?PSXLN;;PE=QV>L:G:
MVELUM;L\GEHV3<!RI8'&%SP>* /HNBOG;XV?M6:=X?TGQ?HG@RTUC7/$^F^'
MGU=]0TFUAEMM+5XP899C,ZY^^C[55SMR2O!%=]^S9XPU?Q_\"?!GB'7KO[?K
M&H6"S7-SY21^8^YAG:@"CH.@% CTNBBB@ HHHH ANO\ CW;\/YU^?6H>/_\
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M +DK*6%K-_#^1C+%46_B_,_22BOS;_X?&_\ 5(O_ "Y?_N2C_A\;_P!4B_\
M+E_^Y*7U6M_+^1/UJC_-^9^DE%?FW_P^-_ZI%_Y<O_W)1_P^-_ZI%_Y<O_W)
M1]5K?R_D'UJC_-^9^DE%?FW_ ,/C?^J1?^7+_P#<E'_#XW_JD7_ER_\ W)1]
M5K?R_D'UJC_-^9^DE%?FW_P^-_ZI%_Y<O_W)1_P^-_ZI%_Y<O_W)1]5K?R_D
M'UJC_-^9^DE%?FW_ ,/C?^J1?^7+_P#<E'_#XW_JD7_ER_\ W)1]5K?R_D'U
MJC_-^9^DE<%\=/@_I/QZ^%/B#P+K,\]I9ZM"JK=VIQ+;RHZR12KZE716QWQC
MO7PQ_P /C?\ JD7_ )<O_P!R4?\ #XW_ *I%_P"7+_\ <E'U6M_+^0?6J/\
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M;V\0:5V0&.W A60J07\H;-Q8BO7:_-O_ (?&_P#5(O\ RY?_ +DH_P"'QO\
MU2+_ ,N7_P"Y*S^JUOY?R-_K5'^;\S])**_-O_A\;_U2+_RY?_N2C_A\;_U2
M+_RY?_N2CZK6_E_(/K5'^;\S])**_-O_ (?&_P#5(O\ RY?_ +DH_P"'QO\
MU2+_ ,N7_P"Y*/JM;^7\@^M4?YOS/TDJO??ZH?[U?G'_ ,/C?^J1?^7+_P#<
ME1S?\%B/.4+_ ,*CQSG_ )&7_P"Y*:PM:_P_D5'%44_B_,_1*BOSF_X>_?\
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M6_E_(CZU1_F_,_22BOS;_P"'QO\ U2+_ ,N7_P"Y*/\ A\;_ -4B_P#+E_\
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MX_M!?]"!_P"5G3__ )(H]I#^9![&K_*_N/G.BOHS_AWC^T%_T('_ )6=/_\
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M^9![&K_*_N/G.BOHS_AWC^T%_P!"!_Y6=/\ _DBC_AWC^T%_T('_ )6=/_\
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M3W_RM:=_\D4>VI_S+[P]E4_E?W'S;17TE_P[G_:'_P"B>_\ E:T[_P"2*/\
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M]>Q^M\!8/&4LME.K%J,I7CH]K+5>3_X)\VT5])?\.Y_VA_\ HGO_ )6M._\
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M\8S):S7>E7.GQBT8V^;>-+AF=X0=V&!P0Q /&:_2FBD*Y^4>C-%I'Q:D\/\
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M'_PC<_\ T']5_P"^HO\ XW1_PC<__0?U7_OJ+_XW0!N45A_\(W/_ -!_5?\
MOJ+_ .-T?\(W/_T']5_[ZB_^-T ;E%8?_"-S_P#0?U7_ +ZB_P#C='_"-S_]
M!_5?^^HO_C= &Y16'_PC<_\ T']5_P"^HO\ XW1_PC<__0?U7_OJ+_XW0!K7
M7_'NWX?SK/JI<^&YUA8_V]JA^K1>O_7.J7_"/S_]!S4O^^HO_C=:QV-H;&Q1
M6/\ \(_/_P!!S4O^^HO_ (W1_P (_/\ ]!S4O^^HO_C=46;%%8__  C\_P#T
M'-2_[ZB_^-T?\(_/_P!!S4O^^HO_ (W0!L45C_\ "/S_ /0<U+_OJ+_XW1_P
MC\__ $'-2_[ZB_\ C= &Q16/_P (_/\ ]!S4O^^HO_C=><?%3XP>$?@[Y<7B
M#Q?J?]H2KNCT^S$4MP5_O%0F%'H6(S@XSBL:U>GAX.I5DHI=6<^(Q%'"TW5K
MR48KJ]#U^BO#/AG^T)X&^*FJ#2],\7ZM9:HW^JL]26*%YO\ <.PJQ_V0<\$X
MP*];_P"$?G_Z#FI?]]1?_&ZFAB:6*AST9*2\B<-BZ&,A[3#S4H]TS8HK'_X1
M^?\ Z#FI?]]1?_&Z/^$?G_Z#FI?]]1?_ !NN@ZC8HK'_ .$?G_Z#FI?]]1?_
M !NC_A'Y_P#H.:E_WU%_\;H V**Q_P#A'Y_^@YJ7_?47_P ;H_X1^?\ Z#FI
M?]]1?_&Z -BBL?\ X1^?_H.:E_WU%_\ &Z/^$?G_ .@YJ7_?47_QN@#8HK'_
M .$?G_Z#FI?]]1?_ !NC_A'Y_P#H.:E_WU%_\;H V**Q_P#A'Y_^@YJ7_?47
M_P ;H_X1^?\ Z#FI?]]1?_&Z -BBL?\ X1^?_H.:E_WU%_\ &Z/^$?G_ .@Y
MJ7_?47_QN@#8HK'_ .$?G_Z#FI?]]1?_ !NC_A'Y_P#H.:E_WU%_\;H V**Q
M_P#A'Y_^@YJ7_?47_P ;H_X1^?\ Z#FI?]]1?_&Z -BBL?\ X1^?_H.:E_WU
M%_\ &Z/^$?G_ .@YJ7_?47_QN@#8HK'_ .$?G_Z#FI?]]1?_ !NC_A'Y_P#H
M.:E_WU%_\;H Z.Q_C_#^M6ZYJS\.SMO_ .)[J@Z=&B_^-U9_X1N?_H/ZK_WU
M%_\ &ZREN82W-RBL/_A&Y_\ H/ZK_P!]1?\ QNC_ (1N?_H/ZK_WU%_\;J23
M<HK#_P"$;G_Z#^J_]]1?_&Z/^$;G_P"@_JO_ 'U%_P#&Z -RBL/_ (1N?_H/
MZK_WU%_\;H_X1N?_ *#^J_\ ?47_ ,;H W**P_\ A&Y_^@_JO_?47_QNC_A&
MY_\ H/ZK_P!]1?\ QN@#<HK#_P"$;G_Z#^J_]]1?_&Z/^$;G_P"@_JO_ 'U%
M_P#&Z -RBL/_ (1N?_H/ZK_WU%_\;H_X1N?_ *#^J_\ ?47_ ,;H W**P_\
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M *#^J_\ ?47_ ,;H W**P_\ A&Y_^@_JO_?47_QNC_A&Y_\ H/ZK_P!]1?\
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M/#OV??\ H?\ _P HVH?_ "/1[.?\K#V]+^9?>?1E%?.?_#P[]GW_ *'_ /\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$N?#=[JURUS=VEQ<"("$S,=[A?M!8;F) @//)KB? ?[4WC'X0^!/BSX<N?'
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MDU[>!_AOU_R/&QG\1>@4445Z!P!1110 4444 =-\//'M_P##KQ)!JMEB5/\
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M*Z6%"D9?S8GE#<DDK(I))]3G%^,G[&/@GXX>,+[Q)KNJ:_:7UY8Q:?)'IUQ
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MGOC./H!7344552<JDW.6[-*U:>(JRK5'>4FV_F%%%%08A1110 4444 %%%%
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M?_ E/\:/^$GT?_H+6/\ X$I_C0!I45F_\)/H_P#T%K'_ ,"4_P :/^$GT?\
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M_P"$KT3_ *#&G_\ @4G^- &K165_PE>B?]!C3_\ P*3_ !H_X2O1/^@QI_\
MX%)_C0!JT5E?\)7HG_08T_\ \"D_QH_X2O1/^@QI_P#X%)_C0!JT5E?\)7HG
M_08T_P#\"D_QH_X2O1/^@QI__@4G^- &K165_P )7HG_ $&-/_\  I/\:/\
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M_H+6/_@2G^-'_"3Z/_T%K'_P)3_&@#2HK-_X2?1_^@M8_P#@2G^-'_"3Z/\
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MBW(?L=O_ ,\(_P#O@4?8[?\ YX1_]\"IJ*]\^G(?L=O_ ,\(_P#O@4?8[?\
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M^^!4]% $'V&V_P"?>+_O@57O;&V$0Q;Q?>_N"K]5[[_5#_>IK<J.YE_8[?\
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M_P#SPC_[X%344 0_8[?_ )X1_P#? H^QV_\ SPC_ .^!4U% $/V.W_YX1_\
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M6E+* ,$NQ+,2/XB23U)-="=SI3N6****904444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!;L?X_P_K5NJEC_ !_A_6K=
M8RW.>6X4445) 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5>^_U0_WJL57OO\ 5#_>IK<J.Y1HHHK<Z0HHHH **** "BBB@ HHHH ****
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M4?V!JN@V<,]SK.O7FK:-<&UMO)FF:"&<$QY+G=^[WJQW(>,@UZ=^S?X%\8?
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MM7^U8/LOF]?+\W?MW?[.<U8\*?$SP?X\GGA\,^*]#\136ZAYH])U&&Z:-2<
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M .2J_*"BCZK3#Z]6/U?_ .'L7PC_ .A=\:_^ -I_\E4?\/8OA'_T+OC7_P
M;3_Y*K\H**/JM,/KU8_5_P#X>Q?"/_H7?&O_ ( VG_R51_P]B^$?_0N^-?\
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M7Y)44?4Z0?6ZI^MO_#V[X0?]"WXW_P# &S_^2J/^'MWP@_Z%OQO_ . -G_\
M)5?DE11]3I!];JGZV_\ #V[X0?\ 0M^-_P#P!L__ )*H_P"'MWP@_P"A;\;_
M /@#9_\ R57Y)44?4Z0?6ZI^MO\ P]N^$'_0M^-__ &S_P#DJC_A[=\(/^A;
M\;_^ -G_ /)5?DE11]3I!];JGZV_\/;OA!_T+?C?_P  ;/\ ^2J/^'MWP@_Z
M%OQO_P" -G_\E5^25%'U.D'UNJ?K;_P]N^$'_0M^-_\ P!L__DJC_A[=\(/^
MA;\;_P#@#9__ "57Y)44?4Z0?6ZI^MO_  ]N^$'_ $+?C?\ \ ;/_P"2J/\
MA[=\(/\ H6_&_P#X V?_ ,E5^25%'U.D'UNJ?K;_ ,/;OA!_T+?C?_P!L_\
MY*H_X>W?"#_H6_&__@#9_P#R57Y)44?4Z0?6ZI^MO_#V[X0?]"WXW_\  &S_
M /DJC_A[=\(/^A;\;_\ @#9__)5?DE11]3I!];JGZV_\/;OA!_T+?C?_ , ;
M/_Y*H_X>W?"#_H6_&_\ X V?_P E5^25%'U.D'UNJ?K;_P /;OA!_P!"WXW_
M / &S_\ DJC_ (>W?"#_ *%OQO\ ^ -G_P#)5?DE11]3I!];JGZV_P##V[X0
M?]"WXW_\ ;/_ .2J/^'MWP@_Z%OQO_X V?\ \E5^25%'U.D'UNJ?K;_P]N^$
M'_0M^-__  !L_P#Y*H_X>W?"#_H6_&__ ( V?_R57Y)44?4Z0?6ZI^MO_#V[
MX0?]"WXW_P# &S_^2J/^'MWP@_Z%OQO_ . -G_\ )5?DE11]3I!];JGZV_\
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MPBCB*"LF[-7_ "^XZ>"^,,PS.<\%C)<THKF4K*]KI-.WJK?B?I=_P]B^$?\
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ME!11]5IA]>K'ZO\ _#V+X1_]"[XU_P# &T_^2J/^'L7PC_Z%WQK_ . -I_\
M)5?E!11]5IA]>K'ZO_\ #V+X1_\ 0N^-?_ &T_\ DJC_ (>Q?"/_ *%WQK_X
M VG_ ,E5^4%%'U6F'UZL?J__ ,/8OA'_ -"[XU_\ ;3_ .2J/^'L7PC_ .A=
M\:_^ -I_\E5^4%%'U6F'UZL?J_\ \/8OA'_T+OC7_P  ;3_Y*H_X>Q?"/_H7
M?&O_ ( VG_R57Y044?5:8?7JQ^K_ /P]B^$?_0N^-?\ P!M/_DJC_A[%\(_^
MA=\:_P#@#:?_ "57Y044?5:8?7JQ^K__  ]B^$?_ $+OC7_P!M/_ )*H_P"'
ML7PC_P"A=\:_^ -I_P#)5?E!11]5IA]>K'ZO_P##V+X1_P#0N^-?_ &T_P#D
MJC_A[%\(_P#H7?&O_@#:?_)5?E!11]5IA]>K'ZO_ /#V+X1_]"[XU_\  &T_
M^2J/^'L7PC_Z%WQK_P" -I_\E5^4%%'U6F'UZL?J_P#\/8OA'_T+OC7_ , ;
M3_Y*H_X>Q?"/_H7?&O\ X VG_P E5^4%%'U6F'UZL?J__P /8OA'_P!"[XU_
M\ ;3_P"2J/\ A[%\(_\ H7?&O_@#:?\ R57Y044?5:8?7JQ^K_\ P]B^$?\
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MAB7^ZJ* %'L!658_#GPGI>AW^BV?A?1;31]0=I;S3X-/A2WN78 ,TD87:Y(
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M?VG--ROS<NZBK6Y7V[GY'T5^N%%?0_Z[?]0__DW_ -J?9_\ $5?^H+_RI_\
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M^ 9O V=N;\/^"?S;T5_2112^O?W?Q_X OJ/][\/^"?S;T5_2111]>_N_C_P
M^H_WOP_X)_-O17])%%'U[^[^/_ #ZC_>_#_@G\V]%?TD44?7O[OX_P# #ZC_
M 'OP_P""?S;T5_2111]>_N_C_P  /J/][\/^"?S;T5_2111]>_N_C_P ^H_W
MOP_X)_-O17])%%'U[^[^/_ #ZC_>_#_@G\V]%?TD44?7O[OX_P# #ZC_ 'OP
M_P""?S;T5_2111]>_N_C_P  /J/][\/^"?S;T5_2111]>_N_C_P ^H_WOP_X
M)_-O17])%%'U[^[^/_ #ZC_>_#_@G\V]%?TD44?7O[OX_P# #ZC_ 'OP_P""
M?S;T5_2111]>_N_C_P  /J/][\/^"?S;T5_2111]>_N_C_P ^H_WOP_X)_-O
M17])%%'U[^[^/_ #ZC_>_#_@G\V]%?TD44?7O[OX_P# #ZC_ 'OP_P""?S;T
M5_2111]>_N_C_P  /J/][\/^"?S;T5_2111]>_N_C_P ^H_WOP_X)_-O17])
M%%'U[^[^/_ #ZC_>_#_@G\V]%?TD44?7O[OX_P# #ZC_ 'OP_P""?S;T5_21
M11]>_N_C_P  /J/][\/^"?S;T5_215>^_P!4/]ZFL=_=_'_@#6!N[<WX?\$_
MF_HK^C*BK^N?W?Q-/[._O_A_P3^?+X<^,7\"^+;/50AEA4F.>,=6C;AL>XZC
MW K[*T77+#Q%I\5]IMU'>6D@RLD9R/H?0^QY%?J'6=K'AK2/$2HNJZ59:FJ<
MHMY;I,%^FX'%?293Q)++DZ<X<T'KOJF?!\2<"PSR4:].KR5$K;:->>O3O_2_
M,/Q3XLTSP=I,E_JERD$2@[$)^>5L?=4=S7Q=XH\03^*O$%_JUR LMW*9"H.0
MHZ!1]  /PK^A'2=#TW0;<V^F:?:Z= 3DQ6D*Q+GUPH J[6>:\12S)J*ARP72
M_P"+T-N&^"*>0QE4E5YZDM&[6279:_?\C^<VBOZ,J*^?^N?W?Q/MO[._O_A_
MP3^<VBOZ,J*/KG]W\0_L[^_^'_!/YS:*_HRHH^N?W?Q#^SO[_P"'_!/YS:*_
MHRHH^N?W?Q#^SO[_ .'_  3^<VBOZ,J*/KG]W\0_L[^_^'_!/YS:*_HRHH^N
M?W?Q#^SO[_X?\$_G-HK^C*BCZY_=_$/[._O_ (?\$_G-HK^C*BCZY_=_$/[.
M_O\ X?\ !/YS:*_HRHH^N?W?Q#^SO[_X?\$_G-HK^C*BCZY_=_$/[._O_A_P
M3^<VBOZ,J*/KG]W\0_L[^_\ A_P3^<VBOZ,J*/KG]W\0_L[^_P#A_P $_G-H
MK^C*BCZY_=_$/[._O_A_P3^<VBOZ,J*/KG]W\0_L[^_^'_!/YS:*_HRHH^N?
MW?Q#^SO[_P"'_!/YS:*_HRHH^N?W?Q#^SO[_ .'_  3^<VBOZ,J*/KG]W\0_
ML[^_^'_!/YS:*_HRHH^N?W?Q#^SO[_X?\$_GJ\-:II^BLUU<))/=?=14480>
MN2>IKT#0;ZXUS2SJ/]GW%O9&=K>.X928Y'559E#8P6 920.0&7UK]U:\_P#B
M]\(=.^+D/AF/4-H&BZQ;ZH-RY\Q$)WQ'V8$9^@KY'-\KI9A&=5)^U=K-O1+M
M;;8_<>!^.L9PU5H8*HXK!QYN:,8*\FT[2<M97O;RLK6L?)7@_P#8/^(_@V\\
M/>*_"GB_3+/Q';QQ7@@O(I8/(E* O$64.''+(<@!AG( -??/AVXU.ZT.QEUF
MSBL-6:)?M5O;R^9&DG1MC=USR,\X(S@TZU_X^%_'^5:%;8; 4<#=4;I/I?3U
M/D>(^*LPXF<)9CRRE"]I**4K/[-U:Z[75UWU=RBBBN\^+"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"&Z_X]V_#^=9]:%U_Q[M^'\ZSZUCL;PV"BBBK- HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"W8_Q_A_6K=5+'^/\/ZU;K&6YSRW"BBBI("BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *KWW^J'^]5BJ]]_JA_O4UN5'<HT445N
M=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-:_P#'
MPOX_RK0K/M?^/A?Q_E6A64MS">X4445!F%%%% !1110 4444 %%%% !1110
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MYV4?L,GJOYT?89/5?SJ]11S,.=E6&U>.16)7 ]*M445+=R6[[A1112$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-&IB*L:-)7E)I)=V]$CI:*^;?^&]/A__ - ?Q)_X#6__ ,?H_P"&]/A__P!
M?Q)_X#6__P ?KV_[ S3_ )\2/J_]3\__ .@27X?YGTE17S;_ ,-Z?#__ * _
MB3_P&M__ (_72?#G]KCP?\3O&6G^&=+TW7+>_OO,\N2\@A6(;(VD.2LK'HAZ
M \XK.IDF8TH2J3HM)*[]$8UN%<[P]*5:KA9*,4VWV2U;/;J***\0^4"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HKS'XJ?M!>&OA;-]BG,FJ:QC)L+0
MC,8(R#(QX7/IR>0<8YKB/#/[9GAW5-2CMM6TB[T:"0A1="03HGNP ! ^@/TK
MVJ.2YAB*/UBE1;C^?HMW\D?+XGB?)L'B?JE?$Q4]K:Z/S=K+YM'T+14%C?6^
MI6<%W:3QW-K.@DBFB8,CJ1D$$=0:GKQFFG9GTZDI)-;!1112&%%%% !1110
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MM!U[6[#Q5HVHZ3H)F75;RQOH[B.Q:)=\JS%&.QD49*GD>E 'B?[9WPQ\6?M
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MTWPWM^(WA6;Q#92Z!'<1&SDB"L8I!*[[PT;!LC;M.5^;AC];5YSH?[/7P_\
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M6=[6>M]%;2]OBK]E_P"%<-C^RIX9\6R_!?X70-#X/FO8?%ZNESK+RBUD*2O
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M5)QBX*3L^AA*A2G-5)03DMG97^\****S-PHHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRH&_^S/X;O+/P[KGB*\\0ZCK<OB#5[RY)OH;5,K'<20Q2YA@C)9H8HLY)48
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M8]7\8^)-5N/B-X;\&Z9=2:2E_8WFJ7>IPQQO*(X&AC$,8D5D#,]PI+,IPJ$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M',0H"_O%;Y5 Z "K+?#GPY)I_B*QDTN.6T\0S-<:I%([N+F1HTC+')^7Y(T
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:-51%&%51@ >@%.KSZCC*;<59=NQB[-Z'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>lsta-20240331_g2.jpg
<TEXT>
begin 644 lsta-20240331_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:CJMSXC\;)<7US)=2+%?680,[%B%!M2<9/<FJ/\ PY_^#?\ T,OCG_P/L_\
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M_P #[/\ ^1*/[?P7=_<'URD?D#17Z_?\.?\ X-_]#+XY_P# ^S_^1*/^'/\
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M/_Y$H_X<_P#P;_Z&7QS_ .!]G_\ (E']OX+N_N#ZY2/R!HK]?O\ AS_\&_\
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MOCG_ ,#[/_Y$H_M_!=W]P?7*1^0-%?K]_P .?_@W_P!#+XY_\#[/_P"1*/\
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M]P?7*1^0-%?K]_PY_P#@W_T,OCG_ ,#[/_Y$H_X<_P#P;_Z&7QS_ .!]G_\
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MV_@N[^X/KE(_(&BOU^_X<_\ P;_Z&7QS_P"!]G_\B4?\.?\ X-_]#+XY_P#
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MK$7TNE_V)+X@72K;^UY;#;M^SM>>7YI7&.=V[@'=7Z)_\.?_ (-_]#+XY_\
M ^S_ /D2C_AS_P#!O_H9?'/_ ('V?_R)4?VIE2^Q_P"2B^L8?M^!\<?M&?MZ
MZ]X]UBSB^'5_>^'- /AN'0[O[9I=E'?L>?/5+E0\RQ/B/A9%^[]T=_(+S]JK
MXI:AKWB+6KCQ1YFI^(=&_P"$?U.?^S[4?:+';M\G:(L+QQN4!O>OTF_X<_\
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MTNBOFC_@GY\;/%OQ\^!,_B;QG?1:CK":S<68FAMT@'E)'$5&U !U=N?>O/\
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MIK6JC&;&RFNANZ?)&S?TKY)_X)N_M+>//VC]'\>W7CG4K?4)-+N;1+06]I'
M(UD64L/D S]Q>N>E=-/#3J49UUM&U_F:*FY1<^B/LRBBJ2ZUI[ZB;!;ZV:_
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M*K!COSYQY('W?>OKK]A7]B_3?V?6LOBJ/%\VIG7O"J+-8S62PI;+/]GN6;S
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M_,Q7(*ELD!7!/"BO%OV]?&4GP[_X*$:%XHALFU&?1ETF_CLTSF=HVWJ@QZD
M?C4'[!>?''_!0K7/$.C$G2$FUK4RT(.PV\K.D?X;IH\9]!4_[>D27'_!0WPU
M%(NZ-Y-%5E/<&5017IPI4Z>9RY8V4H7:\WN;J,8UW9;HZ3XW?\$[?B/XF^&/
MB+XN^-/'_P#;/Q#6RDUB^T1K0F*.)%,CV\<WF<%$SA50*"-HXPU>R_\ !)WX
MW:_\2/AMXJ\*>(=2FU63PO/;&RN+J1I)EMIUD B+$Y*HT+8] P'0 5]:_';_
M )(?\0_^Q=U'_P!)I*_/W_@C)_R$_BU_UQTO_P!"NJ\OZQ/&Y;6E6M[C5M+6
MU6B,.=U:$G+I:QG_ !P\>>+?V[OVN)O@KX;\17.@?#[2)IK>\:'=LF^SG%Q<
M2("/-^<;(U8[?NGC<QJQ^TI_P3AL_P!GGX:W7Q*^%OC/Q%#K'AM5O+I+ZXC6
M4Q@@-)!+"D91ESNP<Y /.1S\]_ O]G72/C7^UUXH^&WC76=0TB5;K4P)[0HL
M\UU#*25^=2.5$C'C/RU]>>)O^"3OP@\&^']0US7/B'XDTS2+"%KBZO+B2U6.
M*-1DL3Y5>G5JTL#4I485>6*2]U1OS7[OS-Y2C2<8J5EVMN>L?LR_M=7OQ+_8
MX\1?$#4X_MWBSP;I]ZNIJ4VK=SV]N9DD 7M(A3.,8;?C  KXG_9;^$?A7]N;
MQ9XJUSXR?%/4D\6^>JV>EPWT,-S-&06+1^<K@QJ?E$<:_+CG (K[M_8O^!?P
MK^'OP_\ %=E\/O&H^(WAG7)Q'?\ GSP7$4;B(J\3"-1C<CC*L,XQZU\R_%'_
M ()'VWB#5+_4?A1X\T]=/:5E72=9W.MJ_4Q_:8MY(&>C1[@,9+'FN##U\+2J
MUX0DZ?,U:5MO+R,83IQE-)\M^IZ5\!?V&?BI^S3\>X]2\%^/K.Y^%S2)]LTW
M5)I1/=PL )%,*1F/S%.2L@93P.Q85]W5^)G_  DWQW_X)W_%31=,UC5[AM.8
M)=_V1'J!NM-U&UWE7"H?N,=K+NVJZ\'IU_;&-Q)&KC(##(R,&O.S:G5C*%6<
MU-26DDK7MW\S'$1E=2;O?J?F]^V-=R?&C_@H-\'OAC<A)="T>2VN9[9_F60R
M/Y]P"/\ :A@C7\_6OT>NKJ*RM9KB=Q'#"AD=ST50,D_E7YJ^/P=!_P""PGAJ
M[N\F&]%N8=_3Y]->!<9_VP?QK]"_B7I=UKGPY\5:=8LRWMYI-W;P-']X2/"Z
MJ1[Y(J<?%*&&IK;D3^;>HJVU-=+'Y+SZAXW_ ."G7[3E_HD&O7&A^!=/$MU;
M0R*SPV%BC!%D\D, \\A9,Y.<L>=J 5U7Q,_93^)O[!_Q \)>+_@_J^N^-;>^
MG\FZT^SL)6>1DPWDW$4)8212 M@X!4CCG!H_X(\Z[9:?\7O'.CW#K%J-]H\<
MMNK\%A%,/,4>_P"\4X]%/I7Z%_'K]I[P#^S;;:+-XWU&>S&KRO%;1VMNT[D(
M 7<JO(4;ER?<5[6,Q5;"XI8.A"\$K<MM]/O_ .&.JI4E3J>R@KKL>"?\%!OV
MO-5^#?P;\.67A;[7H7B_QE!YL<D\)CN--M0B-*2K#*39D5!D97YSPRBOGWX0
M_P#!+'5/C!\+['QOXN^(%UIGB7Q#;+J,-NUF;HHL@WQM.[R!G=E() QC.,FJ
MW_!7:&?6O$GPL\66ZW!T/4]%D2W,T3)M;>LN&!'RL4E3Y3S\OM7Z5?!?7K#Q
M1\(?!6K:9(DMA=Z-9RPM&<@*85^7ZCH1V((KD=:>7X"E/#:.;=WZ=-3/F=&C
M%PT;/SU_8._:$\<?!_\ : O?V??B+J,^I62W,^FV#3.9?L5W%N8!';YC!(JG
M:#P"R$  M65_P6#F%O\ %;X:RL"5CTN9B!UXG!KD;QU^(7_!61)- ?S(X?%L
M+.]ODC%I$OVC\/W$F3TZUU'_  6/_P"2E_#S_L$7'_HX5ZE.$5F5&HE9SA=K
MSLS>*7MX2[HZKQ)^P_\ $G]L[P_=_%SQ?XV_L76M:@:]\.^%)+5I8;*T8;K>
M%W+J(RR[<[4/)W,220*W_!)'XT>([CQ5XI^%NL7\]WI=GIQU/3[>ZD9C9M',
MD4L4>3\JGS5.T< J2.IK]%_A]$EOX!\-11KMC33+954=@(E %?E7_P $L_\
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M!&_#,L<V) /IYB<?X&O=O^"OFM6=K^SOX;TR2X1;^\\20RPV^X;WCCMKCS'
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MC+,/]V2YE=/_ !UA794][+(2>ZFTO1J_YFCUH)]F?05%%%>(<H4444 %%%%
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MBMM+L);:<:G=/"V]I-PVA4;(Q7W%177+-<0ZT<19<R\M[]S7ZQ/F4^IS&M>
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M,$AN2*_0[]K3X 7'[2WP?N/!5MK4>@RRWD%U]LEMS.H$9)V[0R]<^M2_LH_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?CSQ=J_AW7-9^'/P)N;'[ VKW&I_8AJ<FQ5W0M/GY2X<[R#QN48W%0N8+GZ
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M:%JMEJ5EX-$-[9S)<02'4[QPLB,&4[6F(."!P017JW_"9:!_T'--_P# N/\
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M]6T^ZL;N/S;6ZB:&6/)&Y&!##(Y&03TJA_PF6@?]!S3?_ N/_&C_ (3+0/\
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M/)RAR3DYK.\1?L7_  <\6:Y?:SJ_A*2^U.^F:>XN)-7OLN[').!/@#T P ,
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M.RZ:DTJC;\JK>NYE"!\-M'7 W$X!KVG_ (33P]_T'=,_\#(__BJ/^$T\/?\
M0=TS_P #(_\ XJ@-3SOQ[^R?\+/B?XGNO$/BCPS)JVKW(59+B35+Q.% "A52
M8*H '10!U/<TM]^R;\)M2\&:;X5N?!MM-HNFR22VD;7,_G0M(VY\3^9YN&/)
M7=@X'' KT/\ X33P]_T'=,_\#(__ (JC_A-/#W_0=TS_ ,#(_P#XJ@-3S;4O
MV0OA%JWAO3/#\_@^-='TZ1YK>U@OKJ%?,<*&D<I*#*Y"J-[EF   ..*W_A7^
MS]X!^"MQJ$_@S0!HTVH(B7+_ &N><NJ$E1^]D;'+'IBNJ_X33P]_T'=,_P#
MR/\ ^*H_X33P]_T'=,_\#(__ (J@-3%\-_!WPAX1\=:YXQTG2/LGB/6P5U"]
M^TS/YP+!ON,Y1>5'W5'2NSK&_P"$T\/?]!W3/_ R/_XJC_A-/#W_ $'=,_\
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MQO\ A"_#W_0"TS_P#C_^)H_X0OP]_P! +3/_  #C_P#B:V:*D@QO^$+\/?\
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M_P! +3/_  #C_P#B:/\ A"_#W_0"TS_P#C_^)K9HH QO^$+\/?\ 0"TS_P
MX_\ XFC_ (0OP]_T M,_\ X__B:V:* ,;_A"_#W_ $ M,_\  ./_ .)H_P"$
M+\/?] +3/_ ./_XFMFB@#&_X0OP]_P! +3/_  #C_P#B:/\ A"_#W_0"TS_P
M#C_^)K9HH QO^$+\/?\ 0"TS_P  X_\ XFC_ (0OP]_T M,_\ X__B:V:* ,
M;_A"_#W_ $ M,_\  ./_ .)H_P"$+\/?] +3/_ ./_XFMFB@#&_X0OP]_P!
M+3/_  #C_P#B:/\ A"_#W_0"TS_P#C_^)K9HH QO^$+\/?\ 0"TS_P  X_\
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M/ELA#%E *$$8? )-!7/K;_A#M _Z >F_^ D?^%'_  AV@?\ 0#TW_P !(_\
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M]-^$?@'6/%VL07=SINEQK+-%8HKS,"ZJ-H9E!.6'4B@1U=%<_P"!_&VG^/?
M^C>*K%)K73-4LH[Z);P*DB1NH8;P&(! /."1[UY?\'?VO/!GQTUGQ-I/A.QU
MBYU'0X&N!!/';Q_;T#%<VY,VTY(7F0H/G7)'. #W"BO"8/VL+6Z\=Z[X,A^'
M'C2;Q-HEF+^_T^,:8S10E48,&%[M<D.GRH2W.,59M?VNO ]U\!;CXLK%JB>'
MX)S:O8O#%]N$PE$8CV"39N.0WW_NG/M0,]MHKR+X$_':]^,&L>--+U'PP/#-
M[X9NH;66,7_VKS#(A?G]TFTKC!'/.>>,GUV@04444 %%%% $-U_Q[M^'\ZSZ
MT+K_ (]V_#^=9]:QV-X;!1115F@4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45\:?M":YKEY^VOX-\+Q1>.=?\/S^
M#;F]F\.>#?$LFCO).MR56=F^VVJG:.#F3)R.#CC6\1?%SQ]\/_B=H?PV\$Z7
M::78-X+O/%=ROC^\O-8U."6.9AY#7"WDN_)*K_K&"@DJQ"A"KDW/J3Q%X?L?
M%>@ZAHVIPBXT^_@>WGB/&Y&&#SV/OVKX0\=?L;_%;0(9_#_AJ[_X27PG)<_:
MX[=;Y+8"3;M#212.J[P.,J3D>G0=?X1_;"^(?Q?\8?"^R\(V7AC0=)\1>#)O
M%>KR:O97-]-;&&=H98H EQ &RR@#=TR3DXP:G@K]KKXE7GA7X/\ Q+UL>')O
M!WQ&\4KX=7PW8V<B7>FQS2RQ6\HNC,1*ZF'+@QJ#NP-O%>/F&5X?,DO:W375
M:.W;T/ S3)L)FR7M[IK2\79V?3K=?(ZG]F']C_4?AYXFM_%WC&6V.HVJM]BT
MVW;S!$Y&/,D?H6 +849'(.<C%?6=?CQ;_M&?$/08+O4;CQ=X@UJ*UTKQ3.;&
M^U[4$AE:*_5(MS03QR#8IPI1U*C@$#BOH_2_VZOB-HO@7Q-XXU?2?"<O@_PS
MXILO#D]K']KCO9894C+3&>29U4IYBG+!MWS9VXRV^!P5#+Z7L:"LM_-G5EN7
MX;*Z'L,.K+=WW;[L_0.Q_C_#^M6Z^$/V;?VD/C;^T1\3O 5^U@VC?#ZY.J7&
ML+HN@R1VL*PR&.TC?4[GS8KT.5ZV?ED$G)P./N^NR6YW2W"BBBI)"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KWW^J'^]5BJ]]_JA_O4U
MN5'<HT445N=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S%Y\-/#>H?$
M33O'5QIOF>*M/L)=,MK_ ,^4>7;2,'=/+#;#EE!R5)&.#73T4 <-XN^"/@KQ
MYXJB\2:[HOV[6H]*N=$2Z^U3QXL[@$31;4<+\P)^;&X=B*P[K]EKX6WUOX=M
M[KPG%=6_A_19_#VFPSW=Q(D-A-'Y<L)4R$2!DXW/N8=00>:]5HH$>!-^PE\$
MYI)7N?"M_J#R:5_8F[4/$FJ7)2QXQ;H9+EMB# P%QCMBO3-0^$'A'5-6\%ZE
M=:3YM[X-WC0I?M,P^Q[X1"W ?$F8P%_>!O7KS7G7QT^,_B[PS\7/AM\,_ \&
MB0:YXN2_NI-6\0Q2W%M:0VL2N56&*2-I'<L!]\!0,X;M\Y? G]I#Q_HGPJT.
MTUGQGH?_  ENK^+]<M+G^V+#5O$=\RP2']UI^GVK>=)$ASRTJK&@'!SPM!:'
MW#X@^&?AOQMXH\*ZYK6F_;=4\,W4E[I-QY\L?V:9XS&S;58*^5)&'!'MFLWQ
MQ^SKX#^(?BH^)M5TR^MO$+6GV"74]$UJ^TFXGM\Y\J5[2:(RH.P?<!GBOBG_
M (:*^+'QF?X":UIWB+3?!US?>.+SP]?6=KIE\MO=3P+,#)/$;N)W@9 G^C2!
M65P29/X1Z%\1/VVO%_@?Q/?36>I>$/$^AZ?XNM?#MUIVA^'M8N/*ADD2-S)K
M!*V<5TI8$V^UL9V[V/7*6YC+5GNW[,?[+_A_]F70=>LM(>&YN=8U%[R26WM3
M;Q00@D06L2%Y&"1IQEG9G9G=CES4</['/PMAU^'44T>_%G#JYUZ+0?[8NSI"
M:@6W?:19>9Y(;=DXV[03P*]LHJ2#Q;4OV-_A%JUS?-<^%YVL+[4!JEWHB:S?
MII%Q=!@_FR:>LXM7)8!CF(@GD@U[0JA5"J  !@ =J6B@ HHHH **** "BBB@
M#R7]K#1=1\1_LZ>.]-TFPNM4U&YL-D%G9PM--*V]3A44$L>.@%<-\*_V9K7Q
M!X(^$NK^.-7\2:K>^&=,M;BR\.ZH+>WMM/N?)CX:..".1FC*  2NQ&W!SDY^
MAM9UO3O#FEW&I:M?VNEZ=;+OGO+R9888ESC+.Q 4<]2:Y&R^/7PTU2Y6VL/B
M#X7U&[<$I:V6L6\\TF 20D:.68X!X )H&?!>F_!CQ=9_ [1UC\#ZY%KO_"T5
MU"5!I4XN1:K'A9B-FX1 Y^;[N2>:WOC[X3^)GB;P_P#%S2I_!6K6#7>LQ3Z;
MI7A/PO;26>IPB;/VNXNDC::2;;@D*X;)Y&-P7[S\$^-]'^(GAVWUS0;B6ZTR
M=F6.2:UEMG)5BIS'*JN.0>HYZBMZ@+GY\_$#X=Z[HFL:YK/AC1/%_P#;^IZ-
MI:7>A:UX(CUG1]::.*)5B67#_9MA0,PF"%2I]@+MU\/O%]O\5O%.O?$70/%E
MA8>(_"=K:PV_@;1+?5HX]L$:SZ;M>WN!"-X;;]Q<C)<]:^YM/\4:-JVK:EI=
MCJUC>ZGII07UE;W*236I<$H)4!W)N )&X#('%<1JG[1OP]T?4/$]C<ZY,;SP
MU+#!JL,&FW<S6[S9\L82([\X/*;@.^*!W.5T+5D_9Q_9TT&+1O!_CGQ*;6,P
MV.@RVJ7>JJ79W59S;!HXT7.-PSM&T8+<5X[X&\-^(/%GB3QE\2/$FE7VM_%'
M5=#N=/T;PM?>%=2M=&LX?+8BVEGN8(XY"WW3N=5)9QEMPQ]I0S)<0QRQG='(
MH93@C((R.M24"/ST\,^$?'NJ?%;X ZCJWAKQ,ATB[G74H!X6AL-,T;<PQ%";
M>(?NNAWR,5[@@[@/2]+M9KW]K+]I&WMXI)[B;PK:QQQ1*6=V-H@"@#DDGC K
MZRUK7=-\-:9/J6KZA:Z5IT"[IKN]G6&*,>K.Q  ^IKSCPGI/PGUCQKKOQ/\
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MN]BNT0D?=<HQ R.QK4TG2;'0=-MM.TRRM].T^V01P6EI$L442CHJHH 4>P%
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M7Y)44?4Z0?6ZI^MO_#V[X0?]"WXW_P# &S_^2J/^'MWP@_Z%OQO_ . -G_\
M)5?DE11]3I!];JGZV_\ #V[X0?\ 0M^-_P#P!L__ )*H_P"'MWP@_P"A;\;_
M /@#9_\ R57Y)44?4Z0?6ZI^MO\ P]N^$'_0M^-__ &S_P#DJC_A[=\(/^A;
M\;_^ -G_ /)5?DE11]3I!];JGZV_\/;OA!_T+?C?_P  ;/\ ^2J/^'MWP@_Z
M%OQO_P" -G_\E5^25%'U.D'UNJ?K;_P]N^$'_0M^-_\ P!L__DJC_A[=\(/^
MA;\;_P#@#9__ "57Y)44?4Z0?6ZI^MO_  ]N^$'_ $+?C?\ \ ;/_P"2J/\
MA[=\(/\ H6_&_P#X V?_ ,E5^25%'U.D'UNJ?K;_ ,/;OA!_T+?C?_P!L_\
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M_P#DJC_A[%\(_P#H7?&O_@#:?_)5?E!11]5IA]>K'ZO_ /#V+X1_]"[XU_\
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M>F*Y^<,PU32_V-?@SK&K7FG:EX5M/%#31:%9VS6VJ2L+BYR$NC(X;)W<+$A
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M_P#AF?X0?]$I\$?^$[9__&Z/^&9_A!_T2GP1_P"$[9__ !NCZ]'^4/J4NY^
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M0^I2[GX 45^__P#PS/\ "#_HE/@C_P )VS_^-T?\,S_"#_HE/@C_ ,)VS_\
MC='UZ/\ *'U*7<_ "BOW_P#^&9_A!_T2GP1_X3MG_P#&Z/\ AF?X0?\ 1*?!
M'_A.V?\ \;H^O1_E#ZE+N?@!17[_ /\ PS/\(/\ HE/@C_PG;/\ ^-T?\,S_
M  @_Z)3X(_\ "=L__C='UZ/\H?4I=S\ **_?_P#X9G^$'_1*?!'_ (3MG_\
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MZTM+^"7PZT.-DT[P#X7T]&.66UT:VC!^NU!7T^5\3?4(>QG#FCTUU1^><1<
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MG_#-OPC_ .B6>"O_  GK3_XW1_PS;\(_^B6>"O\ PGK3_P"-T?6X]@_L^?\
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MJ7_0 NO^_P##_P#%UL44 8_]L:E_T +K_O\ P_\ Q=']L:E_T +K_O\ P_\
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M_%T?VYJG_0NW7_@1!_\ %UN44 8?]N:I_P!"[=?^!$'_ ,71_;FJ?]"[=?\
M@1!_\76Y10!A_P!N:I_T+MU_X$0?_%T?VYJG_0NW7_@1!_\ %UN44 8?]N:I
M_P!"[=?^!$'_ ,71_;FJ?]"[=?\ @1!_\76Y10!A_P!N:I_T+MU_X$0?_%T?
MVYJG_0NW7_@1!_\ %UN44 8?]N:I_P!"[=?^!$'_ ,71_;FJ?]"[=?\ @1!_
M\76Y10!A_P!N:I_T+MU_X$0?_%T?VYJG_0NW7_@1!_\ %UN44 8?]N:I_P!"
M[=?^!$'_ ,71_;FJ?]"[=?\ @1!_\76Y10!A_P!N:I_T+MU_X$0?_%T?VYJG
M_0NW7_@1!_\ %UN44 8?]N:I_P!"[=?^!$'_ ,71_;FJ?]"[=?\ @1!_\76Y
M10!A_P!N:I_T+MU_X$0?_%T?VYJG_0NW7_@1!_\ %UN44 8?]N:I_P!"[=?^
M!$'_ ,74%YK6IF,9\/70Y_Y^(/\ XNNCJO??ZH?[U-;CCN<S_;&I?] "Z_[_
M ,/_ ,71_;&I?] "Z_[_ ,/_ ,76Q16QT&/_ &QJ7_0 NO\ O_#_ /%T?VQJ
M7_0 NO\ O_#_ /%UL44 8_\ ;&I?] "Z_P"_\/\ \71_;&I?] "Z_P"_\/\
M\76Q10!C_P!L:E_T +K_ +_P_P#Q=']L:E_T +K_ +_P_P#Q=;%% &/_ &QJ
M7_0 NO\ O_#_ /%T?VQJ7_0 NO\ O_#_ /%UL44 8_\ ;&I?] "Z_P"_\/\
M\71_;&I?] "Z_P"_\/\ \76Q10!C_P!L:E_T +K_ +_P_P#Q=']L:E_T +K_
M +_P_P#Q=;%% &/_ &QJ7_0 NO\ O_#_ /%T?VQJ7_0 NO\ O_#_ /%UL44
M8_\ ;&I?] "Z_P"_\/\ \71_;&I?] "Z_P"_\/\ \76Q10!C_P!L:E_T +K_
M +_P_P#Q=']L:E_T +K_ +_P_P#Q=;%% &/_ &QJ7_0 NO\ O_#_ /%T?VQJ
M7_0 NO\ O_#_ /%UL5%>3/;6D\T=O)=R1HSK;PE0\I R%4L57)Z#<0.>2.M
M&9_;&I?] "Z_[_P__%T?VQJ7_0 NO^_\/_Q=>3^"_P!JBT\8>._$WA:3X?\
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M>FKK5L;FY650T1CCW[G#J05V@[@01FNVH Q_[8U+_H 77_?^'_XNC^V-2_Z
M%U_W_A_^+K8HH Q_[8U+_H 77_?^'_XNC^V-2_Z %U_W_A_^+K8HH Q_[8U+
M_H 77_?^'_XNC^V-2_Z %U_W_A_^+K8HH Q_[8U+_H 77_?^'_XNC^V-2_Z
M%U_W_A_^+K8HH Q_[8U+_H 77_?^'_XNC^V-2_Z %U_W_A_^+K8HH Q_[8U+
M_H 77_?^'_XNC^V-2_Z %U_W_A_^+K8HH Q_[8U+_H 77_?^'_XNC^V-2_Z
M%U_W_A_^+K8HH Q_[8U+_H 77_?^'_XNC^V-2_Z %U_W_A_^+K8HH R[;6=3
M$RX\/W1/_7Q!Z?[]7O[<U3_H7;K_ ,"(/_BZN6O_ !\+^/\ *M"LY;F,]S#_
M +<U3_H7;K_P(@_^+H_MS5/^A=NO_ B#_P"+K<HJ"##_ +<U3_H7;K_P(@_^
M+H_MS5/^A=NO_ B#_P"+K<HH P_[<U3_ *%VZ_\  B#_ .+H_MS5/^A=NO\
MP(@_^+K<HH P_P"W-4_Z%VZ_\"(/_BZ/[<U3_H7;K_P(@_\ BZW** ,/^W-4
M_P"A=NO_  (@_P#BZ/[<U3_H7;K_ ,"(/_BZW** "BBB@04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-U_Q[M^'\ZSZT+K
M_CW;\/YUGUK'8WAL%%%%6:!1110 4444 %%%% !1110 4444 %%%% !1110
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MC_#^M6ZJ6/\ '^']:MU]9+<^WEN%%%%20%%%% !1110 4444 %%%% !1110
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MM=2\[QUH\?V*^;;;W&YW'ER':^$;.#\K<$_*>E9'QDM_$G[/WP[T&Y\$^#O
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M7.7E%-)O\4>(Z'XEOM _:H^*'C_4_B'J6BK;_#&P\13O+IUI=P11N)7$+0I
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MXXM?A7XG\'7'A#Q'<7-G\0F\17NE0Z5<-!J^F!45A#<!?*D;(!$>_+8R 2M
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ANO^/=OP_G6?6A=?\
M'NWX?SK/K6.QO#8****LT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .1_X4_X#_Z$GP[_ ."FW_\ B*/^%/\ @/\
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MH_X9G^$'_1*?!'_A.V?_ ,;KTFBCGEW#ECV/-O\ AF?X0?\ 1*?!'_A.V?\
M\;H_X9G^$'_1*?!'_A.V?_QNO2:*.>7<.6/8\V_X9G^$'_1*?!'_ (3MG_\
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M^$[9_P#QNC_AF?X0?]$I\$?^$[9__&Z])HHYY=PY8]CS;_AF?X0?]$I\$?\
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M (W7HU%1S2[GK\D>QYS_ ,,V_"/_ *)9X*_\)ZT_^-T?\,V_"/\ Z)9X*_\
M">M/_C=>C44<TNX<D>QYS_PS;\(_^B6>"O\ PGK3_P"-T?\ #-OPC_Z)9X*_
M\)ZT_P#C=>C44<TNX<D>QYS_ ,,V_"/_ *)9X*_\)ZT_^-T?\,V_"/\ Z)9X
M*_\ ">M/_C=>C44<TNX<D>QYS_PS;\(_^B6>"O\ PGK3_P"-T?\ #-OPC_Z)
M9X*_\)ZT_P#C=>C44<TNX<D>QYS_ ,,V_"/_ *)9X*_\)ZT_^-T?\,V_"/\
MZ)9X*_\ ">M/_C=>C44<TNX<D>QYS_PS;\(_^B6>"O\ PGK3_P"-T?\ #-OP
MC_Z)9X*_\)ZT_P#C=>C44<TNX<D>QYS_ ,,V_"/_ *)9X*_\)ZT_^-T?\,V_
M"/\ Z)9X*_\ ">M/_C=>C44<TNX<D>QYS_PS;\(_^B6>"O\ PGK3_P"-T?\
M#-OPC_Z)9X*_\)ZT_P#C=>C44<TNX<D>QYS_ ,,V_"/_ *)9X*_\)ZT_^-T?
M\,V_"/\ Z)9X*_\ ">M/_C=>C44<TNX<D>QYS_PS;\(_^B6>"O\ PGK3_P"-
MT?\ #-OPC_Z)9X*_\)ZT_P#C=>C44<TNX<D>QYVG[.'PEC=73X7>"U=3D,OA
M^T!!]?\ 5TLW[.?PGN)&DE^&'@V21N2S^'[0D_4^77H=%'-+N'+&UK'AFG_
M/09/B=JEK>>']-N?!\=E')!I4]G&]GE_E$?E$;-JE'(7&%PGM78V_P"SM\*;
M23S(/ACX-ADZ;H] M%/YB.O0J*Z*V(J5FG)[)+[CT<9C*F.G"=7>,5%>B_JY
MYS_PS;\(_P#HEG@K_P )ZT_^-T?\,V_"/_HEG@K_ ,)ZT_\ C=>C45S\TNYY
MW)'L><_\,V_"/_HEG@K_ ,)ZT_\ C='_  S;\(_^B6>"O_">M/\ XW7HU%'-
M+N')'L><_P##-OPC_P"B6>"O_">M/_C='_#-OPC_ .B6>"O_  GK3_XW7HU%
M'-+N')'L><_\,V_"/_HEG@K_ ,)ZT_\ C='_  S;\(_^B6>"O_">M/\ XW7H
MU%'-+N')'L><_P##-OPC_P"B6>"O_">M/_C='_#-OPC_ .B6>"O_  GK3_XW
M7HU%'-+N')'L><_\,V_"/_HEG@K_ ,)ZT_\ C='_  S;\(_^B6>"O_">M/\
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M?V'JG_0Q77_@/!_\10!N45A_V'JG_0Q77_@/!_\ $4?V'JG_ $,5U_X#P?\
MQ% &Y16'_8>J?]#%=?\ @/!_\11_8>J?]#%=?^ \'_Q% &Y16'_8>J?]#%=?
M^ \'_P 11_8>J?\ 0Q77_@/!_P#$4 ;E%8?]AZI_T,5U_P" \'_Q%']AZI_T
M,5U_X#P?_$4 ;E%8?]AZI_T,5U_X#P?_ !%']AZI_P!#%=?^ \'_ ,10!N45
MA_V'JG_0Q77_ (#P?_$4?V'JG_0Q77_@/!_\10!N45A_V'JG_0Q77_@/!_\
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MC_V/J7_0?NO^_$/_ ,11_8^I?]!^Z_[\0_\ Q% &Q16/_8^I?]!^Z_[\0_\
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M W**P_[#U3_H8KK_ ,!X/_B*/[#U3_H8KK_P'@_^(H W****!!1110 4444
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MY<A=N=GR[L[>,5WM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<<FO:C+;::[AW8P6[W!AC5G*@HJ!<OTXIQA*;M'<JG1J5I<D%=_Y*[_(\/\
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MJ_&3P/HNH>*/C7?6_BVZNY8FT.TCT>(2*CG:OEM9F0;E&>&!(.1CB@9]$?\
M"G_"]UXRF\8WNF)/XKNM+_LBZU"*::-)+<XW((O,*J"1UY8?WJY=/V2_A5#I
M>A:?#X7>V@T,3KI[VVIWD4T*S$F5?-68.RL6;*LQ'S$8P:\+T?\ :XC^&/PH
M\=^+X] UK7OL/C.3139ZSXF>Y))7.^*1H#Y4?'$0! SUK7T3]NCQ!J_B?4_#
ML_PST[0]=T^."9M+UKQC;V5S<K-M95@$D(C=Q&X<H77'(SGBD&I[/X5_9?\
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M1110 4444 %%%% !1110 4444 6['^/\/ZU;JI8_Q_A_6K=8RW.>6X4445)
M4444 %%%% !1110 4444 %%%% !1110 4444 ?G_ /M2?$SQAX?^.WB;3]+\
M5ZYIMA#]E\NUL]1FBB3-K$QPJL ,DD\=R:\J_P"%S?$#_H>?$G_@WN/_ (NN
MQ_:[_P"3A_%G_;I_Z20UX[7]$97AJ$L!AVZ:OR1Z+^5']K</X#"3R?!RE1BV
MZ5/[*_E7D=C_ ,+F^('_ $//B3_P;W'_ ,71_P +F^('_0\^)/\ P;W'_P 7
M7'45Z?U3#_\ /N/W(]_^SL%_SYC_ . K_(['_A<WQ _Z'GQ)_P"#>X_^+H_X
M7-\0/^AY\2?^#>X_^+KCJ*/JF'_Y]Q^Y!_9V"_Y\Q_\  5_D=C_PN;X@?]#S
MXD_\&]Q_\71_PN;X@?\ 0\^)/_!O<?\ Q=<=11]4P_\ S[C]R#^SL%_SYC_X
M"O\ (['_ (7-\0/^AY\2?^#>X_\ BZ/^%S?$#_H>?$G_ (-[C_XNN.HH^J8?
M_GW'[D']G8+_ )\Q_P# 5_D>#?\ #3'Q?_Z*MXW_ /"BO/\ XY1_PTQ\7_\
MHJWC?_PHKS_XY7FU%?AG)'L?YR\\NYZ3_P -,?%__HJWC?\ \**\_P#CE'_#
M3'Q?_P"BK>-__"BO/_CE>;44<D>P<\NYZ3_PTQ\7_P#HJWC?_P **\_^.4?\
M-,?%_P#Z*MXW_P#"BO/_ (Y7FU%')'L'/+N>D_\ #3'Q?_Z*MXW_ /"BO/\
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MY1_PTE\7/^BI^-?_  H;O_XY7G-%'+'L'//N>C?\-)?%S_HJ?C7_ ,*&[_\
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M6.QO#8****LT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"6W_\ ==?HS11]8J]P^IT/Y?Q9^<W_  Z!_P"JM?\ EM__ '71_P .@?\
MJK7_ );?_P!UU^C-%'UBKW#ZG0_E_%GYS?\ #H'_ *JU_P"6W_\ =='_  Z!
M_P"JM?\ EM__ '77Z,T4?6*O</J=#^7\6?G-_P .@?\ JK7_ );?_P!UT?\
M#H'_ *JU_P"6W_\ ==?HS11]8J]P^IT/Y?Q9^<W_  Z!_P"JM?\ EM__ '71
M_P .@?\ JK7_ );?_P!UU^C-%'UBKW#ZG0_E_%GYS?\ #H'_ *JU_P"6W_\
M=='_  Z!_P"JM?\ EM__ '77Z,T4?6*O</J=#^7\6?G-_P .@?\ JK7_ );?
M_P!UT?\ #H'_ *JU_P"6W_\ ==?HS11]8J]P^IT/Y?Q9^<W_  Z!_P"JM?\
MEM__ '71_P .@?\ JK7_ );?_P!UU^C-%'UBKW#ZG0_E_%GYS?\ #H'_ *JU
M_P"6W_\ =='_  Z!_P"JM?\ EM__ '77Z,T4?6*O</J=#^7\6?G-_P .@?\
MJK7_ );?_P!UT?\ #H'_ *JU_P"6W_\ ==?HS11]8J]P^IT/Y?Q9^<W_  Z!
M_P"JM?\ EM__ '71_P .@?\ JK7_ );?_P!UU^C-%'UBKW#ZG0_E_%GYS?\
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M_P#ASE_U5W_RVO\ [KH_X<Y?]5=_\MK_ .ZZ_22BCZU6_F_(/JM'M^9^;?\
MPYR_ZJ[_ .6U_P#=='_#G+_JKO\ Y;7_ -UU^DE%'UJM_-^0?5:/;\S\V_\
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M^7_&C^VM/_Y_K;_O\O\ C6YTERBJ?]M:?_S_ %M_W^7_ !H_MK3_ /G^MO\
MO\O^- %RBJ?]M:?_ ,_UM_W^7_&C^VM/_P"?ZV_[_+_C0!<HJG_;6G_\_P!;
M?]_E_P :/[:T_P#Y_K;_ +_+_C0!<HJG_;6G_P#/];?]_E_QH_MK3_\ G^MO
M^_R_XT 7**I_VUI__/\ 6W_?Y?\ &C^VM/\ ^?ZV_P"_R_XT 7**I_VUI_\
MS_6W_?Y?\:/[:T__ )_K;_O\O^- %RBJ?]M:?_S_ %M_W^7_ !H_MK3_ /G^
MMO\ O\O^- %RBJ?]M:?_ ,_UM_W^7_&C^VM/_P"?ZV_[_+_C0!<HJG_;6G_\
M_P!;?]_E_P :/[:T_P#Y_K;_ +_+_C0!<HJG_;6G_P#/];?]_E_QH_MK3_\
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M (T?VYIO_00M?^_R_P"-09EZBJ/]N:;_ -!"U_[_ "_XT?VYIO\ T$+7_O\
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MZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\
MA1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5
M>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_
MX4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>
MHH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO
M^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7
MJ* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K
M_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5
MZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\
MA1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5
M>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_
MX4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>
MHH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO
M^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7
MJ* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K
M_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5
MZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\
MA1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5
M>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_
MX4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>
MHH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO
M^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7
MJ* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K
M_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5
MZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\
MA1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5
M>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_
MX4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>
MHH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO
M^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7
MJ* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K
M_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5
MZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\
MA1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5
M>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_
MX4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>
MHH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO
M^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7
MJ* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K
M_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5
MZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\
MA1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5
M>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_
MX4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>
MHH H_P!AZ;_T#[7_ +\K_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO
M^%']AZ;_ - ^U_[\K_A5ZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7
MJ* */]AZ;_T#[7_ORO\ A1_8>F_] ^U_[\K_ (5>HH H_P!AZ;_T#[7_ +\K
M_A1_8>F_] ^U_P"_*_X5>HH H_V'IO\ T#[7_ORO^%']AZ;_ - ^U_[\K_A5
MZB@"C_8>F_\ 0/M?^_*_X4?V'IO_ $#[7_ORO^%7J* */]AZ;_T#[7_ORO\
MA1_8>F_] ^U_[\K_ (5>HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Y^9>W[L_45Y!\2/V;]?^$^K?!#PSKUCX9\6?V_\2-3U.S\%3W$A\/Z=;RP
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MGM<9HWP7^'OARWTN#2? GAG2X-*NFOM/CL]'MX5L[AE"M-"%0>7(0 "ZX)
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MNUCJL:EHD4V\I ^[SE3]#D_IZU+X"^*6FV6B6^GZL[VTELNQ)@C.K*.G3)!
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M+:*WO[BV6[C$$HE0HS,H^8<9RA%?FV=QG[:4J2DH==^6_ET_X)_;/A?6P_\
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M+P^H7&HGYKH_OODV *H3YB0H^<=:LZ'_ ,$^=,M[/P-IVL^+I-6TGP]X)O\
MP7=6\.G"![V.Z+;IU<RN(F4-PI5^0#GM7WI^F#_$'_!1SP?X#T'0M<\:^!O&
M7A32_$U@=0\,R7-O:S2:NH9!Y:K'.WDR%98W F*+M;[P/!K?$W]N#Q5X7\>^
M!-"TSX.^+M.AU36UT_46\16ME&+F)H))0MA<+?B"23"!BY<QJ."P8@51T?\
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M+(](N/A9XGU#0+;6&M_ ^L6^H>'H K+%]JM+>>T'V6X8L,I(C*X7=@\$[O\
MP4$N+_P[\&_AQH6J^(-5;P=J?B_2])\9:\TD=O++IC[Q,;AH%C1$D(4.45%[
M8P<'Z*T7X(?#GPWX?U70M(\ >%]*T35EV:AIMEHUM#;7BXQB:)4"R#!/W@:V
MV\$>'6\)CPLV@:6?# MQ9C139Q_8O( P(O)V[-@  VXQ[4 ?#OQ6\#GX;_M:
M>%O"_P"SJ]EX$UO6?!>K7&N6?A^TB^QQK%%G3KJ:WVM"&-QA/,9,L&(SR*\1
MUC]O[XU_%*7P&W@S4[O1=!B71_#/C&XM=/LDNCK5U)+YS6[W:K%&Q2W8+N=8
MU:09QP5_3_P)\)/ _P +5NQX-\':#X3%V0;C^Q-,AM/.P21O\M1NQDXSTSQ3
M;?X/^ [/1=:T>#P3X=ATC7)6N-5T^/28%M[^1B"SSQA-LK$@9+@GB@#\_/$W
MQV^/VE_$S2?AUI?CF^\.6.K^--/TJRU;7&\/:MK5G;7%L[307<%HTT:E77?&
MS!696QD@8#_'_P"UA\1/AQ;:EK>A_$_Q3XZL='\<1^&WGUCP[H.FZ3<A9%6:
MS(5EO9IE!),\,:)Q]U0":^^M)^"?P[T"UTRVTOP%X8TVWTN[_M"PAM-'MXDM
M+G&//B"H DF/XUP?>J&K_LZ_"CQ!KT^N:I\,?!NI:W<3?:)M2O- M);F23.=
M[2-&6+<#DG/% 'YR?L+_ /)T_@'_ *Y>+_\ TNKU;XT_"FR^)'[07QGU&VE\
M(_%J>STJWAU'PCXON+G1]4\,1K;$J^EW3PR1*LF[S?."A0Q7+Y!+?;FA?"3P
M-X7U6WU/1O!GA[2-2MQ,(;RQTJ"":/S6W3;75 1O;EL'YCR<U#XV^#'P^^)5
M]!>>+O OAKQ5>6Z>7#<:WI%O>21J3G:K2(Q SV% 'PE^SS^V'K&MZ1X^BM/%
MVJVGA30/AE'JF@+XP:TEOX[R+S87FDN/*7[0?,C W-E6^7Y<DUQJ_M*?M)>/
M=*EO?"WQ*%A<:'\+K'QK>6)T"PF.I3F3$ZY,.8\IN;Y>,J  ,YK]&?%'P+^&
MWC@:>/$?P]\*^(!IT M;(:IHMM<_9H1TCCWH=B#^ZN!5_1?A7X*\-S--I'@_
M0=*F:P72C)9:9!"QLU^[;951^Z':/[H]* /SL^)O[37BWX_?"KQ/\0='O;2#
MP$_C3P]H7AFSU30+&]^RS>6IO;D"Z@?,@DF548YV[#MQDUF:K^W5\4H]/A\'
M:IX]N/"'BGP(^K1^.O$5OX5M]1>Z9;M+73TAMB(X]TC3+]UD&5W'(R#^D%O\
M'O 5GX6MO#,'@CPY!X;M;D7D&CQZ3;K9Q3AMPE2$)L5PW.X#.><TMU\'_ =]
M<>()[GP3X=N)_$*JFLR2Z3 S:FJ_=%R2G[X#L'SB@#\Y_B]\=_'7B3P3^TG\
M-/%&IZQJNFZ7X+M=6@'B>#2(]3LYFGB5XI#I;&':P<,%;]XO&0._Z-_";_DE
M?@W_ + ME_Z(2L?2?V=?A1H%GJ=KIGPQ\&Z=:ZI!]EOX+30+2)+N'<&\N55C
M =-R@[6R,@'M7>VEI!I]K#:VL,=M;0HL<4,*!4C0# 50.     * )J*** "B
MBB@ HHHH **** "L;Q#X-\/^+OL_]NZ%INM?9]WD_P!H6<<_E[L;MN\'&=JY
MQUP/2MFBKC.5-\T'9FE.I.C)3IR::ZK1G'?\*:^'_P#T(WAO_P %%O\ _$4?
M\*:^'_\ T(WAO_P46_\ \178T5O];Q'_ #\E][.S^T<;_P _I?\ @3_S.._X
M4U\/_P#H1O#?_@HM_P#XBMCP]X-\/^$?M']A:%INB_:-OG?V?9QP>9MSMW;
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M*S&@I\NSU37S33MY7L=V%QV)P;;H3M?[ON>AP?AOX0Z7HMPES=RMJ4R'*B1
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MM%;PIK$.H75M=0+"Q:(PR12J86!)^:/:QZ$D4 ?*^I?M\>-YOB%X<^&UE?\
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M,S*P(V748P,<Q_,,?>'C;]F7X9?$;3/"VG^(_"L&J6GABUDL=)CDN)U-O;O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH$@\D\,0?F4* ?0=175U#96TMQ<2QP6\*&2265@J(H&2Q)X  YR:X3XA>/\
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M.-[.S^TNZ3T?;3H?7-%?E-\.=1^.'[77Q2M;#4/$OB"RT1IA)J%Q:O);65G
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MC_"WPS/;W\-UI\FH+?Z;%I%TU_=S7+S6L9D*(SR.S$@RN=^=Q)R22!BMX?\
M@[X3\,Z]:ZY::?<3ZW;02VT>IZCJ%S>W7E2%"T;2SR.S+\BX#$A>=N-S9[2B
M@#@;'X&^#]-L;2TM+34;:.S=VM'BUJ]66T5PH>*"03;XHB%7]TA$?RJ=O JY
M??"'PK?V>D6QL;BT_LEI&LY]/U"YM+B/S#F4&:&19&#G#.&8AR 6R1FNRHH
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L,L2N4W8&<;L9QVKJ*;'&D,:QQJJ(HPJJ, #T IU>?4<93;BK+MV,79O0_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089281152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LISATA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LSTA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,307,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005443904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,805<span></span>
</td>
<td class="nump">$ 22,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">21,544<span></span>
</td>
<td class="nump">27,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">4,210<span></span>
</td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,559<span></span>
</td>
<td class="nump">53,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Acquired license - intangible, net</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">48,240<span></span>
</td>
<td class="nump">54,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">2,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,070<span></span>
</td>
<td class="nump">4,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,333<span></span>
</td>
<td class="nump">6,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,497<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">577,283<span></span>
</td>
<td class="nump">576,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(533,482)<span></span>
</td>
<td class="num">(528,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Lisata Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">42,997<span></span>
</td>
<td class="nump">48,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">42,743<span></span>
</td>
<td class="nump">47,894<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interests and stockholders' equity</a></td>
<td class="nump">$ 48,240<span></span>
</td>
<td class="nump">$ 54,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096661888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">8,308,171<span></span>
</td>
<td class="nump">8,150,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">8,307,433<span></span>
</td>
<td class="nump">8,149,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096548656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 3,241<span></span>
</td>
<td class="nump">$ 3,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">6,844<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,601)<span></span>
</td>
<td class="num">(6,844)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before benefit from income taxes and noncontrolling interests</a></td>
<td class="num">(6,199)<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">(798)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,401)<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less - net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (5,401)<span></span>
</td>
<td class="num">$ (6,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_EPSAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares (in shares)</a></td>
<td class="nump">8,294<span></span>
</td>
<td class="nump">7,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares (in shares)</a></td>
<td class="nump">8,294<span></span>
</td>
<td class="nump">7,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_EPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_EPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096082192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,401)<span></span>
</td>
<td class="num">$ (6,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment arising during the period</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (5,463)<span></span>
</td>
<td class="num">$ (6,210)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089152864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Lisata Therapeutics, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 66,324<span></span>
</td>
<td class="nump">$ 66,578<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 574,548<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="num">$ (507,241)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(6,187)<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 60,703<span></span>
</td>
<td class="nump">60,957<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">575,137<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(513,428)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">8,149,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 47,894<span></span>
</td>
<td class="nump">48,148<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">576,971<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(528,081)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,401)<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">8,307,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 42,743<span></span>
</td>
<td class="nump">$ 42,997<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 577,283<span></span>
</td>
<td class="num">$ (104)<span></span>
</td>
<td class="num">$ (533,482)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005450960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,401)<span></span>
</td>
<td class="num">$ (6,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based compensation</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion on marketable securities</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(1,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="num">(1,243)<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,027)<span></span>
</td>
<td class="num">(8,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(18,824)<span></span>
</td>
<td class="num">(30,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">25,360<span></span>
</td>
<td class="nump">34,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Investment in Impilo Therapeutics</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">6,436<span></span>
</td>
<td class="nump">4,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(788)<span></span>
</td>
<td class="num">(3,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">22,593<span></span>
</td>
<td class="nump">32,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 21,805<span></span>
</td>
<td class="nump">$ 28,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366002052448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_BusinessTextBlock', window );">The Business</a></td>
<td class="text">The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (&#8220;TME&#8221;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_BusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Business [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_BusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366002038720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Company's acquisition of Cend Therapeutics, Inc (the &#8220;Cend Merger&#8221;), with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $17&#160;thousand for the three months ended March&#160;31, 2024 and $18&#160;thousand for the three months ended March&#160;31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next 3.5 years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2024 and March&#160;31, 2023, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096101776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001983920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $29&#160;thousand and $30&#160;thousand for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089047520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text">Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. At March&#160;31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001993504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts payable and accrued expenses approximate fair value as of March&#160;31, 2024 and December&#160;31, 2023, due to the short maturity nature of these items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366002027616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366002048736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-388"><span style="-sec-ix-hidden:f-389">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-398"><span style="-sec-ix-hidden:f-399">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the weighted average remaining lease term for our operating lease was 1.5 years, and the weighted average discount rate for our operating lease was 9.625%. As of December&#160;31, 2023, the weighted average remaining lease term for our operating leases was 1.75 years, and the weighted average discount rate for our operating leases was 9.625%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2024 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001381840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. As of the date of this filing and so long as the Company&#8217;s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#8220;Baby Shelf Limitation&#8221;), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of the Company's Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $26.7&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such S-3 filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $8,915,094, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If the Company&#8217;s public float exceeds $75.0&#160;million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. There were no issuances of common stock under the ATM Agreement for the three months ended March&#160;31, 2024. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2024:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.42</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,165.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,453,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443,689&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.22&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.5&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-476">one</span> and four years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(99,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock units issued for services in the three months ended March&#160;31, 2024 and 2023 was $3.08 and $3.00 per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005569312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:62.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.319%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2024 and 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005621232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company had approximately $43.7&#160;million and $33.7&#160;million respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036.  The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in approximately $34.0&#160;million of remaining Federal NOLs as of December&#160;31, 2022. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Cend Therapeutics, Inc. (&#8220;Cend&#8221;) had approximately $3.6&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $3.1&#160;million of Federal and $4.3&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917&#160;thousand each year. The Federal NOL of $459&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. As of December&#160;31, 2023 and 2022, Cend&#8217;s wholly owned Australian subsidiary had approximately $2.4&#160;million and $1.8&#160;million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had federal research and development credit carryforwards of $0.5&#160;million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $0.1&#160;million, which carryforward indefinitely.  Utilization of these credits may be subject to an annual limitation based on changes in ownership.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company had State NOLs available in New Jersey of $19.4&#160;million and $35.5&#160;million, respectively, California of $9.2&#160;million and $9.2&#160;million, respectively, and New York City of $1.9&#160;million and $1.9&#160;million, respectively, to offset future taxable income expiring from 2032 through 2043. The usage of the Company&#8217;s NOLs is limited given the change in ownership.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company&#8217;s uncertain tax positions were $344&#160;thousand and $344&#160;thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2020, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the Company received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;) to sell $8.9&#160;million of its New Jersey net operating losses (&#8220;NJ NOLs&#8221;), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7&#160;million. The sale of NJ NOLs resulted in a $0.8&#160;million deferred income tax benefit and a loss on sale of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div>On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#8217;s results of operations for the year ended December&#160;31, 2023. The Company will continue to monitor the possible future impact of changes in tax legislation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366003567008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock', window );">Australia Research and Development Tax Incentive</a></td>
<td class="text">Australia Research and Development Tax IncentiveThe Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March&#160;31, 2024 and 2023, the Company had $1.0&#160;million and $1.0&#160;million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Tax Incentive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ResearchAndDevelopmentTaxIncentiveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001992976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022 and denied all of Lingmed&#8217;s material allegations. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022, denying all of the Company&#8217;s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company is required to pay Lingmed $0.5&#160;million within 30 days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to 5.0% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $250 thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties&#8217; joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366002052448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Technology Transfer Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_TechnologyTransferAgreementAbstract', window );"><strong>Technology Transfer Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_TechnologyTransferAgreementTextBlock', window );">Technology Transfer Agreement</a></td>
<td class="text">Technology Transfer Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#8220;Impilo&#8221;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with the Sanford Burnham Prebys license agreement (Note 15) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100,000. As of March 31, 2024 and December 31, 2023 the Company owned 38.6% of Impilo. This investment was expensed under the equity method of accounting for the three months ended March 31, 2024 in other expense,net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0&#160;million and an 80% discount rate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_TechnologyTransferAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology Transfer Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_TechnologyTransferAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_TechnologyTransferAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology Transfer Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_TechnologyTransferAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001983120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP did not own shares of the Company&#8217;s common stock as of March&#160;31, 2024. </span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#8220;Cend Merger&#8221;). In addition, Cend received and recognized as revenue a $5.0&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $96.0&#160;million and $125.0&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366002054448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreement</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP did not own shares of the Company&#8217;s common stock as of March&#160;31, 2024. </span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#8220;Cend Merger&#8221;). In addition, Cend received and recognized as revenue a $5.0&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $96.0&#160;million and $125.0&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089140368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn April 15, 2024, the Company&#8217;s Board of Directors appointed James Nisco as the Company&#8217;s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately. Effective as of April 15, 2024, Mr. Nisco shall serve as the Company&#8217;s principal financial officer and principal accounting officer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001325728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (5,401)<span></span>
</td>
<td class="num">$ (6,187)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005334160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089121040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div>The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div>The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div>Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-process Research and Development Expense</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div>If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Milestones, Royalties</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2024 and March&#160;31, 2023, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -SubTopic 50<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482610/350-50-25-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -SubTopic 40<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482633/350-40-30-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366000609328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001992176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001316944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096541664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">At March&#160;31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005245296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366003638624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001348384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-388"><span style="-sec-ix-hidden:f-389">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-398"><span style="-sec-ix-hidden:f-399">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2024 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001339328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option and Warrants Activity</a></td>
<td class="text">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2024:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.42</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,165.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,453,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443,689&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.22&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.5&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(99,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001358464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share-based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2024 and 2023 (in thousands):<div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:62.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.319%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Total Compensation Cost Related to Nonvested Awards</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Share-based Compensation Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2024 and 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096437088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096615552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected amortization, remainder of fiscal year</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected amortization, year one</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected amortization, year two</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected amortization, year three</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089627696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 39,239<span></span>
</td>
<td class="nump">$ 44,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">39,221<span></span>
</td>
<td class="nump">44,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">33,750<span></span>
</td>
<td class="nump">37,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">33,732<span></span>
</td>
<td class="nump">37,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">5,242<span></span>
</td>
<td class="nump">4,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">5,242<span></span>
</td>
<td class="nump">4,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089071840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 17,677<span></span>
</td>
<td class="nump">$ 16,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">21,544<span></span>
</td>
<td class="nump">27,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">$ 39,221<span></span>
</td>
<td class="nump">$ 44,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089194784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis', window );">Less than one year</a></td>
<td class="nump">$ 39,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">39,239<span></span>
</td>
<td class="nump">$ 44,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Less than one year</a></td>
<td class="nump">39,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 39,221<span></span>
</td>
<td class="nump">$ 44,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089418848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089003776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366089154704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 17,677<span></span>
</td>
<td class="nump">$ 16,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">21,544<span></span>
</td>
<td class="nump">27,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">39,221<span></span>
</td>
<td class="nump">44,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">17,677<span></span>
</td>
<td class="nump">16,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">17,677<span></span>
</td>
<td class="nump">16,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">21,544<span></span>
</td>
<td class="nump">27,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">21,544<span></span>
</td>
<td class="nump">27,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005321168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 1,324<span></span>
</td>
<td class="nump">$ 2,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ClinicalAndRDRelatedLiabilities', window );">Clinical and R&amp;D related liabilities</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AccruedGrantFunding', window );">Accounting &amp; tax consulting liabilities</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LegalSettlementCurrent', window );">Legal settlement</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 4,070<span></span>
</td>
<td class="nump">$ 4,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AccruedGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Grant Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AccruedGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ClinicalAndRDRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and R&amp;D Related Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ClinicalAndRDRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LegalSettlementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Settlement, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LegalSettlementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005069696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of-Use Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Right-of-use assets, balance sheet line item</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, current, balance sheet line item</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, noncurrent, balance sheet line item</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Operating Lease Liabilities</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005289616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096441696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366094103280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">34 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 24, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAvailableForSalePercentage', window );">Percentage held by non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OutstandingStockThreshold', window );">Outstanding stock threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAvailableForSale', window );">Sale of stock available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,915,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember', window );">ATM Agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OutstandingStockThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding Stock Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OutstandingStockThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Available for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAvailableForSalePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Available for Sale, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAvailableForSalePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096303040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants Narrative (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366008943136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,322,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted (in shares)</a></td>
<td class="nump">132,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,453,913<span></span>
</td>
<td class="nump">1,322,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,443,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested (in shares)</a></td>
<td class="nump">1,285,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding. Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 10.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">1,165.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">9.18<span></span>
</td>
<td class="nump">$ 10.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">9.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options, Vested (in dollars per share)</a></td>
<td class="nump">$ 9.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OptionsVestedweightedAverageRemainingContractualTerm', window );">Options, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 232,100<span></span>
</td>
<td class="nump">$ 164,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">231,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 215,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CommonStockWarrantsShares', window );">Warrants, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,421,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsGranted', window );">Warrants, Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsExercised', window );">Warrants, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsCanceled', window );">Warrants, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsExpired', window );">Warrants, Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CommonStockWarrantsShares', window );">Warrants, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,421,744<span></span>
</td>
<td class="nump">1,421,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_Sharesvestedandexpectedtovest', window );">Warrants, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,421,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsVested', window );">Warrants, Vested (in shares)</a></td>
<td class="nump">1,421,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 42.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants, Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants, Expired (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">42.51<span></span>
</td>
<td class="nump">$ 42.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)</a></td>
<td class="nump">42.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 42.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsOtherDisclosuresAbstract', window );"><strong>Warrants, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding', window );">Warrants, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermwarrantsvested', window );">Warrants, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest', window );">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsvested', window );">Warrants, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OptionsVestedweightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Vested, weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OptionsVestedweightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Other Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term warrant outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermwarrantoutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermwarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermwarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001997920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (in shares)</a></td>
<td class="nump">205,300<span></span>
</td>
<td class="nump">188,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 632<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value (in dollars per share)</a></td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (in shares)</a></td>
<td class="nump">203,800<span></span>
</td>
<td class="nump">159,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 628<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value (in dollars per share)</a></td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366002249328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">125,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">203,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(99,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">229,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">3.08<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">112,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">97,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">110,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">3.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005280432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 454<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005321296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">2 years 2 months 1 day<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366001146560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005899056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Apr. 05, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross', window );">Proceeds from sale of NOLs, gross</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ProceedsFromSaleOfNOLS', window );">Proceeds from sale of NOLs</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="num">$ (798)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LossOnSaleOfNOL', window );">Loss on sale of NOL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=lsta_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_FairValueMarketOfTaxNOLs', window );">Fair value market of tax NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation', window );">NOL annual limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLossCarryforwardsBeforeWriteDown', window );">Net operating loss carryforwards, prior to write down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="nump">33,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLossCarryforwardsPostAcquisition', window );">Operating loss carryforwards, post acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="nump">35,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_FairValueMarketOfTaxNOLs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Market of Tax NOLs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_FairValueMarketOfTaxNOLs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LossOnSaleOfNOL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Sale of NOL</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LossOnSaleOfNOL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Carryforward Operating Loss Carryforward Annual Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLossCarryforwardsBeforeWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Before Write Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLossCarryforwardsBeforeWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLossCarryforwardsPostAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Post Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLossCarryforwardsPostAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ProceedsFromSaleOfNOLS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of NOLS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ProceedsFromSaleOfNOLS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096141984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_IncomeTaxIncentiveReceivable', window );">Income tax incentive receivable</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="nump">48.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_IncomeTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Incentive Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_IncomeTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366005525360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Details) - Lingmed Limited<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementPaymentTerm', window );">Litigation settlement, payment term</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent', window );">Litigation settlement, future milestone payments</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementMilestonePayment', window );">Litigation settlement, first milestone payment</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Future Milestone Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementFutureMilestonePaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lsta_LingmedLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lsta_LingmedLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366096615552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Technology Transfer Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems', window );"><strong>Investments in and Advances to Affiliates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to acquire Impilo SAFE</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SAFEValuationCap', window );">SAFE, valuation cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SAFEDiscountRate', window );">SAFE, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember', window );">Impilo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems', window );"><strong>Investments in and Advances to Affiliates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_InvestmentOwnedCanceledShares', window );">Shares canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_InvestmentOwnedCanceledShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Canceled, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_InvestmentOwnedCanceledShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SAFEDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SAFE, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SAFEDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SAFEValuationCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SAFE, Valuation Cap</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SAFEValuationCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366113720368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember', window );">Impilo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SharesHeldByThirdParty', window );">Shares held by third party (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Impilo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven', window );">Annual license maintenance fee, year seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SharesHeldByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Held by Third Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SharesHeldByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SharesIssuedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SharesIssuedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140366008028880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 14, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lsta_LingmedLimitedMember', window );">Lingmed Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent', window );">Litigation settlement, future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementMilestonePayment', window );">Litigation settlement, first milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate', window );">Option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Future Milestone Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementFutureMilestonePaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration and License Agreement, Option to Terminate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenuePerformanceObligationPercentageOfNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenuePerformanceObligationPercentageOfNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Sublicensing Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lsta_LingmedLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lsta_LingmedLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_QiluMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_QiluMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MR/<I.]7CQ7;O1VZFRY1$8@92Y_0"QCM5[* 6)UHN\TW(J=1:QOGA0O! */,
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M?]O<2G@:UU:6/&.YXB)'DCU<#&;XPYR$1J&4^(>S9[4S1L:5>R$>S</GY<7
M,8A8RA)M3%#X>6)SEJ;&$N#X7AD=U',:Q=WQJ_6_2N?!F7NJV%RD__*E7E\,
MH@%:L@=:I/JK>/[$*H=\8R\1J2K_H^=*UAF@I%!:9)4R(,AXOOVE/ZJ%V%'
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M;4,:MC!@+SC :9$)?3O*J$89]:*<)8!,LB5*>0*TQ2 =\ES3?,4A6#O!1NT
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M;40PU)X4@/]7E(K#@_Q =8PV^1]02P,$%     @ LX&I6.YS@&-F P  N0D
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ML2(X>JXLRM TW1*6>IXLL&V=R:+:UMEH[Z&.\KDC?I#OH[1 ,;WC:<I;D__
M\LVC/)L-EJVJYSQN,\:RI'J[I"2D>1G O[_+,O9UHWQT9/M U?0_4$L#!!0
M   ( +.!J5B9D =FMP4  %D7   8    >&PO=V]R:W-H965T<R]S:&5E=#<N
M>&ULK5AK;]LV%/TKA%<,&]#4(O6PG#D&$B=% S1-4*?K9UJB+:Z2Z)*TG?37
MCZ0<R98H)@4,!+$>EU?G/L\E)SO&?XB,$ F>BKP4%X-,RO7Y<"B2C!18?&!K
M4JHW2\8++-4M7PW%FA.<FD5%/D2>%PT+3,O!=&*>/?#IA&UD3DORP('8% 7F
MSU<D9[N+ 1R\//A*5YG4#X;3R1JOR)S(;^L'KNZ&M9:4%J04E)6 D^7%X!*>
MS]!(+S 2_U*R$P?70)NR8.R'OKE-+P:>1D1RDDBM JN?+9F1/->:%(Z?>Z6#
M^IMZX>'UB_:/QGAES (+,F/Y=YK*[&(0#T!*EGB3RZ]L]XGL#0JUOH3EPOP'
MNTIV% U LA&2%?O%"D%!R^H7/^T=<;! Z;$O0/L%J+T@Z%G@[Q?XQM *F3'K
M&DL\G7"V UQ+*VWZPOC&K%;6T%*'<2ZY>DO5.CF=W7^9WW^^O;Y\O+D&\T?U
M<W?SY7$.[C^"V>7\$_CX^?[[')R!;_-K\->[O\$[0$OPF+&-P&4J)D.I,&A-
MPV3_O:OJ>ZCG>SZX8Z7,!+@I4Y(>KQ\J[+4!Z,6 *^14>(?Y!^##]P!Y*+#@
MF;U]N>^ X]?^](T^O\^?6&1@J8I#@"5G!5#UQK&DY:I*6"HI$><VMU5J [M:
M7<SG8HT3<C%0U2H(WY+!],\_8.3]8[/Y1,J./!#4'@A<VJ=?5._)F;#F1K4R
M,BMU@]E.S\+ @Y/A]A"]12J"\:B6.H(5UK!"9V NT_]4-:D&) 603'6@A)4)
MS0DH]WCU4WV=Z AN!$EUIK\Y?.$IPW<B94=^BFH_1<[PS3/,R9GNC"E(6*'H
M0F#=<&U&5YK"@T %8= *9E<F&H7V4(YJB",GQ&NB[$XHKGB@3 $N&)?T5R_.
M41=GU()I$8GM*.,:9>Q$^5GGE *84K%F N> +<&2/BFW8B&(M-9'W$'AM7!V
M)7P[S'$-<_PZ3-.JR,\-E<^@(#)C.OFWI*H7&]!Q!P;TVE"[,IX=*O0:LO*<
M8"\/ CW$2<*)R0'UIV:0'T3BA2IH09(--Y5JI2>O ^L,AJB%W2H5];0@>$"V
MT,T.&2Y71+0ZBTD'D\@YQ0N:]W>9O?H3M9E3:3MV!FJ<@9S!?.!DC6EJ#&<R
M(US-.YRKA',4R%[E45SB42=Z%BD8'03Y&''#[=!)G--[@]*!SN]VD3:Y663Z
M$ZOA7.@FW<LD81M-;6O\K(O@/=#5L2%'*77@Z8.G5D,"BP-1X+=ML8EY<4]'
M@@U50R?#F1'B51JVX@Z[@$8>&K5Q6\1B.(YZ<#?4":/?&OZJ'OJ&Z0$Z.?FW
MZ_I$VHZ]T+ S=-/SPX8GF9H?-.&]O2UW"?@,QC%JCQ,V.=^#"/;$KF%KZ*;K
M.<Y_$W&7BE'H1VT6M(CY00#[J+"A;>CF[=N:GW6!W!9KFC.U,5-ULB8;21,[
MYBXGGW6)VR+5 Q<US(W<S%V7])JS+55;/[!XMM:'#3;JLG$4^.T1SB(5H'C<
M@[SA;/0*9[>*>DE+K'8.KQ<U.BE9GTK;L1<:LD9NLG[$3V!'99:Q/-6V*YZI
M]E)J]M*[)J&W#:IBI,R)2<K]-(EWF-O/"9"-I(,VE=NDXI[] VJ('+F)O$,P
MMJ!:07?9VP;:(M4+NN%XY.;XF^62)%+W*/*4F$$2*%(D(-D/E2H2VB8K; M1
MAV$;M46H9S!!#96CUZD\)6I0UX1 *X1F#C$7.DFVJO&6]GD*V>@\CMNX+5+^
M>-Q7^ V;(_=.>-8'%6 )%F1%RU(GC(J'FDXH2ZT6=+>_"(7C]B!E$?,1/-A+
M'YO04#%R4['3!**G02?X4><@!L'8Z^2-12R&83O?AP>'E 7A*W-V*X"96ZOC
MOOII?3Y\:4Y%6\^OX/FL.N5MU%2'SG>8JZ@(D).E4NE]&"F'\NH<M[J1;&V.
M0A=,2E:8RXS@E' MH-XO&9,O-_H#]6GZ]']02P,$%     @ LX&I6,H46<J%
M"@  -1H  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R-66USV[@1_BL8
MW<R=,R/+MNQ[F<3VC.SDVILFC1LG;6<Z_0"!D(B$!'@ *%G]]7UV05"4+-OY
M8HLD@'U[]ME=\G+M_+=0:AW%0UW9<#4J8VQ>GYP$5>I:AHEKM,63A?.UC+CT
MRY/0>"T+WE17)]/3TU].:FGLZ/J2[]WYZTO7QLI8?>=%:.M:^LV-KMSZ:G0V
MRC<^F649Z<;)]64CE_I>QR_-G<?527]*86IM@W%6>+VX&LW.7M]<T'I>\$^C
MUV'P6Y E<^>^T<4?Q=7HE!32E5:13I#XM]*WNJKH(*CQ9W?FJ!=)&X>_\^F_
ML^VP92Z#OG75OTP1RZO1;R-1Z(5LJ_C)K?^J.WM^IO.4JP+_%>MN[>E(J#9$
M5W>;H4%M;/HO'SH_?,^&:;=ARGHG0:SE6QGE]:5W:^%I-4ZC'VPJ[X9RQE)0
M[J/'4X-]\?ISJ<5-&W WA,N3B!/I_HGJ=M^DW=,G=I^+#\[&,HAWMM#%[OX3
M:-*K,\WJW$R?/?"#]!-Q?C86T]/IQ3/GG??FG?-YYT^<]]$OI37_DX2 L;AU
M-KC*%#(!PA;BSNN@;4PWW$+\;JRTRLA*W..F!OIB$/^9S4/TP,]_#WDH*7!Q
M6 '*J=>AD4I?C1J2Y5=Z=/WC#V>_G+YYQKR+WKR+YTY_,7K?OUM\7$$WRJ+W
M)@!( @^];'0;C0IC\8=5$W$4W5)'W =&8RD,7!/:>3"%D=YHK,(S\>,/OTVG
MIV]N7=U(N^&KLS>OA E""@4-C)+5<8A(>-&4$GFE6 8\KM(6Y%2!ZZ@+$1T?
M69B@'-3;C/%L!1YI*"YC#B VU=I3Q+HH4Q2-M6XE*=UI/\R =@($QJ=%<%>D
M V@EPT'$MG8^\'F.[:OE5ZR&7(V$#Q-RAN@L^BF("N0'&2L=HEFR4&C?>%>T
M*@J%4PAA>BR4]E$W.II"BZ/W]Y]G9Z_&Y(A"![.TR3YF):R&=Z"SKD3;1/D-
MOI&Q7,L--)91R K<&6#KL2S  29$[;&=#.)XX/>1F>C)6-0.=-=6TE<;,7>M
M+5[!JFB.H16T$85OEX'=*CU"R1:#WC70#15VG($_6NC%0C-M5IN)N!V8 [5;
M;,%9)456)5][:4/C?!1A Q5K^ AF\7G'H='*+(R":ZW5?@Q"#R!.8Y>T*JTG
M%$#O?3,?&Y!U,\H@CMB2;:#CR":I5%O##?E\CCOI,1;KTE0:O@;R*A%-""VL
MD'3> U3L4#?7HK62C=?%GN55<**4 6LT%"_=VM*.VA5FL=D* E<K[[1=&>\L
MH^VHRXS/'][EK.",\7J^@5>^D:I#WX<V*-U$,X>Z$&#JNK5N"V<RT]C2S T;
M28)K'24R*R B2@8E"78)%O0T%6T"?>=+')K0WDB/5,8#6C9WQ>;5#N*3J$CX
MJRHY=_ S*5E*A%RB0PCP&0&:PHM8P;?V.&>Z*(A+"EV#>7. M"U)@0*W*T-I
M3:*E 'C "?BI'Q#Y'$E0L%^FBRT*>B\@G:RJVH(64+O2^2>SUI[/$F-\^OOL
MF.IX(8:+8;$3C].6 LT1WYJ C0NY@A<H,$$N= 0O1>0=[IC*Q$V'0*0$70!]
M1&R5C@QE!, N'>N;710]V&N7%3H7[7@(D;6%],6Q6\ / ,C X VS&X*EB-R0
M9<E1NV$$+(#QRGF6/H0T<7.MD;Q)-ELFQ8I8/;+L+6<"YZ#:2 @D&J'[P]B]
M1"&M]YRQ.UYF4F2(MO.O6,P'@>@]G'.'"&@QW7HK1(1;4_JQ&<X2Z\)KR\K-
MF3Z8= :Z#U02<=/L@J9+&7+9P'MT)$0A@:R#JY6QKI;BJ+Y[.[M%TJK253#8
M;)\!60TX"'5+4R%CYX\I7U"/.LQ2Z)>5<?-*4E,'AQ/]45>M.XS,T7MP!>/J
MNF/#$/Q>+[DK/E25M ^E:5 59,W0+32Q .<V)6\*A)@;MU=ZN0[LWLKU;%!Q
MF2*A$R%3@MU"V$/)-I\$%?"E\YFI4A$37/=9G>&Q"^]JR-/;C"B]:Y<E(2RK
M058G!NDZMTJV5I7[3E@Z;#>,S4["HRY!YS-#5UR+PE,#9&HJ741@+0@;2.<V
MI!)6ZP+.OF%>A>8[+2-)1[%)\@E0*!M %@%RVVSBXF!?R0S*903&@X1UP>#%
M<;[@]$] P'5KF1 ;I*XRX!(8BHKG&>]XCC*1]E(2?;$LGN6PPC.8#DOZ O1E
M<C\1?YG-[OKFC,C#6%1;4XM%KZFQ:>;+'F=M2((A(FQYJF)/TW@DSDZ/_\'+
M9A[Q!X&<G9+P3WK)=1AGW!__.Q>9^W>W+PN=B!F[ I8386 ?>D.'\A*[!-:,
MJ>[(?6T7SD4LA0N\_K,UY%S4V0-N.^Q?TB[S]D"]T$=O@IZ8!;L&J$U])WH;
MX#LUIW$?&2_CH;-DO^SN]MCH7U3)#4L/M?&./[K6AG8CI4"X7#V+KY@EDQAP
M)L[CULIJ!>AC&$^IQL!&=3/4/@Y4(:"<_?HF#!S1N&"2KUEOS&W0*@]NJ=#2
M :G+XR5DB@-_R(2;OJF0H10+[F]SATXDXXJ0%:(.C/)LFUIJZ,I#P1'45AEN
MS]JJH':.>Y_=^85$H7M%,].-'R\=NA>?K.Y&2Q0[31.P> N'UG-(Z%QQSG;B
MQS3'B//4M3X]S:GSMXGXF'R#8&6G]1-+Z36ZNS1I)SF[_F8X4%[D>!JN@SQ&
M$>%WBN=SF?9J#!?S0=<[M(:$D"+[UEQ,Q)? Q[U#AU8SP5!D$GWUX]=!YW&-
MXQREKH@#T!-13M$PR"!NJFD2TKTH+B1HV.NFHQZF;^XO.ON(P2FE:\IH#ABU
MIS%MK4QJT')-HK&R<J'U.M5'Y@"2_-2>)(4 DCWZ(F8F T]Q'_F"NA0.BY$3
M+8C/;7U:Q_S$B;';U5$K&SB3MHY"& ; 'E;M?L(=^G&.+A/%,D\^2)7@4A.(
M 3*UVT(9CY&*>E"5)_U!;B=2HN"F&8)K)2&JFVN^ML4RP0#S0YO,1_/DF1A7
MLFKU,[%*8>X03GE,Z$:_)7W?/"2; M)*[8WKC"&PC#>IK7D:30!H ;+W-'E"
M*[A/?>L&!;E&WQV2HF&O+/$D7/7.4$PXF 474(AUBZ4+SZ!X@H:BKSIPPNX[
MJF3)2X4CTW^N.1E-3[_*R>R[1BL+;V*([:83?O-!&9IN#6M/TAQ3-X(3V0]5
ME2IX?G/3#3VT=MO; %PU=;:)^=30O GQG\;4TPT&:H-^ 8,(Y21SP.<#-6B;
M#BIOZL8'YI.W-*1VD\\"+6+W>J9?>]@M8M92=PG+Q!V,?Q^+22ZU_.9JT>G9
M^V.S5PWZ&:8_R.ZH\@2VOUL;3@!^P5)UKD2R#@SNZ4D_J)*G,<]H@\O3!$;/
MM80]F)*XN4SO_-/(>Z!<#TOUKFAZ8YB82=*,MGPD$^5@)6$AK^)./N?\8RJ;
M#1J3[2NAE#B=2+[1^?]01)\H-X_\X_5.#29]\K']6;U,ZFQZU<;T[A)Q=K9[
M;=B_7]*93^FQUR5]K5BQ'(>Y[@CE);SB%US$)L@UFM!^$E3MXF9RZ 7PR>!5
M/KWZX \63"LVIK?Z_=W^F\@L?0K8+D\?5- C+-&J8S!<8.OIY->?1\*GCQ3I
M(KJ&/PS,7<1$RC]+'B)I 9Y3"YTO2$#_I>CZ_U!+ P04    " "S@:E80IKV
M<BL3  !--P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;+5;:X\;-[+]
M*\1LD-B 1O.PLPG\ L9.LFL@QO5ZDMT/%_<#U4U)C+N;6I(],\JOOZ>J2':W
MU!HGN'N_V",U'\6J4Z<>;+VZ=_YSV!H3U4/;=.'UV3;&W8N+BU!M3:O#TNU,
MAR=KYUL=\=%O+L+.&UWSI+:YN+Z\_.M%JVUW]N85?_?1OWGE^MC8SGST*O1M
MJ_W^K6G<_>NSJ[/\Q2>[V4;ZXN+-JYW>F%L3?]U]]/AT45:I;6NZ8%VGO%F_
M/KNY>O'V.8WG ?^TYCZ,_E9TDI5SG^G#^_KUV24)9!I315I!X[\[\\XT#2T$
M,?Z=UCPK6]+$\=]Y]9_X[#C+2@?SSC7_LG7<OC[[_DS59JW[)GYR]W\WZ3S?
MTGJ5:P+_J^YE[/-G9ZKJ0W1MF@P)6MO)__HAZ6$TX?O+$Q.NTX1KEELV8BE_
MT%&_>>7=O?(T&JO1'WQ4G@WA;$=&N8T>3RWFQ3>W8@SEUNK6;CJ[MI7NHKJI
M*M=WT78;]=$UMK(FO+J(V(]F751I[;>R]O6)M9^I#ZZ+VZ!^[&I33^=?0,XB
M['46]NWUHPM^T'ZIGETMU/7E]?-'UGM6#O^,UWMV8KV94ZK_OEF%Z &6_YD[
ML*SW?'X]<J 78:<K\_H,'A*,OS-G;[[^R]5?+U\^(NWS(NWSQU;_/YKJ/[6V
M>J?#5NFNEC]^_'=O[W1CNCAZ4M$?9O3$=E73UT:%K?/Q/!K?+M06_M+L56,Q
MKEY@R)T)L>7A]S9N ?+8>QMI2TC50>"X5[7>XZ-7C0D8MC6=VO6^VL(MZZ5Z
MY[H*\[UF?\>D3S9\#NJ7K<&C=J>[O;(!]+/Z#92@HE.5-[6-RF.86GO7*HO-
M=Q!QC<,Z6H%.LC@^#QT2^OILHEXU.):IDJA+]2NP[GFAX418$\K;+U0<B=+8
MED;IEC2<1YL:?T#$:CM:5*WV151-QEADY>Q);S58 J;;>-?OQGI4<;\S+*H-
MH3=^H<Q#9791@<K'J_/3FC8A\7Y=WB[5QMT9W]$B2[$J]+8U3:UTQ-:_.6+"
M[C,)+7,Z2Y+?1AU-5LZ>=\.W:P.%Z :FMEWH<8QT\B4;9N-TPP8>J>:;6=UA
M+^=)MQB\\];)\;7'$0..U""\A!<JZ#7AA&1(+EC0@$E=97>ZX:<U@H$/#/0\
M@'"P2(#$XO35&)6A7Z_)!3K&3DL1DX&Q;LB/"1[>\,@%;Z!5A>.8:"GL*+T&
MZL^C?B 3&M[-P(3=4GT8<'0[&&4,VMJ0Q\ ! FM)[W;>X3"T3M7H,#T$86H6
MFF0[FAX14UD=R7%86&\,L-VS_1A]M0G@ 5D5$XW&=RO=:'B8DFRAQN"ENFF:
M8^N=V!^FJAS".8P(%,!J^D[;AH:= Y+G <Z5Z,-[:QAL4+X%U@E&VGI%,B:$
M>4..*O[RY_P3N4MC?\?,#7(6&=NX$(AGNCF1#HX 6!.7U<(88"5B-]>:(ZET
M5?5MW[#T#@KR# AOMI32 !)IVA/:_"FK UOM-..#1KJ.H ;E(@FH/F]= [V%
M;_B<<;]4_\5+YD7, ]*T8)XN2*)%)EQR)& '6EP0X*'YKB9XMA#2_CYX1H8"
MI&MMWX;D(8'9'Q,>51DIB5UXK*@NG?D\;G4'QL=Q/ 68VE0-(SE1QV#6Z0HX
MPAJK[(4E*A?BP0X!^B!:HI2L)C%HM; S%7F#HI/&P2]:$[>N7DZ\RIL-C.,;
M^NN.DCVE!<M3[@Y,EU\\RW".R2YP!EE]L$C<#FY0+,!?ZCZ8_,%BNO4D0#8F
M!6$>QI$ N6[<TN:%/)-N]HGM@T2;KF]7PIECQ@<X.]4/GD#&!-$&2_(LTG+@
M1YNHM.ZGHAY,)7,A&#,@QR$.F)+# (3"FDC'F[&T&2MY-D(<; IX&O#P9]-0
M3(*HG2/N A_@^;W%$BN3&;<^M>S*K&D9^M:;B@+:/HD/2R4/P&R&%D!DP0W_
MHH0BGF+>Q)_)ZE.CT\J0<Q2V")I4\C"<])!'\59\9M@O#*N%68PMZ,0X9%]E
MY( ;][1.V79J^ZB(*#)%5HB8Q"ML7\(QQP_..!@2PO0LP5)]1%0Q/EF<\KH=
M'V3L?[OQ$%.&\#G '945LKM+.!C8&\A>]PUL>F<*8+T1;D0$,Y0._)"7(*!A
M2>+ /HZ<&YD=U5CGK+#LTI\,.4JF?$8:!RDF1#@*,HYDO-HQCLP#AF!1;S>V
MHV2 MD^2<8C::K\16"52)6Z&#_;>F\0AIP]V0D.':<I/"/TL&X];VP>1\^I2
M[8W&:=[)V?UHB6?IT:U;QWM:+W_QLP$%;ID.$5Z@?*&MG^V:\='08_6SZS;G
M)&6M;EC?XV_$ L)*CQE:#I]&\Y&*&U'H+!92;"%!>@8#/ 4GW!FNPB=J.Z1E
M(>/F2#S"[T"+G/T31RG\0^?%4YBNVPB_5=8C^H9(6* O:@H%9O#BXD>#-\!_
M!0N2N(:9^!3S\9?J_3H%]?_X]F505@G!L,(60"2;F6Q"H8*2;$+TJC <)2[3
M*H/9,L,U<7<.[)3#] S"DL>&M)G@'P;KFRB)#D\-4RV0)!=.JAU60P]_PNI#
M),DTA)+R=\,,.1B02&D:YN<>%@IFB7#4SD"E@;GQWO50QXK(0$MID0).TBI*
MFONM!<>=4'D<T/P'; Z@WH(;S/E;3CE(PV 'H:M?#LS546Y$^43@&9*D[/1>
MR #N6[,Y0?.-VQN*GS5B616=3]4#^2)TKSG]&A* C=<,MI04*K>C[2G\XG2Z
MU!Z4\7G+9N1QBX&3.6S"/!0T_)T%4\+1K:NGB13OPRG^G#98_J7Z":9/9^&*
M'0MQEQ"83R>F:$AB5PA.V$5/L9EA*5H'Y:STRC:I\D+!88UP6=YWM'Y9<8HP
M"1K%*IF_<Z2!QA$T0C[!!.LDZO*QLFNJ!U%\7J@/.3M[V^CJ\_EM!4>E@,"C
MSE&L532@=;5I$B1[0L@*%**0!L#N( @I3#G.=#'5+V0#S5 9^_ TVZ2,B:,A
M5P.>,@=2ZIV&7?M X.U;P8E$_.0D5.Z>KU'YE2*!:]/%H)8[![VQ149?YCI"
M[:U)9%2>-2GFT/()FD2,&9QP($:M@&/65+H);LB501CYW(ND-SJLKLUA-5M
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M[[X]4UY^O"4?HMOQ#Z96+J*ZY3_IBLEX&H#G:^=B_D ;E%_0O?E?4$L#!!0
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MFAV=(+DIE?7OJ.U4#*\_-8;G*%Y/@K=)!5[HC! !/QX[8R3'UVYMVF=P (.
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M>+IYA6%&5UVT;$#K:V-\^\$!NLOSXC]02P,$%     @ LX&I6+1S8)X!"0
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M;^Z4^  (PBY*>:@1R<N 2BK#7ST+M? Y@!>U8L+&R#S9-,14O9TWVP54X_^
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M'P_P?N,<'2?1P/ ZK_X'4$L#!!0    ( +.!J5B.O*NK6P4  #P,   9
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M';W<"2)\]Q0[#PM<[")DN1^$5"3:^X:R!S4!W84(SE_-AI/Y)+KL.::V+"$
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ME-P@2$Q.8)9G#54N88HCZ%D"3&%WR@^/&#@!H\==T0S$[*T21_(8Y4I@@J'
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MI0TP]VLA]-ZP"89EG?T&4$L#!!0    ( +.!J5@FVB\.1 (  (H&   9
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)V576^;,!1 _XK%I#VUA4 ^M@R0
MDF[3\M I2KOMV<$7L&IL9IO0_OO9AK!L2JB4EV";>X_/=>1+W KYK$H C5XJ
MQE7BE5K72]]760D55G>B!F[>Y$)66)NI+'Q52\#$)57,#X-@[E>8<B^-W=I6
MIK%H-*,<MA*IIJJP?%T#$VWB3;SCPHX6I;8+?AK7N(!'T#_JK30S?Z 06@%7
M5' D(4^\U62Y7MAX%_"30JM.QLA6LA?BV4XV)/$"*P0,,FT)V#P.< ^,69#1
M^-TSO6%+FW@Z/M*_NMI-+7NLX%ZP7Y3H,O$^>(A CANF=Z+]!GT],\O+!%/N
M%[5=;/310UFCM*CZ9&-04=X]\4M_#B<)AG,^(>P30N?=;>0L/V.-TUB*%DD;
M;6AVX$IUV4:.<ONG/&IIWE*3I].-.5X"$CU)3"@OT$I*S LPQZY5[&NS@XWS
MLYZV[FCA!5J$'@37I4)?. 'R;[YOS :]\*BW#D>!#UC>H6AR@\(@G([PHJ'<
MR/&B"[QS9=Z@_2O:<$(/E#28G:NZ@T[/0^V]6:H:9Y!XYF(HD ?PTO?O)O/@
MTXCR=%">CM'37<, 38+]['9RJHU61-3Z_T/N=,>!.68*1L1F@]ALE/-=\-LK
MY,:A;\G-![GY5:?V!-+<(GS!;9SYEMMB<%M<?7#C?N/<BW[^27^H0!:N"RJ4
MB8;KKE4,JT.C777]Y6]XUZ7-A2PH5XA!;E*#NX7Y.V77^;J)%K7K-GNA3>]R
MP])\+$#: /,^%T(?)W:#X?.3_@%02P,$%     @ LX&I6$) YY 4%   BC\
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M7H^@*]7"HU91H-[YAFC IW_=-5IIVW.7=:OYIUXW;#JJ'9>&CCXCT^CJ>A2
MKIM@O;"J](UGJRRU,3_-Z;^!VBG0?J:4/2R<@_9/M/@+4$L#!!0    ( +.!
MJ5CB.I2)4P0  -X+   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;*U6
MWV_;. S^5P1OV*V U\2.8Z==$J _MF[  A1MMWLXW(/B,(E06?(D.5GNKS_2
M=ARW2=,]["61*/+C1XFD.5QK\VB7 ([]RJ2R(V_I7'[>Z=AT"1FWISH'A2=S
M;3+N<&L6'9L;X+/2*).=L-N-.QD7RAL/2]FM&0]UX:10<&N8+;*,F\TE2+T>
M>8&W%=R)Q=*1H#,>YGP!]^"^Y[<&=YT&928R4%9HQ0S,1]Y%<'X9DWZI\$/
MVK;6C"*9:OU(FZ^SD=<E0B A=83 \6\%5R E 2&-GS6FU[@DP_9ZB_ZYC!UC
MF7(+5UK^+69N.?(&'IO!G!?2W>GU%ZCCZ1->JJ4M?]FZTNTG'DL+ZW16&R.#
M3*CJG_^J[Z%E,.B^8!#6!F')NW)4LKSFCH^'1J^9(6U$HT49:FF-Y(2B1[EW
M!D\%VKGQQ8H+R:<2/N #?[CGN+B'M##"";#L_0,=V9-AQZ$OLNBD->YEA1N^
M@-MC$ZW<TK)/:@:SI_8=Y-@0#;=$+\.C@!-N3EDO\%G8#:,C>+TF\%Z)UWL!
M[QJFCNU"]=G^3;!_+J;6&4R<?P]=0(4?'<:G8CJW.4]AY&&U6# K\,;OW@1Q
M]^,1]E'#/CJ&/K['XIP52%'/GQ&W1+SUA'>0:I4**3A5P:$XCGHZ',?#$MA<
M2ZQHH1;,D7,F+./;VB9:?)^6W=$R2,M@9C"A6,KMDG$UJQ;PLQ KU%;.,FTP
MU\TC5!Y:YFBE"\.NM+):BAEWB'3))5<I!D_%@+F+.FZI"XO(]N2<80*ERR:#
MV#6DD$W!;"4]!+..W1AM+?NNL,%)\1^BWF!CL_OB;[A''I^L$UGI_3,7AOW@
MLH _"61R;5"*?0:SM17_6];K^4F_BXMW;P9A$'[$U?M@<%*?]$):)'YR%M""
M#JLS% UB!,XR,*G@DN4\QTO8@KST'_AG@^ %*18Z;.IW8O,";YOU_3 *]]0K
M:>2'\6#OK))."B52D2.MYP&'4;)G0[(XW/=#L@?M$ 4#/O/#WMG!:\*3D&XG
MBOPX#I]<$XGZ"3M2J/VF4/N_7:B372KO"O1011Z%/%R1N_R94_ZL*'_LZV7(
M#; %*#!<RDWY>9LQ_%;F1J1D/G68M(1I=,;25M+@.54^.2?-4W:H(U3- +/<
M8B$"2R6W5LQ%6G8BXD;2X_S*&J9"R'*N-G_9/USQS_O-6Q8D?IPDM(C]).BW
MWZR=C8'?CR(6)OY9]#37FHPZGCYQDS[QT?3YJE9@75:2NZKO#P.?;N@BRD]3
M@:XGW!&S#<,1  XEU%$GO]_B6P]*W1=[DT,5H5_/,R2<M@AG6\*O/-E%AB[*
M-EGVU(--\AM8RB^.&:6 ;8";=MG7;W*#_=;ATS_5>]XX]II&;7WH(3NMF0O+
M8E%.EA:C+)2KQJ]&V@RO%]7,ME.O)E\,>D'?!@ES-.V>)EC_IIHFJXW3>3G!
M3;7#>;!<+G$ !T,*>#[7VFTWY* 9Z<?_ U!+ P04    " "S@:E8=Y6$J]0"
M  "+!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R%5=MNVS ,_17"
M&X84*.I++LVR)$#2"S9@!8*VVQZ&/2@V'0N5)5>2F_;O1\F)EP).!O@B4N3A
M(4W1TZW23Z9 M/!:"FEF06%M-0E#DQ98,G.A*I2TDRM=,DNBWH2FTL@R[U2*
M,(FB45@R+H/YU.M6>CY5M15<XDJ#J<N2Z;<E"K6=!7&P5]SS36&=(IQ/*[;!
M![0_JI4F*6Q1,EZB-%Q)T)C/@D4\60Z<O3?XR7%K#M;@,EDK]>2$;]DLB!PA
M%)A:A\#H]8)7*(0#(AK/.\R@#>D<#]=[]%N?.^6R9@:OE/C%,UO,@G$ &>:L
M%O9>;;_B+I^APTN5,/X)V\9V0!'3VEA5[IQ)+KELWNQU5X<#AW%TQ"'9.22>
M=Q/(L[QFELVG6FU!.VM"<PN?JO<F<ERZC_)@->UR\K/SE:;OJ^T;,)G!S7/-
M*ZJXA=XC6PLT9]/04A!G&J8[P&4#F!P![,.=DK8P<",SS-[[AT2N99CL&2Z3
MDX!W3%] /SZ')$H&)_#Z;<9]C]?_3\;GL!*,4GV?^._%VEA-O?*G*_4&>="-
M[,[/Q%0LQ5E !\2@?L%@_NE#/(J^G. ]:'D/3J&?YMU%]B1<-]G' @&-Y=3M
MF$%M,*\%"#HV!E0.U6&O8%LRIA&8@5P).N%F K>UEMS63DMV.7]U:P-Q!&_(
MM($K55:U17T T=]M/:C<;AW>7O$=Z<052F3 2PK_@LZ<U#Q'QTBX;5AU\TH5
MC0[C$B%+2YDU#+G<0(]+TJC:D(<YFP#U6%JT30;7F&*Y)H8[3;^+\W#\V=]'
M*%XF[NJF=@X;K8R!T2CV]R)-Z[(6ON@9TN=(.?,SJS>,AV?0&XQ'9T>A)$WN
MCQ /1NYY.82N5@L/!D2)>N/'H*$*U=(VLZ+5MI-VT0R8?^;-F*92;;@T5/J<
M7*.+RV$ NAE]C6!5Y<?-6ED:7GY9T-\"M3.@_5PINQ=<@/;_,_\+4$L#!!0
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MFR1[S7[K+(G?FUNL:O]M+IVS5AQ'VXR;L%>G)&GUNGW8]=K#K>Y4H%[X'FS
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MG0UZ >AFBC4'JRH_.1;*TASRVX(&/VKG0/=+I>SVX *T?R73WU!+ P04
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MF9"YD0_,#1D-7K]*F,_>PDG.ZQE%F372'CN=VAQE(;)]^-4<!<7E![3!*(+
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MZ19E7W.ZMJ(T!K0^%4(O!V:#_B(\^1M02P,$%     @ LX&I6%KL1S_) P
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MKAEB]);M*+\Q0HZ*2]*1M(<BX506*U<A%:C093*L3*WQ&:IY66"GP'3%37U
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M)@1XR)2\)?1?L@2?E:P9E]T>9W3P>.^(H![AF\F-:G*C?N2^J3$QLAMIS[Z
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M-9 4A G0]Y><J_N!.1QI#L/B_P%02P,$%     @ LX&I6*@^X^D  P  \@@
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M2P\M884KJN_%]ALT?A++EPNJW"_:-KF!A_)*:<$:L%' "*^?^*6IPPY@$!\
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MHUA\4#>_/#ODXOL/$UVJ!N08?5D%NR^#62>"#<@C2V4HB)L&$'3HY]_0#WL
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M7-(>D.6MH9QHL;2-]U1H:N/M,*&;%DKC0,_G0NB7B5F@OKN-_P-02P,$%
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M&%4[35Z+\T0;=$N6W5<V>?<%U!V7ZHZ?V>3']TP>''N[3>Y[VXO!>VV;/\+
M]TN#&W_7I-:O7'?^WQK<GN,[:=5"/''U_6!+,7AE=Q<$GEG@]O[TZR_0?S=X
M 5AU>*?UP#'N;Z]*O_:N^B\.KV>P.<F#1XWN5DJ\%,7<%K)2$UDPE5=[96]9
M+)_F)>)V>%YIZ[IH3IF$!&<ZU#OJZ#M2Y,5KWE \LP7CE"M=?MK76!?\*,P
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M;91^D3LNRA/JY[R9C)+B)]GMR_;=#IEMDU2NR^"L!>LPWO\.GLL_Q%& =2[
M+@/L2P.<,L Y#>B?"7#+ /?2&OIE0/\T8' F8% &#"ZM85@&#"\-&)4!HZ)W
M]]U1]*47I,'D5LD=47GIC):_* 111&==&,:Y=A]2E7T:9G'IY'T\DVM!?@^>
M14)^]D0:A%'R"_F5?'WPR,\__4)^(F%,?E_);1+$\^2VFV:5YJ'=65F!MZ_
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MR2J:G%!LMJM!W0!-W>;]O4&J(FVWHK(-UF^@]:4Q^#SPI63X$>1/4$L#!!0
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MMDZ5/&N6V4:KQ X_6?3!BTG!Y< \!4-UOU!I%(O6%K0QP'R[ W8/0O?CBBV
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M    >&PO=V]R:V)O;VLN>&ULQ9I=<]HX%$#_BH:731]8P-BTS93.$"#;S)#
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M+?Y3UF=KEW\</SSSUM3=(9\-?S*:O0%02P$"% ,4    " "S@:E8!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( +.!J5C%H%5:[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +.!J5B97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MLX&I6+HLOE;:!0  TQX  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +.!J5B*$\75R 4  .$6   8
M          " @1X.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " "S@:E8Q?E,_,\"  #^!P  &               @($<%   >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ LX&I6'"<'X[=!   4A,
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M965T."YX;6Q02P$"% ,4    " "S@:E80IKV<BL3  !--P  &
M    @(&H-P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MLX&I6(6OY(3Z P  < H  !D              ("!"4L  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " "S@:E8_S]3B-8"  !Q!@  &0
M            @($Z3P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( +.!J5@T$^DIYP(  (,&   9              " @4=2  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ LX&I6)<WS7SI!
M6 P  !D              ("!954  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " "S@:E8-97"!<H"  !5!@  &0              @(&%
M6@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +.!J5@(
MS"7LA@0  %D+   9              " @89=  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ LX&I6$( 5Y#Z!P  _Q8  !D
M     ("!0V(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +.!J5@[.T=)\ ,  .X(   9              "
M@6&!  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ LX&I
M6"Y$&@%S"0  _Q<  !D              ("!B(4  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " "S@:E88-I/;WP)   S&   &0
M        @($RCP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( +.!J5C"+:Q@F0(  .\%   9              " @>68  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ LX&I6&T6+:=7 @  N 4
M !D              ("!M9L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " "S@:E8)MHO#D0"  "*!@  &0              @(%#G@
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +.!J5A"0.>0
M%!0  (H_   9              " @;Z@  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ LX&I6+-LMICL @  E08  !D
M ("!";4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "S
M@:E8XCJ4B5,$  #>"P  &0              @($LN   >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +.!J5AWE82KU (  (L&   9
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M970S-"YX;6Q02P$"% ,4    " "S@:E8V[9C1MD$   4#P  &0
M    @(%BS   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M +.!J5A:[$<_R0,  '8*   9              " @7+1  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ LX&I6'X4Y@Q_ @  L@@  !D
M             ("!<M4  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " "S@:E8+/>*5>X#  !H$@  &0              @($HV   >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +.!J5BEQN[ E00
M "L9   9              " @4W<  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ LX&I6 @3F:F! @  @08  !D              ("!
M&>$  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "S@:E8
MV0"SP,T"  #&"0  &0              @('1XP  >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +.!J5B1PF2V=0,  *L0   9
M      " @=7F  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ LX&I6!EFQ\@D P  "PT  !D              ("!@>H  'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "S@:E8 <@^A;0#   8$P
M&0              @('<[0  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( +.!J5BH/N/I  ,  /((   9              " @<?Q  !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ LX&I6#J+E9P"
M P  "PL  !D              ("!_O0  'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " "S@:E89F(M#%H"   ;!@  &0
M@($W^   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( +.!
MJ5A7>,R4HP(  #<(   9              " @<CZ  !X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ LX&I6"[))#7M!   G",  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( +.!J5BGMU,($ ,  +,+   9
M  " @<$5 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MLX&I6%D]O_,X P  3@P  !D              ("!"!D! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " "S@:E85'81A]H"   F!P  &0
M            @(%W' $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( +.!J5@K\\(J] @  "]I   9              " @8@? 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ LX&I6*PN*%SM @
M$ L  !D              ("!LR@! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " "S@:E8H<#J7G$"   4!@  &0              @('7
M*P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( +.!J5C_
M&58<000  #8:   9              " @7\N 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ LX&I6"5B8#J8!   ^!X  !D
M     ("!]S(! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +.!J5AW2W&%!@(  /$D   :
M          "  1Y' 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( +.!J5C_)Z=UXP$  &PD   3              "  5Q) 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !& $8 (1,  '!+ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>295</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - The Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusiness</Role>
      <ShortName>The Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShare</Role>
      <ShortName>Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Australia Research and Development Tax Incentive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</Role>
      <ShortName>Australia Research and Development Tax Incentive</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Technology Transfer Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TechnologyTransferAgreement</Role>
      <ShortName>Technology Transfer Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Research Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</Role>
      <ShortName>Research Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareTables</Role>
      <ShortName>Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareDetails</Role>
      <ShortName>Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Australia Research and Development Tax Incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails</Role>
      <ShortName>Australia Research and Development Tax Incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/Contingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Technology Transfer Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TechnologyTransferAgreementDetails</Role>
      <ShortName>Technology Transfer Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/TechnologyTransferAgreement</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/LicenseAgreements</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="lsta-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Research Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails</Role>
      <ShortName>Research Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: lsta:SaleOfStockAvailableForSalePercentage, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  lsta-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="lsta-20240331.htm">lsta-20240331.htm</File>
    <File>lsta-20240331.xsd</File>
    <File>lsta-20240331_cal.xml</File>
    <File>lsta-20240331_def.xml</File>
    <File>lsta-20240331_lab.xml</File>
    <File>lsta-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lsta-20240331_g1.jpg</File>
    <File>lsta-20240331_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="492">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lsta-20240331.htm": {
   "nsprefix": "lsta",
   "nsuri": "http://www.caladrius.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "lsta-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "lsta-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lsta-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lsta-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lsta-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lsta-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 237,
   "keyCustom": 58,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 7,
   "hidden": {
    "total": 13,
    "http://fasb.org/us-gaap/2023": 7,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://www.caladrius.com/20240331": 1
   },
   "contextCount": 136,
   "entityCount": 1,
   "segmentCount": 47,
   "elementCount": 541,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 492,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.caladrius.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.caladrius.com/role/TheBusiness",
     "longName": "0000008 - Disclosure - The Business",
     "shortName": "The Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:BusinessTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:BusinessTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "longName": "0000010 - Disclosure - Available-for-Sale-Securities",
     "shortName": "Available-for-Sale-Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.caladrius.com/role/PropertyandEquipment",
     "longName": "0000011 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShare",
     "longName": "0000012 - Disclosure - Income (Loss) Per Share",
     "shortName": "Income (Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "longName": "0000014 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "longName": "0000015 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "longName": "0000016 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "longName": "0000017 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "longName": "0000018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive",
     "longName": "0000019 - Disclosure - Australia Research and Development Tax Incentive",
     "shortName": "Australia Research and Development Tax Incentive",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.caladrius.com/role/Contingencies",
     "longName": "0000020 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.caladrius.com/role/TechnologyTransferAgreement",
     "longName": "0000021 - Disclosure - Technology Transfer Agreement",
     "shortName": "Technology Transfer Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:TechnologyTransferAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:TechnologyTransferAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.caladrius.com/role/LicenseAgreements",
     "longName": "0000022 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement",
     "longName": "0000023 - Disclosure - Research Collaboration and License Agreement",
     "shortName": "Research Collaboration and License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://www.caladrius.com/role/SubsequentEvents",
     "longName": "0000024 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "longName": "9954473 - Disclosure - Available-for-Sale-Securities (Tables)",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.caladrius.com/role/PropertyandEquipmentTables",
     "longName": "9954474 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShareTables",
     "longName": "9954475 - Disclosure - Income (Loss) Per Share (Tables)",
     "shortName": "Income (Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "longName": "9954476 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "longName": "9954477 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "longName": "9954478 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "longName": "9954479 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "longName": "9954480 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
     "longName": "9954483 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
     "longName": "9954484 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "longName": "9954485 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.caladrius.com/role/PropertyandEquipmentDetails",
     "longName": "9954486 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails",
     "longName": "9954487 - Disclosure - Income (Loss) Per Share (Details)",
     "shortName": "Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-61",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-61",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails",
     "longName": "9954488 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "longName": "9954489 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
     "longName": "9954490 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)",
     "shortName": "Operating Leases - Balance Sheet Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "longName": "9954491 - Disclosure - Operating Leases - Narrative (Details)",
     "shortName": "Operating Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails",
     "longName": "9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)",
     "shortName": "Operating Leases - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "longName": "9954493 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "lsta:OutstandingStockThreshold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "lsta:OutstandingStockThreshold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails",
     "longName": "9954494 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)",
     "shortName": "Stockholders' Equity - Stock Options and Warrants Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails",
     "longName": "9954495 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)",
     "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
     "longName": "9954496 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
     "longName": "9954497 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details)",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-87",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "9954498 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
     "longName": "9954499 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "longName": "9954500 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails",
     "longName": "9954501 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
     "longName": "9954502 - Disclosure - Australia Research and Development Tax Incentive (Details)",
     "shortName": "Australia Research and Development Tax Incentive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "lsta:IncomeTaxIncentiveReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "lsta:IncomeTaxIncentiveReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.caladrius.com/role/ContingenciesDetails",
     "longName": "9954503 - Disclosure - Contingencies (Details)",
     "shortName": "Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.caladrius.com/role/TechnologyTransferAgreementDetails",
     "longName": "9954504 - Disclosure - Technology Transfer Agreement (Details)",
     "shortName": "Technology Transfer Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:PaymentsToAcquireOtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:PaymentsToAcquireOtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.caladrius.com/role/LicenseAgreementsDetails",
     "longName": "9954505 - Disclosure - License Agreements (Details)",
     "shortName": "License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-124",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-131",
      "name": "lsta:SharesHeldByThirdParty",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
     "longName": "9954506 - Disclosure - Research Collaboration and License Agreement (Details)",
     "shortName": "Research Collaboration and License Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementAccountingPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20240331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r682"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization/accretion on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "lsta_AccruedGrantFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "AccruedGrantFunding",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting &amp; tax consulting liabilities",
        "label": "Accrued Grant Funding",
        "documentation": "Accrued Grant Funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities [Abstract]",
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r143",
      "r488"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r83",
      "r149",
      "r483",
      "r510",
      "r511"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r31",
      "r396",
      "r399",
      "r432",
      "r506",
      "r507",
      "r784",
      "r785",
      "r786",
      "r789",
      "r790",
      "r791"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r682",
      "r836"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r521",
      "r789",
      "r790",
      "r791",
      "r821",
      "r837"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r327"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "AggregateIntrinsicValueWarrantsvested",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants vested",
        "documentation": "Aggregate Intrinsic Value, Warrants vested"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r715",
      "r725",
      "r750"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r728",
      "r753"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r719",
      "r729",
      "r746",
      "r754",
      "r758",
      "r766"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r371"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r44"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r145",
      "r171",
      "r202",
      "r209",
      "r213",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r389",
      "r393",
      "r413",
      "r480",
      "r547",
      "r682",
      "r695",
      "r810",
      "r811",
      "r824"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r150",
      "r171",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r389",
      "r393",
      "r413",
      "r682",
      "r810",
      "r811",
      "r824"
     ]
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, fair value disclosure",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "lsta_AtTheMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "AtTheMarketOfferingAgreementMember",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "documentation": "At The Market Offering Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r261",
      "r479"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less than one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Greater than one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated Fair Value",
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r261",
      "r473",
      "r793"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_BusinessTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "BusinessTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/TheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Business",
        "label": "The Business [Text Block]",
        "documentation": "The Business [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CENDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "CENDMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEND",
        "label": "CEND [Member]",
        "documentation": "CEND"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r141",
      "r653"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-Sale-Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r94",
      "r168"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r94"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r832"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r201",
      "r288",
      "r289",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r513",
      "r514",
      "r515",
      "r516",
      "r666",
      "r772",
      "r787"
     ]
    },
    "lsta_ClinicalAndRDRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "ClinicalAndRDRelatedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical and R&amp;D related liabilities",
        "label": "Clinical and R&amp;D Related Liabilities",
        "documentation": "Clinical and R&amp;D Related Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones, Royalties",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreements",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements",
        "verboseLabel": "Research Collaboration and License Agreement",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124",
      "r135"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee, year seven",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties, net of sales",
        "label": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsSublicensingFees",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicensing fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r689",
      "r690",
      "r691",
      "r692"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r71",
      "r481",
      "r534"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r267",
      "r268",
      "r647",
      "r805"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r789",
      "r790",
      "r821",
      "r835",
      "r837"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r535"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r77",
      "r535",
      "r553",
      "r837",
      "r838"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r482",
      "r682"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value, outstanding",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r535"
     ]
    },
    "lsta_CommonStockWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "CommonStockWarrantsShares",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)",
        "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)",
        "label": "Common Stock Warrants, Shares",
        "documentation": "Common Stock Warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r156",
      "r158",
      "r163",
      "r475",
      "r496"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r802",
      "r803"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r127"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r657"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r316"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r676",
      "r834"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r284",
      "r290",
      "r433",
      "r654",
      "r656"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r329",
      "r360",
      "r361",
      "r363",
      "r678"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r57"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_EPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "EPSAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted loss per share",
        "label": "EPS [Abstract]",
        "documentation": "EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r189",
      "r191",
      "r193",
      "r194",
      "r195",
      "r199",
      "r404",
      "r405",
      "r476",
      "r497",
      "r659"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r191",
      "r193",
      "r194",
      "r195",
      "r199",
      "r404",
      "r405",
      "r476",
      "r497",
      "r659"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (Loss) Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r196",
      "r197",
      "r198"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries, employee benefits and related taxes",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r136",
      "r159",
      "r160",
      "r161",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r200",
      "r254",
      "r255",
      "r303",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r432",
      "r506",
      "r507",
      "r508",
      "r521",
      "r573"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r715",
      "r725",
      "r750"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r712",
      "r722",
      "r747"
     ]
    },
    "lsta_ExclusiveLicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "ExclusiveLicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exclusive License and Collaboration Agreement",
        "label": "Exclusive License and Collaboration Agreement [Member]",
        "documentation": "Exclusive License and Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r411"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r113"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r408",
      "r440",
      "r441",
      "r442",
      "r664",
      "r665",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r412"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r323",
      "r408",
      "r440",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r323",
      "r408",
      "r441",
      "r664",
      "r665",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r408",
      "r442",
      "r664",
      "r665",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r70"
     ]
    },
    "lsta_FairValueMarketOfTaxNOLs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "FairValueMarketOfTaxNOLs",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value market of tax NOLs",
        "label": "Fair Value Market of Tax NOLs",
        "documentation": "Fair Value Market of Tax NOLs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r440",
      "r441",
      "r442",
      "r664",
      "r665",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r412"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Minimum Lease Payments",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r286",
      "r300",
      "r401",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r495",
      "r663",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset, useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year one",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, remainder of fiscal year",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year three",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year two",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired license - intangible, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r472"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Remeasurement",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "lsta_ImpiloMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "ImpiloMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impilo",
        "label": "Impilo [Member]",
        "documentation": "Impilo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process Research and Development Expense",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less - net income (loss) attributable to noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r112"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r84",
      "r118",
      "r202",
      "r208",
      "r212",
      "r214",
      "r477",
      "r491",
      "r661"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss from equity method investment",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r85",
      "r117",
      "r205",
      "r249",
      "r490"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r558"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r558"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r372",
      "r376",
      "r378",
      "r379",
      "r382",
      "r384",
      "r385",
      "r386",
      "r518"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit from income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r133",
      "r186",
      "r187",
      "r206",
      "r374",
      "r383",
      "r498"
     ]
    },
    "us-gaap_IncomeTaxHolidayLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxHolidayLineItems",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Holiday [Line Items]",
        "label": "Income Tax Holiday [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxHolidayTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxHolidayTable",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Holiday [Table]",
        "label": "Income Tax Holiday [Table]",
        "documentation": "Income tax-exemptions and reductions which may be granted by a taxing authority for a specified period. Such \"tax holidays\" are typically granted to induce business investment in the tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "lsta_IncomeTaxIncentiveReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "IncomeTaxIncentiveReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax incentive receivable",
        "label": "Income Tax Incentive Receivable",
        "documentation": "Income Tax Incentive Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r719",
      "r729",
      "r746",
      "r754",
      "r758",
      "r766"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r770"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r770"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r770"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r468",
      "r469",
      "r470",
      "r472",
      "r658"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r91"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment owned (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r586",
      "r612",
      "r637",
      "r687"
     ]
    },
    "lsta_InvestmentOwnedCanceledShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "InvestmentOwnedCanceledShares",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares canceled (in shares)",
        "label": "Investment Owned, Canceled, Shares",
        "documentation": "Investment Owned, Canceled, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Classified by Contractual Maturity Date",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities - available for sale",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in and Advances to Affiliates [Line Items]",
        "label": "Investments in and Advances to Affiliates [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LegalSettlementCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "LegalSettlementCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal settlement",
        "label": "Legal Settlement, Current",
        "documentation": "Legal Settlement, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Amounts representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r171",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r390",
      "r393",
      "r394",
      "r413",
      "r533",
      "r660",
      "r695",
      "r810",
      "r824",
      "r825"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r116",
      "r486",
      "r682",
      "r788",
      "r801",
      "r822"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r140",
      "r171",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r390",
      "r393",
      "r394",
      "r413",
      "r682",
      "r810",
      "r824",
      "r825"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "lsta_LingmedLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "LingmedLimitedMember",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lingmed Limited",
        "label": "Lingmed Limited [Member]",
        "documentation": "Lingmed Limited"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, amount awarded to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LitigationSettlementFutureMilestonePaymentsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "LitigationSettlementFutureMilestonePaymentsPercent",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, future milestone payments",
        "label": "Litigation Settlement, Future Milestone Payments, Percent",
        "documentation": "Litigation Settlement, Future Milestone Payments, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LitigationSettlementMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "LitigationSettlementMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, first milestone payment",
        "label": "Litigation Settlement, Milestone Payment",
        "documentation": "Litigation Settlement, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LitigationSettlementPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "LitigationSettlementPaymentTerm",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, payment term",
        "label": "Litigation Settlement, Payment Term",
        "documentation": "Litigation Settlement, Payment Term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r274",
      "r806",
      "r807"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r274",
      "r806",
      "r807"
     ]
    },
    "lsta_LossOnSaleOfNOL": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "LossOnSaleOfNOL",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on sale of NOL",
        "label": "Loss On Sale of NOL",
        "documentation": "Loss On Sale of NOL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r782"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r324",
      "r467",
      "r505",
      "r525",
      "r526",
      "r582",
      "r601",
      "r605",
      "r606",
      "r634",
      "r648",
      "r649",
      "r662",
      "r666",
      "r677",
      "r684",
      "r812",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r324",
      "r467",
      "r505",
      "r525",
      "r526",
      "r582",
      "r601",
      "r605",
      "r606",
      "r634",
      "r648",
      "r649",
      "r662",
      "r666",
      "r677",
      "r684",
      "r812",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r115",
      "r171",
      "r253",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r413",
      "r485",
      "r537"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "NetCarryforwardOperatingLossCarryforwardAnnualLimitation",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL annual limitation",
        "label": "Net Carryforward Operating Loss Carryforward Annual Limitation",
        "documentation": "Net Carryforward Operating Loss Carryforward Annual Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Lisata Therapeutics, Inc. common stockholders",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r96",
      "r119",
      "r138",
      "r154",
      "r157",
      "r161",
      "r171",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r192",
      "r202",
      "r208",
      "r212",
      "r214",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r405",
      "r413",
      "r493",
      "r555",
      "r571",
      "r572",
      "r661",
      "r693",
      "r810"
     ]
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewJerseyDivisionOfTaxationMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Jersey",
        "label": "New Jersey Division of Taxation [Member]",
        "documentation": "Designated tax department of the government of the state of New Jersey."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York",
        "label": "New York State Division of Taxation and Finance [Member]",
        "documentation": "Designated tax department of the government of the state of New York."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r746",
      "r754"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- Controlling Interest in Subsidiary",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r303",
      "r789",
      "r790",
      "r791",
      "r837"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r208",
      "r212",
      "r214",
      "r661"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Lease Liabilities",
        "verboseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities:",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities \u2014 current",
        "verboseLabel": "Accrued liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current, balance sheet line item",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "lsta_OperatingLeaseRightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-Use Assets:",
        "label": "Operating Lease, Right-Of-Use Asset [Abstract]",
        "documentation": "Operating Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, balance sheet line item",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate for operating leases (percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r681"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r681"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "lsta_OperatingLossCarryforwardsBeforeWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "OperatingLossCarryforwardsBeforeWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, prior to write down",
        "label": "Operating Loss Carryforwards, Before Write Down",
        "documentation": "Operating Loss Carryforwards, Before Write Down"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_OperatingLossCarryforwardsPostAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "OperatingLossCarryforwardsPostAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, post acquisition",
        "label": "Operating Loss Carryforwards, Post Acquisition",
        "documentation": "Operating Loss Carryforwards, Post Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "lsta_OptionsVestedweightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "OptionsVestedweightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term",
        "label": "Options, Vested, weighted Average Remaining Contractual Term",
        "documentation": "Options, Vested, weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative translation adjustment arising during the period",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r19",
      "r155",
      "r158",
      "r162",
      "r416",
      "r417",
      "r422",
      "r474",
      "r494",
      "r784",
      "r785"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available for sale securities - net unrealized loss",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r248"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r717",
      "r727",
      "r752"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "lsta_OutstandingStockThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "OutstandingStockThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock threshold",
        "label": "Outstanding Stock Threshold",
        "documentation": "Outstanding Stock Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Lisata Therapeutics, Inc. Stockholders' Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment in Impilo Therapeutics",
        "terseLabel": "Payments to acquire Impilo SAFE",
        "label": "Payments to Acquire Other Investments",
        "documentation": "Amount of cash outflow to acquire investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r288"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ProceedsFromSaleOfNOLS": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "ProceedsFromSaleOfNOLS",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of NOLs",
        "label": "Proceeds From Sale of NOLS",
        "documentation": "Proceeds From Sale of NOLS"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of NOLs, gross",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r471",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r651",
      "r667",
      "r683",
      "r773",
      "r808",
      "r809",
      "r813",
      "r833"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r471",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r651",
      "r667",
      "r683",
      "r773",
      "r808",
      "r809",
      "r813",
      "r833"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r154",
      "r157",
      "r166",
      "r171",
      "r178",
      "r186",
      "r187",
      "r202",
      "r208",
      "r212",
      "r214",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r388",
      "r391",
      "r392",
      "r405",
      "r413",
      "r477",
      "r492",
      "r520",
      "r555",
      "r571",
      "r572",
      "r661",
      "r679",
      "r680",
      "r694",
      "r786",
      "r810"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r128",
      "r131",
      "r132"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r142",
      "r489"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r478",
      "r489",
      "r682"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r128",
      "r131",
      "r487"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentTables",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "lsta_QiluMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "QiluMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qilu",
        "label": "Qilu [Member]",
        "documentation": "Qilu"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r317",
      "r324",
      "r355",
      "r356",
      "r357",
      "r443",
      "r467",
      "r505",
      "r525",
      "r526",
      "r582",
      "r601",
      "r605",
      "r606",
      "r634",
      "r648",
      "r649",
      "r662",
      "r666",
      "r677",
      "r684",
      "r687",
      "r804",
      "r812",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r317",
      "r324",
      "r355",
      "r356",
      "r357",
      "r443",
      "r467",
      "r505",
      "r525",
      "r526",
      "r582",
      "r601",
      "r605",
      "r606",
      "r634",
      "r648",
      "r649",
      "r662",
      "r666",
      "r677",
      "r684",
      "r687",
      "r804",
      "r812",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r712",
      "r722",
      "r747"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r284",
      "r290",
      "r433",
      "r655",
      "r656"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ResearchAndDevelopmentTaxIncentiveTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia Research and Development Tax Incentive",
        "label": "Research and Development Tax Incentive [Text Block]",
        "documentation": "Research and Development Tax Incentive"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "ResearchCollaborationAndLicenseAgreementOptionToTerminate",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to terminate",
        "label": "Research Collaboration and License Agreement, Option to Terminate",
        "documentation": "Research Collaboration and License Agreement, Option to Terminate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r75"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r713",
      "r723",
      "r748"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r714",
      "r724",
      "r749"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r108",
      "r484",
      "r509",
      "r511",
      "r517",
      "r536",
      "r682"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r254",
      "r255",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r397",
      "r398",
      "r400",
      "r403",
      "r506",
      "r508",
      "r521",
      "r837"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from collaborative arrangement",
        "terseLabel": "Revenue from contract",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r820"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue excluding taxes",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r207",
      "r210",
      "r211",
      "r215",
      "r216",
      "r217",
      "r314",
      "r315",
      "r471"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r650"
     ]
    },
    "lsta_RevenuePerformanceObligationPercentageOfNetSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "RevenuePerformanceObligationPercentageOfNetSale",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sale",
        "label": "Revenue, Performance Obligation, Percentage of Net Sale",
        "documentation": "Revenue, Performance Obligation, Percentage of Net Sale"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "RevenuePerformanceObligationPercentageOfSublicensingRevenues",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of sublicensing revenues",
        "label": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues",
        "documentation": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration amounts, milestones",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "lsta_SAFEDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SAFEDiscountRate",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAFE, discount rate",
        "label": "SAFE, Discount Rate",
        "documentation": "SAFE, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SAFEValuationCap": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SAFEValuationCap",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAFE, valuation cap",
        "label": "SAFE, Valuation Cap",
        "documentation": "SAFE, Valuation Cap"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering amount authorized per agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SaleOfStockAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SaleOfStockAvailableForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock available for sale",
        "label": "Sale of Stock Available for Sale",
        "documentation": "Sale of Stock Available for Sale"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SaleOfStockAvailableForSalePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SaleOfStockAvailableForSalePercentage",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage held by non-affiliates",
        "label": "Sale of Stock Available for Sale, Percentage",
        "documentation": "Sale of Stock Available for Sale, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SanfordBurnhamPrebysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SanfordBurnhamPrebysMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanford Burnham Prebys",
        "label": "Sanford Burnham Prebys [Member]",
        "documentation": "Sanford Burnham Prebys"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option and Warrants Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r58"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r106",
      "r107",
      "r108",
      "r146",
      "r147",
      "r148",
      "r201",
      "r288",
      "r289",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r513",
      "r514",
      "r515",
      "r516",
      "r666",
      "r772",
      "r787"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited, Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average estimated fair value (in dollars per share)",
        "verboseLabel": "Granted, Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, Weighted average grant date fair value (in dollars per share)",
        "periodEndLabel": "Ending balance, Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options, Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average estimated fair value of shares granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)",
        "periodEndLabel": "Options, Outstanding, End of Period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)",
        "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options, Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r333",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "lsta_SharesHeldByThirdParty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SharesHeldByThirdParty",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares held by third party (in shares)",
        "label": "Shares Held by Third Party",
        "documentation": "Shares Held by Third Party"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SharesIssuedUnderLicenseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "SharesIssuedUnderLicenseAgreement",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued under license agreement (in shares)",
        "label": "Shares Issued Under License Agreement",
        "documentation": "Shares Issued Under License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_Sharesvestedandexpectedtovest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "Sharesvestedandexpectedtovest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest (in shares)",
        "label": "shares, vested and expected to vest",
        "documentation": "shares, vested and expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r169"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement, Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r27",
      "r136",
      "r159",
      "r160",
      "r161",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r200",
      "r254",
      "r255",
      "r303",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r432",
      "r506",
      "r507",
      "r508",
      "r521",
      "r573"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r200",
      "r471",
      "r512",
      "r522",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r688"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r200",
      "r471",
      "r512",
      "r522",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r688"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r716",
      "r726",
      "r751"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r108",
      "r513",
      "r573",
      "r644"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options, Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r108",
      "r339"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of shares issued",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r108"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Lisata Therapeutics, Inc. stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80",
      "r81",
      "r98",
      "r537",
      "r553",
      "r574",
      "r575",
      "r682",
      "r695",
      "r788",
      "r801",
      "r822",
      "r837"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r68",
      "r136",
      "r137",
      "r160",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r254",
      "r255",
      "r303",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r416",
      "r418",
      "r422",
      "r432",
      "r507",
      "r508",
      "r519",
      "r537",
      "r553",
      "r574",
      "r575",
      "r645",
      "r694",
      "r788",
      "r801",
      "r822",
      "r837"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r170",
      "r287",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r303",
      "r402",
      "r576",
      "r578",
      "r646"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r577"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "lsta_TechnologyTransferAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "TechnologyTransferAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Transfer Agreement [Abstract]",
        "documentation": "Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_TechnologyTransferAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "TechnologyTransferAgreementTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology Transfer Agreement",
        "label": "Technology Transfer Agreement [Text Block]",
        "documentation": "Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r286",
      "r300",
      "r401",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r495",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r55",
      "r56"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal debt securities",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r834"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r377"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r123",
      "r125",
      "r129",
      "r130"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r689",
      "r690",
      "r691",
      "r692"
     ]
    },
    "lsta_WarrantsCanceled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WarrantsCanceled",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, Forfeited (in shares)",
        "label": "Warrants Canceled",
        "documentation": "Warrants Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WarrantsExercised",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Warrants, Exercised (in shares)",
        "label": "Warrants Exercised",
        "documentation": "Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WarrantsExpired",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Warrants, Expired (in shares)",
        "label": "Warrants Expired",
        "documentation": "Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WarrantsGranted",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Granted (in shares)",
        "label": "Warrants Granted",
        "documentation": "Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WarrantsOtherDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value",
        "label": "Warrants Other Disclosures [Abstract]",
        "documentation": "Warrants Other Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WarrantsVested",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested (in shares)",
        "label": "Warrants, Vested",
        "documentation": "Warrants, Vested"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Exercise Price",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsCanceled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Forfeited (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "documentation": "Weighted Average Exercise Price, Warrants Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Exercised (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "documentation": "Weighted Average Exercise Price, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Expired (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "documentation": "Weighted Average Exercise Price, Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Granted (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "documentation": "Weighted Average Exercise Price, Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)",
        "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r195"
     ]
    },
    "lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageRemainingContractualTermwarrantoutstanding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Weighted Average Remaining Contractual Term warrant outstanding",
        "documentation": "Weighted Average Remaining Contractual Term warrant outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageRemainingContractualTermwarrantsvested": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20240331",
     "localname": "WeightedAverageRemainingContractualTermwarrantsvested",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term",
        "label": "weighted Average Remaining Contractual Term, warrants vested",
        "documentation": "weighted Average Remaining Contractual Term, warrants vested"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "SubTopic": "50",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0000320017-24-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-24-000031-xbrl.zip
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M&=L*\59:J<&&=#ZOPUS$A.YI[CWK4?9B: N@?[2GQ'2G)QF#J$GK#X>-M+I
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MF]/7GS VCN]\F+*$LMF:J/[N@<*ES)P^THG-W)PRM-F8N* -87]@;\%.;'-
M3--V!_9;0'XJ\EJK4:U_64F!KGXD4";%JAR@?W]J/_8[C[?_5!X[#_>/?>7A
MZ;'WU+[K*_U[!;1.'U2+4JXH]X]*N?9)_ZS<?U?Z?W24B$(*E5'[NH]?EUN5
MZAR4..5=<-[*]-.&$M1FBCNB2DB]R@.W_I2.I5/] [)5O-X1)N4<$USJ\$EA
M#$.,\+6"3J:%*26L0*V &RJYJQ]X+E&IE/,*AM87F4+)K(]MEGG_F$X]MDHK
M@5>@-I/28ZV&FNFQ&.,(L^8&NLA;*;*JK\BJIZ[(^H_MNUZ7JZM,DTDDZP)-
M-J/?0)4-F3U6_K7TG]A7]*=KQSSF_Y<IGFV6>6V/QX:# 3+ENP%J!60!ALTV
MET8='O;"=\6K@9BI8;BR7*A4ZK726I\M0]$[R]P6%X_TF7=NMER,Z ;XJ.>N
M;KN]=K^-(NZQ_=!YZG>O>WFE>W==W-BGE@4DGSIO1'/YSA5[J+!PQPIQ%&="
M-0R)ZXIA*8;K*-J(F\R?M]Y67/AR]]>.;] U2HUM Q.U2K%4JB5BT56KQ4;K
M_:$^;M$)1$AEAVS+OW@6E$W\[ <_[>FW&;JV=;ILY#GXQ(39+SC.S$-KY*YN
MJ$E>":/)VGDG .$^>>OZB3/1!G]>=35S5ZI:4"O52JW>?!=X)T6GGSBM*6"=
MV6">,>7?D7/.*&6-*%WRQ]@SL8S_\+\_GQQ1?>H6'XN]HN)W&F?*/,DH=W;Q
M<T+$()WKM& 9G88_&+.I/:%,+HOI0R*RK>N,.H[_SRV,5P[$8RMW52Z7E+9I
M4@N61O2\HEJZ\MVT;;8H+?-;>Q+^C-?PZSWKVZ^A0L-N@=^(\Q,0HCP:^O.2
M6OOP7%SNW;,'T*$@XS97L=C:#M$CVC6];T2?C%C\((P?; "B^?\9$V'$^ !4
MP4ELM-35#N+I*5D?'JA0)PS(S9@04Z%O5//PF M\# J&.B>H3O]C3& 7.HU1
MFEG\;)MESOS[__FEJ98;7QS%I2:=C&R+*A:W9/-HK)D>DH<"#@#A@+_<0CZB
M^&W#BW/<6LE=M4I+!G%A\U%Y^YP'7.>\P8WMXII5+(HJK8\5;8J. =%^/C/P
MG/2"CYDA_ <0/0R>!#OJ5/,-YDM8"&7X5&X^/G ,$E*V#VP<.$C1+#8KI6V#
M%)5J4:TE$Z106\5F.9E*C(I:K*])AL6JN%8JK>P>:#)FN :,*,)RE%%=F7C,
M\3 ^Y]H*/,$=J++Z:? 9]2 F ]J:>WD*6K\1GXHR7)-'*BG11HIF$L=)L8)?
ML4=&N+[I3<<#V_R4:A,F?H=W?KB9(Y&^:2.L9E: DE]'!GPR(_=3(.1=K7]?
M#DS+ZH!3?ZCK:R+I!&#C=[?EE0EAR@LQ/:K\=ZE8*I65"9;"CPX4N'3MB?2P
M]%E+<%8(2,SH]/KM_6?Q!8CDLH2%R '%L3U%=GS.%=FQ15\?^7K!S6\@ZSLZ
M^6NIR.F:3 QP:Y4?A/VD;HS''^_>+&2"?,.H4JS KGW<%! 1EW517!]\QOC>
M53!RCI W I #=VYMDX$EURK%?[5@_01?^BCV]QA+P/YF_>6K$U=Q;-/0E8#D
M @(O(7F'4Z3#S=R%***<_&_/<8WA5'QD6!B\OBQ7B@*LQ]AWU](Q=DZ5P531
M1E3[J<!6?X+RI#S=@%9@))'[J?Q9&1%'&1HFV(_$-.%+K')"L_(OST"C$FS)
M ?4?@#%#N[*"R0E1T>-;EQ&C-.!^M#CQ:ZSH473X%DP7?'3"J$:Y(5-6%5X#
MZ2B?8#R0$XKC@9IW1C9FDQ5Q^ ;>(>[BVE_)_"IQB>)E?P^?\PJQ=.63*O8X
M &D#WP_^#3O Y_FC\!*NPA\'"[X<O@B^2.*X2JNDZ&3J%+<.>UY[C,%PHFH,
M]8I+7,\)Q5TS=_5/ZBS)NK#Z>2NW=??J.-]A/:*W?&<K8<5<QK3O,2T2,]#Q
MV'!=H'QJ CTSVT*U8DX5"BIFJG317L!>/R]4N2$N$65'"SP]&R/J.#YZ\&2U
M5$.V?:3/GBD2<;U"7_F$0K7Q15'!V?:?<$<&+_V88.G'OCE<+)@S]<0&W@PX
MF#J?M^?/"(@00CZ[AOS9RO@SX\^/\2=P!%%,@ 55B*8!?S*"3(:$RE EQ7ZJ
M )458K]PQL#8, L+- G0]AB ,,VC!H;A0&TAW)^59V:_NJ/@ZR(H9*KH=&A8
M1E!=@+%L%7:X8G'\Z_*7X+&E!_SO\\$#*Y<6#(2LZC^[8I7!DX8E) ]XL@4U
ML"BB9L2EK*5>'S39U5JQN<9DW_P\6[.:4!2U451+U606E>S^6A(?3DC4W;Z-
MY\V3*Q.95R7K=Q5ZF>G??/L,D7M"'/J1LGUV#=A^MMDT)A;&'^)TH/D/S<)B
M>%?#79QE<.+'BA;L[/.2#[U59M6)(7E;1N)P^>8Y,)#CS!^F'1IO5"^XS M3
M('C'QB9GR3<43!N25[*/I0&)G7B[_LQ)-8#*[QPHUP(FFS9!4#<[//I^VB/J
M/%?JQW.=A^^XJ%A!%>M9&\.XH!</=8$"M&P>J?(<RI^"C5)^/-^=G77THTH8
M;<*YS"E._FK U#"M8L'>;)2O+X;#%2I>Z640$\UN/ 6"#V,7,ITPW5&P)M70
M5]575#Z1SW'^:G'Y0&7P\_TH2A1Q*C@X,]QM?E(J-H+23%/\Q!E1TPSH1/D$
MV.>1#''>[/U(P>?B%B Z$D3^29TY:EA-+/CSSO;36=LJ3 1BG/#Q]>60F,Y,
M85;6*\QM(GYKHGL?I>ECDS!2FZC_1-KC%12.8GLNEQ<H.(+:%9\R#<?Q*/O5
M$05)E-<D:Z(TPQ&E&<0)GC5A L<%@8-Q:8U'L;!+R&IZG@]]+==A'#P85BOC
M$481A8L/AH5VSWS@J5(6[\6'A;;\HMD\\&#QR?6R^DYV74[K)[XFZ_K=6KJZ
M]&56\;NZCS"MX,$?9*JT@E8[RS["(GK?*YZ0$[WQQNWUG#@*ZL/"@K%(I=@*
M"E!CMUU28C;/M8)4N_>5ZG<F[D91/,L0*E7(]MR"FH6]ZE0SP!5U?LMU[[['
M9/XY.'G=78\/$2&T>2T,>J2@V[R '0<$* ),8*Q2J).Q9C]?*37RU4HET,K!
M2E<<((PG0(Z+TJ:8. G/5.!O"Y=IM>6R;$)OUGY@=2JT7$3ML& L^1\NB\V/
M+6*A>^S$%L[1):,FO^YGJ9_LS$S@RR[-7B$#QS8]=_F5=2UHMVV%VPA;X8[8
M#"_/M#!@E/PLD"& XY*8KV3J()5^I%]N#!T.AQ^AP^:N)U2(+$M11@REVR\;
MX0=,8?KV]8+$XGL;'J@6EZL!Q&>'KWU=,A%$XY[V$_:O:C_^4[F[[W>4Q\[O
M[<>;[MWORO?[QS_AU\+M_?W?\&_>T/A'YZZ_45/C-?[Y5L*EN4'QQ/%<_SX6
M"/T5ME,4(6WE$Z\;\BL#9LT61;&<7Q+PF2M>8ECA@Z Z7PG3"Z9MXP'EH'2
M'QP6I7L8X3$L[DN-*;%\=PS_?&#&"[IOD2+%V=6N,#&JY5FU8JO&W;)7C$'
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M -%?L"6>0L&.UGCD:!;F<83IS:WDV?(B8V4:0!(-(&(NG/EG(4#?MT,O" T
M07<"K\(GXDVWL;!$]Q_R[49' XTOY+_M! /$JH\8(O?IBL?AN<$],Q)GX3M8
MG4X=0P04@I/2(+>X+;I 5'F1H(Q37A$#E<[47!"O1/,&0(86L#>QA46DF<08
M^Q$^ YP^?IMFL,.,?(]'OA.;AQZ)&?%H[*A;-* 6'1HB]!CC$ 4WCR+Z37P:
M8T)(%WJ&U:/J08 W*!B,"7);U)A0' :Q&(UNQ_FAHE63B 'YD1AQ[A6$B$@H
MHPO-GO& :^CN@TP8 ,T$P?&"KTEG<<T9>?%"7U$$(9S>!7'*8U6@%WDG"TY5
M,[$)Q,<SBDA[(/?L($9J"H\>1X@,SY4T3]M8?@AL;FYC&+Q+];R8"0#+O3"T
MQ$>V*:( ID<S8CXL,8MPAP@@^GII+BDCXJ(&=;XLWZ*68>: 8B9@(!':XVP<
MY (7XUZ?>, :L,9;Z(O:<?[-9^1L+-YG.@; A36-XP69%N!)V!:NSU%TCW+Q
M1DTR=3 99FL&?X2_12WPP'A3&+ M#*Z7_!=XY2\8TZ8;YLE<4%4NTI-O?J$U
M$^0@Q=N@'B>^S9WG6P4QPP6+6"+?0UQX+\CP^'D,#/#[ _J1',-ZP<T]HW<)
M3P- R N!5WS \LR?AF$AP__$WP6>EF 63#8F&K.I]6(P.W!>HAD1OEN*%M]P
M!@E,WE(J8DM<L/.PJ\8,'L2?0<6()&U?#2<3?D<0?OQ8#$^ "74<21I-O %H
M5]_=1/0Y1HAT Q/Y,!XF"WW?TN$U",9X N21![. P6?FU,\>^7_EYRW_2 P^
M+H"-<\T,1'0?.%/PA'5&*H>5QG.Y4-UP-,_Q*UK\[/.CX?P,LGN1=AV(U[9E
M85I/U+I@D\[O6$93+A7^YG<,XU)NH3D8(C\\KQ.Y&NT3/N?/V>M<AV5 ."P=
M, _CVZI?G@VJ *;W'X8/*K.9@_?6GIIXMW[J:.52- 87F-4VYDI&A'\O<M/@
MCP,+#^9PUG4I0*-=5.*0QY-FID-?<=P E?- ])/B49W,3]2!U! MTYP(:CO7
M@<F/D2M?#?GA 3QC!Z !"WK/A,]'O,1THJ%M .C7U]>B0[7BL_V2/VJ3\&BF
M?"%+CCB8"Q6OJPL05/%N!C^:L6^#N_)>R84+TGK@B0-$(F,:*>F V?^"Q89W
MP G5@9$ 1L':@/G@$]S38KT%T*1?\X&CP<91\L].=8+M!P:<9Z&Y<M3*YIBR
MS:/>2* JJ^NKLUKIDZJ5EDHE 4\9W*D2@5CG_>I3H0><"1 @O !"8G:Z4?>/
M3TZ55]0[8Q "130$Z(3?*!F&F$%TF.05AJ*BBL(E/]'QBI17<&DTX>-QJ_;=
M]?B1(3Q4[$>!8#UX CQ2RIL/+&,L=W6=.=]E4SN"%[C+<S!#-O%5R<27%$O)
MCGK$'_7HM[_==O#V\>O[N_Z[YSCB-KMP$'N'O:>B>6&]6"NIB?3V:]:+I4HR
M'0>KQ7+]_9'6]/I9OLQ(TR@%+MVP;<_:]S<\-3DV=-VD>Y%CK8UXX:']V%>Z
M!>5[]ZY]=]UMWRK=N^_WCS_:>!AJXROW/@*.^&/B(4!B8%$IU<I#=2^PX'SQ
M !H)KR'=IFE4_*U8*20$$48H[H#RW3>^^OC<:DVQ/Y@<2,GON)3-E3Q>^/D]
MC,3V0LOY,D;K'QWOZPR$9& =;[_N$;D;67"6O1U>*[FKV@H<[JH&DY1>'[/I
M-D-9W!T@">NK= FOXXNH;:FXCMU)+'[O#$_1?B,FCT7T1I3R$*7":3Q]N_J!
MYT252CFER^=9F)2NO9K2=2N?/(MXN@%\\)F'U6^H1GDCLDH9\)'27974RHZF
MQEZD=&9J;(7%Q$R-!;MQ:X_[U/R-]*GLUH+*[LWU'KB?G=T,JL==&)NF4H_#
M5OVKC<0Y^I3N(;!%\BE=?UIMD59*;1$$.=H?Z05[):7KCIJ 68 FW583H+.>
M!6B.':#)3+KUI(H7$KQCTF&#<49'>)[KA2JWMG,"IAUN.>VF'>XAS:8=KC^E
M-@8N/8VF'0=Y>DT[7'X:33L.]N1,NRP@=ES3#M'9V%- [&Q,NY163*1-\M3>
M->TZ?WEX=##]YESM!,RY6LK-N5IZS;E:2LVY6KK-N5I*S;G:0K(V"]6EVYX#
M?#:S4-VQ0W598G8W*FZ^'\7#+OW?L:M_:.ZE4?0VL?E!6JW4Y@E8J<U4U[;A
M\M-:VX9K3Z65VDRWE=I,J97:S(*.IV2D CI;6=#QV$%'V8S4.]NEO''(4\#H
MRIP1&'?V1S8 9E)@8RE0*>>NRJ44^*I[/[6H[G)J\?2<U1_AA1+8!:K<^.(H
M-Z*_E'\[A-*VB#G%1G#@#,ZDPG70FXT_\SAKJ#DKY)4-SIFXV%A<M$!<J-44
M6 U[%Q>5[)!S%"9_]_ B+I=WH^&<_W?L]>7_C8+#M!V/P73M 39L_R&N,<%F
M<[*!,9,&6YP%KX KFUD/( ZJF?40A0E8 7@QC6A)^,!LC>I>]&YU26"4\?H6
MO%Y/DM>/?VSOB(URN@7EOO]'YS&A+CFK8'E6 GBGIC.G)X!OZ3,X8USR4MQ3
M)GI3+'K+6*:L9EX7[U!]?B6BT9;<F;>48C:N)<G&:5;66:QU#B9/%J//A@.,
MA%4VQ*316NJ%BQ">''YCC*_9,[6>9GG0S-1Z%DR-@<D-'1*>-GG"RRQ[U#)L
M%I$#LL$JX_G->5XM9S9 %C&-R[?")Z#[AW@72B1?(AN,,E[?@M>KF7X7O%[+
M]'L4)O?\AI'N[#H1V:"3<?D67-[(-+K@\GJFT:,PZ;R-C(&Q4W5DIL*/W12]
ME!(5GE5)'Y2W>[ "XNYHH&>J^]C<C>5+J[I)<^Z^X!<E!9^?^8ULU7=N9,/E
M&OION<TN$,FN<3OX4O9RC=OA*?.]LIKB)O=/;;#Z%9<Q'F=KW7[GAU*.;JW7
M;\-GL3?.O7^9Y(;\6<EM.F(BT]5S$A/6;;?7[K<5+-9J/W2>^MWK7AYHZ[JH
MM.]NE-[3MU[WIMM^['96W_XGRU:N[^]Z][?=&R">&^5;^Q:HJ:/T_NATWKFY
M<.]KW\RN^-3%FV1M#X;0G;Q"Q16PS@CO@]:)2SZONWK1OV;QX+<EMEK%1JFQ
M[66)#;58JC<2N>*P7"ZVJJVMAEK]>:U226Q1M?<G7^-:;5@VNO6]@0)Y^R;R
M^'L#9ZVZ4)RJ)3QFXU/U:J?B% $1O:4F@$5EM]L4/Q9'.280VKU>5#!_(&CD
M"S<4?664EGB"5PG6G2J"^/04Z3GP<8#L>BGK1@#]>/%U?#1 X?^J1;4F"[TN
MJ6B.(]X-".N3-/P%;V9_(>;<V7 ?8]OLOZ1(Q:GQ.__OG788W1F_Z5FFK7TU
MWC"F\IT1C9_H]2S#?40OTG/T'%"UA8OG'V@%(&WP.XTQ,9W?<OB71<84GRP\
M$S*Y1/IH6SK^TYD11]N])HQ- 1K_(*8'3JK(B('?\.9>6MZXH-O<G<5A@74
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M/[4"/X(UMY6#;XYQ:1GF;SF784^\A49ZLWUA/[WHKD(ZK L<'[[^8"\0J28
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M+@'?+QW ZE !D*+93+EG)K,UP]@H4\V!!8#^U@!A?'SJ@KZ*:]K6"B >##^
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MJ?L>:A*M2;04$D49NE^D>'@<MV$=*2X3S7ZW&:A*]G:UH([SE4YJ8+P#E)#
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MR\IR7%&3*;?Q-X?_S@%6I9B6"\M8#_H<JT<5?;4&;-!=O@UXSF:N9YO18]A
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MT//W?"S WO7N^X9[*UC1WN]@9U3^XO2(;]P#(J;:#4<MM9_^7>9#F5\,.L3
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M8_5**L)^4L>W?W[\<.5G=1"OHY7NV&QIPJ'O-\I[+'! PP/4$9#S-L!+QSF
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M2+6BZA/A\(/Q3 ^R?)3;M2&*DSX^B0XO/Q!NT3R.E$!JN&,9QRZL#86KH%Q
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MY'-1G9*,S.>.<S4CU<)<+\)\ 'Q'40G>;3]CI&C4P::/G5U^PK24J4R_(4!
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M/]R=A[D_7$P0TD26B?U*N=#>4+XE)8O2,]P!:1F>"=H;T)."1AVBFTA5;2J
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M62?/)(,BI+0+K/L^?T:;*XR9LQEC5<7,;9**_]<?Y8>V1<CK&T?5(L=O*R<
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M&IN*-D>080X>YI19YB6/Q$4JUG!SO[1;8N2$S"RY$*^D7%(,O=!*/#2#BXG
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MP-H&TW,0AA9.2V7Q6F+$$DP&?G8C0CQ=*,FCPO%KQ2F8A>.N_FOAQ[[A\-V
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MJ@9T L 1%S'6;Y",A;W8"ZB1C2>/>6YMLQ6=]%8D9H]OMH)8B3("*(1D9Y!
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MG(3SZX\DVX"1;4E<)IXQ?4C!UOYT^;:TM_86]H=?7V8>>$*8N(%_76N\J=<
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MQ6VQ-C<'(UV;:RD&9\[UD6$^1GU$*'9MBAQQCXW0QI7/K/(]$&Y6CY)_K5]
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MRB>8X@ZN3D9Q+]AEC:F:*/0#?.&//5GFSK/.!/5PX(1V_J[R8/65=1^F==*
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MS=QG+ZEW)488?_E^13P[@MA3-(,??_H_4$L#!!0    ( +.!J5@Q"QBT6Q@
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MI>![6!%>3:;D-X^_Y6H.I6A! ]3"AWH_)(U<2(*89+U=AWYK6Q_MO0W'$V'
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MD)W1D$:*F4(N)E( ],T/RUQNEPY%$%^E\DS=M'I< 39[S[1E&D8[_M7^2*R
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M=3W!R3K&X75\0NVI[RRKU$61\\=/#FP>VTPKG/#\K:28#)J9MGC^FNHH6-G
M#L_D#1*29O\/=!;.Y8/W&U:0EFI7"]G<X"E&D[@G1WP9II^D-.@+B?&^/+;D
MZNL[]T9#![D=@G/42[I_VS'JZO#WX9T,?/O0H]%7U:>F:[[V ?ST5QXOBYJ%
M_RKM !J"L_]6*&N?FDB"[2@ 4=:2%Z=0NK6,]-.7P=ICI5=KG(.5_#U<_4F9
M+YC(W&/!I6J[\(-TR.1YTY6^.5,6/7%QL2J%H1D49BI2U0T-X]G(D$T\[83R
M[<,J/58K:Z4]5AVAFLDU^TE''7:U4@>POW?,2Z:D=#> QQ(A=JRS6-#=@]U9
M$TQL3*!E$LKII+8P1WXPUY4_+]+9.RB?3^OEGJC3WALY4<TK$   P,6!'R2T
M)XE.XURTBG,3QE(MD[0J0HS=?GF%$MK=[V0$_]S_.O4'_G=JB@%YO!^9]!\V
M6>:X=8?;UNSS<E*??/+?+'_)$_^J2QARP^/3E"@)Q,]X>@E$-P4P.X99BU&3
M((]ER)=C_0J+Q.(72T%;8YIY\WWLDO?N-R2'?KQ9V=^KE\5XLD]F,,-E;&(T
M6TNU.])JB%,G0V&'M/$_ZS_V"9L/?;EZO7.9B/%=^ZYOO1)<Y',CFG,EI*S)
M<C/C4GM:H??V$XF\IA*G7UM<G/95@H"[KATJ=/K&/B2#@>>1N15-H7L*MC'X
MO>(W':$,= 4'"#52;LL5%R C]"QAK:M1NX>[.-<Y4<]I[[N/6;V1J-XY=^&X
MPYQK_3D3"DU^U\3%[4;_(-) BW"X@*H%;G_Q*5D,]^W /*X\;;#K<YJ SYL
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M^AHK[F;! HR=3Z]YS4F4X''<R4(Y\JOC6U//[DKKM#/H70[YN59XJ2EJN$Q
MH2%"_VF:TS8FP,$W2D3@R]P;P*'(A)N2V=CA>\?REMH6]=-!MYN]M-Y3YTZ
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MK>S^P<]2%M"<RW;;"W)-1)C0+G:3P#\:7IT6V4HE(+)0)O%..!W1$M<3-8*
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MA"!JL]CE!V9M=E$3ACA:?M6$K0V=[]2OCRCN;%?@G8N[67(K)G#J)Y(3MIB
M7[@\(7L(#!-2'9O2<S8ST9KTOSV#- 3.V"X\YOLSLD/#=SV@C.ENL+1D#9KA
M=O"@^?/9@=YNCGP^'?$!:'YN\'G2!Z@D=! DM#3>S+.T>0<>-G@UI$IG0NR3
MGO\%@(@AHX;=/N=RR=M/V#O<7$>^4#%8NPX.169 X0S5QQ1BK='5JPS^I 2A
M[^[5\QI3 2:,X3MR,P--+HW80%]216QG0G',FPYA8=KFK9EOIOU<C@H*HCF)
M-=NHGSUL?%9:3:B"#8FL9IJ8_]]_9_2_(%(8X(PP-2!VM\^?6D' W?PY,\H$
MYRR%KP\F=K[.#9QS6WO*%*2XLOQ2[\?1@XS?B+J"LA(UL3QN79\C9T3S*-<E
M)4A8\.!I$'2@,77[/K;NR5CS;?PS"/SQ^/.-4==C)L_/7Y[H\-F4:$ UUB?E
MP$]']!]48P^%GV?\>9;T_E,"KJ<#.9V*\4LZ921D+TY%B(TLXS@CO5US=,XO
M_4 F")=\?[QZPRC<61. J\,N4#-9"/DG69;TF4B#"0%VLSM7SF^8I\VW^\Q^
M^.)'GZQFVUNO0MM2F-589%<T_GZ]R=Q]=WS4.%=D"66(!A(D6+<,<73X-$(R
M>MZ_G<-I9-KY1.]W'G_R;#O9\9LPEENQMR/N\!#>A0Q3A/&JL6Z2:<;77)T4
MW$!;'S!R]1V7 3EO/+^5%?U>4N[R]S'2YGO^.O\"M96RM3)3X/I-;"/<.F4A
MCR$!Q  '#S2"=QW?PI&J'[JD3_XUD?-8YJJ)U6DFI&U!WP][9\E/:@JT^!U5
MD1^/=$;Q0?2,L,$SJL]GK-[7CL7JKJ/=ML70U9**&E([DE)E9F57)N.N#GP)
M\("N(DWA-^&&GR>;Z?((/>C!H?>J#U_5I3F0TTGP 'K5FY_QBF._X[X?GJ,!
MIRL!L;J(&;I%6$S-M186"(Y#HZ7_PF<%I?)ZIP]^I9TVKUY:]3#E'%V6\007
M5INH\0 M&'YFOLQM=/D3Y9NKB]\(MCCE)[<>H<X'.WOCQ#%J/X!1:I>?BNRI
M?A%)N_/\(]OU0?G/S@Z^M@V7 7PM>*\;2&?6W_D8GBZ/69H.)(>/6;41=B6L
M.U5DP-=OW3,Z@"NGG;Y7E45E;:9E-ZN:/-H9Y&C5U%<<8-$+70B>(^E]_+=/
M[AQ@TX@EVDPL2(N0C+U%K3?QFXTQ=8JW6Y)\;\1))4>]9.M-3_Y83L=K(Q?Z
MT$L=&@Z=A -D0,X>[XZ$&&LGLX<=4O8N(&JUW1V?"8MLS_ %KDWFDCY!:2RA
M@TC:+556[Q+-L@%7;\_7'K9U-XH#XBP$M)6>GDSY,@6_)K ZTGX]KG59+P[I
M+B_)U$SV\%Y&3,/)#+-+3;#88:(^8:+,?",P[-OBN&U5U$K96E.3 :.V?-B#
MHBN,#T*U).GZZ=263GVAW9KX(NQ"4D#6QC-J:S?<&>TLNNA1-?^((,T4YF6X
M^LRX5?GX+5!1<[S:Y-S^]:>;/6Q!RMMNB=MVXM;N+B'ZQR/49(I_02I'5*?+
MTD"B,25J EA!>NG<C-%U&5FUGS?RE'-,W^>O\)[)>4:W8I[!\-<!(2#0P.W4
M+,AI6_CC6H)_[M#%* :$H#6]SL?08$3J!]O!*[]VTU64!Z%O1\P'%,J.2Q(-
M=.23DY!@?9)MX,P,7 DZ!Z\,I@!J'#N^W>S0&B_U0;#_J=/Q?J& WZWJ+6NR
MC^P/[6>YN,/X^AF3=T\JM!->M;O-AC7I'C8E''6.S!/OE)>G+<QJQQLI252R
MMX!3<KT* ,I\ ,?<D"YU[P[@<V7_#R,]@VY_'I2*LCH.$RXL31$YZKIJ*0 >
M,0(<"^SZ2#"T;FQ(W%MM7_6O-<V%6K:).'6X)GISQ#9GO'X0I[:&YR7EP)Q*
M7;7K"/,XH059IM]]JP&*^R5[:PUQO"-7%^Z_6)43]1Z.8UUWXQH1G.7@S<UV
M?31C KZE'I$&1ABF8^,[J'Q8H-4<]DX^5E%"5<G.$<^[9>GQ//K<C6 29EHT
M<L,T:1*IK$ E\^*RW8A0))<L]>^W4.G06>UZ&>D<UWU7WW/7VYHC/Q5J&7F^
M2VIR?U*(&+\M!6>.+PWS\O1?G;]K>"O?W&BVSG!?& ,G<FABX/&J7'9%&U"9
M<ARL2^J4 KCS?+S&8OW1#?,2==NZL!B'"*:?>OW9.V_4+.'#X% R>PN6M0UU
M%F)G**>8F_5'D=]MI,YVY,N+NL<HY\L._M?:6C%-DM=LY28JGAEMF/?-.Y.<
M.$HE(Z_Q+LB/.N+HWOENRXQ_;_A1GC$C?*5]%S*MH?<B46H93A"/WXI>@D_[
M[?=X$;JMQ(PGLRLMP%L#J9_?L7UMV>ZE=O*F]9L++4-9E?F1A;HQ?S31R8@]
M,05!V\5:QT%@G?]6/FA;$]O=/?;(]8X'K]/4@R6=^A^V"=4>81EB-@QG/DGY
M@.1=E,^-0;G)@]2N,0IDGX#U7WI<U9RX<,O.+21GGL_*;;C8XG')'\4^MN-[
M;>?M+-<\N0X&N3R[G\?RCN@];BI;/V:=&4C6K#C^D@7M@M68;!VI9>80Q0CQ
M=DIA.S),">IXA 0%T(+5$1!QUSBS]WN-1KS\$#3M2F8@E1!D,9Z$8EQX9P6A
MIT=*6,_MG%>?ZNO!83V1LC,)[=CB:LG7&J^;H(O4"O&R/BK!<T3%?;0*6C)J
M&MFG,/<3I_;N!0;!O#$C4\P_F+NAF#@]W]US)C.!45F<-.JZ#R0S/,1:+X!C
MA%1QY0D*EVYU1)VH?0GF6<DPL]Q)OBO'#C6<^D&>1%;T='G$HSA%)YIOX:2#
MY=!W8M6DKAVD_F@RME4*B'D1\\JF+=SPEPH"1DJ' OX@J\#M/T!M:==W0U::
M+!<VV+]K-C4$>WPL$'=J+PKK:R^*24KT#7-Z\=KPO:2UL70^M6M>-DC,U\K9
M62$(9:MSFKSW IZ%]B/+=SO![T U&ODX5G#ZHY"S2Z</;:?GFY/(QY%/"V-8
MB/M@=>@,D-:7 HB'5Y$;%H>8?GP-[%KI*JE0(.8I5PC^V4YA[,G*F-B1-\DT
MO&1>"L&(NCO-H(2=GW_*RSO2'*0 RL%;IYCXZ;K%EDRT!W??"[%\M1JU[^$Z
M7W+C!R V]Q/[FU<5EX22E\!U1UN:.%;\9T)I)B2:6F@KUO'FDLY[L4^V,; ;
M>O+A9^Q>Q3QN7IML.<PJRGAAGB&*R79_J6"N#Z^V@-\F_X8#B#JX6;Q'=.N"
M0&*;0FY]U<>:@T%!Y>C=X#:M$T\+4 6L[1ML$;A% 602;G4..8I5.'KZ7B]]
M<2WQNM:=1G14X9^.FJ!8KG==1CYJ"+P'[(O0J.77;TIJ%TD)2%MX!/@<R'F7
M'4(!=!HZ(3)=+H)[&*>MFI->.H\^ZO_<*GAM2&$;7"N^!<N"3BRP5X9:C&5!
MLK7V!9Y.<-_8W'_;>"VU6*/+".N58^_X$?5@Q$(/:.V[%/$CIXE[4V=0K_ X
MW?54!CK+#PHW;..&L6]I?IADK<S!;3*_C^:EKZP&.AG3O*&[WXIIR23%PNPN
M">#UL23B*+@,N<1L*HG:R+K%+V*7<.Z)UA4:+].]GG-+ -8<IU*I5>/-MK'*
MJ*!I<W+VMP =KRVH#U&7FNY]B9J$()S[*>8O:RQ)^ 1%-SA\73]*^BQ:MV]:
MU1E?D6A:-6)/ V#:$5: 8UA_3^'S2;DOQPZ0,7!V^0$]IIFG8C=F2W1GW[3Z
MABY(C,PRM=XJ%Q:?1&H5E-JE8]A-]+TLM')]]Z4V;^TA@UQ>D]D)2FC$>>*5
M6H)KOL5C53F6=+$4NX1]D83')2(O/7;E_&WO=9LNLB0?=^50NS15F#/K6^@M
M9#W!9"F(]Y7,[T[94@7QZH K3'XA6=PZN1^T6A?HE!5.BM6]T?N,!'>HA8+T
M#L+KBKG/KGO^(*K&?POF=FH8+#U\,/_0P$JVN_'Z_:T:KPS[EQKJ')J7%S_/
M%:@(AIYI6]'K5:0V=^';X< PS8X)W$J)&O/O5T3D]K3:S\OK51%$E)3@JVZY
M[AF27E9UQZHO%HMW&90VGMC^HVSRE4?VX=K0[TW\PQ$*P %(:VW>$ZB Y-CX
MF>@2B$BMT!WV>\A^R%9FNN?5F>C9COA )7@5P$Y0-*HF+QHG_"!=78_5K"^O
M.MK?;UWM\NO1%X_L?02]!T,VU1WT;B!TJRMXFG.SZ[/-771#S'X2=;';4]$M
M_(2J!Q5RT?.&6DV5;WYV&?Y,Y%&?>_WZ9H>J23\*JP><YND!56ZOQ:W@8AJ?
M%I=JVM=2.;*L'*VP2LAL@B>YPG/J1PA<W4Z/R^ ;WW!\AQ1X^4'!$L_Y*C4Q
M4AEL$>Y/ 7"K7=;$*:%A$=G8U/CFWIQZLY5$^I>)-\X."59<@^0"SK1>*6?M
M]])+VH17H+8]<#-2,";B4T*R'=W[% =G:HO\OJGUS\)3N?RO]P%OA5D">A5.
M[-3]Q@8].3-YG8[]W*P0&JZ"CS")6Y"I#S '61J"(]ZWD:#B<6ZM([76RV+!
M,OSL:@#\?)FV3?RMUTS*E]WT8YA,NJV!I @*@+K]=+[Y./7DXNATX?=_I/Z4
MDLIQJ/C(;Q&P!.G8;IW+6:,9-EE/YDH6;/\A9+\M*FV>V.C1(%>JC"H]A6=D
MG/N+Y!!U" B<Q5/<T3;'DJM;2 F_HHY85W/WEV>IIF;)PG&\'8E/NO-!2L(J
MB.%&B1(YY<;ZO&\Z*7U2HG\B"PV,E?YPZJM[?CG/J7_O'_E'_I'_[X5M\$J<
MXHOQP EPG=8?9+)I(Y6&^!%!WQPG$[2R344F<^/_=1_HGC0"DT2H@R7E5]3_
M\RW! A5]N^W10-D5S=F< W!_\8BF)(N1Z:E/1O2Q/G[]+L]>T8%^_[MD;K5Y
M\2RR44BCGCJQZ >GU_?_/AOQ;.<[U[D#[$;SBU) /028>9V9MC>#4WN41*'(
M_]L?#$E*13Z5"P6(*Z_F%AVA-L)/QR=7-+V _TEOM_[8X_]-3?G?9B/+#^O+
M"49A;0?%QG!7"@!X@4 !2 Z7Y&;+I54-4QV9>#9*XOO_BM"[(Y?FD:QK9H>9
MU-Y!:)L NSU4:E?1K'B+^-"[P.S/[9@3G;0-_A*_O;NY.8GTD\ZAB1&FV.^U
M9^X68X;8@LVI^F#KNH0 0L(XVO0BUPPQ9((H5N1V2)5"M9J-4>?P2L3EKXID
MQCTP<WQ-35/0YJ 0GODF_JZ2?B*W=E"?S?XD'WU[0[S7;ML:'U]7\,IB_#2H
M1XT9=_#7=ZO"6A4NZ>ZA19 -C=B:YKI;G?3SC#HB<</9$K/O6P4]6_-V#%6D
M=J-1W"URP4\)\#P"1Y>B-<M(,WMBCJ=67H>WZ$&$U>OMJ[7S@QQ[<F],0@,0
MSTCI:G=<D?PM-/.$".?A!4B3[JUIA<8$)B7_:[R07UKM'UB^;+%LV=B8B.-<
M\3HXQDUK)9QC!ROO'"'(&'>I)+K Z27]C,":1W/QM1?+*7?BMM@O"'+1-@&G
MX>C:)NSIHBQ1V/$1!?">HS,HCW0X\=,\[WA:0^;S(^/'0V=5L1?/ZADD[_!G
M<& 0,2 @E(WPKK62D-[)[U=80HC: X-:/_ZVX*Y]\YC+4][,EEZ<"1S:G-IA
MQPB;25_B;EB,9PLV&R4^S/T-<=6:$A[+QC:GO?*Z7E%^CCM5Z"74_I>@X_7[
MEH"0XC98I4><ZI6E/N)S%,^4X3C"T61<1H8H[2;=U:DB@#;+29CA=!!X_9DF
M3IDKH1#:.CPDEIM-Y6T7#W5DT?C<@K)<;W3!UDCZ3SZTHW0K7VL_L+%ASHC_
MN>WX2HMP\ O"DOC;0T3D.H*ZA*59L!;O_>>V4<ID:J++@"++A6\[\=7+,2S?
M .>+\CMWXT#<U2@:@D=7X%%<->R#WTEMU)$Y--XA1]O?O\ JJW!6C/#EA<E"
M#H<8YXW>5^QW@5WP2IYH5>TE 69WV:C7YN;KC%=&?+XTRS+/EZ4S+FH4"E;=
MY'G&<Q3FSWZFMY7&L1-5Y=%YR5UKI8:P4FI1FYE/"C>N:QX3;JRN%WW0BVVU
M-ZJ;#WW]/:'^3:NG^F<77V0E*JY9$R>P6!M91BC:Z#XR_=J+\'PA\E3$V):S
M/N:328\Q;\]KEGN':?L4P%L8;?706Q#K=K-LGM6<"WWEC\XID\NT*2;=&,[7
MV6_?_I(;SW =EISLHE; IXZ=H!J>;ME(%"/1K(2'D)E#"/0S+9-GO;#>J-40
ME.[WJ=LZ8#7<_M79*K8?;]L $MU^S8:G]X*?X(1^8%/1%$!XC9OX?1PH\J#^
MD%G/LO:#U!^[7_L1;Z4%F"M4E'M%WO#:*<P0[Y&2@ZV65(+57WC@4BWJL'E-
M5W_\BBPRD\E>*7";O9J\3*L@:"-QB1;SNS!8_Y3?V9_?XRV\W5IB7%4<(TO7
MA@]BMF]-U;G*(Q,\+OKPTJ]EF[?[Y9?C)*_WCF>?*A&=<"F9N*!N"H"1&%0P
MNWG2_9X?,V5:5Z,-NWVYO^32Q?."6GR\?'PV6I@&6'S+;<+VXF^B!V8-)Y2^
M"&1TYE"G#<^OJ<E=VA3(D?HV^&.DG_B[]: 54.,![0?3$AVQ:QC-.%\/P3]>
M5ALGV56RT>D&'QXU@6]<BGP%EP]JP5WWW"MZ(S>(BH!5(F-;K@1KZ'%;$DT_
M*%4GIS\=VU&E1D!-:%+R]%\!( C%EF'NJ? "^'\'_MX+D<(G$'IPZ5V>!,<'
MXR5J0!=^<+B "=)_;-2OX=.C,MKIA\<N[8^Q<LD#'$UOS5',9&6B.RE3531S
M[H]2&CBT.O;NSA4<3PS_!6=C:_F%^KHO<9S9&J9O8SN_%L689!(&\/<GB \Q
MCX--<H.?_A@.=O#-I0!>NII7W[9\FO91[KWSN2=_KKX$^(@+&,6P)2670#O-
MXXF7^<&AJG=P8B$7.KBW\>D#6O)A]6X:?VK-S3X_>9MTQMCV<@']K?K])S_-
M,P(6A^+A?,'>6!/CJ9UFJTR(G?J(KW'M#USNKR\B27HT-Q$[;DMA";V.X$5P
M<[;D0_X#\.^Z)?$8J/@&6:%RJEG/ 3//H_/%1'>\^;.;^XK5%DVZ3X?DS3<=
M@<L<;W3I+[&3!UO4XCO2K'* _(?2MPQ&W6E^]^4XE9O^%@'(7$GL%S-=!GP0
M]NSY>=\ 4(I\"ZNR(6AB$.R0*F/<W9YH56,$N\QNVHCTU1E3E<XGIK37:74]
M>P#>*4GUAW>+HB2*):1:02YZ\?QU;]S<@H47U2V&(F[GZ'GR&IG1PEVBS+6_
M<%7>EG*;D^O@^&IS2@H0[P)-VZ&GNN8-3LVFJD&@3AYNE*..YK:_U,K'7/WF
MZF2C[<4EP:4T7?RPYJ\9I6W?I1!6O#J,?T.I?%--IGD*];BZL;XF5C@RN/PT
M2J,@'Z"HO-&A0L,U/!UL12C&6BR)=PRQ!M_#&>?'''CP=G Z]HV]J$G\Y6_S
MYEJLR6N6OD2(I!X@ZD^P["D-P5"3H%Y*4#*8R!M7N&2P<:=VRFWQAI: >E/?
M6;&$J164A(A-^<>XUCBP%NDK5,0)5"T;>AC/J07J K$XE3\\GU$V]<RY0[<-
MO5PGFF$%A[BIV%6G+''Q)Q5NH@1%"$TAF$$!/:Q&MMWB+KVFA^@D C-0L%W&
M/U?@7=67W+)S]ENKKVHYH_?>K^C3E\'FDZI269# .TUGRES-=_%6J='676?[
M+MH_?\$]_/Y#LIK;YYG'W3N:XZAJV58]SF#O4X4P1*<B%ADN;.SL\_D@X;6,
M Y/NNN7/IJD\86$//I4EP98?I\ -M1M8C83<3>1%<[>@>\T\MUDJ\IP49X(#
MO5Z O*0Q5\S\+[_Z8$!_Z>WYI@.A_+1UV"7H'3@79!^M]FG&/X;HF5L?I -I
M.P]/]FAXE"C_ZKFBC4BTR^)BZB\B(Q(M&P421**](0AT;'C4@:P@RMQYP1&_
MLII1.WGRZI3S(_F!UT,YG1Q%BTLW!JS*DDZ!A/ '-3BU;#N<P1Y(D)"BTY@:
MF:YE*#Y]+"9AQQXO43&;RO2:[4%8/H05KXDS"6V^50 )!$77U3:J_WQJ].>V
M"+_#[_HYQI]'$MLB^6<^?5"YTAC#^/Q%X0J<A@)PTA/:! -5%= )N#LZA+=9
M"[.[$T]G? )='BH"??Q.1Z\Y.$CF<($_*TD"1$*FP,H$1[S6Q"Q&[T.SW1(R
MTJ1%N1F[[)3FX_@T[F=HN-1JO;^SBLA78N>>Z3X\NR@;FJW>!%PB@DHM_H.:
M#W@SN'L!.0\1/$[6;&E+K61@'4X\@E\]3LIBH*8N2D'E9YEI;%O@]CF.F19/
MTB>8LQX/I .MU$D!\! P)-\OJLI[>DP79]4!CQZ;/^3?TO_XN%4Z:1>L2=3%
M#D4U&Z,))<0K2T#" P6%>C.@/GD@^AGJXG-:D,P#0)^DOZ^ YT*SU")BRQD1
M#$QZ-C;4V58"T339IZWZ7A>>%0$N[AQ9^G6SJ>>H:N^P2TL\KN_T'M&_CB#M
MBFMH!N>TA,N4XKW1]W/:KUX,EZ, RGJ^A&YH*#G2W6DR&8>QJWHL40!<P:RC
M"E0B$_A4"7IYRJ:V/GR[LA-N%VIZ]$5.^/Q+RX*VWN6O@C9$-$X;+XX[^A!\
M*9_@V$:^,J[JNZ@P$;;5<C'1(D0-,B68X+-<S#&$?<,PQ_EU:AQZBQ"" ?,$
MBXX2E= A,#)72%_-![[!'^4M*3-7N,<\!"(YS@FRRNF^;K93R;FU/!B$+R4@
ML)H]0K>QY%(,LQ+&AU_F:]Q)XOK(K*:=']F\")E4?5$DR?6:R-?71A_._DHZ
MU2(Z$OP1P8IP\*0\E=":$^^-O<>;Z_W.K'(U6[[SXKZDI&<#9H"*H?LF#= $
M"]JR@GTG*)ECP1%JE\6:%N<-IK/3]2JQ*Z7O5Y>\JOVEO2[TB428Q!X/\2W:
M%D'T\,#QZKO>#R9JP)%UUE?JL3_2+2 O!;Z)<C.KD.T$&@/R?]$_MKGY_M,S
MW6'N-\/[2 ZB+>D[F1V2WLJ,B6=W#DRIP;BN/X>=Z<F?Y7 &?)2$JUVO,&#H
MX%GR$,7^'B0LG3H0[[?@!K_M=@SL;L'#]3>BL]4+!93%R!/U!DR_/CSR^'@6
M,!M'+[*,#K'K %8@8^6!O"Y"EYL)[0I!I69XE\IYB/G\CGOI;.1E[?#DC'/V
M_1C5,]UT9S,)"13 N16"+\;IH )-=3J]Q>S0JE6MNP=Y"@ALZDRE<81]]AX\
MDWD8QO4-C6+]#3&\/U9M)<E:N9X6TNR74N[AN(=19XQNB!0'G$G4*N6W#W.$
M1&WJ5V+)N9XY9GG915UNPC/F6I=C7WZ^)A$6SWC!AF-6(=O(=\#U=)#_A%F&
MROD-4O[B_*7$P] '-\KLYIJP ;,)7Y_1=9"%"3].'Q"OX?0Z1C!@-N?&LB9,
M[(-'Z:TWUO$_)\N/,PW_!WOO'=5D]ZV+!A$0Z=)K5*K2>T\$I(F(!>D0%.D"
M@I0 (:'W(J @H"!=NO1.**&)@/0J)32E)M0 2;A\^W?WO7M_^]R]SQUGCW/.
M.&/_\6:,C#%'WO7.N>8SGV>]<ZTP:J3<#'XSAQ/NA\G)NQ$E85:X0:P&.B5M
M"<@\C1/7Q$@]2.P62*/YD;J?[=554SSG(_/4XY+RWS60G<)Q'NM@-X*)M_30
M%P"<1>[3"7&Q&_KJZUN=*:/S\_?97,,$DXP=GKQWZ;2F55AZ[A:S6"4>F6J.
M'8YI8X$.;74UU4>Y\%EJJTMH_5QL#E@SC:'CJYSWL7YGLO15)OKG%M(.DN!W
M >C9"Y3/Y.5XS=HF,1;7G6Q^AU[#QR,Q(G;UT\TWV-U_:(HP:/6*^ X%!H'B
MN9+:S7-[S,O2&95:=4HDB3"H$W6^G UHARH4_2,V))FO>'AO*_$'F/KHDAHB
M .!E#B4@_J85/XW\7OENSH3/T'=)S\[;Q5I0AHW P!M^F08=X"KQ^!;NE5.\
MR2([ZR7I+S0>=Q7#WW$1';PD_4NZ>1_^(OW>!4SNO5<"5;16CLMQ@^4X5A2"
MU;."P=&(AVW4:[IF&B\LD,$5(_*0A*R@-RTK33J"?8#>&,!3C=;N@<2/0EG-
M<84\R$*8/.;EG.GP,D% SUEO1M8V@X)LZ$1[UD.+XE'@E:.)30C&H$&,;_S0
M4ADM5I*/5QZOY1_?A4EROW_=<X^.ZHUYH'30Q^'K?VF*,:S/]EOT'B-NV&#J
M-J["S=XQ]VO$_5$!3*F\=_HKX2"./(\??9;W( L?YG4H> $ &94#=,).(I9\
M:SD^PG%96>=PD:LK3ZP1[=]7EJ13TR"E4CLC9%TA],JEE/+Q)H6@\.'4]L"*
MJ@V:M3WK&BX&Q9KE-BF^DZF7D76'=Z'3^+'WE^L*I%^XA8=5',^IH(*];9SC
M_!,?YV'JX[?(M[HWAB!2&W%CA$0!D_ W<+5 ::OD<Q">;O0"8'\9%6\B^UCA
MN>>Z46,K<GJ$4&S7N;<_LVC?][7A64*JJNX7,YX/FDS/Z(W[LFI/4!61$.JC
M]=8$M%WR$IA6WT;:H2F@_ ,_X;C0ZT:1PYHHI4Z0/4 . ^!=<]4YVVT!HB.V
M]U;$V:$9)N,P16R$&68HH]2L-G\]RL>AZ<-'+8!$&(\FPRO2)!*WC\N!Z*#<
M+B^#V6;T*\A5.*OYW*+#1F^FS+AMI:4=?SAT.>J5SL0,_<?)I[8/RZ\]+KQ+
MV;[;QHY_B8M:@LQ"\;=Q86AA-_:N(M. $H.)+V/HZB1YAIH,4UZ RRT^"D7%
MZVJ 1#.?Q6\1X1G+M"%+YW3TFW(</5&PL_RLR/M.HZ(#80NPEH1W[V/#J*]-
M(R4W%,#D<%*\!B9A1[,86M&;DH3[Q3-3MMWB,%5W/-(9+(+H35H[H;_R1KW<
M!#_3I_'S-]A!].V*2T(D7O?K;S]B!F9K>2$D3W75;P+%4I_P=9[LV6J5;F/N
MP(UB]0O HF8@SYVE"\#LP IK=YG&,C+HM5LI[!::QLLV<P5E4,C7 V7JNZ$9
MMA]R^X[T?AR*)E_3?Z\7,1/3O<C98NKV51<+4A57JTRTK<+@,[GC]R>X %3?
MJ_2KO 7! =< 2[2-1>B*&58+[,-,1BQU%J.K*(@7!Y61P&5.W:^/5KPITGU;
M+O)[KO7++[L=U#.7$]+!UZ +D9 %;)-P;(H(;E$EI%T *,7"RD13JE?(PN>O
MB>I)19&UA K7_5X;&C_/OO=8UREC>6HG#IUPM1[U6\6EU QW8H#!7P!L1FIC
M.._7N3PZ^I3G_;LR,$_BZ88#OWKE $WMG#FQZZPM K-[WL7#@\OWSS,HMU =
MCJPU&D55;[Z&&EY]6"#48_%AOCNFSAPHZ@K5.Q8?R^KZ!O5!BS6ZK"S2.:Z"
M/A3,_*',SG\?RL 7.MO'8>1>S]^_RMBO^$5&86_Z K!BWPWFP=MC"\-!O$YW
M]PI,3B\ ,\[V5V^//KL+RT@DY2X^?_-CX51E:MKKP*T3.!W1N7@-+@6!HGM.
M=EB*^8A]H[ BXW.9AEF#=#L;^3Y+N!=1Y.A*6U*! -,3S2LJ(<?O< N7!0<F
MZF*?8XYPANY9I6XKT2:%^.M)TZOT6&R\?,6X^2!>2N=T;&ECYP66U #'B_7O
MYI$:M\&RU"['Q/CKL:W6A@N-.K+GGK:\U_\.O'K2B=%RWA2/AE37=RW&<<1]
MN #$MH )E5[V#,&4H#EW<I2@.UNT)D66V3Y=.!)C<'EWJ* NMC6\J$BW7#QR
M9_8[>TY066;G?$/RRW53YFFE^QTS'M0VE;>#:U2Z'A.^@*3QMS%370:11&&L
M5T)4BRBZ2,/20?+/XWN3E0JTV7R:U(-K25H&5P$^7A4%<) !]N7Q5%>Z6V?#
MSNLXPC1'0>O;567'G[9PK_!G45)4]B3QK(!7J["Y%?$9*C0HJ!P/&FN;\<+Z
M+Q.#E%7,A.?G_M#8-7<\M_=VDWU#[CY$\IB>:VH,7$/1"6:"V6#FS6@C5F94
M& ITV-TFYQZ=WZ]W<@\]N/KUB=(J7>LGQOCKI"ME>L=3N$+,!4 7>YP**BO
MC?\Y2__CYQ:3TJGP\L:-4V7>3G _IU0L%X^N5X^_ T@5]A;GBWVPL9S_:ST-
M*XQJZHE-;9(IF.1DH.G27&=^J5(C5)R$F:^D_+X:?6B">-E<9K-L>1+8\GP%
M-7'XRJ%P9$H/LU:>1LAXDU$MQBLX),9)TQ"L]<C#@[$+43D<6:/J_P1K.]SM
M7&;<.VB=[II1_LNA[YE!J)"6;<B@\NHTNP8+P,WN[H^W]QQ\B:G8+O1>)R2.
MR(!!QN,="Z %DQ< ?4L-E!S$NC[D_+J*M(Z9R;VK.>4[J.6@\Y8B126?'6>L
M= ^BQCAH\KO]3Q G-,/01.87R%F(.C4E2C!E3+J*]>E.5E,[M;5G_^$%  #O
M5NH-6Q]_?;0818E.H-EZ-%C^9Q_G)R1V]%SQUJNV&[7M))AY>9O85Q,(Q@M
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M3O[:840Q: G:9WO*<05"_COE9$&BK?HVC9(CBQ!HM(HM[V8S20VS-Z#^)L#
M[W3#^#+CI& TN)@\1]!=+'-" E_J_0!CDY$7W^K##EMXF^^DT),;"BE'=5#L
M[N<1A)>R2+9F$=N748&:JT-P1DKS1L%D!RVMIMOQ!XTQ=^XG3MO64P,@A6P5
MJCC'\UNXD/;ZV5B_!%0>ECRJ-"K9O#JUZQW_9$$2[QU3<0[M#':77X\4>Z0-
M+"F*T'47@%KY[@O =9QVQP6 Z0A)[]B$##O:,?-7;)%FR>"RNJ\S#;+X0C'$
M?+S[-IA5N>K>(JX6:W\<C+//26!W3B>F+O\1]\JO&5.A33&JMUM?=/6)>N89
MZGG5E6)]R/AN[:PC\)O9[+Q#DVL^EN[II I#SJ(NHA#G[<RD7R5)<>,!<..I
M]H\K8FHNS52,QH6$).+->9A:<D\5S#X:0I]8QQF316D^+YKC;>Z58F=R;^,]
MX-.GY.0/=J(&C%B#G2=83=!-:,_" 6KA)J8\+:_&MDS&C7+&*<;V'6EIA7#/
M$PT,6_6KS(GCQ8X*1LT58#@/]^1M+"N>'^%81W84XE!7]F;IW5JV%>^MH*>Y
MV=QG4\G0K6,+;%9TN8J&FRVVT+(:<]S*%G^N,_ZZ^RR,*!N6_GS?<!43Z-XA
M0N9/T8D,;S+N!)(X6C&-Q%;86(=2VK_N%ZYF\7'S^/&(@E2!Z[K3"4?CY!--
M9MMKJ.(D<C0%P*<B BX.,[H42*Q_*+K/CI'Y.#_GUM>F?]HH](2=D35S.T-8
M*==WL4L,#< ,18OBJ7DI<H=I7C(8=VG731Y4;.S4P FP"H(2KHA\BIN%Q&('
MT0*<+QH;,1]:VVLL,'5;(C]ND0K^PTEI'\XHT\Q.>L2CP4P@%37,6*=2=V'7
M:0V!1U3#L"G#('[?0#4[;N%FU16YD@<Q/734'E#F*6(?F!NFB376PUI%H%=H
M%J/PXK['CGNBN2:C:VQ-13=?:+A&]0*H75;*3'"YYQ*;\-O839@Z!A)7#KNU
MXE5YSM_=5QT/=7/G^6FJ2T+9&0RWOE)$E9B>>\Z&%\0".R\Y:?0P:H$]@ [2
MTLRH5SQ<U.5/^/)FVKKR E#RG+@E*6(9KWVOMJ&V<0W"VB8,_XF@.@Q!$_PA
MHWA5V84ZD<-%TOP/M8NS+L<;T#1Y':TWU^;I!C^5/W<&/R;D@R3PZ@VXA#(H
MPNP;QNKSDKG):L,(Q"!Z;3>/ULC0D=LDY'WR;N*(MD6M7USO=BKV^A::J4TN
M=47E+30J?-K5%<;O]D:4546T:4#ZVKW^-8"@(-_JVH(L(<IN2D43[7P!H(-I
M(#$]6>C\)Q6._85Y ]".$$4CVDP3N_X>.K&NW<\UI=U%EZG4^1LWAS5H#^EM
MLKL4 ](8S?@PT?GT7#473_$]&V6>FTFIT(D\(\K>AP'[]RI4VPAE;1);'#Y=
M>4KAV=GZ)7/S['8C*F WA#N<Y9(.<=U88E$VH2\-"6[W9-ZUDB#$U'[VF[HW
M4E,1!9ZQ8L"<W?[31#,9Q+RMW'Z:WT CI/OK8_6-_AK7FT+<?F7/CN&X*%^W
M+Y:S,-=)F3WZ/\58/7?RU!M_3B23O$FMRV]3%WNO[@[]?'-MD.7%U\495G3I
M(I.*;+E>P$K&(NNFM\^#I+E-,^ZV#^XO\^B+1SIW2]E*N.<2U"4DK4ZM-,Y!
MQ*$Z\!7K*=<LTP8L,+)V+J'&2:D,I0Z4"$:1Q4J[L/L()NF" DFV)IQ='EP7
MRODXG(QP=HL"TH,XMN+\@:C/PNT+/.G?[49*13T+VUK'RW.?BR2EA.;=2_V'
M,E!)['="U,JC/A*OXR7KZ]M&#>)AME_U7C6A]*BQ73?Z$DNJ;DF6YGU/LZ#/
M?F3(&+23Q8BP7V2#=J&:VG*7]V+2I\)K?EE-E(G+F#=KCKM<D2 )%=H7BKG)
M]8X*UGN55OA3*R&\16&1TE/\VC0TY/&WB4/SJ?$=E7N\1HFN%F(':ZNPT!SZ
M["!.UG65==E&I30D#5P,KX8![TC &6'WL&3(V)?CK]LF"C>__<'.ZL3R2EGG
M6=/D\05N"-[24> S*NP==%O13XALT?SZN^GX,^9D^3@LKW75;_"2Y[M]M2![
MMB;U3SS_2]@%H"T&( &GQ=/@@I;!LV[/L ;Q+GS88M7&X($>?7\WUW=?$X#8
MU<8 %. 3?4D*6,Y#Z0(0#ZG6C@')0HL7B 91[G_\F-_'B*8$"4:L--=I Z[L
MEPS6_3\D7_:;LTVG"N_Y<Y@5K@R!V6H_EI^TNC%5VYWDB+]WYO?0/NQA$/<+
MV)>^Z(<8>7H)0Z.IKJSX11ZXF&,]D?JOGFU'+$]$:5EF)7HM&G"S5N0['[V.
M>K-KO,6.01,3V=64BF=8[>V,,FB.P75HL$&4,4L6@PJ(@ZU%SSFG@\GCGFFT
MELN3X+B@Z)#FJRQ]BFP](<=W)FH@$2<+')<_CCH?% AP6BZ'J17+?>3+>FK3
M^>6VK62/U&KYNHAEU?2IHVG,LVZOX=EZ]%X$3!Q+.P1D-(>&>7(;<0I#V$S_
MO+G;**5PI]HQ,MQ0<#=) O[RFNPFI-J@5]^_.XLY!W,2W79[Z\2XRE3F)PX!
MP81E)KF:%&#Z19XJ<PF)D% U>$C'&MMF$P= 8J-PH"74$&:%'-M9V5]\F-KE
MIZ($GN'V<9.ZQL7>M6K_EO3#D(>^%0YQ+FKU^P+ \@47MX+@ML =H%*\%^TJ
M$VM^;]L$NKSJ-_2F5J^V*131[5^/D1@_V13*J1$1[D<X5,098%([CR?311LF
M8.[E \>B5 ^>M.:G1?+8B+VME*(\XM=F[SLJ/D!&+58O!H*DG%B,%R1^@FMW
M2]$2'8)S8C>G0U=C-6^'#)<)PH-!-CB-<T/<6==2?7<%(Z[K<0**8SB\L+ZF
M*E[/Y&6<0&(Z.*/?<+X98P 3OVI7[ 3D:9/$\V,6NQ(BV^YB;1.B5"3149<,
MWS&_B\H,M:1 >5O(SDTD20IZD[2YS,^^*V%:O-.*>K3%V:;82;PL@<&\]M,S
M35+SUKA&=X'N'U7"WSRC0K[U2<:CH@\JV.#]8 89[K?M2CZSNVVB4"JUSYFB
MW+LNARG5ENW%U<WRZ0VD"AN K]=HG60%G_T>CC_ &[;48BXSHDW97#K D[RP
M?/Y4S/.W%%*J^T[7*LL0*9<8H+_O5/ )H;I-$$>GAUU(DRLIA/Z8=M++_],F
M8LZ&CM316]U^R(M/K!;JZ%A-L;#?6DR 4.+UL8BN2@<SP?BL#K/702D$ETLR
M##*O5>AT.WB<X]4']%<0Y +*QQS+-$VTL2[@6+MYE/3-=8RB76YY+M*9_4'.
M3%$V2Z&E8*/+W^8B^5Y=YG'S(6?CQC>8)V[Q<J:BO7J[_)L'Y='@*-D ;G%/
M7_U2N=N<X3$_;D7NC^<4ZW5YH 2%D^Z6+?9DQ2&I0 *_%]BF8$]L5_3.=VCU
MM9^-+HVYC!QZ,S2_LZ(G9;K.R?=/[!Z4MKPX0X%2$FO^"BW?0'^8+%FIJ[24
M?S0E5N-YI["3Z98P7;J/[C=F:A.2UB@C09F]2[2H@D03N3:-R^$BPSZV16F/
M"B9GJ>7.XF:\K-D6TWAL[Z(D5@.U'^D+2SK!+@"8Q>-2[&2^8(08W@:KC>(@
MBSLZ2>3O@M[MU%<,;I@/_JU4_Y!<F%W(O(&]8L3+NIW>@^YF]*G;T\M*L\>.
ML'&$*^":2Z'(3C_+%<ON_%_3Q?.*?)@3+2/OI0_]7%?4=RJ^YL:]B./5O!YY
MI3@^D#:X6'Y3QJ3V I 0AD=\<# *J,##Q%?P)>HYYFD&'G7YJMWEG[UD\^OG
M7%>B%CC=)+37&ZX6NZJ(/2(W>#C5A[A&!,%,L(([7F^7$)S\F4&%W86M73CO
M_A=IUFYW7B7( UCLNF*7ZS:^5)35;BG_TM 8%_7\I7$N_"1]06>G O\A8WOT
MPRV^_;F(V3?>F;22$-$Y8@^2O@PN9 '32%@)7V2ST%S5^WI9I/E=?02Z'_K"
M?5) SY^\:UR9_!)"?@%88>W>BUUD MUQS"3!6B8$'T)(^8JXGCJ^F^]'W&6U
M4'Y05O]64Y"7C<PC[\"JZ%P*[S]%E(>1M&#9QJQ;L>&?7$729W2".9O?QZK8
M\RV31B3X6/O8D%YIV(L!5@&C7DZH.*.'PWGDFG[65C#,*#GY2=8E](^_>G$0
M]O[;/M7G7@4^5@5;\F;$3,1R)A*SMT2!Y]76N!1+5*CL L+1KW&S\K]W5U!C
M#%A@MI>$DNZ2]3_%Y:+,7$O*H$G'$/!?B\G=9=8WR"ST64R"*;M8ERKX,=/M
M#822-FGG-C(LL/N7,,KL>42XS&=O43GP]?Z"WML#C  UQ\IU^_6'RST>*.9V
MBKD6QO/;N*V.!7!6=QPVT4OUP9E7@-:E?/UK*5DCL>UJNJYEMM:3>J<7VEQO
MA'F?_M7,VN$N4)CS9Y'!RU)\>2&_2*SP[7+D=JZ=% !J'CQ/\HFZ!_I\"/UE
ME(;VV?^?5=8>7.[Q!*X037<#BE"O58H(V8C0C3]XKD07D3,AMI:8<^ 3*?B&
M130V[B3(HI(O]OH)'2N\%R2&!<<>$CS$HX^/O=.5(CWU;[M=[_)Q+%!O8"C6
M%OD1-DY&^&.)"O20 (QC$[83RIT7[E9BXQ.P2@==1,4 $4>_H6J61*J" KFK
M4KXD$S8O 5PWR"=ZKO63:C02/L+YZ*(AUUUD4[ 0//_)%?MP_WZ9FK'"N':*
M@12FQ)\*5[F*9C6HC<N,TXC#R"LU63,'[93+96*;ENJZ@LXES7_>\5H\:*?>
M89\%/ >\.MQT'KN3Q&3,>:G%CL^)$8@;%X#% 0A14ALO/+=WQHW7NP @1!&X
M;E+EN\)Q%X P_X +@ 8R"K&W5G$!8,LE,N^<$&B)_!< 9 H2_S+POZS^UUDI
M#53@3MRZ3B<#WDZ!Z2KNBR"6Y;!WSOJ=MRX %G<3\#?ED8=*T 0BT1R!C9Y4
MYM2PJ<AII,/=<T/\]L0""?A+4;["-*-"Y47MQI<ICV5R_RKR8W0V$+"INW\W
M1IE#> W!"!^#T,'D2_4*"U%@ULUU :$3I=?>51H-7/1<G?)T7GVJ416&&)K)
M1*RRIJ5Q%^2&UZ]'8\J05RD#?/J$*0V +0CEH<AE3,,%9V60?_#A_FJ3@&^-
MM C+W=Q<]5);_A'I":%R#2(]Y^(9MXKV7Q,/B>L&8@(7+@ __Z#!YZ<N%X >
MX8;#H;;H5? R2>L%('L,A3C9G[L Q#ZY %RCV2/09O+^Y8[%O]QQ)OSN$L3(
M3X@1!@Q_S6JWOV;UOW("8.OW?W@_(=+_AI<0G:3^E[$HC+P [*W57P;C"VU;
M-'JWA54VKG1*'J2$)6MM$7J5Y&A7:ZA)RA\E80U0GOIDBC?%^0:4T,@!XSB"
M&NVGV3?J=:*.W\V%XM\.OGC&\"#F0>FX6^VLMNCKY]3*#VK&S6=WA D;K2,6
M@1CF%8!V'$Q+[??]OQXMX5^/AKEQU.O0^-;?'? W*R;J_]2'_=\O )N]N$NQ
MO&6T%5J-0_A=#@E=A[WY9U3O$LR,$,M6BXB?>VC(^:GS7W/HCNO;@;=5.0V+
M../ZQ4-E7"J1:'8!P$:#_[7=7=W_77/]OZS^#[8J'EXFCS]3%L2%5?!OQ[2*
MSJ)_Z@P,WX+%)G;@XP ^GO]QM09X&_ZG&3VW.B<\O@#X-4+^EBS!!\N$S1[P
M99K=VFCYZVG2Y[_N>GK^ATC$7/GSOP>O2*9&+"+^-5S\'7,>4T T/?X-7OP=
M<^YQ!S#W_1O R/T;[ #^:TS_-:;_Z6.:G;T ]'82P=]KA(=W6DC\["[+*&5%
M%,6HGIO!V;(Q\F]U2]'UA>K0]^B5O]4SH7\#(5]O;G\ME_\;VB3\+8$!_W-M
M<J*O,CW1!/SW7AK_[T8)JG\FML[<<<O?C*/A4QS#QSZ=7TMM)_)^UNS8/ W1
M1X[G1.4[^]O3CG)_"5:[QA2[SQ9]W+1&%(2ICK7=P0$-,9-%'^I;$ZBD8FND
M2-\G!DP$*NSUJ7"L]C[]#)-]X$D4^(P<V*CL^CA2%-DQD:^'=IS#M_D#,U,0
MU3SYRQ< >L@OZ- 9MV![DUGO6W"DM346HKY4X^R 6"OI(P< ?53.@ \(Z7 Q
ML?ISS3_IVN$U4$^Z:_V%PX5=-M=I=J@=]O/J:163GB[A>[,_!"Y].B!*$Y+@
M,J4L5IS!S['RX34SW*77G21[J6\-BZY]WS3,7"+O51!4!)V>BQ 'I&'L#8U8
MNDA7EUV\]ENZ1"ZY&8<=7D$1>6#+3MC5H)YK5U?3\1OB[2]S8T,=1CXH%'S*
MV/\#_\5<_^L4KO]A[>/TRI_.,,JGH:\^?6II$ISP-%KT63MT87H"*0;6AOUM
MBQGP+G$^HKOMYE_KK^"(L<&1FCG/"=F/UA]]][6&_G"R]?YXJ<')HBKU'1&:
MN+_1!0P]9O6C;E/"#J+2M8-<^*:#%!HF"M@O -KUW(]TNL":&YFTH)^$@A92
M]$J1 Y@!!*04P,J%5I!UQSHW[WB'[MZI!RM0W/RR%O+)@QS.B8M:26"!.6#?
M2\P[CHK\O #D_"$"QUS2;*K5 F]'TTLI46.3SXS7V+=Y#3COUN:LB5>U#>Q4
MI)H<!7B!&=!F[KD?O[?=EGJ?U9G5>:Y\;*YPY+?PX]SX6!+W%7[3@4=HC+=&
M3LD[P2_"H%:J!FE7^U%1QZ=2I..A6VPF">D7YD-;J/%V%,;H K!T >C:2IE<
MV9?=L7)W?^OV#A;Z)'*%[P;EVL<+0&O\#&@+\L56LHR+1C825W;V!P?\^LH=
MI2&64PGA;MNQ_-!D:OXH2)/)N-R_X^_'K4,DX%/ FKI:S-!]S$;HL^_C/QSY
MCXM_GL;8 044IA0ADL&2IQ& -Y2*D,*M%?%9/<MQ. />KFU<MDP!%[(\'%OV
M(N+)V*OS^)';/0^ 2VD 8R.V(3]L[[!];?&33JM/C:[;JTV"4WM5;L,::]!D
M!G.ZH-8[#99YJVW??:;ZK?IKBPWT#:1PG-AG*^(Q,)OU/PNB#<F/*B$UFZE^
M8Z=U+)-+:[./_:A) _,D>TBXG?? $6#Z&D34 KN^\_VF<]O"S_R-R0.2:R/1
MR37)@= 7_<MA<!?\$UQC(>2WXU("R<Q@-N[Z)$0RZ25HHOB!Y/EY"O<C;:J?
MUN[MI#N0Z>8.>2(5#FA/R.7L )5X"11\ZS])DC<T/+.UH4DX;G5>Q_DS/]L2
MIV)7[!GLKYM%IJ:NPU*OKS@17)96Y)_*N3YUJ0T0'8!G!OC, .]-7P" RP2G
M7X:51'#7V433^:DK/$OTKUU\-_]'=^V%8POT%&=_:<Q?F^XI?4-E$XC@P*_C
ME)> (7 Q0DP^+@SK1ZB!L.E5#/I40&>O72J-+]\F5I"VT0IY#"K%6Y$3+Z_=
M,UKV'80G3'U>A \AJ6K%V>MC7(D\.*<-5-F;>I=B_?S.,9FM[S],*J1(1X9_
MJ#J0HK,8B2.+C-DXX\O0D%4D5(AZ <EQYT2&7\KM._:N(KNBO WAP-N>$KX[
M,B7"BM:;:D A"^M7OQ$,*F\Q/B:XM94*.FB82\T:KLNMP +GBNYA?]%H'A&N
MF+8FO%[BXDE5&4A&JS8,](/@R7!NQ= UF+WOD@&=);3,-MZ]5*\ -<7C1*U]
MQZ-1+#<WZZ-[2+?C/$P8\_Q7>;8+.%2&O>R(ZFC"[5;RPZ"D=:R.\-N;PA'O
MF9_R*;ZH>=L-@/&O0&:ET0$57>"8+-:=%I^W-D4X<30I].TCS-U9<T[*,M[&
M:.!M6XFT!5,CHP#T/2WRGY+12X<(>KP.;L+Q7 DWT)/%Y/76OQ2OW5KY+7Q8
M?TQTZH%."C0Q62[BQ_OWO"<9J31Q:>M(32^Z0"3-$81+/+9"A7)YJX)9I')(
MUK=F.GUE4"UR5<R8?_P-%[XKEN?NKY..A(C9PM 53.M&$$S69_EC.<>N*DO
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M;;KB_)D!KN22X%&F?KC\F J7&:;9)0X,3[?UD\0,]7X^'SP=&DYUT^\M\[T
MH,1Q FO#<65>)2^PI'II7OJ\^J,I>R@>1HZRA924;R+ZA"S>7W=G2YM]) Q%
M*)?/1\?-,F/^*J%?IF N^<2??J'>LWJST.N.X1%\$M_)?JC_&(H#O3J-4CAO
M5E!-D%U=H"(TM3B65@2^BC#&4,27J^@NGQ.,#4=:Q&W=N1?#\X+'AC4\X3-*
M'T^(.R&1)DF2\\:U, E"$GC9'&>,'KJ4D)20XP2\8%3U,'%HOZV+&''\>N?
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MU8B,LB(=:[L# V&!(4?VZ:KR%M\R#!J2?@7W1=UF$LD+EJ=>?<60V"=S[71
MC5#OUF*.;>ZTXJG"B+7F0C6,,;4;4; =B-[B5XA6- =YM9[OZCR;ZX_7F78/
M,-*6MAL[L,1Y@UQPEP&G0Z9(PT^!J<,X0?/@3E9DN!0S-J:3U^&$ KKFL.B@
M0/:-CMOYG '7=&XTXNJU%TOWECQLF0I)\<<E]S=PYN2-ILQ+28\Q0M')@^QG
M"L\IK-N?ZH($,8Q+X<G+D#G)%F&YYFRIWSQ,#3]9W.AP+C*]X^M00WV1??8U
M7S&)'V;:HLF<UN)PIP_9FMV&WNO>5H79(0.5'W$3F1P92?FLBBYYSW21O05M
MYEG:,&9"28ON"C*8> 4K5X:I[C:KB(3I<C)0A(OLQ&7<+5]YPY^R-Q#,>V)H
M\2!)FC24-_T(&0)DJS&(AU/$='-0LTYZKZ_[W]FN53 2SC"/?"79SQ1=^IU-
M@LC"FS@(6T)^TXXT[T30P90#L*P:4YX(4GX4A_>',JC:;LU6PYH1286H/DYW
M/?;=$^)CR>]R;ZU&SH6)PWOGLC#A"T H2-]/G*'/B_.S6H7UF+%!@C0('7.E
MN5CH]Y5/-E^8?Y;[?M_X=AG][__X,_-__Q+X;_3/5Z6L,\X+Y42'2.1$"P'^
MQ44*ML(<?T"7"02(FXV)',5)K5QQ%C[WS&27T*#I6RKJ .PK!3T_<B/_S7$I
M@Z;4Q@]5Y9_\G'C"^K"Y)M[<NB@N\'Y[.2LI*9?URQ*\1E/Z0#N/0$-]BH[8
MK3&QO'B3CR6YUSZ&7_6XIK)JW+]8:97OC.5=C@_S1Y>9H^6JT8YN]D;CX-JC
MQ4KZ).Z@/%W--@" "SO3.$@*^CQ.I,0K3U:DG#S&L(:+[S$_U^R>C'/A"Q3J
MC/L1ND32F^\"C>D <6.]DUE2RW]S6-46W'^>6SW^>J4A['KLG6N;]VYZHMNX
MQI". >;+\AT&D6UW,?5A*M(%BW.X,\M+JBCV4!Z0+>!(DB7P+*CO%F*F;&YQ
M]@ ]%0HS#5B^ / 4!L$H_+F,#DP&BAW],DR=R/5+1V*^_@JUI7]GD2MVQ%LH
M0Y904H@3QYQM:=:-K&,$P^U&15\Y?OF6K%WO<#NQ[2#/5JZ$9Y4Z/4$;!\1L
M=#7EU^7G0TD[S^QR7Y\OM52/E.6D"Q#WF[[<#>BH2 5=P?M-,*Y,=0M@D=UN
MU*8.C^=G(EV.J%+,%<>[!?$AZ>9?*L7G[91?+7Y0L)B*VD+0RWR\ #@/WUB<
M_M-$$7-(,._AD#&JGZ(^Z*6W?6W@BOE>;.(M^.8X3QF8.[5(A><LLKHLX)DW
M?I:7UT(G1;5\#Z<M]QXSW[)[V?CN2DS@S'GN3T,X.TYO"4'F1'X!Z%J@QA!#
M8(;936,R#:+YLWYQ?8$KLVWW1I$N>U%&1.8J;'EU ?1)BQA1XG+NVCDKF^N]
M;Y8,71@3"?=^?&^%C%9'MO[2B7/2:/'8FJ\P\^5%,KGZY1G9E!I+\MXNO]*3
M@F[X,P7D/9>6]E\V<^TKB@7"TC/PF\3!NLN2#5+X302UM8V)R\Q9"CFRPKDG
M:E[XD\U;.?>9NW]0KS.Q$6IGIJ"H+W):H/DI>TFARD.*?ONYYF87YXBE^3AR
MU74\XP1$!5F(D9,KM'=#67LJ$C+!&&3O#N/R7J@H7BFE?@&889:^9UZ3Z4C?
M(_CRB[8,C.%ZK,W-2L4="\$NY!POFK;U4D$GFTP>(FC*@U;BS%RXRUZ_;##_
MRB&G@U_F?3!0TRPY;?B.B095=X]B7 H/Q##-CBNU9%[#K*;7\%,;[^3-I:T(
M =2K7L_+!4J&]-R1'0Z! [!RI6<%E4N(2\:?\<[L^%RG/MV.-UNLSV1E"W(-
M)]V=*8A%7#*6*.F9+3#C4444RP)_YIQZLE;3I)AH3IS5C<I&=1=FK5?S5; .
M@_/:$?B/%!YE7,<*.-:,%07AA!8,H)0>ONGE_ .ZW5P7\ZC13499F^MI9"29
M\=KLLY"@: U0?Q5.;WF++NJ$1R5\SJY1+)7GW95>CEZNZW-MEE_9*D^U3"-)
MF "*@^LX^Z53%7GYB(S.=$X'1KV-@7QN)4:G?1::UIRYFKHE6ITA+>>#'LCL
M6 ^0"42-$^]XBAN!":*W!IW0D^?=;O['=(?*T(E1[?=29&*C5S?EV>)]G<8P
MPSNJZ,5H,"V<"D<[ASJ9!165;%7D0$,LZIO=ZONY]&D[JP/6Q)*I&Q1%/KN_
M,S'-\K""D>)LOEK(G$!H8?QOE0$<IC7*QI?\O5]R(Q" %WY?0\@HK<F*6^#"
MMB6ZY_U6X@FQ<;=U7&X5U#)_1<" ;&IBQ.9W7T(C_;@R'1>N8GB:,2<K KED
M]0GKD[!; 86E)<NM_H8IYT]J/]&K_,Y[7WVJS14\/0!4LQJX%QPM]$7M7[P
MH1A$8IXDG$I#(B$GE_1O+*X6SC>U4X]GLB$^G$*S$B[UP^&*"R1*=F<)$4Y
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M%#<Z+MII)M@7^TK M% (7C-&Z+@XJ*J+P$Q8>>G7X(^B>/3]<S3\>*<LM,B
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MK-D.A1\4%Y&!7AHR(,Q*%"$-#R.^4I&!Q$@2>XTF0$G]G9W!FX<H0:V54B.
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MNQ20%*EJB'6N*NM35<N*B!U:B:I+*Q?+%')X)[GR7D2P].IB/6C?%*I]FR+
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MBSV##&U\WDCP[1P7*I%XO7]+^<X1<$N,!T0%2M66LACB(ELX164V**O2*6M
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M8OM*QG'.Y7EYAF/CKR3@IOLINOUK6^^YQ=9.&XN_5N5W+5:_?8'6FPE)9.O
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M5HCSQSH#W"$@'=$4T?I69UB%?T"2:(1_BCR=Q'7:T#^C737RX8*PTO#Y&=U
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M>\S+J)T!,-'9/R7!$$@4=",#>N &9$!#.ADPZPYOE@,=T&^#]Y<E27)7^'Y
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MCB^^F8!,'X?J#Y1/7FH6;&F@JB\KXQSF3-+ +)U-Z@3(5S<_I[XLHBD8T8?
M#^"&$2"TZ "1"OVPN'SM&(;/T>E\G7*>@YQ"_,(E1/DX\]D1_YUK$5K+KC<-
M55*J":>P\^L\:&2C %<R7WA#O_23AT.?2[4#E-II+S]BVQ3PEG'>1X/\MW6.
M=E^KP[J$KF\YRDXZ9>MF->*Q;)."YRMT>XRBB(\.WBBYH/WNS'Q)0>L(WNPO
M)OI*/G=SP3AJ36G3G:8N3]<ZSMC@2$<?=_>8Z*=X_! !:85F4FN3V],,FN^7
M!G-DA[@4KJVMZYN5:B<FGKUTG)/])%7@UQ(E:QHFW=*W6,F0(JB$TB6YT/)<
MJ/QQ:U[%T6N/\/ET!M]NK#:>9)%J @Q_WT98PV:3PA&!<*RJ/1G0OO)UA&CA
M5TPT/$B77KMC0HC-,5\JI<'.(8.=*\+5,POY1VXG!K6^M!*@:92D![:9C,F6
MX#3(@%G)1M!AJ :./LQ]/]7H>K63F6[)D(28Y>/")U;VT75AT,EPSEM>KB$+
MTJ'6R\SAP-*-H#H+M'8]L,7G5O",V?>,-%,[=_O<Y3F7M<40LI,G9-F/Y;&\
M>D:GT6^9F<;39]1BC][,-NU,%\\I)74GGH$P4GEZVQP^631U =(&%<9,CVFW
M LNR(U7D('1P%@>!4V7]JZP++5ZU%9WFDV/FYH>?!GWN\ W>5[6J"3]$W7VV
M&DE%&IB2(JC-Z$:J\-?@&G&HL$>KC[9/ "U2]$F],;()+>R=?&7RUL"T3 G7
M&J!@SFLQOR7@ZB:V2,Y(-P3&K'GG6>?KL4/,.0>3#@[ PW4,^>9:RCL!=8K>
M2O$,H7&S-P(T[#4>?TV8"]%5]I:9(1TGN& *@<VHHU#P6ZC)0+QAK9ECM .0
M?<5MPGCYHX(8@O'QA\\EU5\&OC6>]$G>2WR!.(/C:MR?-,.'4A:8;:*2+$VV
M[I/GEB[9&_&ZZ2RT]BF6B:4_&!F!,N931<UL%=5*!L'H EOAV&?J,RAFS>+=
MM_ U@[[77)96RR3GKO'ZS>25<Z\U03;8G>8QY\C<A_@TWMXU]U0*HZT<?G3Z
MNL3+QF-][5R.B8!#QOS^76>#L1O-:5S))NXNC(M[UTK'"PL0UE;LC-CBR:CG
M>@DGDEX7A40 <&#*O)7=0N*H&WV\ HE2$H@9\:-,MY3U,=.ZO>SA#Z("9 N>
M7,NY=?E^@>X)J>Z*OWP*^NX9T7*3 ?$RA& RX#$9<" _;H31@8W#FS1 7[M@
MI^ 3E)7<+=E!0KSE%#W!99B(X.,AJB]2VOK0_]5$]$.5<!3_H:68535O]/Y=
M,L#(U6'A:W78P5>715\6)K^.F7'P44)<YRV<972FB9KX9_6,6NV[,3;TIQ*>
M77KVA%FE KO14B^H.@A5/XZ3S1=XGFY&PJ/#;.-N,^^5'SWR<;N#6AD'!A,D
M9ZL"H*K%]B2N'E,/B1#%1V;>MP%AU_7B#J,ALQ6^\D?.+<D6]GK4[$L>NF^E
M<3%$HIQ=:%C(S'QB>%*\;VD>/VXYW"H [)$LR5U1L(E&EX:_,+<8+W@K!+QT
M_)EK?P54"X? 1"%9E:ZH= )'MAA.6Y>4&1P]M!/[=-;MGA\=?2[('+(_:Q?2
MP+=BF&Q9NB.JW*H"6SR]R<$F=&AB(8[YBH_11Q"/&%%0EF(49B9OB:8J[$9J
MWQ>$I(W=RJ2U 9Y:EFJ\?$+*=/;K*R>ZNN$[/;-U-T5NN[][_L:=#/!F[TL9
MFW*2R._=ZN]^F!Z!U6W^_64@_R-?8%9=;/O7,ZK]*S^$"A*9*WR<$6="JAR9
MOIFVGKGS\9R<X+$Z3-VG]L-%$K%G7SIANKL%/8&SEL%O"2G7@]?<]P4%Z:QX
MG:+\XQY?2O.6P?+?T3#(8,[OC\^I<L#KK4Y_K?==.9":F;?2IM:OPJ>))%SH
ML]?@X/?.,ESN"S*K+>W]-.0C/CCLC4;R04*;G#Q)P&&9$\>TJUOO-*2Z8Z7#
MCGG&!;%> K\%E6RL[KMA=UHZ9R4Y=25R9_T<:*W%!][:EE;=X[[&';\I1XMX
MI]<3CZ5O H\NM*& 0D-&S2MV9 !KSFR<9_V+U@+S=W?UV:,[' 4>RZ^ 7X-*
MU9%MNJ&U)ECA5EWFS](KTE]B"S7=.%H=N5><Y_C?4>=Q4D<5[ZA#/=5NW2AP
M, ATW9=,AP_?V49QX :RD@:;[TE)SQK(K%FYY]W@U#E3.&8J=\+,4BM[B^(
M@=.1[?[_Z&3Z;TZI__1Q+:_-J($,N N:>ELEHIA F>2)I?_0S?LOEG]T07!I
MXCS;Q+GTB, +O[LM]U!,3:8:AHGM=M\Z[[6JAJJX,8VPIVB+&W%':.SHJV4^
M$CD(BAG0(UBFXB!WAI25>MDQ$ULMC_/'Y\]JB#W18[$6CA&M37^J AT@ ^Z#
MJ1VFJ(?KSLCF8VC[/5*AA!C,W>JG-ZMHCI<<"3VDXL.BNV_0#]G'N[PC!$M4
M<6Q$0VT<,QSU-&E)H719_(D715@>ATOK2RN^D_,6>UELD>Z?IHQ=P%MB4<U
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M<K!S)0-G!]DL!CRT\_,_.MN$?O0^$SMW%CQ)? ,6R5"\(I0<,HQ7)&AG@TW
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MZHE#S,?/3"7-(N@@V6N&O)ZOON32UG])D@[BT/,7K*B;BV1[KX0L)9["]K?
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M,O]]4P=H_@7X#_3_0/]_"GUI'P5 8T:T%@,_A5GVRG/YKLAENUN"WY^8/Z$
M>% ^K70XUT@L XJJN\1JX,MF'R+8L_A6TC<+0&E4@&:1GMPL/Z1YZ9+2[VFL
MK(>]O.GM=NCECZ^4/?L&'VIMCE1.Q)".HBK'*M0Z"VTSK?K Z1-W*0"EX[#.
M-L[^ZB/CZZF!DCH-H_E2T$"NG-'=NOI:I+_K,0JSB0#" N9U1FK[6SUZ[P[O
M>@UO,&1NO@WG4[OQ;>HAW2WIW*&#3"#+>MIQPOM )G+VDV9L4_T3PC?4G(4
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MYWV$H ^%L^4P_+Y*7I+Q.[]G] KIM4JZ>E=Y[)H,.&V?!G.M_EAY?LAP-:7
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M7OMC0CO:IAQ^C\4-4DSB/&[6[>M?D:X[%@MQ,G'HI@ 8HPF>Y' (J<@&0<!
ML,E@6<3/ @H@5=J8K.EXEFAYNE  ^ZS,)'K("N(1HM1:_I3VS(5U)%$ 2KV>
MDZA'QK^O(RY2 -/SY!0C/9*B9#?RF(,"V,N'GJ5MGL,(-\C4( X82E8D!ME/
MP+4.!:].; OY]TY[+4TWS9DYIHK)//V>^W*N9690J7VT?>*U=$?]1;&W:4T0
MI<[!ZJTO=?=C"XRY[YJFJN>]Q4U[R_5);TS"JLW&6_1//$D&^-,?[PG2/1I<
M'S]!U;@R],) #XZ5+11OB\V+7AXM':M?>";WM.7E*(ZD>YI',L(#N^;Y'IRY
M=N&SCG6(+[;"P)!6H_[Z%M O9K =-4=]5A>V:_*LC%V,7Q?H3Y0,B6?I/S^.
MJWXQ5DNMCZ!;ZTF3>GJ6<$H__XG.O@*OZN;V7OQ6* EZ8]<;#W'UB4"QU!IS
M>8"%\?/3NR!+)Y_\3<7@IA5(K>TM+"[QHO#%VK<"GTQ]^U2(5"1O^,F9OV(X
M#"<^QJ.BS[+8BU;NL=C=[6BX.13+Y&PZPC2$5LE[-;QB[66J<LGH>TP[_A9]
M]B$',9) A[/LDH_CRXYJ\<\E%OP5>:]:X69^Q[/#J+VI;BE5-J.G<^9M#*Y*
MO*Z2 ?=3D7Z$U:UJ_ A.MU*UI,S=TK!P!IJKU]0P?)"YK8*4Z;TM!QY0#GGA
M'*??G'!U_B7*=3X2P0@WAT3!13_U84LVHQZ^"@J6-VEZU>.2(']523SCF^QL
MZG7&H31!ORQWZN5Y*O*T(\=T9S8S*0AWJMGALS#/"1LVIF."&-8WO2(S#LB8
MS/Y&@J+,E(V:M-ZWGU<;".\C&&^7$41.R*S3LMQ=0@RC92#KH$*HB8>-6KA*
M776%0EY<HD_1@#*+HZJHBS-+HB>\_9JI]"P8$-*9!2!*%ZS_\E"M(**[QBV/
MT@F>W,G?DG-G- 7[/$;TV31Z++06O"_?Q-4K(R8C%WK"RMWYR@I>[\ I .9^
MF2:CUI[FPD&W!RYB7RLP?4]^YB@XO[W L9H/@ NZG4#A]XCL^%6L1'61,5WB
M@:Q;QWW[J8'G<D4K,LB )%WO48<6RSN\L;SPY,L\.E=2C*M@_8??B?/X79OA
MFNLUTHYL.F6.4(N +*D).',9[$4/?VQTG-)4DYV7#'HI6>S^4>"Y.+W^?8OT
M$T82V[#-M2S&H'Y8J>3P0O5H;>S)M&V0=28\6>?\2(OO%9]WCTUJVYS"!NSK
M3^/!+&@_'W_Y"#E__I.@?L,UGP,CGWNM30F&%K+>7,\+GI_WZ,J64NU\471&
MGOF+\QAI' 40AW!'T,/XYKLP\A%(N.;BVC[#EQ'ED_FJC5N&ZFX)ME'A.)]8
M=XQ7_Y/-YN\=# ZSA,W%"!1^XC!^:#_S@NR.20APTP8++?>QD&BH,UUCJK*3
M8<PK[ =Y"9\/]T<:$.BVWN!+NC K)66.,%>7<7\M&Z:GBZ;58T@O;XMC'LSU
ME1BK+Q:O7S]4X+WW(NDV9^O9Y ?3$%Q;7<H\^4"8A#*WG$'LFH^<"O^7-UM*
M<E.YSBOP+;1Z<M5O]=FS,=5)IB*/S6D0 N/![.X.ZB-PM7J<6K@K@>EMT_E
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M=##.D:--$29]HX8 ?H^MS"/=X*,*0C!M9'AL7#WT4=1_[J*U8;B\W:XZ&-9
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MD#E[PWNU8QM03.]<GF'R;X%)F-JCD=4@N3K47YZFL=_VBM\J*-Z]_T*^F2Q
MU+M/C%\$1FJL]CP'L2*9F38P@SW;:G^E_"[]W,Q TW4A =1H%C9)".L];^&X
M+4F@[A'2P!MW(2_"8GO21_3P% !.(MJ)9E_5XA[_I)Q+]&)0XDSRR@WSF'==
M'GZ_2A+HUN)[.U$T]OI^8G/,/UU35DT2+3\NC0@[R^X]2;]C0!J1HQ6#7.NE
MC=T-=Z ?W3X@RH. G^S1.&Y]E7>K(\+^H^\5*LMO.LYSMG? %P4L]Q7PD5U
M]K9K<*=$7'T/D&F][2I!I<8!,%RJ&^OOHQ8ILY 56,_./VN.=& :THS/N_&2
M4_L)/_(*H7I1KQO)[TX!\.6C"/Y?TC_#;-LQ0I62X4[#RA]-.U<.]WCFS)]+
M1/C*4(4E<4X*%#&]')Q+SZ[>[9R]Q23$@(QH8VF,U#.6-TKPHAT;[U9+G[Z@
M0-[R$:]H6%HM\_) ,+8 R_3+^@J)QMJH-W81FL'FY363CS1>FU  )0E/O\''
M'+&67P4+J7\E #'<BV7SH;44 /OZ6:!JQ 4&C;3P.^>J1=:,5\?,X7@ZDI(!
M254UQ6:T@//"8<V)>6 N\L\,"N#E,Q^,>)L(++7%Q G?:^)2.U;^>*&NJ>$U
MIK1?(-8[FE\5Q\*I(PDZ":8#=C)3H9UDXT(NXC>L#8.%"L2KUJ]=F-N^QK90
M_IW7T@-+QF.NP8IJF<.S&,9*#Z8-=R^XJ]4U[1>!D30][\]'%W[-#-#J3.TJ
M;;:DV=,=2GA+]5L0NN@8XU@I'^$_SV-OLTGFFB!+NR<6?K2TL@>OT(P/KVY3
M?8H7R[PP/M*TW?!7\-*";_BQ_-F8K-5+;.,C/0)>.,B.YOOX([]DRKT>8T2.
MQ=KR'M@VQT9<T4IM^CJ$Z13 IMF&GG _$4]@"IY8-(X@LQ*3SYP2619?%XO+
M9(#"UV3]RS3XO^8DG6L>>V1!/RGVR.^5IV97-DV($.S'1E V"XP9K;'=W:4P
M;:2:GSL] TK6]1-X;'_Q:D'J_78M*>J]>5Q@]WS,/ _('_N1VI @.$B2".$D
M1CYWQ@Y86M2.B+?$_\@2NRUG,>B?V>#OWB]Q8_;KU^X7;F$(3_D$5(UE8LV
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MY1?> 8&]IBO.+QID=Q\ECKRW-D3^:JQ[" CHISP]N2WM0^T@CIF'42Z[7O\
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MVYEFXJ3AN-*.)#VC/0.]D^X/VQLMH=__4-&$O_41/G<:IQ26^<#!9Q)!_&M
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M86G>YP2B&1V3^:RZPU"_X>'<#YT)J(24#:P]0#-'G9.0BP"Q,V8SM%!Q@?=
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MZ$JOOFIM2?7CMV2,TQP6^X]/J66BC7NR="_Z5(K\&EW$<;5G:P6/2ENS+E;
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MH$*N04CBE7;RVH$'D1[DD6Y< - ^I(]@\KH<EG,!$#"'^2RW(!IA=OG0NW_
M<"1Z\P+P'G8LCR.OE+L7@#.6>)S?!: 3<<X52E[?8F&$*%TLB:$%_W[G2_Q/
M<@CC__-#3<AQ L,I7P"T9.-@:,W1"T""& G9&0A[&>:;<$:I#47 _I/\H!7R
M-AIR#W3&C))H9R\ A\+ >9S,P3Y3I2F(WPT^??"?Y?C/"N)AU(O$SI-!W35&
MMG/B?R'&!2 "1."Y 'Q/[0?A@*X7@)]?_@\+:#8])+S-18 1_X4<_X51]@@<
M@:>TT^+_OJ5-B(AW^Z3E\W7!0YIH(O2_$N0_&Z4!;8]< /[CG'^<\X]S_G'.
M/\[YQSG_..<?Y_SCG'^<\X]S_G_HG%NMM)C5/AACJ'@9Q/%!^_AH1)W[:E/[
MN*(A^Y#)NZ#K^W(&7YVX.#G[7V77P9X0"]M%//D4T*/119A'?SPUN>[QQ4P%
M_+:UG>'GG&5K?5@E\1G@3/>1DC$!7/!O*6REOBKM-=!O21R#UMP_;5B&OH#@
ML>D8>(\L Q(7L(D7U/Y3)XG<X]6?OCOV[0=W>+^[J)R8_#7?NZ)<*GUW!>RU
ML-6XNM(E"-_V3E^JKQU.S/'^%RWZ.OC/XL!K;T:^W"T:029\]FO<//[T;]E2
M7 HII;^ .),- R[+EC_>PP%S,*2%'+;CH3 =QDL7 &UTODU^XDB)3,0W:UMB
MNQZ'ISJR62V.X1E6RMC.P@E9+]I+5TNG@)TLUSYN!F.%VOGM)>;Q3VT96Z"_
MIK/!Z9:<FP'[%(O@7-B_8QP38DFR;-4%(/'3#B<4^1;3O\>%#]Y9TIB20N'\
M82$K(P"<-^_5@[UT^R^!NT%'DS)/U(>NHS39M?&(UX&'#*-S9:B4[W#()YM&
MC&Y:"2Y"YP+P 6:6@]><",OM]T:*NGUBZ.?Y0G,*'_/Y-]*SP/CV8(FVCMP%
M8."^(AIC88 &J=:"YJ^C"B,*9MQIG]9/U/)H".+I7GOI&M2E_[*5D6.M^GH!
M"'I'PU7=G?WRH1SD/;89EX-BY#'Y VJ0KD5>1;I[YK9'%6ZE_+;N=Z'SD1'K
M@;4(1PFG7H$,= "@L?]6)(.Q]98AA^2;>>=]0'+\>/U%U/GT@IATO_<ZHG)D
MD-IC0K]?[*V-[SE]L/KYI)5%!\.69C1Y ;#BQ$Q5I:Y.QZ[\463D&W]2/_ZZ
M;,^&T==30]F@MC;RZ7U M-64V!?=!K<S,X_-1#KX./+?L%$I:6:(O11T)D:J
MT2(+XPGYA,W'?4<-Y7 M>"Q))&+!G+;W7"M2:QHN;7#")ODOW1)@2"+!O7W]
MTI=\Y@-7'16\U5])&=^8:J#_O85-J,?[SS-)7A.B/M,_?O;PV:SB.<>_5123
M07.SMA8OR8Z"50[M<TS=(B(HC_Y"YW/87F,#?BM*2W9IANUL<Y2M$-FG_OC3
MS>JG-)GPB7"ZG-FQ#0Q0O=$Q1.R%85R-D^ZIND8+_/[V>S\;VS7Z8.Q%+=YJ
MT]\IB/ORS8=KPM81ORJZ@6;@O'\KE WPEA)@QPN ,%.Y QY*NYF=@7<)-1BO
M$*AS#U4.]/$,)'YWN$)B'P^MT#S(.<Z 3%%;K0\L6%TU%A45J5$<G4.BIJ/4
MO59@'-O9LHGX'BC7$:S:9Z.Z7MIGPQ6JFUQWE'3:[5@O>0S[]]*\?%K2:!MX
M)A;FR#2/!FD<'\Q;HF)C@NV2D&[G]27Y"B,%GMR%4>Y^(45<>BZ'PFZ';^2$
M=6]"    VW7L"*XK27@6XZ%75I PGFJ7I%<59N[UR_<=KLM;+3MT^"AS^F_.
MO]-33$D3@XBD_VF3M>NWU=B?6W]=2QI02/XWVU_RY'_T)12IZ2$^)5H,/AQ_
M60S>=P&8'T=MQFB*D<:S%7Z@ TI*1>*7*T"[X[J%BP,L$G?O-26_^RQ?/?C3
M.)?^_(A$9XW)WD'I=E08=*?7$:;/1\-/:.*'&S\/"-J,I@E(]:P14/Z;WTR>
MKH>6OK[UB74]K++%;B>;MRN]Q&]/7ZRPI=SMURX;JU/-#8"&9[<*K8GY:Z+I
MD$54057+NT/%YS'8P[(WW>_H:(N/X9K$@O:;'D!ZZ"7<9F^S03][68%[HK';
MX;?7UHU/A(VIO 7C3O+%!_,G%5L"Q$5%'<?^PM-!RSDY/.JVF*/E1R013-:Q
M3=R/])'>K^D\K]\$Z=W0UID ^ =L+K5> +#GQ SHK=!7&%BX3SOW-O!Y5555
M"D,=:<I38XQ+6;P#I,R[4W]'H4J6T<9#J0UI_/N/V>F9T&X87-OL3\5ZS9_=
M9YD;D&^Q0BJCPZR4HU"WB;I/C'P*(?@=3]8 ^@H_B3[.1  @4=[W+D$["#OU
MLZ=)6TF%Q6WJX>Q3)8KD+VO7@J]YKAS,26*=<4.K!W/(;I(RNCYO#2(R%B:W
M_XPT[2;_XV>%\OZ]SI^T._96P;<JE+E&= UVSKCO2QB-S.#CHB54]@7JPM?3
M'WP4YG)->%?,MS9],TV8S=9XHD+1T[RIJOGCX6S[[M0AW37BY3ME"@ 3Z[GX
MR-HL/K<5Q,3N;L'G\(?[,BQ*S_W>4*@?@Q+*?@^G,@M5J0[PQ [^]>7D^\!W
MO'M*<6SY$XDV@<]I]8%J<KJ1]$LXD7.D\:2_H>%RHOM>(FPA7SN2?CEF7_*7
MY!93N,W)9C24 P>RF7!BV>:.BW4-\A,H?CPV<$GM,RVE4#;UZU'&.X]C VLS
M#-;<EB>>G-\NR<U+A^Q]#W))>!Y%8[WXYK&&GJ*MP=3QGK=(JA&B#A%KQ+7G
M8@U0$:0JT>@DQ/I9[[O8YT9W8F3C6^66&\+5[Z$T1.\'O963*0AC:WJIFKS4
M#0JGES$:8/(+CB:L7@#>-4/&+@#&OZ$L2Y# ITWU]:UA>KU]J9"?297SID6^
M2IR^+\-V]HQG2[<]#V9'5^Q'AL?L[ Q7#"7T1)(_J5751*8\#Q+*]O5L+V0<
M[S;K:< H5<SU51<-&1KALQ.T_6 LZQ#-&[C2AXMY"0H9]99F[_+OX_BQBF>G
M%P"J,(Q1'<K0 /5MLBZ$^%B+_:LC1X.LTG#=5,"^*%?'UE]QTR[5QN"OGPCL
MXVTS.CD*PFJ[T"\FVFP=SUG->0V>CK\&BWEPQU9$);_KQZ9-::QE I29D]*;
M;D0I> J]@/, !@=]+VM<5B [:<)$FY]>+/<-O5BI887[3C$##:*.8\W))BUU
MI)]V?U.C?_,10ZV94\+SV*P9 ;&AVS< M*:&EN,G!AHV["F#^PP_DZ,Y&A+L
MM:Y^^QP<KP^HTX: ]DK0+7T(3DU:>TA@!P?("7,=:?LK,>S''&F/,Y7O&79O
MJ1+:#V)L=4"G+LM\6H'S+H25]:2,+ZH?AI4O.C]U=2*N[!PF'%?F.#(Y[#5-
M*^X-34^,)_OZ@9_VUYN D\%H8QC'SES_7O>J 0_1QZ2].F[<7-S++U HH83#
MY&VXT-NWX-*Z2N7+:']SI8-<6)"Y.U[<=T&L'(MA3^;+5]B8V)U^K"%MV$5G
MS!\VO%G"VQ+]NY)'L2G2Y%&ZVQXJR-D_6H@G;>$-X$1HTDO9>OSD@^N/]OIV
M;?R(E_Q/&K]IJG/@X">-CB9M)UR+E28ONK"N-,:E;]#S>TO1 (_R,3P1MIR!
MJ&V(![D1@?T-3U4F*D[H%%HR'M2R8Q,Z!*W93;O7*$&O@C<+7H]W&Q5P3=OJ
M3)^E2WB;^/V-KQ'++9&I*VK/?<%^/@OO6/!Z,.A,.>WM9]?G/">6^YF:S?3
MLNI'XSN&C/F0H$VUY]'NYC9:H_1T W^#@\V;G[&:WJ8V';X+<$J:*W9?XA\[
MB7*.[C:M:4L4C&)9>OWY.^?R&\@V2$[[*S>KB;D_K\60[AM#6)"/\]6 LU26
M<L^<1TD&+Z5-3&P6M4+H1WP4_+J0 0^_RF?>N,%\8/J;0AOBNA>/U[4E#5\
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M[IR/_GI44,=+/ZN[ML/?TOO25V/>!7'M?[?AC#3[R%[]OJZ)^P]BZ@)PVVK
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M^&636$SBG)ESBW7U6F7D_FOGWL!1;JH4BZ[I&:;@EP_WCMB(U06D^W0A9UO
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M#P%9IM6>66@WCY]P.E[%!DI<MJ1_U?1RN+R)R^(._W+\NUK03 .V#0?.7X2
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M.D,D\FEN@]7M;US:2I?>D\N[$O'<8U:>C,9FHU,2EN$1(.IFVS*,D[)O.QY
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MPCI!)!BU_$>18%P1!ZXR[5R,Z[S7.G[P<@MB\)SB#7>3D_55+0"9KX:=N3:
M+I-;CM2TD)#5_@:BUM^M@>Y!#.8!RLF-&$N $T8!GF+IJN.5%TEQ5F0:]9E3
M"/X13+(";+Z;47^Y*SG+.9V0D1\;A#1>++,KFL;<4 ^P5[!2O3(A9G7C9?OK
M;<>7<CSNJDR;OV$I4=%:>OU6*BK&"AV*R3UK.X6<=B4'YFJ*70O1D4P: L"N
M1REEYO3+RY?NTD.[\0 *I;]6I[ /K7^M3OP3NU4[O?Q+!D'*@#82P$/38MCO
MEDE>8-W;D4UM#9'E)DZ^0]'Q>.299I;@:^B/Y^'[)&Y;\O/9+T91X% O6&0K
MRR?4;N06KCUO^DK\[-R@O\SUQUVN'F9[!O=?C,$14JCC<PJO(2Q- AX039 4
M!G2P8=^[A&1!4 *88L!,;N7O;$B?3;V!W#Y/P3%C3:;B:Y&P"W.+&Z4Y3YHB
MD 'VJ0" 5<=Z<Q" K.H6:_G^'^\%_>W8[^TE/V)), '%6%!H.XL*P]ABQ]&:
MEPQ5.*E;B%*W]Y7.S,S/+KV"@NG[0V&@*HW"MMWHT^PHB""2K!HUB'TJKZ0H
MFIY\)\_M2\F+';L+0-H:[[;O^D05CK\5QK0&BNC=K6Q4-1(6M=.LCDR@Z2]Q
M.KYBHALEK=N%N$7%=/]A,8"+D6C\6*I^L<JMPT6W/=TMW!7"X2(34]#/7Y=8
M^Q7G)<+G"C%8]?]LVV\]+<?I+CQ,J/9_OG4D#P9KQ6:H$<QEB!;)SGV,BO3(
MP3JW<X"96'D.6+PC(O'+'9IRM8\+/]X" '+(>AP3;FB!""/\_*/!TB# 8<SI
M0I0''N"<Y;$1]@;8DE@YP/VVO.1W6RPM#I%%^79PTZ,G&Y:Y!+7/!%\>?C*]
MUW)V=VB-N+UU65[CA]:\X6B3PN_;"?IJ#=O?,I6HV@H8"B7#L+3)V/!6CRB!
M:%L*7UJU%KD]EZH7G[_,>FE ^"8@TI6<0EDX[[<SLNU/-IU1^MD:H!?"D?!(
MBU@HT;C43.SH[2,2XXBG@E?>B/+S"G &&3WRXR&6M.E$&RR!0Z#26H^ L0=1
MTB]+J:6;P6X-P9?J)'RZ>4/\.%]IKW'I>67_-KRSV,^3H0Q^6EJ3!V6R[74#
MA9N&'TR/CF4EOY<6AU79#B;6,?&_&@BY>-&/Z6+"V14([["4,EA[# OD*LLJ
M8^_TZP_T7M-E?;@ SK3;9Z(TOLH44D>N6J'S7Z"E]+]6TN@;2AI_K:2/NP?F
MOK_3W+&.-2I2M#%YT*ZL6M[9_:LD+!NP.ZC<F/1*J/,+5;M2LSE4\S5+E?8S
M)!IAF05]Z.S\6VK(.+4<G^;@#NW_X%7C725[Q/ZEGJ:"[ P<C "-W?EYK\?\
M(\QB.[M@EQOU L:WRP0\JZ#\TU"Y/AWM-HN86M4T8;6C")W-_W/Q5/8M^4N-
MVS1\:3'R,(;K?F?[@L;AZW5/-[&C=\O/"%6OCJ:+\Y(<3_17S- 9$X8$6;6X
MP6QBZ&?;+7N_M->L-N[#_;FJ[NWC4K<F04% \C?G6= _%MA.S\)MTVLQ!BXE
M$,%:E&QL.2$^!6K-F!<VG,WB4U*IREX;<C5=B[M%U62T%+Y6+IR!2MB*0Z6V
M9?%63WD94(H4%#TUSTG;W2F@NO,&Q)]4E<4:K[IID_P;J69P2^E8X_PU@3X!
MW;I(9<5V'Y/9*NVG\1HIMIP&F1'QO#B+2_[WBV5>7>A^;'!V"<+4^#G)OYE]
M3(^/Q9]0&-+2HOKYTT[XI\I_UVIF^A4>:6&TEI6?'P9:MJ>,.5UV6>27-65&
MH&Y2\WL(51[R/SD>?)$2EV>&\=6I&9,:T'XF=:8]R2I2-LRK&?3P&LG[XNQ_
MW%\ZD+<P)?YFJ7>?EB9&\3UYA@BF<.3!D7H(=]J?OU2AFK?245J@=2Q(C&E.
M<CK^^K5K)>DN-LEY"O:/7>7HT/4<Q@"W!T8NLHAL3W5!N2-6-R87MR;K/_6A
MAJ@ :G%];9_NZU#-L&T;@>RS@WVSB2&",$1_\]TLGK&K&5]KS0X^;]G0K$'7
M-$6$94S7;!-KB(*#E.G^9DE_4,9QLB1]A7^"%]8#K!KJ@ .=$YW9UT*W70]9
M1QB^Q3N^WR<&L'PUF[\=!B W8PBBN+,+_],>;[#9^(P7>Q5=4':>7X+1<16]
M;=@6HJRVP8J,EJ9*[.7T*.8M#B+^2#*;@@<<:6"TBC"^=X=W(&QN N\*TF@_
MLIA2"[D]_DJ3:R#^NE+069Q$B>K@;YGP=TZZ$32(\47!.Q8I#V1&E03S5//,
MI+*</]S]-JHBWC#?_U2.=25+N*CT-Z.0.X^8 _\Q/]H0K5>@7\$T*M<W"\W1
MLF';NX>:]RJ\F;HFAP0  /CKS7_1 &5ZZDM:G></VF[Z":UU- 9@GI(T"C.I
MA<BV<S]N?(7XIF\ELYR</.CU)T<=-?3+8$J8';5!"(Q)6HP>8VIC":)=U+1-
M[MQ;[Y>*EL$6U\>OW@O^-*=E19,<Y/P!/;55AH(C[:-<(:I(-]K^XHUCHE^5
M79%0V0%DYFH? 5Z BX4M+^C^O+5D5K4=VH7;@<,M4D,/%JF_8U06K#GTDG1<
M^&093CY5UZUU+=BG12B]F8^GX*0*-3Q/@C(X97&.>;%A^=C7V0.:/UFT!WI2
MG<0#'#D_O.];$8K;,0]BI> TS?M=8&>L ZO$.I3I-"=J2@S(+<]#C>AC/JXU
M?GY;U]%-5=UG(<.1L:I&I^QLBZC8VD1M(BX6JN0A0#2J^8N#P-=3>DI3ETF5
MC2U,'[]?LO_5G'WZ73LK_?-W7+#]O0E@#0)$@=IP)-5HLJR8]QIDA2\Y"45?
M:?1[KY?V0_4;I9VDBNXWY==M-,JAG5#V,>SS'$PA8B<'&"QVL'YW5/.(Q.@O
M!5WPU<MISY \DA  WZ]W7O\Q*TK#/+,952@P8LL29H*Q7FG2?J6ZTLTPU\__
M7NXS$[\II'>@UGX=['2\T*S-7U^@J[<&F<?QMH:L(@,2A7*NBJ_VS5WXUUK^
M\T_X[D"1Z0BL,NAPH;@]4?,.U"$^.^OTL=)& FQU,MK#*INZQ@;I5C/6T7A8
M%OS*28P&VHL'7(  RRTW3DU#<Z-/O\MIII]N>'5>T227O_KDH?'+=HJR%_:_
M(> M__)(@KK@0:V]?#_U3(G)F3F/M!6B=W6PJS)OC>=EEEHH1>(>.EYXVIGO
M3Q,=8/[?GKF8BCDOBP#T&Z:D1J9P-LL'IQ,$8? '&5(B[VJK/&!Q%&F'=*&[
M-W)X#3I6Z,2\9_&]LR7Y:]1X2?D/GM@03=5?/XW."EIZN(:[!,.6+,+0IT>_
M;0_?QQF(8/K/KF#E,?UN_IZ!>5J%F'A=-UXNUXEW=G$A0?$_RYGO$P?OA[B+
M)UHN4D%I]9; 83!4T.8I$I/2I76U:M#^<:/^G/T?#X!_*^G^*YUV;:W;C!B"
MN6&9 JUQ''QP<A@E<'8[UL:0-,G^:A8 ]^"RO[QZDH>G3>3OFNTL4Z080>*L
MQ4@/;-N;HEZGSKX[&%3N[DIO.;*>7LFD1%&\9P4\I*$:0VMMY:'R>BQ,H@J=
M<'3U#74C+B9?NLJ^HG4YA8]M)?B#O],DR2;W"Q9)__Q=3_IQB S#IX;Q10Q8
M4W2^>,*NF>A$]\8%($>:F:3#7RE8Q)]L^2;N-\!Y"-X2(WB+F."MBR"<0 )&
M#4MPYRT1@CL!A"!'.C^-!O3\T^A_HU%[(\H^LHLVCEJ/"_3C&PA\[!2)O3)+
M<0XX6,22)F"%"QL)*< '"WIG/UDYO<#!!D1%$E(="2'570:A\G"7MDEP02_<
M<,1:.*8*#?,<@O2[X$-(\+>4"0F>B!#*5"#$18+*H?BE<OAA"(N#>^1:_W&"
M:P20BK_2%S<A?041;@]W'KGUY[, GL ZN B)BNY7HM(F5,4$C#JAQ!"MPS&4
M0(Q)"R/1/U'\_T AW*T4>*:)9<7 RG0_?+>8W:C_5*DSI3N6E\;["'OU&V-6
M%[&[YD5:7WB-5E2%TA44N%LA/W9TSJK7M;*LBT3B-G^BK;V^UM?BE7@MWE8.
MMQG8]HL#A;+4EU?<PJOF8 [U,8* "R*]"U%C%;-$)Y#*?B5T'_!ZYE.STAO+
M6A2D/YK<<GW!/NDMJ5\QF7B 3,_2AA9=4(A'E4MK5%U*ZIR>Y8CC]S-?1&IL
M*SO6>G1VO]-GUJX_%NEL_BQ)'BE'L:K6T,NWRL9].$O8C+_9F58:C#^Z?Q6S
MOJ1,UVYBD.LG,'#/6F6RS5.DRY.>L_H[_?&[SY[3+EP^H> <X_G7J\!9Q@\+
MY:*#95D9>2-]^^#M.Q(NA=<49=XDCWE#LU&GS^Y7HMPBYZ!>(E('>$"J'&&*
M,E@'"Z$?)G+,QE 0^F$&TU)8 @I7Z]KB[QI0]?V_$H])-&Y__*_#'VZK<WC_
M3Z-_&OU?9>34LA:JI,++.EPSL@\;RH0AK&E-6_$ (]!"0;V08N;4[[*DY3N!
M_X69])\H_A]  0D^TW!FGYC:#ET"T713Q$MODZ]U^$XE8P+:6_D#N7ZDB=*;
M^#P*<"BKN2R?K!1/]T0@T/ WL,'\?GG(N@H4##D5>6 MK#YYT)?1EK[:^@QB
MAU0\-]D1C@G\&B4J3?D^4>>6AVY5R2-K"0VQ(-BS"DXA#*/?ZER[3\RR >D\
MIKAGC]+UF8O7"8^!I-W7>#L5RRLTYK>NJ;)"B/7(/#?=_N-"_AX3=A<S<>8(
MN=6 \:UP@,V9,'#9MYNR+V0C#:A_LO=&9HTBKS\>FEEMALRK]>$!-T;(-OO8
MUB:@($Q>%UT)=."%%PNWZ(1+[<\=4*U4!?7FJ&-J>OF\BCS L7OP,S]H*.7-
M"UG^3"8OSMYIYE;:89K-=W1ZRK ?HR"#?/ ?4@9<P7L3'+- @6;I5&;I?N!W
M4@.^A#DVP@VB\E-C$XZ6U\%V\TPUQ^@%S7+UD"7I_MEF-\'H ] EB! FT1G-
M@XFGHX(\@46(?=!Q% S?;A7\(EVBN]0=A\(#HCY$23#.EK!^IO"H%.>6M1?Y
M^N109>RW=7KE E2!+@Y,IT2$VD38QS0_*/V^D7)_ WH%+5"H,+/9:/+&69(_
M2KB3G;0QQ6&PL:I<VQPHN)O-']IM<ZWR//P9R/$V)ACIG!U5:)QP;^_'E&NV
M7I)D4>#;=?@C"7]N<"H><'=@AW2GB.><_;=8D'0L0$X(UT0S>!D8:Q'9=6;-
M@+NL,2ZUR(%AZ!J022MPW.4ME1E;OZS2SAY+25F;<35J/LM@(67_:A?] $<4
MGS=-N<)-/IYA<E/L%>BO1S+,:830>(X'H*7^H&8LI>Z1R_Y/&1%I> (95'@<
M%ZFP%*68:I.(C67]T??[:]&#3 5V?:SWOK[/"DBT<;$],_?S+V^^W#@4T:R#
M" 3U/ )52NO=%]:J^VQO+%["*GK58::^G*3X<(U5#G!,)=R!(\%-9C%C^NT\
MTL,G$Q!Z_MXZ7G.!%]<LHG5+7F7X]+U4$_^N R #>>TYCQQ6Q"R0HA9JO +!
M/:U<HX?NQOK9 <7MM#V6.PDBF;+RK,N9PQ26&AX+/)BB)3CEQHBCQ5K, 1>'
M49IQ7M6XM!Q/6B?G]0M;K"%^K)SCK4*8-P@ZXGXW8!3$.-?OA6ZX")538ZQ,
MSSV%-Y=O]G&/$XT:6LEV@V);V3#J2]-8W;+O \IONA+;[<BS@=G*!U4TO9Q"
M%]G>$FOQV+;88027CV*0NUQ@/XEC[4FEJ\@22^EQS=0*#2JER4$\0,36P2[Q
M NE27%MHEIP<X&!6.&D8*NK'TFW1>Z1)"'XZ9_:*05SHH^)V)3Q ;.%\5MY5
M$=WM_@HWPC" +NF%7E#AC/,:HEB/*EK86)PE'122HKYFMHTM94BN7WWM-50+
M"-!@0D(OG1?=@#@O:3>[V2X9,&DL3>H\3;9H#)20RXD6L$O12MAN=1V_-D,5
M'K_XFC,VB_O\8YF2:8YC^DXR:K,W/3ZT6(??A/U->0;IR+<OYJK74LFUWZ1I
M7[[S\MT T2")<E4T6@1XE%L_I2+@! 748OR729#O)$@;6JI]1MM"!"^HIZG,
MUT;PJX?S[X]%'XA%@^D/%L.@1)-*UJ6JOIX%Z\]+JS4>1^_?%"V6B; C_1%Y
M_QK]Q(@5'A",=2G$'+>=RD:7WG>VEC2JBC^]VDR5Q.^:$X%B#;JEM)2X:P-&
M^1XUH^Q[]>R[9@W"MKQCWFFI!Y>3,O2Z >>&Q:WFDF7&DEC2J.C>>6C]E54/
MSTM%7)M]RS$2P$ANJ8RNV:MOX?"Q979;J7MO-&E8;;8]U N_A-7+=9O7GI<W
MTWFCF)>17[J+!2.7,F=;8CI9YL(Z#%D3'B8_77ZU"-O)/+LG.>=0P8MA0,\>
M+Y-7+NN)&:+:4(.[$:XYM2GBL*.*FWWA)^>C+L*Q]$/R:['9UN]5-1@)(<-X
MCU06C-Y9C-PO/1W^V\:<C-'0Q.&__<J]:4]VC4!#N0UT%D>+:C;T6P.CL#C:
MAI:,SBQ:](UTQ7Z%[V_,9UKGG H=EE;O9L9?E)M$LW0/ 2$@S+L<K Q*/]4Q
M?UHV9%?)U*,5U-P\*2UW-?XIM[J5R$K3WIV*TQXJ2J&N:VKE>D-%2AJ(,R#3
M3X6(N*(.4:DS#/>"7P)'8@2=<@+<":/>"ZZ$=[L0LV%!B!(X1@<B>'5H=KG>
M<J6.6*])78<QOJ3YHL2'E1=>7+ PV#.QES 6["-4ZT"'C WKL%<VO9^$&]/&
MGM.1J>R8):N]@UTT(/42^< U$M^[R<FQ[%E4Y^6M5VW\3)?P@*Z69WX>;A00
M3?0=C#=$UM:>UWJ]<O!&I>47T=BN.QN/!D+90YM(W)B65]EL@!*ZL_/2$P[;
M<\,HR;L9E!E7MW?21]$^/H$*\Y#XPJ-'YPF'P,@L@7JT;ZQ=G4)<<?UTS9S/
M/JF^IE(_,.<A]2--+9XU/J;#=U E2]Q(]J4#5M%#C@06OU"+Z*D[Z+NK/6<V
MXY?9+(0/M>NE&'IYI@NI#,<_+EV2J\@[@,^5(&5BEL ,?LNFHQ!!L5"L)#)#
M[**!,W!VN26%[;[$&-M*VL0=_VB/]GK(S%QL'8:3B:8UM?)]:?V^O8EE*J*J
MD;OS8FF][WSKUCE))0[4>3K1B%$_<CG_H"*#&P$R-)-!)VGS("H-"OD]GQI%
M0_E]/I5*L&[S!>JO#48?R-O40<U),S,OJNR6][OZZKKG1@OI_/7+R/^#5T4@
M[B.LQ43HKX^2I1L,O^=I,)JL:1MJ, +^)RY3<7_46.>+R"X]Q5Y3=K<T9)E*
MA[7$+!XP]-K?9_2FK\$-F<Z4>QY&B?&T7@?W*&B1NR$J5.BUZ%RT0%/N>9-%
MPIV&D<N;VP]Z8Q2#;H^X:%'O$T.?N7*]+%6LF'%&N!S"(UUVF@69)N"1!^98
MY8).Y?FN*-JPD1./#J.^V\')<4,-D?=45UM,HDG]&* =8-+5)-,&5!GN_9XC
M>#JCENZR4^K5&W[=C6RBEH]I:,AZ%!^W2-[#J"*X'IB@;/*]/YS4M](N2%V'
MCMT\X\;<%FF#Z+QM R^0'VX.^D_U&L3B1%%#W4,1BS18.O(H\@;D"KPQV01-
M<_^[I86Z\^4&XXCK?(Y< T3';?<D([;W4]NR9]5[3P4[RBZ.F:.S?IU$NU8@
MSSU&U\X>=YJ@N?9O7 ;..YX&EOB/WHY4JBFN?,_)B:IACORNPH.Q1\ Y_/(Z
M&E=K"\[KC5"#XZF->KW9-V!/TY;%JUU,J$[N:W+2;Z</HGNW-I= +Z%"*@(3
M7@.;;I=J"Z>OCA_H.9WI?,Y:E-_+#]#)E7B_!71G0[9>QP,BHC&5Z#0<L;.%
M[\N:10JK13_D?N?4I$^CW=[<O 'Q5YKD+E>D;_ KP5.I8'.KRT]P]#_!]""7
M"A8,L.MXS'S#YA):);(0TSC566_A$XG8?KS\)4+GLJR$,VE9IND=,P:WVLIW
M3=.'7RS?#I@$U&_UGHEA8$=VP]Z;(E<0#0V3TBS-298!#]P8+X7<9JZ\XL_*
M[]AC/O,N;3[>:MP=UPNB?C2%&'^@!6=VWUBSB5'%33<IJ#F1U0=^,/?/TG:9
MD9NK86BK>);[(;2[5FQZ$<%<Y@F94F%Y5RI62U1L_3.J=+$@\;D7*RA#(*LZ
MQO1JD.W;EX))M %J'XVIW@/( 5Q%#N^)HZ_]VT5W];Q4REJK"U9=&'\P+]"Q
M:33N^DQ&U=Z>6D^JK$6?B?%R;WR0*2VJXNAI+9HB1.7R!DYN JM3O("QOUO[
MN0JU\U%D>[OF+%M A5UN*5[3X0N M+S+I?V;/C1BTKM%L3/=NB>_!#R[_L*[
M:C=K;\\N@C55;D#Q$J/G>/K*LU9EB-2$J,EL)Y(N_)"CGC2_+*7236GTX64U
MS7CS>*(E8@<VE$T&RK9[$D92XYW0=KIBL8L581J_JIJO+ZI1W!O^-BXC[-;:
MZEF#8/H"Y@P!BLH2(&CK[D$A&)G3)*UO:;=*1KZ?0<?1J/F&>U3U45/,A[B"
M))?/_,(1_2NV[N!F+,-R(! I&.ER.$B.M"R3\+&+URFSJ_,PCL[L%2J)5]V0
MWQ!^$=1PLH\F02PTY3JSKU8CXABZ\8"YTZRX_/R%\#(_7F5[K<ETN5SC*+O.
M\XQ'M[X*7# J.B+>GNK<99G#FJ#U6] LM]!VX9$OL8+.SK3PX!K=0 NYHW;V
MH8+M@(#@"PL<;M^M8E.5G7=<0-WL,F4E3A;6\66V 47K^62';UJ^Z$@7N=^A
MO,?5_YE8<TF"@JG+*;O&K7,>> ^M'/>M0;P9-?ZIO;B3/,-7TK)Y9J_G,A]<
M3JE@21$9_/V'EX@YR!XX,Z8:HXF"Q4/NN-C>G/XI,9N_4)P_,V_B^8Q=;L0S
MKE-1<R3DNVD\AJ,3RH.VCU*R0_-UI1L?U:.UC(=WO,XY.J86F,;+O)SE('6\
ML^8[#^/EJ0/'&B9T[-E<.H&.ZA)6ZIR5[T;Z<EXOQ89(*(R_OH ]0 V%00**
M(288DH\;"^QH"2[>'>_Q]]S,$9UW1^IO=MW+\(O<:>3:$[=9"OU,ISNZ_;3E
MO!3NR!'@]R$+Z48UV\MI>-W>1^8E<9 \?]9-X4T19^LQB'2!09'3:7CYF\);
M305-+>\>18MO?.L"J!0T+W>\^/4C-SV-NUUX *VSPM.<TAI>$4O34>RMO3E_
MQTL  _:[CX@,54]28UTW!XD\UT SO6K#$(XST+J%:6PS$*VRWZ7+]%T6RA'2
M"6:N+JV^0PK5F;.+B&N_&EVNKT.;;+63@QJR1LFCL(O58U@CU&JU_\=0;P28
MWG%*W.'H^27?F@JIQPPA%+PZ.D,4+8%I'[ >&+<*)Y-3:!J:HF,V/L<=*>?B
M(EWB:/<F0</(]&K")Z9J!!X ]+/M3JF?4A!\>?#NZ4)WM/5@X:*&@N4GTL0K
MFE<N$BDMYQ.PBE'X!8 )G-YN1X.[ZZ%<$XMJ,-KV%;"Z[96(G=O1TS7W&HBL
M]V*)0S-#A,'+LK$91R_/8[&&I7X&G:?+_<66;[>]FF)N+#3$KQM7,MKM'[.B
M#(A;ICJYY5#P+F'%(B5%)"U?5UTE4 A1TS1=/D()]/XB3L)76:8GJ%,Y[#7G
MHGBWJGZLYNP)?;NCX^5NQCL*0KE!C %$MX"\&RHJ4P>PZ3$]E&D$]OKR=<B+
M6=JZ6!<0@FD\]Y*D4*\D6Q81ZVS^">T4J:D871L=.VX0QMQ*YU>B4T]H+>OU
MZH,A\B7=B!9FOP5AG_FT-6+SF'>CDBQ$+.+7VOHJFAS>BT+@J./VT\/L[6VT
M;!<+NT >>;!_CJ6Z6[&N(^_L-X2(ZNW7<:6:DTN<V,+19OW>(V]T,ZAF<*BS
M8-2;".5AP)# 4CL[ Y^>+M68!"JZ+GRX_4#^1'4[_9PF-ZAA'[S5@@=<[3R*
MP@,JHQ?Q (U^\!W3*TO@,!PKQCFP? $#[0EP'O3P;AQW%77;$5WYG*A*E%:0
MV(=(N&L*OA7R+^GS@BM\>1Y.MV9^F//O/R!E6]DL0Q :I</7<J,!_YT+ ^X%
MU["T5[Q<D*I$^U2B=I%W500JJUU4%HU&#A/SOZ5L_9A5GFS\X$\6K^\Y-YJL
MBSE'@76F<J<H.A->'I]^?6%URKO!7O>I?O\\WGZ?_V7S:48E60-IDNE[GN=@
M)4-P%:SH!+9OL O&1IT3VOA+38)X0/8$% /;J_YI0(3UQK"@!AX,>]/10JZB
M"S)\<QPE'%Y LAWJ4ONJDFPENZ.DF6G3*%V^4OM0<)H(1JCP8XE1D5%2@V ]
MC#6:Z(%.:^J#T8.TBJ54O3'7_&\G9=L<AN*:72E\U.$W[H17,.<F'(+$<([G
MFWA (@M6;2L;!S,^(\3!ER&+[*[LZJO=-9-[D,OH$G4IEI1O\%GZV%YOGA0$
M;$40JT\T9#C\\+D%>VI7PLSN?13PI1(G]++?QJ+ZE#3I1 5?R!'9JP7>W%Z%
M_O.\!G-(31N%J^DK_Z'H$:W3=ZDP*=PA'M 7B57[_F\S?L%=0J=VNH5 >3&>
ML%*!VF=9+.-/QGG&:\!DCD<*JY4ABXWP<;X)\+>[VB1T(KY+3UNK\8#(>@@/
M'I#CUH,'8$CL\8!^XY.U,S785Q+< NCHG=\A1,#^S2.47\-PH<^;^L!1^_U(
MEH>(5VO&>UM2&6'RSWX\/0Q[LOLD9;>N=],-J]R$H#BGALKB 6T<(-R=/!SW
M/"H4%P[GP .6:+,)S#1=></TXUP_<0]H60RMPP,ZYUHOP8;KEV%8(@*6E6(0
M8GOQ NBG)1J. \S@ 7O&4!U#K?%UBLF-[#(XZF@W#'@@@B'P&O ,#S@12L $
M^';0G3)CW?" (!D8]@TXR<CP4$'UL+'POPB&,5#_5:!KT>D<'D#GBE'% ]06
MX_  %/D0'I#T\3_=G*L:P <?_HG^G^C_B?[?T$<OXZ@F4!$.;=R<Z$_R0S)_
MA73PX/0=C]F7C^=@PH"5OS[ED^/; \>0.!+&,X)U3K?2XP'#3<M@+%'-KT&P
M[W-+-FH&3@]M#V$X[FY4 BY\D?T7Y$("9$,"SL<8+0+.W3@8BGR, +-D+R1:
MI>2N2HO9N6THCJH6E;OA@(CL5)%-<63EU4QA#D^+:@-0E^N] &)ERB.][=V>
MVR&LGTKR[OA)"T90,HSQRKZ"UIX$GDE@?*:,T#)Y1=]Y^P7>7?876NS8,7,]
M#?H E3[H#FS5[7QK90PL?<S@N%7ADM#G5QU?30-G1,DQYR[;7S>7+6YY<S#7
M=^IK<]ZL)(+08]Q0R [#ZKD7)=\<?5S_F?X:CJ_5X9MR!SK>.>SO=\%X.39G
MO 3P1?.",BW$$FW0>81CP027KM?%5,W*&R^KCAB/6%T[XJC$F(KZ=V(@5'%.
M+#]<)UN_'GQ6CQ-OZ"H,ZY[Y)K2>[UPR,^\2:-*[7H%5CD$ SZE;I7_YWN O
MOO_#1IK^(&/: QL70-,.-WHW\(#_TAV,@29O U]4GL+_W@L?_Y-5G:AJ (T+
M@#:ET H"5_[H9Q!B"WP!#_AIC:[  69A!*K?,]2:<(R<*@&6$"AX)!8&.Q#%
M3!&X[@+Z"]59.D"G+!#G7U3/)O#J-:/AH<6C?Z+_)_K_S^C73;LJYM:.O#"-
ML[=;!5&@>-==*?_T9?WQ&UT^LBFN [5?39F/^X7(66E( .X2%\F\%BEOX %V
MBR^SR7:E$RA^LF=%N2P9P>&6Y),5I=[.(&6ZC#.,:VP<9[O:DO87 U8*7KA(
MJ5O^6'G>Y^"ZODB^X3.@TR'LXD;B=POI[7@7&Z0D#<ZTS]R#FH_^.)6'DUN.
MHA;2XQV#&PA)+_0ZT#]3B2IQ6?,\;"5"I"O9O?2RB[Y71)X1FM"MO[$C8>!=
MK:_\H/7HG.@\"L> E<*4G2FM<W.T#MM<AX@A*6LOI/<:-=<VUC4^:[32>,XY
M(/6D9/O$BN3'P9#T=NKBI\5V9;53@0;4Q$&^])5RD0R_5*,S^58.U::;@84#
M$IFBZU0_HDZB^H=^$+H9K!TR^^+)*2SB</"!#F[4;]3,:ZX^=)M&XI+,J.3Q
M$-CBW/@\%4=4T0XB2_/6T<]9%C&[,5N+C7_R</I+6ZF_4)H2'L!P^<5#NNPO
MDD)O^WJ2PT],JMQV#I^=@>D_BY%U3A3;(JPU3%)WUC55XBWFK_7(CO8?V&2-
M:#":CF6'_O'C>]SB9W:P_D\0=3S@DQMN_ X!X=-Y]>Y/N*\J[(Y;4B5ZW&(T
MDI8V%DX/I!=NW\YC_4I5'(!:XXJJ>%_[CD4?S9WZO&!CDKFQX)U'DV!U<_C3
M".-O[GUM$9Q>O!F%/Q6>)N=I?#!;GTQY<=?0GWYZKJV(6"OV&7UPC:A<C_BM
MH4$XQHP;A)9M6YS9F%U$4D1);9MV0?F;Q\H/'6IUL"=,Y4E2^QS0)U0<05WQ
M$[.0O[SHCH#%*%GL8]:Z6N51]I%;97R2/Z&@^"GS$:8[*2D[W^.J^_F2X,UQ
M5:7*<F<6P' ;JOJ:49?'*&@P4UVB?,-8CIX$(.4!,\V3<#6DS VB[Y_EV3Y,
MX1@Q@MTO.IQF%T-K:&V-8Z_I;JO?#?$?O_X%,:]+X[,6K=Z !F_%E)IO -E4
MA#'9FF-*CY %CC5S)1Q2DY"2?IX4MH0,K^1Y=<8EXM UL9K/UP"KS?M(^W@E
M]9S-[)KRIGR=4HR8N<L##3+;)C/7);),1D>1'W8K,.^^]HJ1DU9.C/YRU[!?
M/)CZ9Q4FXKM09XE*-F53+-DL\4"]7QL_#7?$^W$HDY^P6;)1 !Y \9.EHKC9
MPXGV>8'JE>8G9W'7A<\Z6F+LN3Y29V=SWT1'QL[IG+]O-@0F8"U=_!'6E@8Q
M.O7U4Z+W%XA$VDW)><Y8F0 N?"3ILZBA^%8![+-:3'*9#69UKMVB/,'7F;:V
M)V^9.HYY2CN6,Z_E@[O2@]+>D-%/_4N/6W<R$/8A.R+>SHZ0*^_[W4H:=3]V
MG#XA$[.^:%C \?P*Q2M+.6GN(E1RV^Q"OO/'#15JU"$NQZDROV5^\@UI4D?1
M,1/7JS?4TR2]3L1K \#:\,'SB>,MA&SL[HU=K*!HB>OI^7Q&Y)A]@S"EZ?=;
M7Y\I(2D!+B+=@K'-_HAIG +D-@J#LDFV0Y[!R<&U4R^E0/1#SSENI6S91@?8
MTCP_R3"F0S.1N?>T=DTI@?(QV7<R[DY*S2E;ZKTE$GEW0"DE ? @X2.FX_M<
M#M/!R"YQD<4X9E&@%C('&5\QUXR*( 7DR?D-WE!\Z8S@HGOQN.&D\^:$%'QZ
M:NE;98F-XVQJN(O2O3&-'/,YZ;HB8>J8S+!&";EG[[[?T+[%EQP[!42M]:B(
M8CQS,7GZPV46.\!HS^^8%V-KXAG.79^-1(973GSY?7[T'ON?:XY"R2&RP]["
M@>IW,8$(:P7<3-<K:PN'NA%=AHNQY1^ILMV=[PPA8*%>AU668$H'GP%;GZFC
M7"X91N9CD;@QK?"3)W)LST/<Y3\H9E^#M4L<F*(F(]'JVOXFOF.':(?1CVV>
M[%4I)'7/P4Z3H$@LQWL_C0I+]>&#>::*?%D6+8.:>)+G5S;VGI%X>OC+*TUV
MB]_,C;YVZ0_/)8AHI[ !]0CLIDJ-Z+^>6I3ZR$:T:S :I_]W/ZP)3#PPW6#!
M7L<#B B5)QFQB&4D*&0T(ZPC&P4\IU3AP@/:]0BUC!Y<B@>4OX6=[.$.8)IX
M0-?]=H*]5.L!U&8$_!&,*L12$$J=020,]8 @T;L(ZI4*U@8[X,?XX@%D,H3:
MJ0'<+ #B(/ 6"JS&#> YB>ZNUH]MIM/P_\3P[P;#-3[" ]8&SH9A_SZM*'0X
M>Q^ !]0GG!?:*(.'&;,!.-9-,]PPQA.AN"NV$UBH7IOL^F+9RYZM#5N4C?J*
M!Q#:C=<80OFEG /A9,'T:4]1/8\+;6XZ*D(I^4[VHRN?#U5'G[RY.L"V]_/8
M)-;V%!C$:+I+0"0)(K0>5U4(A;C#A] NQ(W@ 31#A 8CRB $A'I'Z >6_P][
M[QW7U+;MBT=1$1$I@G2B@H @(%*E144$1(P@16I41#J1W@)1D%XB(*"@1)K4
M4*2$'GI4I#?I)$AOB;0 (?F%4^X]9^][WM[GW?/>[]YW]Q_K\\G*FFO,N>8<
M<XSQG7.,,3UF]WU!7V'9_5EC9$ Z!DX%X-Y26. ]%PF:E-,5<+(S@O043D,T
MMV$T_?YRA09)>#.6>BCW=E_7(']W)>[^M#J ^DENA,,1^U3:IX?8'."8F]F-
M0-)=&H0B5H-^66N1YH[ZHOYJ $ /0AO#7_6!YJ]KW9RG D3];UMT-9P0WZ8"
M*-Q(&K1B0QZ!XY1IJ*AM_C^H5:T..,.<JU-%.J01<-"L9ADR#4JEWY]"D$5H
MX(TT#OQUQ4,9Y+3-BUX@@&@1#>/]NG-^5>_N!ORU6I;DW-11CKV#2G[9-_!?
MUVJ)^!GZQX#\,2#_=P=DD;%K.!MWHNTXR7#JE=MH\T$MR*&,[V>.Z8Z^(=.G
M8_Q N)0 VD?V7"(84TX/(O_TZ9,T0UY'Y2!_Z"8-1_#F[X[Y\<!MNG80C4KB
MVZ44;C0->+!U'87C5.W^,NA.!]CB9FDCA 0VA=/&'"W0N(\$S8+8ZQG)UQ -
MEF*3GBX?)W("<=4[L!D(/\%W[S3$[/NDV:)1K(4IF+^C+,-5Y_0Q(X$/$7NC
MOZ2_I*-#ND!84H^.OTM@#M[8L$HTL^ 9N1Q0<\^X;P:FNWG<C[LY655N )CJ
MP@DH6/S4JI>7=M_&PWUE1V8]I57M4I\*?Y8V/,^\@%54^31(!86H#JHJBB0;
MXKG)QGCQ?4O<#1V/B_[/?XC.YY, ]#A(K6E2 RA$J87B3V-6) -$-\HG28F_
M(!J1&S4 _E7G%,*&PE*?]!M<?5P-?SO>_.XT7_#MS#RW_L3HD2^2[9L[P$!W
MXS4;L@R4AH4NI)Z@#9QOWU_8990&U\)M C&$U+(#J3WE[ZR***=T(==_]SON
MM%>"]M3@WP(8>B!U2$('Y@"?)7J+TQAF"?PGAODEC<W*+>;E'2I FB2B$; %
M;Y8_2!B2;C)51!9!@0XFXZ]H#$Y_!Y7.D;%3[SGVAG_=A%^3,$,\_.,K_OB*
M_P-?$>3)HN'BP0.^C Z]ZL/\:&7-<HZPU*A4A("!BNP%N'H+)3? ITS]/U(V
MA#\_NCXJPOLNJJ*GD^YT0]$0\-<S-TF7Y(6+9FX:2N7MA8$^SH]PX&_'V^U:
M9WIV%\=Z5GU_?C*V4;$HM>.9>ZE6D9UP09FQ$<8K:W(B(*6Q5B]R:@$=G$7?
M.:22[.Q\L<A5ZJT0>L%SVU<\P(C,NY]<:T/LTQDH(DOSQVMDWWY5/7'W\94:
M<7F6E;-3A][%;B<5*>X+[">M4H3LZIEI#3+#6X:JIN9FBF'M\KFG4Y5'79I6
MW9_NXPE7&Q\%]<N9[K\-8($WQ9*@=KAADPOU#OF1*;D9"^*E+"@J(&!0FF1<
M/!2::*U#SV7HE%N^)HGL5:M!**["-"SK#]U_22 FK<[8=**R^NI0$NX.3ZNS
M'D>(%J6!SOQG?9[._;O/7O!?44!Y3!OANVAZ1.FU_\1I5X?'_YR>:T#GSV=%
M%%A7=4DT18CFGOUG-S]_Z_J+N]:#O.W)Q="]_L&9@]3@>F;OS_W%0?%?>1T9
M_'7R5R/]L2:_8':]>T]_Z<Q( QG.]L@-R7'XU$T@V0(XFIR]SXB&D%AI:(33
M[/4]&>8]-P,J(,USB0HX3+-M\/.4L0'0O 5M3!K"0*3JL?3GEVF 1 Z\R^F,
M(9QGID@B5CKN4X)'B\C'@ZB 2-174;H_2/PS)*XNO7<PN%P!4W6GWX==7Z+L
MZU.^]V/F#WE0 7 <[8VEG+_U81WAY:("1GF2]@&2F#4RZ& $_^;&4<_ !+%?
MD@OO/KQ$H=D95$!KS]_?#K:R'_JCQ'_/$MZ(MJZ1]B;D,0_AG@GNS0[_:W:.
M3L<-G[,<7^<C,-"?!8#O3+&FFM\5CCF%+"]2,W#!$]_ F*2<PI.C8%0 "FST
M]XPU_PL^PZHQ4H:2@:T=^M-W_9GU>IS/&5HI2R$=Z9320V,U/^M<IGL&V)V+
MV*Y^8&[(]T0UB\'M_#/O934U9'DS./D"HZK#?0L28;_/G0I(.F#MTOVJ/'AW
M#8W\"Q8XT2/#B@P/W<SW*$,K),X"MV9SJ8 ;*T.4(]?_]*5_5[1*0UOXMTK\
MIB []@>%/RC\'Z70SYD\^-&*F[#9/4<).)#M2QE_U??3,7,ROS&9.4JZK:@
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MITA>*UE(!JZ43$%7("=MZX7Z92U$'@P&-^M()N$9535U^UY>2]C3^.Y^X@G
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M5MQ/0JGP[ED[U)_]U(LK)J!"WB7'O(5"3V2R@I_Q2$FP SY()3V[\>)G8.K
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M8"1#Y++J?4J(>!&9/H@&UPJRJEZB%40+0'_W;\8OIKR8]F\6$:5SC6C^>\D
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ME_O]4Z;'H!Y2/^AU=CM*X0?M;(E$Q#)?VNF&H)D/3&<EU-V8)(]O%!UBD8@
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M&V.X@28N0(DLJYP$10[ ?O,VH)&I1\AOO)X[:S&< \9&HJ:K7W]<U>R3#3K
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M8$&R#P0^P94@1NJ9]XU5XIFX*Y?J(V9[I@$:BC_:>(J40#&D7LK5<_4J^)H
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MG/1$,&*^W@4ZCB>LQK1QN!!^0TX:D]*KY]/N]4_]&)RNJMV42IKI7E"/"OK
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M\"V1X[$Z/0C7V31,UGD<ZX?!095$&O<R/6N9 B,+]A?;9IU=J95-A:;[4';
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MOT>9-3K=6XO[.32&+GM:J/$L[!T <.EW]&9!#9J\?[I-KV;?;P9:9A.4V$K
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M6S\><3'R#L"D,83PCQT5 >O=?MN0Y"5XNMO$1^L8<$<ZO9);'04A-(42_EA
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M !8P'-<'L'EY\&7"@TNV;2[17)1?A):VOC^OU-K!C;@@3"@/90)%%%*(<QI
MDB02HIAD&4^)4#K'\8JA$T-CJYSNM;H-@U"N"ECJ:^,['L$^D\XW$MUFQ5 S
M38BUI=(Z"_/77IBGNM8X""[_EQW=V'FI*Y"#P.NY&#EL7#?]^;G0=P6J9YWM
M4UTO:^_]2>OLF\<G,B_TGV9!BGD@$@JC4&H5*6)(*(]A*A)&:19F+$0V*M*
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M-7:T?19<,I'16]6E7F(3EUXR$?RX_I+16PXU;/?Z2G34TA>M9\KK);^EBS8
M5'Y=JS_KTMC*\?T@1#D+LTQIA2B"J8A2B".6PRP,$T@0PT$>!5FH[&W3@K9#
M.!E9773) 2EL*JT.PK=?7TR*FITJ.=OBY HTC-4)UAW6KL >QIJ[J4"VJ&T[
M%=ANA6Y'!=VN[JT/H'J+X XB,%U%7!\X[)7']3+@T.N3YYC0]#\I5,[\\YWZ
M4TE8S5N3P"P)X7$28YACH2]:"@()P3%$.MU4YIAGW"Z X9W%D3<6'ZV@AMW;
M]#:7AA&+%YTA3YN8O\D9<&'4-W[>KY9Z8_"%+J'Z!OC\=57OE%XF#;$W4G%<
M6FZF%'R0QQ+#)!69\AYX BD-0\B1B,. L4CGN$UXD]62_Y&WAFW<DK1Q2^4
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MM!#'4.98\I0Q3(CMB:<K+U-I-6U%\!UO;O4E7; V4VT3(6BGW_; Z[ %6K[
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MD=P!.E10 T:R=RINEJ4B4B@3J3Z'48/JW.Y/J^J:KYXJP:V;=QL/.++":?D
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MCC")WHY-Q^#-,::\(&5Y*VN7\Z.R,V\J\5C.$,]%E,L(<A*J+19E&.993*'
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MI%' $/:T@T"V7$RLL5_N/DFG5Y$$JSU-@S"'-;@:,:$Y(#-3<LD1Z%(&>YZ
M8NKX9S5;X-.LL!I$E.: UR[*-!',9K&GL?#TQJ.L%Y\O1C56_J.XU>C%9FYC
M]6G?3YKAT*<T2Z'P:*B28M7 M51 &L<100E*8F[4EF0\2U,GYW1:DPRW1*+G
M+9%&M/1V\+WT?,)YOX+9)C.Z)]5$_<7=8?;6+:4^O4WG<G< .FL,=;ZR9?E/
M._;@M]?]'_\]ET:^8-]?/XD7B:LJ<Z$D\*.,)A!CE481$U4XAWQI6PE"."8\
M38V,J1[9B0UF9Z#KGG852/YR\P^[(B$],/4LG7N(S*S9&'3,2XF,A'556:1'
M=-Y"(R,@SNJ.S-ZV,QE?Q9:H 7JWI% -!,H;)H\*NZI-TWN1Y2S?+D./X,P/
M(A@D:0H1CWSI;Z0)S##A24"3. RUFJ[KDYPZ:GT@"'A-T<PT:("F9Q;<0F%F
M$EK:H"4.?ND"T]"_WOK V"SH"^O()&@0G-4<Z -P:@H,WC2_>6H*MJO=3/.V
MJ?/*Q+K:4/HW_1NDKCC#MT:6DIBI6D/$V49[A7&K:Y_N.K-=]5Q@OGN]<^G'
M(^:Y?RS+G524G6KG7_=VJ5,9OXIR6^2J VOU6.6*_UYL2I4I@\,8\PP*FOH0
M17+?2R.?0^SS+.'45UVSC8>\&[,Q=="Y:MNFJG_J+C<@KQ@T[WLS$FS-6,'D
M$!K&!ZI&,35#H.:H:1S4YBPOP(&MIJ],TZRZ8LWQ)'EK:%R.ES=G8OZ9\]9
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M6$A/**4>I)0C**TAXWY$HR!(C1KF7B$TL;UKR1Z&RX(_6]*&GL]5J/3<'1<
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M9/6)E4Z16U09'O5E'".:HX\O0Z'A0(X1T$S+:MGVM,"[<;*9)+N/D-$RP]U
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MJ_NXW0'KYH7D*Y7"^V%3J(;BA\LT=;?6E&#+O^U=Q'W&J1>R$ 4X@+&7"I7
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M9MOV+XO0W>RO/&&F"5SDR]OU5NK9#>?RFY7OY!_OBH?-7^MEF'J,TE@>JWF
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MI@B^UZ,%C_KY?1;ZEFSWESI9(IF5M&2%+&(D<9TC7&<5(F62HU)04HH2)Z(
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M$@MAK11':P=6"T,MVKEHFB# W3P6P[AV7 $.IA\07" EN8# 24V.UYI,42Z
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MFW&-*.4IJG,I.,NYC 5(FR]2"JS,^\#_CO"_.:9&G(C(3GN] (<I[RGF( W
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MQ"IIRDJ1<I293K9%3E#%L428<9R5"<,)Y["\T; ,A[8@)B?(\!:Q'G/0Q-/
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M^OS]+&SKI;]4OD_(/,_><@$RUU5EB1"X=I"1ZX3:%>5;QR3WHVS<U)7ND#F
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MQK4[GQ'3N[7NF/#HP&JX*8,=:[\NJ%W]<G[]-Q?R>/%G6.8;PU&=4UQ(M[V
M5"DD<,)R,)YYRVHFES0#*IH&2QC7Z!UQ3XP)A0YVPD.NZ\V%W71=ZX7YEB.K
MU=GI]K,[EIE/05DD#S:*X$%Y37K D%H@]U9:4^C_8O,FB4U7,*Z%W<79\.Q
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M;ERS ($YI3$HIN6S39=L=9VQ]WA(I[+'B %X=DA*V27P 0T4DQ-+Y ;PU/I
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M[PA*\T!Y_ @ >\+>RHY+&Z6%(EUMUD:K#CH:X+3CLF/,.=8Z>M20_"YUYZ'
M>BIL!Y)ROP"?R&*%2MJ",(H\L%P*^!082%^*UP(-EM;Y=#M(&3?#8P1M^23>
M_RB7$K_7;KRUXUZ[6XA[CQSDVN%QP@>Z9Y BD+T7P2;DH(+0$#/AP62=K)"2
M^=+G/</#R/X[UD 0YA?DSX1/!*):VWCYRQ-<GO()=Z4D*3645$+=1@EJ8CBD
M'&-PVECO6K?3?"J-?5U5/ $ACZN=QL+I[DB[L[Y:05#[=WZ@ _T]+M/&\_*H
M2;<2"XLQM4ET!E_H!/<B9R.BL?QN-NNPX'N QK[B=4.![UCA=-MG]<Z9\OIL
M?;;$WVB?G9Z=;CYZ'\Z/[;WZY'<,<EP^<6G#G)^Q6$=JR@%J(6IJ[*9L/@,3
MT45'6DPV;T_>]OS<.AEXRRZ<XNJ*E6?7L[H,"R5HVAK),C(6T5O:*5K3WA1!
MI)(+<ZUMA?VIZ^K,? HJ[M67#R.0#D[+M[A:(>YP12[7M[4*2%K5_UV1%O@/
M#,N)#K$4FQ@Y.XE4LW2DI%5VD(7Q.J!BFI7FV^Q0:D<N+Q\(/XM1A/FCP);8
M^CN=,"=_XNPK_K:8KS^O)B4Z]#$2>X-,9,QJT@*I.!#D9TLA7&:IM;%W**TC
M%Z!W!-EC!?D# 7;B$TI-=AU89&1=H^+@:X.I%)B12":O9*U=X7UI&[DJO2]
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M8H,>$X#GL$$+V>(.VZB\,(C2G% IC$-&>8T86 ):T$B\/E,?[+-YTF]B.U:
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M]WRLD<FX/(IIHL 6DTBN@(>1PBQ*820VLGA7Y-U+:J'.3&$DE11" YAZW<W
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MXO+I\!XG1U%9;2G6B/&054B92VXDL$"""\YJSGTJG>3QY*+J>L1/B+.BTFD
M;ILMX'Q"S^9?Q]]6[T7V2QPYP6,DFB'*HD?<.E!/,P.=QL U:1G&Q>NN]EU<
MW;*KIX/?<:156P7[=/'Z52YBO H?^S8R23.;0D!"^9!+Y#$$9G= .$9M @F)
MTGZ/">LCUZV7>B)%:Q [6\!"CD#/T3,YQ6DDD@@J=[.6(0C$!;?("4:1BD(I
M'0#BZ^K4#BS<'[EN?=,38N%@=C;[AOMV['/MJ-LGJ2&9/UO'*O->VV^IA3*
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M CL0;370Q%$4!$H.M'(%F[-9"7EDB>1VIERJC:OAQ\)IC8XT&5J34H;+3FR
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M@BH4'QH4QQT:\MIA$Y3ED<988VH(87\B\CTC3S?%R4CJ.L@7AYGR'!6D&B%
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M8=7E#UX0:C_3ZTJOXFM2OP-02P,$%     @ LX&I6+JRK]I"!0  01H  !<
M  !L<W1A+65X,S(Q7S(P,C0P,S,Q+FAT;>U9;6_;-A#^OE]Q<[ V 2Q%\EO\
MU@">XZ 9VCB-'73[-- 2%7&52)6DDKB_?D?22N+8W8H.;9.NAB%(.M[QN>,=
M[XX:ICK/#H<I)?'A3\.?/0^.1%3FE&N()"6:QE JQB_A;4S5._"\U:BQ*):2
M7:8:&D&C!6^%?,>NB*-KIC-Z6,D9[KOGX;Z=9+@0\?)P&+,K8/&+&NLUHX/N
M0:/725!.THQ(V#EH-%M!W.DEP:+3_C.L(2L.=SQ*+S/ZHI8S[J74S-]O-?R#
M=J$'URS6:3\,@E]J=NCA,!%<XWP2^=VM$[,A3-,;[9&,7?*^5:GF6"MR)#(A
M^SN!_0T,Q4M(SK)E__F<Y53!*;V&<Y$3_KRN"%>>HI(E;J!B'RAB0GCV\=I!
M/D Y&>.T4B%L&-"3FY0MF(9FPP_7$=]J\^4@M;9">K83=H+!!I@MAHMPI:G\
M1I8;3\[G)\<GX]'\9'H*9Q?GLXO1Z1SFTT>//.S"A3_SQS[,)F.+/FRV@_JC
MQSV:P>AH>C:?'#TI<U=&[@4=F![#_.4$9J/S7T>GDYDW_?W5Y \8C>>&T@B"
MQB/2YK]&YU^ETBQ9?B.<)QPBP3F--!,<KIE.0:<4WI1$HO&R)9S30D@-2#P6
M,H<P\-Z 2. 54T03F*=4DH*6FD6J#B<\\F'7\#_;Z38:P6 L\H+PI7T*!WN0
M"&G%OW?B@?(8D]AK(J/4&:P9UEW22EB&E%L\,QJ5DFF&BA,>P^0F2@F_I)CJ
M\IPI9;#CWXR,,2\"HJ((\CX4IT>%!+'6X8A<L1A^\Q' AP^B#F>2*A:;]&KF
M&*>,)C@3SJS9%85IDK (,:-<(W:E6AWPG5F_.A2E5"5!;BW@WMZQ,JW=.X @
M_E@4)G7?'UX-,KZ_DC\C<D$X5=[T)J-+&$7:4(SOUPU'OH1W7%RCD= *.B6H
M6;O[!/SM<^-B2ZUPCZT@<8R%D)?11/>;'42R*<B]8MPL<-\+N\67KR6VFR#T
M*SV^_NR#-4N%@=\V9L HKN(\*3,,^@B=.S/!=AN DKXOF:2F:%3&$>_<>I?L
M 89UV-Z-]VZ=]RY<;T-UY<%AK]FR89#;X$>W[0U,O/VO7:+Q*%V"<=RO<V+7
M&9.$)L@9XUN[Q)6_$&:R1(%;IW&-NB&3+ -D0S D0\=1!?H*4@Q7PCCAD7F/
M F-F1:]OJ,8W5F_,5JXJT3BSV96=+ZHR<VXH"LP_1HIZ**9*-3B B?B>&/_[
MW22_-LXCTX/:Q.,0N^MKLG0WO54N?[H-DR:+C%8#%D+&5'H(-R.%HOWJ9A S
M561DV6?<3FJ9!CF1E]@(+X36(N^;)OC*% H1R5:3V/D<>=4?][I^N]DU+;+&
MC4W'U<2K[MFWW?.^CC=I[9;?;;8^2@[\\*.T?Q*+[7NOT_DDL?L6LH.-AE$8
M@R]JS=J#W;C?*&X@7-^+S;;ST#;.+%_?JX,M?K+2_$DKY:#%-!)NM^R7F/.D
M&674;1T,E+UN5L3I$9C?FC%^+/7C5FK+(OY8OR>DU%T;^FRGV1U\M!'=/9,,
M:ZD"BZD-XM[FBN_;O/2$LO"WK6U, 8PU)+T4YH3=-?GH(;9B90H6U+Q.2LF9
M2K$V52*CI@[^W*8>=E6Y4(Y#@>FI3+6[N]A;;[;,&<(X)84Y/.DT#6UN#O A
M[-;A@C-3)<^T+9O'(J9."*+E0E>([;D*UM@%D;J"=>]D1]K>#!1%NCE)P=HF
MRH0J)=ZN/AI\5P7TVB'A]H[R4[K-!]\["J%L;].7-",F+C>^@-P5E;8^#.Y8
MR )]J=2;+/_RT61U=9]P]NVGH[\!4$L#!!0    ( +.!J5B8 ?GZ5 4  ),:
M   7    ;'-T82UE>#,R,E\R,#(T,#,S,2YH=&WM66UOVS80_KY?<7.Q-@$L
M1_);+=L-X#D.EJ&-T]A9MT\#+5$1%XE422J)]^MW)*W$CM.MZ-8FZ1H$AJ3C
M'9\['N^%'*8ZS_:'*27Q_G?#[ST/#D14YI1KB"0EFL90*L;/X5U,U05XWFK4
M6!1+R<Y3#4V_V89W0EZP2^+HFNF,[E=RAGON?;AG)QDN1+S<'\;L$EC\JL:B
M;B]*2! FW9"VHW80!GX8)FVZ(*$?=$+Z>U!#5ASN>)1>9O15+6?<2ZF9O]]N
M-EYV"CVX8K%.^X'O_U"S0_>'B> :YY/([QZ=F"UAFEYKCV3LG/>M2C7'6I$C
MD0G9?^;;OX&A> G)6;;LOYBSG"HXIE=P*G+"7]05X<I35++$#53L3XJ8$)Y]
MO7*07Z*<C'%:J1 T#>C)=<H63$.KV6AN(K[1YO-!:M\+Z?FSH.L/ML#<8[@(
M5YK*![+<>'(Z/SH\&H_F1]-C.#D[G9V-CN<PGSYZY$$/SAJSQK@!L\G8H@]:
M';_^Z'&/9C ZF)[,)P=/RMR5D4._"]-#F/\T@=GH],?1\63F37]]/?D-1N.Y
MH31]?WL//IPV_W9W_E$JS9+E ^$\XA )SFFDF>!PQ70*.J7PMB02C9<MX906
M0FI XJ&0.02^]Q9$ J^9(IK /*62%+34+%)U..)1 W8,__-GO6;3'XQ%7A"^
MM&_!8!<2(:WX]TX\4!YC$GM#9)0Z@[6"NDM:"<N0<H-G1J-2,LU0<<)CF%Q'
M*>'G%%-=GC.E#';\-R-CS(N J"B"7(?B]*B0(-8Z_$RL(9F*1!UGX S1_<(B
M"B>2*A:C^]3AD''"\9.9=8Y)5Y5R:5_&*:,)C*)(E%R;)#Q-$N25QCAFVI7J
M=<!O9GWK4)12E0276 M8BRTKT]O8 @3UBT5A4OOZ\&J0V1LK^3,B%X13Y4VO
M,[I$(-I0S-ZH&XY\"1=<7*$1T4HZ):AYI_<$_/%3]\T]M<0:6T'B&-?(RVBB
M^ZTN(MD6Y#XQ;M:][P6]XO/7&O>;(&A4>GSYV0<;E@K\1L>8 7=Y%0>2,L.@
M$*%S9V8SWFQ02=^73%)35"KCB+=NO4-V 3=6T-F)=V^<]W8[WVSEE0<'8:MM
MMT%N@P.Z;3@P&^Y_[1+-1^D2C&,\SXE=9TPBFB!GC%_M$E?^0IC)(@5&5.,:
M=4,F60;(AF!(AHZC"O05I!BNQ(9;\QT%QLR*W@RHQC=67TRH5Y5HG-F$9>>+
MJLR<&XH"\Y.1HNZ*J5(1#F B7A/3^'J#Y)?&>6!Z5)MX'&+W^X8LW4.XRO5/
MMZ'29)'1:L!"R)A*#^%FI%"T7ST,8J:*C"S[C-M)+=,@)_(<&^6%T%KD?=,D
M7YI"(2+9:A([GR.O^N>PU^BT>J:%UAC8=%Q-O.JN&[:[WM/Q-JW3;O1:[0^2
M_4;P0=K?B<7V/NQV/TKLGH7L8*-A%.[!5[56[4XT[C>+:P@V8[$).W=MX\SR
MY;W:O\=/5IH_::4<M)A&PD7+?HDY3YI11MWVRX&RO^L5,YB_#2-\6^+'K=3:
MXGU;MR>DU'_6F>Z<2(;%58'5U>%-G541#><M?9M[=]MG]FPF>T)Y^V&K(5,R
M8]5)SX4QJSL60!^S-2Y3L*#F<U)*SE2*U:P2&365\Z<> \".*A?*<2@P79A9
MXIW%[F9[9DX=QBDIS'%,MV5H<W,E $&O#F><F;IZIFVA/18Q=4(0+1>Z0FQ/
M:K J+XC4%:RULR)INSE0%.GF; :KH2@3Z*WXN+J&^*I*[HUCQ_M[T(_I3^_<
MH!1"V6ZH+VF&+G-)M^Y4;LM06U'ZMRQD@;Y4ZFV6?[B&6?VZ2Z$]>QGU%U!+
M 0(4 Q0    ( +.!J5B]8J@@I^T  "7-"P 1              "  0    !L
M<W1A+3(P,C0P,S,Q+FAT;5!+ 0(4 Q0    ( +.!J5CDL''IYP\  )BV   1
M              "  =;M  !L<W1A+3(P,C0P,S,Q+GAS9%!+ 0(4 Q0    (
M +.!J5@Q"QBT6Q@  "CC   5              "  >S]  !L<W1A+3(P,C0P
M,S,Q7V-A;"YX;6Q02P$"% ,4    " "S@:E8 K/_"<8[  #TJ ( %0
M        @ %Z%@$ ;'-T82TR,#(T,#,S,5]D968N>&UL4$L! A0#%     @
MLX&I6(W"M%=GCP$ >28" !0              ( !<U(! &QS=&$M,C R-# S
M,S%?9S$N:G!G4$L! A0#%     @ LX&I6.#1N%L@.@$ 3KX! !0
M     ( !#.(" &QS=&$M,C R-# S,S%?9S(N:G!G4$L! A0#%     @ LX&I
M6+R%ZS.NZ@  NFL) !4              ( !7AP$ &QS=&$M,C R-# S,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( +.!J5@C@"_HN80  !=7!@ 5
M  "  3\'!0!L<W1A+3(P,C0P,S,Q7W!R92YX;6Q02P$"% ,4    " "S@:E8
M?:=U]_L&   #)0  %P              @ $KC 4 ;'-T82UE>#,Q,5\R,#(T
M,#,S,2YH=&U02P$"% ,4    " "S@:E8KH*: 0X'   M)0  %P
M    @ %;DP4 ;'-T82UE>#,Q,E\R,#(T,#,S,2YH=&U02P$"% ,4    " "S
M@:E8NK*OVD(%  !!&@  %P              @ &>F@4 ;'-T82UE>#,R,5\R
M,#(T,#,S,2YH=&U02P$"% ,4    " "S@:E8F 'Y^E0%  "3&@  %P
M        @ $5H 4 ;'-T82UE>#,R,E\R,#(T,#,S,2YH=&U02P4&      P
,#  B P  GJ4%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>lsta-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lsta="http://www.caladrius.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lsta-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-04</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-04</startDate>
            <endDate>2024-03-24</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-04-05</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000320017</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-388">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-389">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-394">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-395">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-398">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-399">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-85" id="f-476">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lsta:SaleOfStockAvailableForSalePercentage contextRef="c-93" decimals="2" id="f-506" unitRef="number">0.33</lsta:SaleOfStockAvailableForSalePercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">LISATA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">842-0100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">LSTA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">8307433</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">21805000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">22593000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">21544000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">27942000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">4210000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">3389000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">47559000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">53924000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">146000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">175000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">245000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">263000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">290000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">332000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">48240000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">54694000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">1263000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">2421000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">4070000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">4169000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">5333000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">6590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">164000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">210000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">5497000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">6800000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-56" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-57" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-58"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-59"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-60" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-61" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-62" unitRef="shares">8308171</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-63" unitRef="shares">8150635</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-64" unitRef="shares">8307433</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-65" unitRef="shares">8149897</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">577283000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">576971000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-70" unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-71" unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">-533482000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">-528081000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">-104000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">-42000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">42997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">48148000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-82" unitRef="usd">42743000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">47894000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-84" unitRef="usd">48240000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">54694000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">3241000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">3179000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">3360000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">3665000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">6601000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">6844000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-92" unitRef="usd">-6601000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">-6844000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">589000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">670000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-96" unitRef="usd">-187000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">-13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">402000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">657000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">-6199000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">-6187000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">-798000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">-5401000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">-6187000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-114" unitRef="shares">8294000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-115" unitRef="shares">8294000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-116" unitRef="shares">7987000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-117" unitRef="shares">7987000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">-23000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">-5463000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">-6210000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-128" unitRef="shares">7867000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">574548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-131" unitRef="usd">-29000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-132" unitRef="usd">-507241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-133" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-134" unitRef="usd">66578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-135" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-136" unitRef="usd">66324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-137" unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-138" unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-16" decimals="-3" id="f-140" unitRef="shares">132000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-141" unitRef="usd">589000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-142" unitRef="usd">589000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-143" unitRef="usd">589000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-18" decimals="-3" id="f-144" unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-145" unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-18" decimals="-3" id="f-147" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-148" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-19" decimals="-3" id="f-150" unitRef="shares">7999000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-151" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-152" unitRef="usd">575137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-153" unitRef="usd">-52000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-154" unitRef="usd">-513428000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-155" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-156" unitRef="usd">60957000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-157" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-158" unitRef="usd">60703000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-159" unitRef="shares">8151000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-160" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-161" unitRef="usd">576971000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-162" unitRef="usd">-42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-163" unitRef="usd">-528081000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-164" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-165" unitRef="usd">48148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-166" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-167" unitRef="usd">47894000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-34" decimals="-3" id="f-168" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-35" decimals="-3" id="f-169" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-36" decimals="-3" id="f-171" unitRef="shares">157000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-172" unitRef="usd">312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-173" unitRef="usd">312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-175" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-35" decimals="-3" id="f-176" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-178" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-35" decimals="-3" id="f-179" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-39" decimals="-3" id="f-181" unitRef="shares">8308000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-182" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-183" unitRef="usd">577283000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-184" unitRef="usd">-104000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-185" unitRef="usd">-533482000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-186" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-187" unitRef="usd">42997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-188" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-189" unitRef="usd">42743000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-191" unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">454000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-5" decimals="-3" id="f-193" unitRef="usd">675000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">46000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-195" unitRef="usd">48000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-5" decimals="-3" id="f-197" unitRef="usd">-3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">152000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-5" decimals="-3" id="f-201" unitRef="usd">167000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">872000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-203" unitRef="usd">1652000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">-41000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-5" decimals="-3" id="f-205" unitRef="usd">-167000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-1243000</lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="c-5" decimals="-3" id="f-207" unitRef="usd">-1083000</lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">-7027000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-209" unitRef="usd">-8196000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">18824000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-5" decimals="-3" id="f-211" unitRef="usd">30121000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">25360000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-5" decimals="-3" id="f-213" unitRef="usd">34410000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">100000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-5" decimals="-3" id="f-215" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">6436000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-217" unitRef="usd">4289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">142000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-219" unitRef="usd">85000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">-142000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-221" unitRef="usd">-85000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">-55000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-223" unitRef="usd">-7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-788000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-225" unitRef="usd">-3999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-226" unitRef="usd">22593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-227" unitRef="usd">32154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-228" unitRef="usd">21805000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-229" unitRef="usd">28155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <lsta:BusinessTextBlock contextRef="c-1" id="f-230">The Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lisata Therapeutics, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (&#x201c;TME&#x201d;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</lsta:BusinessTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-231">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-232">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-233">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-234">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-235">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;) acquired in the Company's acquisition of Cend Therapeutics, Inc (the &#x201c;Cend Merger&#x201d;), with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $17&#160;thousand for the three months ended March&#160;31, 2024 and $18&#160;thousand for the three months ended March&#160;31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next 3.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2024 and March&#160;31, 2023, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-236">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-237">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-238">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-239">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-240">The estimated useful lives of property and equipment are as follows:&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:358.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-46" id="f-241">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-47" id="f-242">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-243">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="c-1" id="f-244">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-245">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-246">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-247">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="c-1" id="f-248">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-249">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-5" id="f-250" unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-3" id="f-251">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">17000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-253" unitRef="usd">18000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-254">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-255" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-256" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-257" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-258" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-259">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="INF" id="f-260" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="INF" id="f-261" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-262">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2024 and March&#160;31, 2023, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="INF" id="f-263" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-5" decimals="INF" id="f-264" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-49" decimals="INF" id="f-265" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-266">Available-for-Sale-Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:94.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:360.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:361.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-267">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:94.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-50" decimals="-3" id="f-268" unitRef="usd">33750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-50" decimals="-3" id="f-269" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-50" decimals="-3" id="f-270" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-50" decimals="-3" id="f-271" unitRef="usd">33732000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-51" decimals="-3" id="f-272" unitRef="usd">37791000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-51" decimals="-3" id="f-273" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-51" decimals="-3" id="f-274" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-51" decimals="-3" id="f-275" unitRef="usd">37786000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-52" decimals="-3" id="f-276" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-52" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-52" decimals="-3" id="f-278" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-52" decimals="-3" id="f-279" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-53" decimals="-3" id="f-280" unitRef="usd">1981000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-53" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-53" decimals="-3" id="f-282" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-53" decimals="-3" id="f-283" unitRef="usd">1981000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-54" decimals="-3" id="f-284" unitRef="usd">5242000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-54" decimals="-3" id="f-285" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-54" decimals="-3" id="f-286" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-54" decimals="-3" id="f-287" unitRef="usd">5242000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-55" decimals="-3" id="f-288" unitRef="usd">4268000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-55" decimals="-3" id="f-289" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-55" decimals="-3" id="f-290" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-55" decimals="-3" id="f-291" unitRef="usd">4268000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-56" decimals="-3" id="f-292" unitRef="usd">247000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-56" decimals="-3" id="f-293" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-56" decimals="-3" id="f-294" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-56" decimals="-3" id="f-295" unitRef="usd">247000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-57" decimals="-3" id="f-296" unitRef="usd">622000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-57" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-57" decimals="-3" id="f-298" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-57" decimals="-3" id="f-299" unitRef="usd">622000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-300" unitRef="usd">39239000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-302" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-303" unitRef="usd">39221000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-304" unitRef="usd">44662000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-305" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-306" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-307" unitRef="usd">44657000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:360.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-309" unitRef="usd">17677000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-310" unitRef="usd">16715000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities contextRef="c-3" decimals="-3" id="f-311" unitRef="usd">21544000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-3" id="f-312" unitRef="usd">27942000</us-gaap:MarketableSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-3" id="f-313" unitRef="usd">39221000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-4" decimals="-3" id="f-314" unitRef="usd">44657000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-315">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:361.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-316" unitRef="usd">39239000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue contextRef="c-3" decimals="-3" id="f-317" unitRef="usd">39221000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue contextRef="c-3" decimals="-3" id="f-319" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-320" unitRef="usd">39239000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-321" unitRef="usd">39221000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-322">Property and Equipment&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:358.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results included depreciation expense of approximately $29&#160;thousand and $30&#160;thousand for the three months ended March&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-47" decimals="-3" id="f-323" unitRef="usd">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-58" decimals="-3" id="f-324" unitRef="usd">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-59" decimals="-3" id="f-325" unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-60" decimals="-3" id="f-326" unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-327" unitRef="usd">661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-328" unitRef="usd">661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">515000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-330" unitRef="usd">486000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">146000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-332" unitRef="usd">175000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">29000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-334" unitRef="usd">30000</us-gaap:Depreciation>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-335">Income (Loss) Per Share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. At March&#160;31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-336">At March&#160;31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="-3" id="f-337" unitRef="shares">1454000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="-3" id="f-338" unitRef="shares">1493000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-63" decimals="-3" id="f-339" unitRef="shares">1422000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="-3" id="f-340" unitRef="shares">1424000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="-3" id="f-341" unitRef="shares">354000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="-3" id="f-342" unitRef="shares">237000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-343">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:116.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:12.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of accounts payable and accrued expenses approximate fair value as of March&#160;31, 2024 and December&#160;31, 2023, due to the short maturity nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-344">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:116.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:12.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-345" unitRef="usd">17677000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-346" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-348" unitRef="usd">17677000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-349" unitRef="usd">16715000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-350" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-352" unitRef="usd">16715000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-354" unitRef="usd">21544000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-355" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-356" unitRef="usd">21544000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-358" unitRef="usd">27942000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-360" unitRef="usd">27942000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-361" unitRef="usd">17677000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-362" unitRef="usd">21544000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-364" unitRef="usd">39221000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-365" unitRef="usd">16715000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-366" unitRef="usd">27942000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-367" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-368" unitRef="usd">44657000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-369">Accrued Liabilities&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:313.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:97.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounting &amp;amp; tax consulting liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-370">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2024 and December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:313.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:97.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounting &amp;amp; tax consulting liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-371" unitRef="usd">1324000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-372" unitRef="usd">2665000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lsta:ClinicalAndRDRelatedLiabilities contextRef="c-3" decimals="-3" id="f-373" unitRef="usd">1724000</lsta:ClinicalAndRDRelatedLiabilities>
    <lsta:ClinicalAndRDRelatedLiabilities contextRef="c-4" decimals="-3" id="f-374" unitRef="usd">1046000</lsta:ClinicalAndRDRelatedLiabilities>
    <lsta:AccruedGrantFunding contextRef="c-3" decimals="-3" id="f-375" unitRef="usd">92000</lsta:AccruedGrantFunding>
    <lsta:AccruedGrantFunding contextRef="c-4" decimals="-3" id="f-376" unitRef="usd">57000</lsta:AccruedGrantFunding>
    <lsta:LegalSettlementCurrent contextRef="c-3" decimals="-3" id="f-377" unitRef="usd">500000</lsta:LegalSettlementCurrent>
    <lsta:LegalSettlementCurrent contextRef="c-4" decimals="-3" id="f-378" unitRef="usd">0</lsta:LegalSettlementCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-379" unitRef="usd">172000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-380" unitRef="usd">168000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-381" unitRef="usd">258000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">233000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-383" unitRef="usd">4070000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-384" unitRef="usd">4169000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-385">Operating Leases&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:325.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-388"&gt;&lt;span style="-sec-ix-hidden:f-389"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-394"&gt;&lt;span style="-sec-ix-hidden:f-395"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-398"&gt;&lt;span style="-sec-ix-hidden:f-399"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the weighted average remaining lease term for our operating lease was 1.5 years, and the weighted average discount rate for our operating lease was 9.625%. As of December&#160;31, 2023, the weighted average remaining lease term for our operating leases was 1.75 years, and the weighted average discount rate for our operating leases was 9.625%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of March&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-386">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock contextRef="c-1" id="f-387">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:325.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-388"&gt;&lt;span style="-sec-ix-hidden:f-389"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-394"&gt;&lt;span style="-sec-ix-hidden:f-395"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-398"&gt;&lt;span style="-sec-ix-hidden:f-399"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-390" unitRef="usd">267000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-391" unitRef="usd">308000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-392" unitRef="usd">267000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-393" unitRef="usd">308000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-396" unitRef="usd">172000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-397" unitRef="usd">168000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-400" unitRef="usd">92000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-401" unitRef="usd">137000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-402" unitRef="usd">264000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-403" unitRef="usd">305000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-404">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="5" id="f-405" unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-406">P1Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="5" id="f-407" unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of March&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-409" unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-410" unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-411" unitRef="usd">286000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-412" unitRef="usd">22000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-413" unitRef="usd">264000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-414">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;At The Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC, as sales agent, in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. As of the date of this filing and so long as the Company&#x2019;s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#x201c;Baby Shelf Limitation&#x201d;), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of the Company's Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $26.7&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such S-3 filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $8,915,094, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If the Company&#x2019;s public float exceeds $75.0&#160;million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. There were no issuances of common stock under the ATM Agreement for the three months ended March&#160;31, 2024. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,165.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,453,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2024&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,443,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,285,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:322.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:4.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vesting terms of restricted stock issuances are generally between &lt;span style="-sec-ix-hidden:f-476"&gt;one&lt;/span&gt; and four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(99,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:343.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average estimated fair value of restricted stock units issued for services in the three months ended March&#160;31, 2024 and 2023 was $3.08 and $3.00 per share, respectively. The fair value of the restricted stock units was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement contextRef="c-75" decimals="-5" id="f-415" unitRef="usd">50000000</lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <us-gaap:CommonStockValueOutstanding contextRef="c-76" decimals="-5" id="f-416" unitRef="usd">26700000</us-gaap:CommonStockValueOutstanding>
    <lsta:OutstandingStockThreshold contextRef="c-77" decimals="-5" id="f-417" unitRef="usd">75000000</lsta:OutstandingStockThreshold>
    <lsta:SaleOfStockAvailableForSale contextRef="c-78" decimals="0" id="f-418" unitRef="usd">8915094</lsta:SaleOfStockAvailableForSale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-79"
      decimals="INF"
      id="f-419"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-80"
      decimals="INF"
      id="f-420"
      unitRef="shares">64394</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-81" decimals="0" id="f-421" unitRef="usd">270774</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-422">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2024:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,165.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,453,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2024&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,443,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,285,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-423" unitRef="shares">1322501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-424"
      unitRef="usdPerShare">10.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-82" id="f-425">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-2" id="f-426" unitRef="usd">164100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <lsta:CommonStockWarrantsShares contextRef="c-4" decimals="INF" id="f-427" unitRef="shares">1421744</lsta:CommonStockWarrantsShares>
    <lsta:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="c-4"
      decimals="2"
      id="f-428"
      unitRef="usdPerShare">42.51</lsta:WeightedAverageExercisePriceWarrantsOutstanding>
    <lsta:WeightedAverageRemainingContractualTermwarrantoutstanding contextRef="c-82" id="f-429">P2Y5M1D</lsta:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <lsta:AggregateIntrinsicValueWarrantsOutstanding contextRef="c-4" decimals="-3" id="f-430" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-431" unitRef="shares">132575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-432"
      unitRef="usdPerShare">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsGranted contextRef="c-1" decimals="INF" id="f-433" unitRef="shares">0</lsta:WarrantsGranted>
    <lsta:WeightedAverageExercisePriceWarrantsGranted
      contextRef="c-1"
      decimals="2"
      id="f-434"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-435" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-436"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsExercised contextRef="c-1" decimals="INF" id="f-437" unitRef="shares">0</lsta:WarrantsExercised>
    <lsta:WeightedAverageExercisePriceWarrantsExercised
      contextRef="c-1"
      decimals="2"
      id="f-438"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-439" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-440"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsCanceled contextRef="c-1" decimals="INF" id="f-441" unitRef="shares">0</lsta:WarrantsCanceled>
    <lsta:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="c-1"
      decimals="2"
      id="f-442"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-443" unitRef="shares">1163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-444"
      unitRef="usdPerShare">1165.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsExpired contextRef="c-1" decimals="INF" id="f-445" unitRef="shares">0</lsta:WarrantsExpired>
    <lsta:WeightedAverageExercisePriceWarrantsExpired
      contextRef="c-1"
      decimals="2"
      id="f-446"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-447" unitRef="shares">1453913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-448"
      unitRef="usdPerShare">9.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-449">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-2" id="f-450" unitRef="usd">232100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <lsta:CommonStockWarrantsShares contextRef="c-3" decimals="INF" id="f-451" unitRef="shares">1421744</lsta:CommonStockWarrantsShares>
    <lsta:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="c-3"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">42.51</lsta:WeightedAverageExercisePriceWarrantsOutstanding>
    <lsta:WeightedAverageRemainingContractualTermwarrantoutstanding contextRef="c-1" id="f-453">P2Y</lsta:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <lsta:AggregateIntrinsicValueWarrantsOutstanding contextRef="c-3" decimals="-3" id="f-454" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-455" unitRef="shares">1443689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-456"
      unitRef="usdPerShare">9.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-457">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-3" decimals="-2" id="f-458" unitRef="usd">231500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <lsta:Sharesvestedandexpectedtovest contextRef="c-3" decimals="INF" id="f-459" unitRef="shares">1421744</lsta:Sharesvestedandexpectedtovest>
    <lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="c-3"
      decimals="2"
      id="f-460"
      unitRef="usdPerShare">42.51</lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest contextRef="c-1" id="f-461">P2Y</lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <lsta:AggregateIntrinsicValueWarrantsvestedandexpectedtovest contextRef="c-3" decimals="-3" id="f-462" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsvestedandexpectedtovest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-3" decimals="INF" id="f-463" unitRef="shares">1285911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-464"
      unitRef="usdPerShare">9.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <lsta:OptionsVestedweightedAverageRemainingContractualTerm contextRef="c-1" id="f-465">P5Y9M</lsta:OptionsVestedweightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-3" decimals="-2" id="f-466" unitRef="usd">215900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <lsta:WarrantsVested contextRef="c-3" decimals="INF" id="f-467" unitRef="shares">1421744</lsta:WarrantsVested>
    <lsta:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="c-3"
      decimals="2"
      id="f-468"
      unitRef="usdPerShare">42.51</lsta:WeightedAverageExercisePriceWarrantsExercisable>
    <lsta:WeightedAverageRemainingContractualTermwarrantsvested contextRef="c-1" id="f-469">P2Y</lsta:WeightedAverageRemainingContractualTermwarrantsvested>
    <lsta:AggregateIntrinsicValueWarrantsvested contextRef="c-3" decimals="-3" id="f-470" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsvested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-471">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:322.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:4.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(99,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-83"
      decimals="INF"
      id="f-472"
      unitRef="shares">203800</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-84"
      decimals="INF"
      id="f-473"
      unitRef="shares">159950</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-83" decimals="-3" id="f-474" unitRef="usd">628000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-84" decimals="-3" id="f-475" unitRef="usd">480000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-86" id="f-477">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-87"
      decimals="INF"
      id="f-478"
      unitRef="shares">125775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-87"
      decimals="2"
      id="f-479"
      unitRef="usdPerShare">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-83"
      decimals="INF"
      id="f-480"
      unitRef="shares">203800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-83"
      decimals="2"
      id="f-481"
      unitRef="usdPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-83"
      decimals="INF"
      id="f-482"
      unitRef="shares">99686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-83"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">5.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-83"
      decimals="INF"
      id="f-484"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-83"
      decimals="2"
      id="f-485"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-88"
      decimals="INF"
      id="f-486"
      unitRef="shares">229889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-88"
      decimals="2"
      id="f-487"
      unitRef="usdPerShare">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-488">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:343.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-89"
      decimals="INF"
      id="f-489"
      unitRef="shares">205300</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-90"
      decimals="INF"
      id="f-490"
      unitRef="shares">188850</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-89" decimals="-3" id="f-491" unitRef="usd">632000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-90" decimals="-3" id="f-492" unitRef="usd">567000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-83"
      decimals="2"
      id="f-493"
      unitRef="usdPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-494"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-89" id="f-495">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-91"
      decimals="INF"
      id="f-496"
      unitRef="shares">112800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-91"
      decimals="2"
      id="f-497"
      unitRef="usdPerShare">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-89"
      decimals="INF"
      id="f-498"
      unitRef="shares">97400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-89"
      decimals="2"
      id="f-499"
      unitRef="usdPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-89"
      decimals="INF"
      id="f-500"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-89"
      decimals="2"
      id="f-501"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-89"
      decimals="INF"
      id="f-502"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-89"
      decimals="2"
      id="f-503"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-92"
      decimals="INF"
      id="f-504"
      unitRef="shares">110200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-92"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-507">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:378.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-508">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-94" decimals="-3" id="f-509" unitRef="usd">86000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-95" decimals="-3" id="f-510" unitRef="usd">187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-3" id="f-511" unitRef="usd">368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="-3" id="f-512" unitRef="usd">488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-513" unitRef="usd">454000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-514" unitRef="usd">675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-515">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-98" decimals="-3" id="f-516" unitRef="usd">371000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-92" decimals="-3" id="f-517" unitRef="usd">290000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-88" decimals="-3" id="f-518" unitRef="usd">751000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-99" id="f-519">P2Y3M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-89" id="f-520">P0Y11M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-83" id="f-521">P2Y2M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-522">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:378.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-99" decimals="-3" id="f-523" unitRef="usd">199000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-100" decimals="-3" id="f-524" unitRef="usd">324000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-99"
      decimals="2"
      id="f-525"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-100"
      decimals="2"
      id="f-526"
      unitRef="usdPerShare">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-527">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the Company had approximately $43.7&#160;million and $33.7&#160;million respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036.  The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in approximately $34.0&#160;million of remaining Federal NOLs as of December&#160;31, 2022. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, Cend Therapeutics, Inc. (&#x201c;Cend&#x201d;) had approximately $3.6&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $3.1&#160;million of Federal and $4.3&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917&#160;thousand each year. The Federal NOL of $459&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. As of December&#160;31, 2023 and 2022, Cend&#x2019;s wholly owned Australian subsidiary had approximately $2.4&#160;million and $1.8&#160;million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had federal research and development credit carryforwards of $0.5&#160;million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $0.1&#160;million, which carryforward indefinitely.  Utilization of these credits may be subject to an annual limitation based on changes in ownership.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the Company had State NOLs available in New Jersey of $19.4&#160;million and $35.5&#160;million, respectively, California of $9.2&#160;million and $9.2&#160;million, respectively, and New York City of $1.9&#160;million and $1.9&#160;million, respectively, to offset future taxable income expiring from 2032 through 2043. The usage of the Company&#x2019;s NOLs is limited given the change in ownership.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the FASB&#x2019;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the Company&#x2019;s uncertain tax positions were $344&#160;thousand and $344&#160;thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2020, the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 4, 2024, the Company received final approval from the New Jersey Economic Development Authority (&#x201c;NJEDA&#x201d;) under the Technology Business Tax Certificate Transfer Program (&#x201c;Program&#x201d;) to sell $8.9&#160;million of its New Jersey net operating losses (&#x201c;NJ NOLs&#x201d;), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7&#160;million. The sale of NJ NOLs resulted in a $0.8&#160;million deferred income tax benefit and a loss on sale of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp;amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#x2019;s results of operations for the year ended December&#160;31, 2023. The Company will continue to monitor the possible future impact of changes in tax legislation.</us-gaap:IncomeTaxDisclosureTextBlock>
    <lsta:OperatingLossCarryforwardsBeforeWriteDown contextRef="c-101" decimals="-5" id="f-528" unitRef="usd">43700000</lsta:OperatingLossCarryforwardsBeforeWriteDown>
    <lsta:OperatingLossCarryforwardsBeforeWriteDown contextRef="c-102" decimals="-5" id="f-529" unitRef="usd">33700000</lsta:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-4" decimals="-5" id="f-530" unitRef="usd">88200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-102" decimals="-5" id="f-531" unitRef="usd">34000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-103" decimals="-5" id="f-532" unitRef="usd">3600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-104" decimals="-5" id="f-533" unitRef="usd">3100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-105" decimals="-5" id="f-534" unitRef="usd">4300000</us-gaap:OperatingLossCarryforwards>
    <lsta:FairValueMarketOfTaxNOLs contextRef="c-106" decimals="-5" id="f-535" unitRef="usd">36100000</lsta:FairValueMarketOfTaxNOLs>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-106" decimals="4" id="f-536" unitRef="number">0.0254</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation contextRef="c-107" decimals="-3" id="f-537" unitRef="usd">917000</lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation>
    <lsta:OperatingLossCarryforwardsPostAcquisition contextRef="c-103" decimals="-3" id="f-538" unitRef="usd">459000</lsta:OperatingLossCarryforwardsPostAcquisition>
    <us-gaap:OperatingLossCarryforwards contextRef="c-108" decimals="-5" id="f-539" unitRef="usd">2400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-109" decimals="-5" id="f-540" unitRef="usd">1800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-110" decimals="-5" id="f-541" unitRef="usd">500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-111" decimals="-5" id="f-542" unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-112" decimals="-5" id="f-543" unitRef="usd">19400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-113" decimals="-5" id="f-544" unitRef="usd">35500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-114" decimals="-5" id="f-545" unitRef="usd">9200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-115" decimals="-5" id="f-546" unitRef="usd">9200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-116" decimals="-5" id="f-547" unitRef="usd">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-117" decimals="-5" id="f-548" unitRef="usd">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-3" id="f-550" unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefits>
    <lsta:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross contextRef="c-118" decimals="-5" id="f-551" unitRef="usd">8900000</lsta:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross>
    <lsta:ProceedsFromSaleOfNOLS contextRef="c-118" decimals="-5" id="f-552" unitRef="usd">700000</lsta:ProceedsFromSaleOfNOLS>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-119" decimals="-5" id="f-553" unitRef="usd">800000</us-gaap:IncomeTaxExpenseBenefit>
    <lsta:LossOnSaleOfNOL contextRef="c-119" decimals="-5" id="f-554" unitRef="usd">100000</lsta:LossOnSaleOfNOL>
    <lsta:ResearchAndDevelopmentTaxIncentiveTextBlock contextRef="c-1" id="f-555">Australia Research and Development Tax IncentiveThe Company&#x2019;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March&#160;31, 2024 and 2023, the Company had $1.0&#160;million and $1.0&#160;million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</lsta:ResearchAndDevelopmentTaxIncentiveTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-120" decimals="3" id="f-556" unitRef="number">0.435</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-121" decimals="3" id="f-557" unitRef="number">0.485</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <lsta:IncomeTaxIncentiveReceivable contextRef="c-3" decimals="-5" id="f-558" unitRef="usd">1000000</lsta:IncomeTaxIncentiveReceivable>
    <lsta:IncomeTaxIncentiveReceivable contextRef="c-4" decimals="-5" id="f-559" unitRef="usd">1000000</lsta:IncomeTaxIncentiveReceivable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-560">Contingencies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#x201c;Lingmed&#x201d;) claiming Lingmed was entitled to a success fee based on Cend&#x2019;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#x2019;s response to the complaint was filed on June 6, 2022 and denied all of Lingmed&#x2019;s material allegations. Lingmed filed an answer to Cend&#x2019;s response on July 11, 2022, denying all of the Company&#x2019;s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company is required to pay Lingmed $0.5&#160;million within 30 days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to 5.0% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $250 thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties&#x2019; joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-122" decimals="-5" id="f-561" unitRef="usd">500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <lsta:LitigationSettlementPaymentTerm contextRef="c-122" id="f-562">P30D</lsta:LitigationSettlementPaymentTerm>
    <lsta:LitigationSettlementFutureMilestonePaymentsPercent
      contextRef="c-123"
      decimals="INF"
      id="f-563"
      unitRef="number">0.050</lsta:LitigationSettlementFutureMilestonePaymentsPercent>
    <lsta:LitigationSettlementMilestonePayment contextRef="c-123" decimals="-3" id="f-564" unitRef="usd">250000</lsta:LitigationSettlementMilestonePayment>
    <lsta:TechnologyTransferAgreementTextBlock contextRef="c-1" id="f-565">Technology Transfer Agreement&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impilo Therapeutics &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#x201c;Impilo&#x201d;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in connection with the Sanford Burnham Prebys license agreement (Note 15) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100,000. As of March 31, 2024 and December 31, 2023 the Company owned 38.6% of Impilo. This investment was expensed under the equity method of accounting for the three months ended March 31, 2024 in other expense,net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0&#160;million and an 80% discount rate.&lt;/span&gt;&lt;/div&gt;</lsta:TechnologyTransferAgreementTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-124"
      decimals="INF"
      id="f-566"
      unitRef="shares">766000</us-gaap:InvestmentOwnedBalanceShares>
    <lsta:InvestmentOwnedCanceledShares
      contextRef="c-125"
      decimals="INF"
      id="f-567"
      unitRef="shares">766000</lsta:InvestmentOwnedCanceledShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-125"
      decimals="INF"
      id="f-568"
      unitRef="shares">574500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-126" decimals="-3" id="f-569" unitRef="usd">100000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-127" decimals="3" id="f-570" unitRef="number">0.386</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-128" decimals="3" id="f-571" unitRef="number">0.386</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <lsta:SAFEValuationCap contextRef="c-3" decimals="-5" id="f-572" unitRef="usd">30000000</lsta:SAFEValuationCap>
    <lsta:SAFEDiscountRate contextRef="c-3" decimals="2" id="f-573" unitRef="number">0.80</lsta:SAFEDiscountRate>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-574">License Agreements&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanford Burnham Prebys&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#x201c;SBP&#x201d;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#x2019;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#x2019;s pre-seed preferred stock in Impilo on October 3, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#x2019; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SBP did not own shares of the Company&#x2019;s common stock as of March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;Research Collaboration and License Agreement&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exclusive License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#x201c;Qilu Agreement&#x201d;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#x201c;Cend Merger&#x201d;). In addition, Cend received and recognized as revenue a $5.0&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $96.0&#160;million and $125.0&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lsta:SharesIssuedUnderLicenseAgreement
      contextRef="c-129"
      decimals="INF"
      id="f-575"
      unitRef="shares">382030</lsta:SharesIssuedUnderLicenseAgreement>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-129" decimals="-3" id="f-576" unitRef="usd">10000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven contextRef="c-129" decimals="-3" id="f-577" unitRef="usd">20000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven>
    <lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-129" decimals="-5" id="f-578" unitRef="usd">10600000</lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="c-129"
      decimals="INF"
      id="f-579"
      unitRef="number">0.04</lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-129"
      decimals="INF"
      id="f-580"
      unitRef="number">0.25</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-130"
      decimals="INF"
      id="f-581"
      unitRef="shares">191500</us-gaap:InvestmentOwnedBalanceShares>
    <lsta:SharesHeldByThirdParty
      contextRef="c-131"
      decimals="INF"
      id="f-582"
      unitRef="shares">0</lsta:SharesHeldByThirdParty>
    <us-gaap:ContractWithCustomerLiability contextRef="c-132" decimals="-5" id="f-583" unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-133" decimals="-6" id="f-584" unitRef="usd">5000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-134" decimals="-5" id="f-585" unitRef="usd">96000000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-135" decimals="-5" id="f-586" unitRef="usd">125000000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="c-134"
      decimals="INF"
      id="f-587"
      unitRef="number">0.10</lsta:RevenuePerformanceObligationPercentageOfNetSale>
    <lsta:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="c-135"
      decimals="INF"
      id="f-588"
      unitRef="number">0.15</lsta:RevenuePerformanceObligationPercentageOfNetSale>
    <lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="c-134"
      decimals="INF"
      id="f-589"
      unitRef="number">0.12</lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="c-135"
      decimals="INF"
      id="f-590"
      unitRef="number">0.35</lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <lsta:LitigationSettlementFutureMilestonePaymentsPercent
      contextRef="c-123"
      decimals="INF"
      id="f-591"
      unitRef="number">0.050</lsta:LitigationSettlementFutureMilestonePaymentsPercent>
    <lsta:LitigationSettlementMilestonePayment contextRef="c-123" decimals="-3" id="f-592" unitRef="usd">250000</lsta:LitigationSettlementMilestonePayment>
    <lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate contextRef="c-136" id="f-593">P60D</lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-594">Subsequent EventsOn April 15, 2024, the Company&#x2019;s Board of Directors appointed James Nisco as the Company&#x2019;s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately. Effective as of April 15, 2024, Mr. Nisco shall serve as the Company&#x2019;s principal financial officer and principal accounting officer.</us-gaap:SubsequentEventsTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-595">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-596">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-597">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-598">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
